サイトカイン・ケモカインのすべて　第3版改訂新版

出版社： 日本医学館
著者：
発行日： 2004-08-09
分野： 基礎・関連科学  >  細胞/細胞工学
ISBN： 4890445625
電子書籍版： 2004-08-09 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

9,900 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,950 円(税込)

購入する

商品紹介

本書は、学生から第一線の研究者までを読者対象にして、基礎から最新情報までを含むサイトカイン・ケモカインの現況をなるべくわかりやすく、なるべく全分野にわたって解説したものである。第三版改訂版。

目次

  • サイトカイン・ケモカインのすべて　第3版改訂新版

    ―目次―

    オーバービュー
    新しいサイトカイン
    主なサイトカイン
    ケモカイン受容体とそれらのリガンド
    サイトカインの細胞内情報伝達機構
    神経：内分泌・免疫相関
    生体内での主な役割
    サイトカインの臨床応用

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

オーバービュー

P.17 掲載の参考文献
1) Maini R, St Clair EW, Breedveld F et al.:Infliximab (chimeric antitumour necrosis factoramonoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:a randornised phase III trial. Lancet 354:1932-1939, 1999.
PubMed
2) Weinblatt ME, Kremer JM, Bankhurst AD et al.:A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340:253-259, 1999.
PubMed
3) 西本憲弘, 吉崎和幸, 嶋 良仁・他:ヒト型抗IL-6 受容体抗体を用いたミエローマ, キャッスルマン病, 慢性関節リウマチの治療. 治療学 30:66-69, 1996.
 
4) Adams MD, Kelley JM, Gaocayne JD et al.:Complementary DNA sequencing:Expressed sequence tags and human genome project. Science 252:1651-1656, 1991.
 
5) Kasakura S, Lowenstein L:A factor stimulating DNA synthesis derived from the medium of leucocyte cultures. Nature 208:794-795, 1965.
PubMed
6) Oppenheim JJ:Cytokines:past, present, and future. Int. J. Hematol. 74:3-8, 2001.
PubMed
7) Smith KA:T-cell growth factor. Immunol. Rev. 51:337-357, 1980.
PubMed
8) Waksmann BH:Lymphokine research:a historical overview. Lymphokine Reports 1:1-6, 1980.
 
9) David JR:Delayed hypersensitivity in vitro:its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. USA 56:73-77, 1996.
 
10) Bloom BR, Bennett B:Mechanism of reaction in vitro associated with delayed-type hypersensitivity. Science 153:80-82, 1966.
PubMed
11) Ruddle NH, Waksmann BH:Cytotoxic effect of lymphocyte-antigen interaction in delayed hypersensitivity. Science 157:1060-1062, 1967.
 
12) Granger GA, Williams TW:Lymphocyte cytotoxicity in vitro:activation and release of a cytotoxic factor. Nature 218:1253-1254, 1968.
PubMed
13) Kasakura S, Lowenstein L:DNA and RNA synthesis and the formation of blastogenic factor in mixed leukocyte cultures. Nature 215:80-81, 1967.
PubMed
14) Kasakura S:Heterogeneity of blastogenic factors produced in vitro by antigenically stimulated and unstimulated leukocytes. J. Immunol. 105:1162-1167, 1970.
PubMed
15) Cohen S, Bigazzi PE, Yoshida T:Similarities of T cell function in cell-mediated immunity and antibody production. Cell. Immunol 12:150-159, 1974.
PubMed
16) Aarden LA, Brunner TK, Cerotiui DP et al.:Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors. J. Immunol. 123:2928-2929, 1979.
 
17) Taniguchi T, Ohrlo S, Fujii-Kuriyama Y et al.:The nucleotide sequence of human fibroblast interferon cDNA. Gene 10:11-15, 1980.
 
18) Nagata S, Taira H, Hall A et al.:Synthesis in E. coti of apolypeptide with human leukocyte interferon activity. Nature 284:316-320, 1980.
 
19) Leonard WJ, Depper JM, Crabtree GR et al.:Molecular cloning and expression of cDNAs for the human interleukin-2 receptor, Nature 311:626-631, 1984.
PubMed
20) Yoshimura T, Matsushima K, Tanaka S et al.:Purification of fuman monocyte-derived neutrophil chemotactic factor that shares sequence homology with other host defense cytokines. Proc. Natl. Acad. Sci. USA 84:9233-9237, 1987.
 
21) Matsushima K, Morishita K, Yoshimura T et al.:Molecular cloning of cDNA for a human monocyte derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J. Exp. Med. 167:1883-1893, 1988.
PubMed
22) Larsen CG, Anderson AO, Appella E et al.:Identify of chemotactic cytokine for T-lyrnphocytes with neutrophil activating protein (NAP-1):a candidate interleukin 8. Science 243:1464-1466, 1989.
 
23) Oppenheim JJ, Gery I:Interleukin 1 is more than an interleukin. Immunol. Today 3:113-119, 1982.
PubMed
24) Baza JF:Structural design and molecular evolution of acytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 87:6934-6938, 1990.
 
25) Disanto Jp, Dautry-Varsat A, Ceitain S et al.:Interleukin 2 (IL-2) receptorγ-chain mutations in X-linked severe combined immunodeficiency disease result in the loss of high-affinity IL-2 receptor binding. Eur. J. Immunol. 24:475-479, 1994.
 
26) Taga T, Kishimoto T:GP130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15:797-819, 1997.
PubMed
27) Miyajima A, Kitamura T, Harada N et al.:Cytokine receptors and signal transduction Annu. Rev. Immunol. 10:1880-1883, 1992.
 
28) Smith CA:The TNF receptor superfamily of cellular and viral proteins:activation, costimulation and death. Cell 76:959-962, 1994.
PubMed
29) Leonard WJ, O'Shea JJ:Jaks and STATs:Biological implications. Annu. Rev. Immunol. 13:369-398, 1995.
 
30) Durbin JE, Hackenmiller R, Simon MC et al.:Targeted disruption of the mouse Stat 1 gene results in compromised innate immunity to viral desease. Cell 84:443-450, 1996.
 
31) Thierfelder WE, van Deursen JM, Yamamoto K et al.:Requirement for Stat 4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382:171-174, 1996.
 
32) Shimoda K, van Deursen JM, Sangster MY et al.:Lack of IL-4 induced Th2 response and IgE class switching in mice with disrupted Stat 6 gene. Nature 380:630-633, 1996.
 
33) Endo A, Masuhara M, Yokouchi M et al.:A new protein containing a SH2 domain that inhibits JAK kinases. Nature 387:921-924, 1997.
 
34) Yoshimura A, Ohkubo T, Kiguchi T et al.:A novel cytokine-inducible gene CIS encodes an SH2 containing Protein that binds to tyrosine phosphorylated interleukin 3 and erythropoietin. EMBO J. 14:2816-2826, 1995.
PubMed
35) Yasukawa H, Sasaki A, Yoshimura A:Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 18:143-164, 2000.
PubMed
36) Sakamoto H, Yasukawa H, Masuhara M et al.:A Janus kinase inhibitor, JAB, is an interferon-γ inducible gene and confers resistance to interferons. Blood 92:1668-1676, 1998.
 
37) Savino W, Dardenne M:Immune-neuroendocrine interactions. Immunol. Today 16:318-327, 1995.
PubMed
38) Besedovsky H, Del Rey A, Sorkn E, Dinarelio CA:Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 233:652-654, 1986.
 
39) Weinstock JV, Elliott D:The substance P and somatostatin interferon-γ immunoregulatory circuit. Ann. N Y Acad. Sci. 840:532-539, 1998.
 
40) Delgado M, Ganea D:Cutting edge:Is vasoactive intestinal peptide a type 2 cytokine? J. Immunol. 166:2907-2912, 2001.
PubMed
41) Kincy-Cain T, Bost KL:Substance P-induced IL-12 production by murine macrophages. J. Immunol. 158:2334-2339, 1997.
PubMed
42) Kawamura N, Tamura H, Obana S et al.:Differential effects of neuropeptides on cytokine production by mouse helper T cell subsets. Neuroimmunomodulation 5:9-15, 1998.
PubMed
43) Street NE, Mosmann TR:Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J. 5:171-177, 1991.
PubMed
44) Okamura H, Tsutsui H, Komatsu T et al.:Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378:88-91, 1995.
 
45) Nakanishi K, Yoshimoto T, Tsutsui H et al.:Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol l9:423-474, 2001.
 
46) Akira S:Toll-like receptors and innate immunity. Adv. Immunol. 78:1-56, 2001.
PubMed
47) Medzhitov R, Janeway C:Innate immune recognition:mechanisms and pathways. Immunol. Rev, 173:89-97, 2000.
PubMed
48) Agrawal S, Agrawal A, Doughty B et al.:Cutting edge:Different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extra cellular signal regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 171:4984-4989, 2003.
 
49) Dillon S, Agrawal A, Van Dyke T et al.:A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J. Immunol. 174:4733-4743, 2004.
 
50) Seder RA, Paul WE:Acquisition of lymphokineproducing phenotype by CD4 T cells. Annu. Rev. Immunol. 12:635-673, 1994.
PubMed
51) Pflanz S, Timans JC, Cheung J et al.:IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naTve CD4+Tcells. Immunity 16:779-790, 2002.
 
52) Yoshimoto T, Paul WE:Role of NK11+ T cells in a TH2 response and in immunoglobulin E production. Science 270:1845-1847, 1995.
 
53) Ogasawara K, Takeda K, Hashimoto W et al.:Involvement of NK1+ T cells and their IFN-γ production in the generalyzed Schwartzman reaction. J. Immunol. 160:3522-3527, 1998.
 
54) Glimcher LH, Murphy KM:Lineage commitment in the immune system:the T helper lymphocyte grows up. Gene & Development l4:1693-1711, 2000.
 
55) Szabo SJ, Sullivan BM, Stemmann C et al.:Distinct effects of T-bet in Th1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. Science 295:338-342, 2000,
 
56) Piccinni MP, Gudizi MG, Biagiotti R et al.:Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and mernbrane CD30 expression in established Th1 cell clones. J. Immunol. 155:128-133, 1995.
 
57) Liva SM, Voskull RR:Testosterone acts directly on CD4 T lymphocytes to increase IL-10 production. J. Immunol. 167:2060-2067, 2001.
 
58) Ito A, Bebo BF, Matejak A et al.:Estrogen treatment down-regulate TNF-aproduction and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J. Immunol. 167:542-552, 2001.
 
59) Katamura K, Shintaku N, Yamauchi Y et al.:Prostaglandin E2 at priming of naTve CD4+Tcells inhibits acquisition of ability to produce IFN-γ and IL-12, but not IL-5 and IL-4. J. Immunol. 155:4604-4612, 1995.
 
60) Bonecchi R, Branchi G, Bordignon RR et al.:Differential expression of chemokine receptors and chemotactic responses of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187:129-134, 1998.
 
61) Monney L, Sabatos CA, Gaglia JL et al.:Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415:536-541, 2002.
PubMed
62) Lohning M, Stroehmann A, Coyle AJ et al.:T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl. Acad. Sci. USA 95:6930-6935, 1998.
PubMed
63) Meyers JH, Ryu A, Monney L et al.:Cutting edge:CD94/NKG2 is expressed on Th1 but not Th2 cells and costimulates Th1 effector functions. J. Immunol. 169:5382-5386, 2002.
 
64) Reiner S, Locksley RM:The regulation of immunity to Leichmania major. Annu. Rev. Immunol. 13:151-177, 1995.
PubMed
65) Karp CL, El-Safi SH, Wynn TA et al.:In vivo cytokine profile in patients with Kala-azar:Marked elevation of both interleukin-10 and interferongamma. J. Clin. Invest. 91:1644-1648, 1993.
PubMed
66) Barnes PF, Lu S, Abrams JS et al.:Cytokine production at the site of disease in human tuberculosis. Infect. Immun. 61:3482-3486, 1993.
PubMed
67) Liblau RS, Singer SM, McDevitt HO:Th1 and Th2 CD4 T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 16:34-38, 1995.
PubMed
68) Liblau RS, Singer SM, McDevitt HO:Th1 and Th2 CD4 T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 16:34-38, 1995.
PubMed
69) Ottenhoff TH M, Kumararatne D, Casanova JL:Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Immunol. Today 19:491-494, 1998.
 
70) de Jong R, Altare F, Haagen IA et al.:Severe Mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280:1435-1438, 1998.
PubMed
71) Jiang H, Lin JJ, Su Z et al.:Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogenes 11:2477-2486, 1995.
 
P.25 掲載の参考文献
1) Yoshimura T, Matsushima K, Tanaka S et al.:Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc. Natl. Acad. Sci. USA 84:9233-9237, 1987.
 
2) Matsushima K, Morishita K, Yoshimura T et al.:Molecular cloning of a human monocyte-derived neutrophil chemotactic factors (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J. Exp. Med. 167:1883-1893, 1988.
PubMed
3) Yoshimura T, Robinson EA, Tanaka S et al.:Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J. Exp. Med. 169:1449-1459, 1989.
PubMed
4) Matsushima K, Larsen CG, DuBois GC et al.:Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J. Exp. Med. 169:1485-1490, 1989.
PubMed
5) Harada A, Sekido N, Kuno K et al.:Expression of recombinant rabbit IL-8 in Escherichia coli and establishment of the essential involvement of IL-8 in recruiting neutrophiIs into lipopolysaccharide-induced inflammatory site of rabbit skin. Int. Immunol. 5:681-690, 1993.
 
6) Akahoshi T, Endo H, Kondo H:Essential involvement of interleukin-8 in neutrophil recruitment in rabbits with acute experimental arthritis induced by lipopolysaccharide and interleukin-1. Lymphokine Cytokine Res. 13:113-116, 1994.
PubMed
7) Wada T, Tomosugi N, Naito T et al.:Prevention of proteinuria by the administration of anti-interleukin 8 antibody in experimental acute immune complex-induced glomerulonephritis. J. Exp. Med. 180:1135-1140, 1994.
PubMed
8) Sekido N, Mukaida N, Harada A et al.:Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 365:654-657, 1993.
PubMed
9) Yokoi K, Mukaida N, Harada A et al.:Prevention of endotoxemia-induced acute respiratory distress syndrome-like lung injury in rabbits by a monoclonal antibody to IL-8. Lab. Invest. 76:375-384, 1997.
PubMed
10) Matsumoto T, Ikeda K, Mukaida N et al.:Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin-8. Lab. Invest. 77:119-125, 1997
PubMed
11) Larsen CG, Thomsen MK, Gesser B et al.:The delayed-type hypersensitivity reaction is dependent on IL-8. Inhibition of a tuberculin skin reaction by an anti-IL-8 monoclonal antibody. J. Immunol 155:2151-2157, 1995.
PubMed
12) Wada T, Yokoyama H, Furuichi K et al.:Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1) . FASEB J. 10:1418-1425, 1996.
PubMed
13) Furukawa Y, Matsumori A, Ohashi N et al.:Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ. Res. 84:306-314, 1999.
PubMed
14) Kimura H, Kasahara Y, Kurosu K et al.:Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab. Invest. 78:571-581, 1998.
PubMed
15) Boring L, Gosling J, Cleary M et al.:Decreased lesion formation in CCR2-/-mice reveaIs a role for chemokine in the initiation of atherosclerosis. Nature 394:894-897, 1998.
PubMed
16) Gu L, Okada Y, Clinton SK et al.:Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. 2:275-281, 1998.
PubMed
17) Libby P:Inflammation in atherosclerosis. Nature 420:868-874, 2002.
PubMed
18) Chen XS, Sheller JR, Johnson EN et al.:Role of leukotriens revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372:179-182, 1994.
PubMed
19) Hopken UE, Lu B, Gerard NP et al.:The C5a chemoattractant receptor mediates mucosal defense to infection. Nature 383:86-89, 1996.
PubMed
20) Murphy PM, Tiffany HL:Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 253:1280-1283, 1991.
 
21) Holmes WE, Lee J, Kuang WJ et al.:Structure and functional expression of a human interleukin-8 receptor. Science 253:1278-1280, 1991.
 
22) Imai T, Yoshida T, Baba M et al.:Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector. J. Biol. Chem. 271:21514-21521, 1996.
PubMed
23) Bazan JF, Bacon KB, Hardiman G et al.:A new class of membrane-bound chemokine with a CX3C motif, Nature 385:640-644, 1997.
PubMed
24) Foster R, Mattis EA, Kremmer E et al.:A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87:1037-1047, 1996.
 
25) Nakano H, Mori S, Yonekawa H, Nariuchi H et al.:A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on mouse chromosome 4. Blood gl:2886-2895, 1998.
 
26) Gunn MD, Kyuwa S, Tam C et al.:Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189:451-460, 1999.
PubMed
27) Nagasawa T, Hirota S, Tachibana K et al.:Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382:635-638, 1996.
PubMed
28) Tachibana K, Hirota S, Iizasa H et al.:The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393:591-594, 1998.
PubMed
29) Imai T, Nagira M, Takagi S et al.:Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int. Immunol. 11:81-88, 1999.
 
30) Yoneyama H, Harada A, Imai T et al.:Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice. J. Clin. Invest. 102:1933-1941, 1998.
PubMed
31) Yoneyama H, Matsuno K, Zhang Y et al.:Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease. J. Exp. Med. 193:35-49, 2001.
 
32) Yoneyama H et al.:Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J. Exp. Med. 195:1257-1266, 2002.
PubMed
33) Kawasaki S, Takizawa H, Yoneyama H et al.:Intervention of TARC attenuates the development of allergy airway inflammation and hyperresporIsiveness in mice. J. Immunol. 166:2055-2062, 2001.
PubMed
34) Vestergaard C, Yoneyama H, Murai M et al.:Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J. Clin. Invest. 104:1097-1105, 1999.
PubMed
35) Ishikawa S, Sato T, Abe M et al.:Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by CDIIb+CDIIc+dendritic cells in murine lupus and preferential chemotaxis of BI cells toward BLC, J. Exp. Med. 193:1393-1402, 2001.
 
36) Onai N, Kitabatake M, Zhang YY et al.:Pivotal role of CCL25 (TECK)-CCR9 in the formation of gut cryptopatches and consequent appearance of intestinal intraepithelial T lymphocytes. Int. Immunol. 14:687-694, 2002.
PubMed
37) Murai M, Yoneyama H, Ezaki T et al.:Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat. Immunol. 4:154-160, 2003.
PubMed
38) Feng Y, Broder CC, Kennedy PE et al.:HIV-1 entry cofactor:functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877, 1996.
 
39) Stantchev TS, Broder CC:Human immunodeficiency virus type-1 and chemokines:beyond competition for common cellular receptors. Cytokine Growth Factor Rev. 12:219-243, 2001.
PubMed
40) Belperio JA, Keane MP, Arenberg DA et al.:CXC chemokines in angiogenesis. J. Leukoc. Biol. 68:1-8, 2000.
PubMed
41) Muller A, Homey B, Soto H et al.:Involvement of chernokine receptors in breast cancer metastasis. Nature 410:50-56, 2001.
PubMed
42) Staller P, Sulitkova J, Lisztwan J et al.:Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425:307-311, 2003.
 
43) Ueno T, Toi M, Saji H et al.:Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6:3282-3289, 2000.
PubMed
44) Usui M, Egashira K, Tomita H et al.:Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 101:305-310, 2000.
PubMed
45) Szabo I, Chen XH, Xin L et al.:Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc. Natl. Acad. Sci. USA 99:10276-10281, 2002.
PubMed

新しいサイトカイン

P.39 掲載の参考文献
1) Adams MD, Kelley JM, Gocayne JD et al.:Complementary DNA sequencing:Expressed sequence tags and human genome project. Science 252:1651-1656, 1991.
PubMed
2) Kim JM, Brannan CI, Copeland NG et al.:Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J. Immunol l42:3618-3623, 1992.
 
3) Kotenko S, Krause CD, Izotova LS et al.:Identification and functional characterization of a second chain of the interleukin-10 receptor complexes. EMBO J. 16:5894-5903, 1997.
PubMed
4) Gallagher G, Dickensheets H, Eskdale J et al.:Cloning, characterization and expression of interleukin-19 (IL-19) , anovel homologue of human interleukin-10 (IL-10) . Immunol. Lett. 73:208, 2000.
 
5) Blumberb H, Conklin D, Xu W et al.:Interleukin 20:Discovery, receptor identification, and role in epidermal function. Cell 104:9-19, 2001.
 
6) Dumoutier L, Louahed J, Renauld JC:Cloning and characterization of IL-10-related T cell-derived inducible factor(IL-TIF) , anovel cytokine structurally related to IL-10 and inducible by IL-9. J. Immunol. 164:1814-1819, 2000.
 
7) Jiang H, Lin JJ, Su ZZ et al.:Subtractive hybridization identifies a novel melanoma differentiation associated gene, MDA-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11:2477-2486, 1995,
 
8) Knappe A, Hor S, Wittmann S et al.:Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpes saimin. J. Virol 74:3881-3887, 2000.
 
9) Bazan JF:Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 87:6934-6938, 1990.
PubMed
10) Kotenko SV, Pestka S:Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19:2557-2565, 2000.
 
11) Weber-Nordt RM, Riley JK, Greenlund AC et al.:STAT3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 271:27954-27961, 1996.
PubMed
12) Kotenko S, Krause CD, Izotova LS et al.:Identification and functional characterization of a second chain of the interleukin-10 receptor complexes. EMBO J. 161:5894-5903, 1997.
 
13) Parrish-Novak J, Xu W, Brender T et al.:Interleukin 19, 20, and 24 signal through two distinct receptor complexes. J. Biol Chem. 49:47517-47523, 2002.
 
14) Su Z, Madireddi MT, Lin JJ et al.:The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc. Natl. Acad. Sci. USA 95:14400-14405, 1998.
PubMed
15) Mhashilkar AM, Schrock RD, Hinde M et al.:Melanoma differentiation associated gene-7 (mda-7):anovel anti-tumor gene for cancer gene therapy. Mol. Med. 7:271-282, 2001.
 
16) Liao YC, Liang WG, Chen FW et al.:IL-19 induces production of IL-6 and TNF-a and results in cell apoptosis through TNF-a. J. Immunol. 169:4288-4297, 2002.
 
17) Kotenko SV Izotova LS, Mirochnitchenko OV et al.:Identification of the functional interleukin-22 (IL-22) receptor complex:the IL-10R2 chain (IL-10Rβ) is a common chain of both IL-10 and IL-22 {IL-10-related T cell-derived inducible factor (IL-TIF)} receptor complexes. J. Biol. Chem. 276:2725-2729, 2001.
 
18) Xie MH, Aggarwal S, Ho WH et al.:Interleukin (IL)-22, anovel human cytokine that signaIs through the interferon receptor-related proteins CRF2-4 and IL-22R. J. Biol. Chem. 275:31335-31339, 2000.
 
19) Pittman DD, Goad B, Lambert AJ et al.:IL-22 is tightly regulated IL-10-like molecules that induces an acute-phase response and renal tubular basophilia. Genes Immun. 2:172, 2000.
 
20) Chang C, Magracheva E, Kozlov S et al.:Crystal structure of interleukin-19 defines a new subfamily of helical cytokines, J. Biol Chem. 278:3308-3313, 2003.
 
21) Wolk K, Kunz S, Asadullah K et al.:Cutting edge:immune cells as sources and targets of the IL-10 family members? J. Immunol 168:5397-5402, 2002.
PubMed
22) Michel G, Mirmohammadsadegh A, Olasz E et al.:Demonstration and functional analysis of IL-10 receptors in human epidermal cells:decreased expression in psoriatic skin, down-modulation by IL-8, and upregulation by an antipsoriatic glucocorticoid in normal cultured keratinocytes. J. Immunol, 159:6291-6297, 1997.
PubMed
23) Asadullar K, Sterry W, Stephanek K et al.:IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy:a new therapeutic approach. J. Clin. Invest. 101:783-794, 1998.
 
24) Lejeune C, Dumoutie L, Constinescu S et al.:Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. J. Biol. Chem. 277:33676-33682, 2002.
 
25) Dumoutier L, Lejeune D, Colau D et al.:Cloning and characterizatiorl of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J. Immunol. 166:7090-7095, 2001.
PubMed
26) Kotenko SV, Izotova LS, Mirochnitchenko OV et al.:Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J. Immunol. 166:7096-7103, 2001.
PubMed
27) Aggarwal S, Xie MH, Maruoka M et al.:Acinar cells of the pancreas are a target of interleukin-22. J. Interferon and Cytokine Res. 21:1047-1053, 2001.
PubMed
28) Lecart S, Morel F, Noraz N et al.:IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. Int. Immunol. 14:1351-1356, 2002,
PubMed
29) Wang M, Tan Z, Zhang R et al.:Interleukin-24 (MDA-7/MOB-5) signaIs through two heterodimeric receptors. IL-22R1/IL-20R2 arld IL-20R1/IL-20R2. J. Biol. Chem. 277:7341-7347, 2002.
 
30) Caudell EG, Mumm JB, Poindexter N et al.:Theprotein product of the tumor suppressor gene, melanoma differentiation-associated gene-7, exhibits immunostimulatory activity and is designated IL-24. J. Immunol 168:6041-6046, 2000.
 
31) Chaiken IM, Williams WV:Identifying structure-function relationships in four-helix bundle cytokines:towards de novo mimetics design. Trends Biotechnol. 14:369-375, 1996.
PubMed
32) Huang EY, Madireddi MT, Gopalkrishnan RV et al.:Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing Properties. Oncogene 20:7051-7063, 2001.
PubMed
33) Garn H, Schmidt A, Grau V et al.:IL-24 is expressed by rat and human macrophages. ImmunoBiol. 205:321-334, 2002.
 
34) Soo C, Shaw WW, Freymiller E et al.:Cutaneous rat wounds express c49a, a novel gene with homology to the human melanoma differentiation associated gene, mda-7. J. Cell. Biochem. 74:1-10, 1999.
 
35) Ekmekcioglu S, Ellerhorst J, Mhashilkar AM et al.:Down-regulated melanoma differentiation associated gene (mda-7) expression in human melarlomas. Int. J. Cancer 94:4-59, 2001.
 
36) Saeki T, Mhashikar A, Chada S et al.:Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. Gene Ther. 7:2051-2057, 2000.
 
37) Sarkar D, Su Z, Lebedeva IV et al.:mda-7/IL-24 mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38MxPK. Proc. Natl. Acad. Sci. USA 99:10054-10059, 2002.
PubMed
38) Pataer A, Vorburger SA, Barber GN et al.:Adenoviral transfer of the melanoma differentiation-associated gerle-7 (mda-7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR) . Cancer Res. 62:2239-2243, 2002.
 
39) Sheikh F, Baurin W, Lewis-Antes A et al.:Cutting edge:IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. J. Immunol. 172(4):2006-2010, 2004.
 
P.50 掲載の参考文献
1) Sheppard P, Kindsvogel W, Xu W et al.:IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4:63-68, 2003.
PubMed
2) 石田 博:インターロイキン23, 22. 臨床免疫 38:420-426, 2002.
 
3) Altschul SF, Gish W, Miller W et al.:Basic localalignment search tool. J. Mol. Biol. 215:403-410, 1990
 
4) Novick D, Cohen B, Rubinstein M:The human interferona/B;characterization and molecular cloning. Cell 77:391-400, 1994.
 
5) Hubbard T, Barker D, Birney E et al.:The Ensemblgenome database project. Nucleic Acids Res. 30:38-41, 2002.
PubMed
6) Bazan JF:Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci, USA 87:6934-6938, 1990.
PubMed
7) Kotenko SV, Izotova IS, Mirochnitchenko OV et al.:Identification, cloning, and characterization of asoluble receptor binds IL-22 and neutralizes itsactivity. J. Immunol. 166:7096-7103, 2001.
 
8) Dumoutier L, Lejeune D, Colau D et al.:Cloning andcharacterization of IL-22 binding protein, a natural antagonist of IL-10 related T cell-derived inducible factor/IL-22. J. Immunol. 166:7090-7095, 2001.
 
9) Xu W, Presnell SR, Parrish-Novak J et al.:Asolubleclass II cytokine receptor, IL-22RA2, is a natural lyoccurring IL-22 antagonist. Proc. Natl. Acad. Sci. USA 98:9511-9516. 2001.
PubMed
10) Kotenko SV, Izotova IS, Mirochnitchenko OV et al.:Identification of the functional interleukin-22 (IL-22) receptor complex. J. Biol. Chem. 276:2725-2732, 2001.
PubMed
11) Kotenko SV, Krause CD, Izotova LS et al.:Identification and functional characterization of asecond chain of the interleukin-10 receptor complex. EMBO J. 16:5894-5903, 1997.
 
12) Nishio R, Matsumori A, Shioi T et al.:Treatment of experimental viral myocarditis with interleukin-10. Circulation 100:1102-1108, 1999.
PubMed
13) Dumoutier L, Louahead J, Renauld J-C:Cloning andcharacterization of IL-10-related T cell-derivedinducible factor (IL-TIF) , anovel cytokine structurallyrelated to IL-10 and inducible by IL-9. J. Immunol. 164:1814-1819, 2002.
 
14) 石田 博:IL-10と自己免疫疾患. 治療学 36:1279- 1282, 2002.
 
15) 石田 博:IL-28, IL-29, IFN-λ. 臨床免疫 40:431-441, 2003.
 
16) 石田 博:サイトカインネットワーク. Immunol. Front. 1:16-24, 1991.
 
P.60 掲載の参考文献
1) Wolf SF, Temple PA, Kobayashi M et al.:Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple Biologic effects on T and natural killer cells. J. Immunol. 1450:3074-3081, 1991.
 
2) Presky DH, Yang H, Minette LJ et al.:A functional interleukin-12 receptor complex is composed of two B-type cytokine receptor subunits. Proc. Natl. Acad. Sci. USA 93:14002-14007, 1996.
 
3) Szabo SJ, Dighe AS, Gubler U et al.:Regulation of the interleukin (IL)-12R B2-subunit expression in developing T helper 1 (Th1) and Th2 cells. J. Exp. Med. 185:817-824, 1997.
 
4) Bacon CM, McVier DW, Ortaldo JR et al.:Interleukin 12 (IL-12) induces tyrosine phosphory-lation of JAK2 and TYK2:differential use of Janus family tyrosine kinases by IL-2 and IL-12. J. Exp. Med. 181:399-404, 1995.
 
5) Naeger LK, Mckinmey J, Salvekar A et al.:Identification of a STAT4 binding site in the interleukin-12 receptor required for signaling. J. Biol Chem. 274:1875-1878, 1999.
PubMed
6) Theirfelder WE, van Duersen JM, Yamamoto K et al.:Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382:171-174, 1996.
 
7) Hsieh CS, Macatonia SE, Tripp CS et al.:Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547-549, 1993.
 
8) Oppmann B, Lesley R, Blom B et al.:Novel p19 protein engages IL-12 p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715-725, 2000.
 
9) Devergne Q, Hudak SA, Lesley RE et al.:A novel interleukin-12p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J. Viol. 70:1143-1153, 1996.
 
10) Pflanz S, Timans JC, Cheung J et al.:IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4 T cells. Immunity 16:779-790, 2002.
PubMed
11) Praham C, Chirica M, Timans J et al.:A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R B l and a novel cytokine receptor subnit, IL-23R. J. Immunol. 168:5699-5708, 2002.
 
12) Cleary AM, Tu W, Enright A et al.:Impaired accumulation and function of memory CD4 T cells in human IL-12 receptor B l deficiency. J. Immunol 170:597-603, 2003.
 
13) Lankford CR, Frucht DM:A unique role for IL-23 in promoting cellular immunity. J. Leukoc. Biol. 73:49-56, 2003.
 
14) HoIscher C, Atkinson RA, Arendse B et al.:A protective and agonistic function of IL-12p40 in mycobacterial infection. J. Immunol. 167:6957-6966, 2001.
 
15) Brombacher F, Dorfmuller A, Magram J et al.:IL-12 is dispensable for innate and adaptive immunity against low doses of Listeria monocytogenes. Int. Immunol. 11:325-332, 1999.
PubMed
16) Decken K, Kohler G, Palmer-Lehmann K et al.:Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect. Immun. 66:4994-5000, 1998.
PubMed
17) Cooper AM, Kipnis A, Turner J et al.:Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J. Immunol 168:1322-1327, 2002.
 
18) Ling P, Gately MK, Gubler U et al.:Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biological activity. J. Immunol. 154:116-127, 1995.
 
19) Gran B, Zhang GX, Yu S et al.:IL-12 p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis:Evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J. Immunol. 169:7104-7110, 2002.
 
20) Zharlg GX, Gran B, Yu S et al.:Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-B2-deficient mice:IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J. Immunol. 170:2153-2160, 2003.
 
21) Fossiez F, Banchereau J, Murray R et al.:Interleukin-17. Intern. Rev. Immunol. 16:541-551, 1998.
 
22) Starnes T, Robertson MJ, Sledge G et al.:IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J. Immunol. 167:4137-4140, 2001.
PubMed
23) Aggarwal S, Ghilardi N, Xie MH et al.:Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278:1910-1914, 2003.
PubMed
24) Kopp T, Lenz P, Bello-Fernandez C et al.:IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice:Evidence for enhanced cutaneous immunity. J. Immunol. 170:5438-5444, 2003.
PubMed
25) Wiekowski MT, Leach MW, Evans EW et al.:Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J. Immunol. 166:7653-7570, 2001.
 
26) Chen Q, Ghilardi N, Wang H et al.:Development of Th1-type immurle responses requires the type 1 cytokine receptor TCCR. Nature 407:916-920, 2000.
 
27) Yoshida H, Hamano S, Senaldi G et al.:WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 15:569-578, 2001.
 
28) Devergne Q, Birkenback M, Kieff E:Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc. Natl. Acad. Sci. USA 94:12041-12046, 1997.
 
29) Divergne Q, Coulomb-L'Hermine A, Capel F et al.:Expression of Epstein-Barr virus-induced gene 3, and interleukin-12 p40-related molecule, throughout human pregnancy. Am. J. Pathol. 159:1763-1776, 2001.
 
30) Nieuwenhuis EES, Neurath MF, Corazza N et al.:Disruption of T helper2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. Proc. Natl. Acad. Sci. USA 99:16951-16956, 2002.
 
31) Christ AD, Stevens AC, Koeppen H et al.:An interleukin 12-related cytokine is upregulated in ulcerative colitic but not in Crohn's disease. Gastroenterology 115:307-313, 1998.
 
32) Wegmann TG, Lin H, Guilbert G et al.:Bidirectional cytokine interactions in the maternofetal relationship:Successful allopregnancy is a Th2 phenomenon. Immunol. Today 14:353-355, 1993.
 
33) Pflanz S, Hibbert L, Mattson J et al.:WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 172.:2225-2231, 2004.
PubMed
34) Takeda A, Hamano S, Yamanaka A et al.:Cutting edge:Role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol 170:4886-4890, 2003.
PubMed
35) Szabo SJ, Kim ST, Costa GL et al.:A novel transcriptional factor, T-bet directs Th1 lineage commitment. Cell 100:655-669, 2000.
 
36) Mullen AC, High FA, Hutchins AS et al.:Role of Tbet in commitment of Th1 cells before IL-12-dependent selection. Science 292:1907-1910, 2001.
PubMed
37) Afkarian M, Sedy JR, Yang J et al.:T-bet is a STAT1-induced regulator of IL-12 R expression in naive CD4+T cells. Nat. Immunol. 3:549-557, 2002.
 
38) Rogge L, Barberis-Maino L, Biffi M et al.:Selectiv eexpression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. 185:825-831, 1997.
 
39) Villarino A, Hibbert L, Lieberman L et al.:The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19:645-655, 2003.
 
40) Hamano S, Himeno K, Miyazaki Y et al.:WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19:657-667, 2003.
 
41) van Seventer JM, Nagai T, van Seventer GA:Interferon-B differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells. J. NeuroImmunol. 133:60-71, 2002.
 
P.68 掲載の参考文献
1) Adams MD, Kelley JM, Gocayne JD et al.:Complementary DNA sequencing:Expressed sequence tags and human project. Science 252:1651-1656, 1991.
PubMed
2) Parrish-Novak J, Dillon SR, NeIson A et al.:Interleukin-21 and its receptor are involved in NK cells expansion and regulation of lymphocyte function. Nature 408:57-63, 2000.
 
3) Ozaki K, Kikly K, Michalovich D et al.:Cloning of a type I cytokine receptor most related to the IL-2 receptor B chain. Proc. Natl. Acad. Sci. USA 97:11439-11444, 2000.
 
4) Takeshita T, Asao H, Ohtani K et al.:Cloning of the γ chain of the human IL-2 receptor. Science 257:379-382, 1992.
 
5) Nakamura Y, Russell SM, Mess SA et al.:Heterodimerization of the IL-2 receptorB-and γ-chain cytoplasmic domains is required for signalling. Nature 369:330-333, 1994.
 
6) NeIson BH, Lord JD, Greenberg PD:Cytoplasmic domains of the interleukin-2 receptor B and γ chains mediate the signal for T-cell proliferation. Nature 369:333-336, 1994.
 
7) Noguchi M, Yi H, Rosenblatt HM et al.:Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73:147-157, 1993.
 
8) Kondo M, Takeshita T, Ishii N et al.:Sharing of the interleukin-2 (IL-2) receptor γ chain between for IL-2 and IL-4. Science 262:1874-1877, 1993.
 
9) Noguchi M, Nakamura Y, Russel SM et al.:Interleukin-2 receptor γ chain:a functional component of the interleukin-7 receptor. Science 262:1877-1880, 1993.
 
10) Kimura Y, Takeshita T, Kondo M et al.:Sharing of the IL-2 receptor γ chain with the functional IL-9 receptor complex. Int. Immunol. 7:115-120, 1995.
 
11) Giri JG, Ahdieh M, Eisenman J et al.:Utilization of the B and γ chains of IL-2 receptor by the novel cytokine IL-15. EMBO J. 13:2822-2830, 1994.
 
12) Russell SM, Johnston JA, Noguchi M et al.:Interaction of IL-2R B and γc chains with Jak1 and Jak3:imp1ications for XSCID and XCID. Science 266:1042-1045, 1994.
 
13) Asao H, Okuyama C, Kumaki S et al.:The common γ chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167:1-5, 2001.
 
14) Habib T, Senadheera S, Weinberg K et al.:The common γ chain (γc) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 41:8725-8731, 2002.
 
15) Wurster AL, Rodgers VL, Satoskar AR, et al.:Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon-γ-producing Th1 cells. J. Exp. Med. 196:969-977, 2002.
 
16) Mahta CS, Wurster AL, Whitters MJ et al.:IL-21 induces the apoptosis of resting and activated primary B cells. J. Immunol. 170:4111-4118, 2003.
 
17) Strengell M, Sareneve T, Foster D et al.:IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J. Immunol. 169:3600-3605, 2002.
PubMed
18) Adachi O, Kawai T, Takeda K et al.:Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 9:143-150, 1998.
PubMed
19) Szabo SJ, Dighe AS, Gubler U et al.:Regulation of the interleukin (IL)-12R B 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J. Exp. Med. 185:817-824, 1997.
 
20) Szabo SJ, Kim ST, Costa GL et al.:A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:655-669, 2000.
 
21) Strengell M, Matikainen S, Siren J et al.:IL-21 in synergy with IL-15 or IL-18 enhances IFN γ production in human NK and T cells. J. Immunol 170:5464-5469, 2003.
 
22) Barbulescu K, Becker C, Schalaak JF et al.:IL-12 and IL-18 differentially regulates the transcriptional activity of the human IFN-γ promoter in primary CD4+T lymphocytes. J. Immunol. 160:3642-3647, 1998
 
23) Yoshimoto T, Tsutsui H, Tominaga K et al.:IL-18, although antiallergic when administered with IL-2, stimulates IL-4 and histamine release by basophiIs. Proc. Natl. Acad. Sic. USA 96:13962-13966, 1999.
 
24) Kawai T, Adachi O, Ogawa T et al.:Unresponsiveness of MyD88-dificient mice to endotoxin. Immunity 11:115-122, 1999.
 
25) Ugai S, Shimozato Q, Yu L et al.:Transduction of the IL-21 and IL-23 genes in human pancreatic carcinome cell's produces natural killer cell dependent and-independent antitumor effects. Cancer Gene Ther. 10:771-778, 2003.
 
26) Kishida T, Asada H, Itokawa Y et al.:Interleukin (IL)-21 and IL-15 genetic transfer synergistically augements therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol. Ther. 4:552-558, 2003.
PubMed
27) Li H, Chen J, Huang A et al.:Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc. Natl. Acad. Sci. USA 97:773-778, 2000.
 
28) Pan G, French DW, Mao W et al.:Forced expression of murine IL-17E induces growth retardation, jaundice, a Th-2-biased response, and multiorgan inflammation in mice. J. Immunol. 167:6559-6567, 2001.
 
29) Starnes T, Robertson MJ, Sledge G et al.:IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J. Immunol. 167:4137-4140, 2001.
PubMed
30) Fort M M, Cheung J, Yen D et al.:IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15:985-995, 2001.
PubMed
31) Yao Z, Fanslow WC, Seldin MF et al.:Human IL-17, a novel cytokine derived from T cells. J. Immunol 155:5483-5486, 1995.
 
32) Hurst SC, Muchamuel T, Gorman DM et al.:New IL-17 family members promote Th1 or Th2 responses in the lung:in vivo function of the novel cytokine IL-25. J. Immunol. 169:443-453, 2002.
PubMed
33) Aarvak T, Chabaud M, Miossec P et al.:IL-17 is produced by proinflammatory Th/1Th0 cells but not by Th2 cells. J. Immunol. 162:1246-1251, 1999.
 
34) Fossiez F, Banchereau J, Murray R et al.:T-cell IL-17induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 184:2593-2603, 1996.
 
35) Javanovic DV, Di Battista JA, Martel-Pelletier J et al.:IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1 β and TNF-α, by human macrophages. J. Immunol. 160:3513-3521, 1998.
 
36) Chabaud M, Lubberts E, Joosten L et al.:IL-17 derived from juxtaarticular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 3:168-177, 2001.
PubMed
37) Linden A, Hoshino M, Laan M:Airway neutrophiIs and interleukin-17. Eur. Respir. J. 15:973-977, 2000.
 
P.78 掲載の参考文献
1) Montgomery RI, Warner MS, Lum BJ, Spear PG:Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87:427-436, 1996.
PubMed
2) Mauri DN, Ebner R, Montgomery RI, Kochel, KD, Cheung TC, Yu GL, Ruben S, Murphy M, Eisenberg RJ, Ware CF et al.:LIGHT, a new member of the TNF superfamily, and lymphotoxic a. are ligands for herpes virus entry mediator. Immunity 8:21-30, 1998.
 
3) Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS:A newly identified member of tumor necrosis factor receptor superfamily (TR6) supress LIGHT-mediated apoptosis. J. Biol. Chem. 274:13733-13736, 1999.
 
4) Crowe PD, VanArsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, Browning JL, Din WS, Goodwin RG, Smith CA:A lymphotoxin-beta-specific receptor. Science 264:707-710, 1994.
 
5) Marsters SA, Ayres TM, Skubatch, M, Gray CL, Rothe M, Ashkenazi A:Herpes virus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-κ Band AP-1. J. Biol. Chem. 272:14029-14032, 1997.
 
6) Zhai Y, Guo R, Hus TL, Yu GL, Ni J, Kwon BS, Jiang GW, Lu J, Tan J, Ugustus M et al.:LIGHT, a novel ligand for lymphotoxin B receptor and TR2/HVEM, induces apoptosis and suppresses ii vivo tumor formation via gene transfer. J. Clin. Invest. 102:1142-1151, 1998.
 
7) Granger SW, Butrovich KD, Houshmand P, Edwards WR, Ware CF:Genomic characterization of LIGHT reveaIs linkkage to an immune response locus on chromosome 19p13. 3 and distinct isoforms generated by alternate splicing or proteolysis. J. Immunol. 5122-5128, 2001.
PubMed
8) Tamada K, Shimozaki K, Chapoval AI, Zhu G, Sica G, Flies D, Boone T, Hsu II, Fu YX, Chen YL et al.:Moduration of T cell mediated immunity in tumor and graft-versus host disease modeIs through the LIGHT costimulatory pathway. Nat. Med. 6:283-289, 2000.
 
9) Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, Chen SF, Hsieh SL, Nagata S, Ni J, Chen L:LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogenic T cell response. J. Immunol. 164:4105-4110, 2000.
 
10) Morel Y, Schiano de Colella JM, Harrop J, Deen KC, Holmes SD, Wattam TA, Khandekar SS, Truneh A, Sweet RW, Gastaut JA, Olive D, Costello RT:Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells:LIGHT down-regulates its own receptor. J. Immunol. 165:4397-4404, 2000.
PubMed
11) Castellano R, Van Lint C, Peri V, Veithen E, Morel Y, Costello R, Olive D, Collette Y:Mechanisms regulating expression of the tumor necrosis factor-related light gene. Role of calcium-signaling pathway in the transcriptional control. J. Biol. Chem. 277:42841-42851, 2002.
PubMed
12) Wang J, Lo JC, Foster A, Yu P, Chen HM, Wang Y, Tamada K, Chen L, Ful YX:The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J. Clin. Invest. 108:1771-1780, 2001.
 
13) Shaikh RB, Santee S, Granger SW, Butrovich K, Cheung T, Kronenberg M, Cheroutre H, Ware CF:Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J. Immunol. 167:6330-6337, 2001.
 
14) Wang J, Chun T, Lo JC, Wu Q, Wang Y, Foster A, Tamada K, Chen L, Wang CR, Fu YX et al.:The critical role of LIGHT, a TNF family member, in T cell development. J. Immunol. 167:5099-5105, 2001.
 
15) Scheu S, Alferink J, Potzel T, Barchet W, Kalinke U, Pfeffer K:Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveaIs cooperation with lymphotoxin beta in mesenteric lymph node genesis. J. Exp. Med. 195:1613-1624, 2002.
 
16) Ye Q, Fraser CC, Gao W, Wang L, Busfield SJ, Wang C, Qiu Y, Coyle AJ, Gutierrez-Ramos JC, Hancock WW:Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J. Exp. Med. 195:795-800, 2002.
PubMed
17) Wang J, Foster A, Chin R, Yu P, Sun Y, Wang Y, Pfeffer K, Fu YX:The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function. Eur. J. Immunol. 32:1969-1979, 2002.
 
18) Tamada K, Tamura H, Flies D, Fu YX, Celis E, Pease LR, Blazar BR, Chen L:Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J. Clin. Invest. 109:549-557, 2002.
PubMed
19) Nakagawa M, Harigai M, Kawaguchi Y et al.:LIGHT, a co-stimulatory molecule for T cells, and its receptors are expressed in synovial tissue of rheumatoid arthritis patients and contribute to TNF-a and IL-12 production. Arthritis Rheum. 46:S558, 2002
 

主なサイトカイン

P.91 掲載の参考文献
1) Lomedico PT, Gubler V, Hellmann CP et al.:Cloning and expression of the interleukin-1 cDNA in Escherichia coli. Nature 312:458-467, 1984.
 
2) Kuida K, Lippke JA, Ku G et al.:Altered cytokine export and apoptosis in mice deficient interleukin-1-converting enzyme. Science 267:2000-2003, 1995.
PubMed
3) Gao W, Kumar S, Lotze MT et al.:Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J. Immunol. 170:107-113, 2003.
PubMed
4) Nakae S, Asano M, Horai R et al.:IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J. Immunol 167:90-97, 2001.
 
5) Okusawa S, Gelfand JA, Ikejima T et al.:Interleukin 1 induces a shock-like state in rabbits. J. Clin. Invest. 81:1162-1172, 1988.
 
6) Besedovsky H, Rey A, Sorkin E et al.:Immunoregulatory feedback between interleukin 1 and glucocorticoid hormones. Science 233:652-654, 1986.
PubMed
7) Daynes RA, Robertson BA, Cho B et al.:a-Melanocyte-stimulating hormone exhibits target cell selectivity in its capacity to affect interleukin 1-inducible responseso in vivo and in vitro. J. Immunol. 139:103-109, 1987.
 
8) Freidin M, Bemett MV, Kessler JA:Cultured sympathetic neurons synthesize and release the cytokine interleukin 1 beta. Proc. Natl. Acad. Sci. USA 89:10440-10443, 1992.
 
9) Szucs A, Stefano GB, Hughes TK et al.:Modulation of voltage-activated ion currents on identified neurons of Helix pomatia L. by interleukin 1. Cell. Mol. Neurobiol. 12:429-438, 1992.
PubMed
10) Griffin WS, Stanley LC, Ling C et al.:Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA 86:7611-7615, 1989.
PubMed
11) Onozaki K, Urawa H, Tamatani T et al.:Synergistic interactions of interleukin 1, interferon-B, and tumor necrosis factor in terminally differentiating a mouse myeloid leukemic cell line (M1) . J. Immmol 140:112-119, 1988.
 
12) Sims SE, Acress RB, Grubin CE et al.:Cloning of the interleukin 1 receptor from human T cells. Proc. Natl. Acad. Sci. USA 86:8946-8950, 1989.
 
13) McMahan CJ, Slack JL, Mosley B et al.:A novel IL-1 receptor, cloning from B cells by mammalian expression, is expressed in many cell types. EMBO J. 10:2821-2832, 1991.
 
14) Sims JE, Gayle MA, Slack JL et al.:Interleukin 1 signaling occurs exclusively via the type I receptor. Proc. Natl. Acad. Sci. USA 90:6155-6159, 1993.
PubMed
15) Greenfeder SA, Nunes P, Kwee L et al.:Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J. Biol Chem. 270:13757-13765, 1995.
PubMed
16) Cao Z, Henzel WJ, Gao X:IRAK:a kinase associated with the interleukin-1 receptor. Science 271:1128-1131, 1996.
 
17) Cao Z, Xiong J, Takeuchi M et al.:TRAF6 is a signal transducer for interleukin-1. Nature 383:443-446, 1996.
PubMed
18) Ninomiya-Tsuji J, Kishimoto K, Hiyama A et al.:The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398:252-256, 1999.
 
19) Eisenberg SP, Evans RJ, Arend WP et al.:Priming structure and functional expression from complementary DNA of a human interleukin 1 receptor antagonist. Nature 343:341-346, 1990.
 
20) Piguet PF, Vesin C, Gran GE et al.:Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleornycin or silica. Cytokine 5:57-61, 1993.
PubMed
21) Wakabayashi G, Gelfand JA, Burke JF et al.:A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 5:338-343, 1991.
PubMed
22) Fisher CJ, Dhainaut JF, Pribble Jp et al.:A phase III multicenter trial of human recombinant interleukin-1 receptor antagonist (IL-1ra) in the treatment of patients with septis syndrome. Lymphokine and Cytokine Res. 12:390, 1993.
 
23) Kary S, Burmester GR:Anakinra:the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int. J. Clin. Pract. 57:231-234, 2003.
PubMed
P.103 掲載の参考文献
1) Taniguchi T, Matsui H, Fujita T, Takaoka C et al.:Structure and expression of a cloned cDNA for human interleukin-2. Nature 302:305-310, 1983.
PubMed
2) Eckenberg R, Rose T, Moreau J-L, Weil R et al.:The first a helix of interleukin (IL)-2 folds as a homotetramer, acts as an agonist of the IL-2 receptor B chain, and induces lymphokine-activated killer cells. J. Exp. Med. 191:529-539, 2000.
 
3) Schorle H, Holtschke T, Huenig T, Schimp1 A, Horak I:Development and function of T cells in mice rendered interleukin 2 deficient by gene targeting. Nature 352:621-624, 1991.
 
4) Disanto JP, Dautry-Varsat A, Ceitain S, Fischer A et al.:Interleukin 2 (IL-2) receptor g chain mutations in X-linked severe combined immunodeficiency disease result in the loss of high-affinity IL-2 receptorbinding. Eur. J. Immunol. 24:475-479, 1994.
 
5) Kondo M, Takeshita T, Ishii N, Nakamura M, Watanabe S et al.:Sharing of the interleukin 2 (IL-2) receptor γ-chain between receptors for IL-2 and IL-4. Science 262:1874-1877, 1993.
 
6) Voss SD, Leary TP, Sondel PM, Robb RJ:Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor γ chain. Proc. Natl. Acad. Sci. USA 90:2428-2432, 1993.
 
7) Fluckiger AC, Garrone P, Durand I, Galizzi JP, Banchereau J:Interleukin 10 (IL-10) upregulate functional high affinity IL-2 receptor on normal and leukemic B lymphocyte. J. Exp. Med. 178:1473-1481, 1993.
PubMed
8) Schwarz EM, Salgame P, Bloom BR:Molecular regulation of human interleukin 2 and T-cell function by interleukin 4. Proc. Naatl. Acad. Sci. USA 90:7734-7738, 1993.
 
9) Gesbert F, Delespine-Carmagnat M, Bertoglio J:Recent advances in the understanding of interleukin-2 signal transduction. J. Clin. Immunol. 18:307-320, 1998.
PubMed
10) Taniguchi T:Cytokine signaling through nonreceptor protein tyrosine kinase. Science 268:251-255, 1995.
PubMed
11) Schwartz RH:T cell clonal anergy. Curr. Opin. Immunol 9:351-357, 1997.
PubMed
12) Shapiro VS, Mollenauer MN, Weiss A:Nuclear factor of activated T cells and AP-1 are insufficient for IL-2p romoter activation:requirement for CD28 up-regulation of RE/AP. J. Immunol. 161:6455-6458, 1998.
 
13) Khoshnan A, Kempiak SJ, Bennett BL, Bae D et al.:Primary human CD4+cells contain heterogeneous IκB kinase complexes:role in activation of the IL-2 promoter. J. Immunol. 163:5444-5452, 1999.
 
14) Kempiak SJ, Hiura TS, Nel AE:The jun kinase cascade is responsible for activating the CD28 response element of the IL-2 promoter:proof of cross-talk with the IκB kinase cascade. J. Immunol. 162:3176-3187, 1999.
 
15) Barz C, Naagel T, Truitt KE, Imboden JB:Mutational analysis of CD28-mediated costimulatin of jun-N-terminal kinase and IL-2 production. J. Immunol. 161:5366-5372, 1998.
PubMed
16) Thompson CB, Alison JP:The emerging role of CTLA4 as an immue attenuator. Immunity 7:445-450, 1997.
 
17) Watts TH, DeBenedette MA:T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11:286-293, 1999.
PubMed
18) Byrd VM, Ballard DW, Miller GG, Thomas JW:Fibroblast growth factor-1 (FGF-1) enhances IL-2 production and nuclear translocation of NF-κ B in FGF receptor-bearing jurkat T cells. J. Immunol. 162:5853-5859, 1999.
 
19) Boussiotis VA, Freemann GJ, Berezovskaya A, Barber DL et al.:Maintenance of human T cell anergy:blocking of IL-2 gene transcription by activated Rap1. Science 278:124-128, 1997.
 
20) Bonnard M, Haughn L, Julius M:CD4-mediated inhibition of IL-2 production in activated T cells. J. Immunol. 162:1252-1260, 1999.
PubMed
21) Zhang W, Sloan-Lancaster J, Kitchen J, Tribe RP, SamueIson LE:LAT, the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 92:83-92, 1998.
 
22) Deckert M, Taartare-Deckert S, Hermandez J, Rottapel R et al.:Adaptor fucntion fot the Syk kinases-interacting protein 3BP2 in IL-2 gene activation. Immunity 9:595-605, 1998.
 
23) Gringhuis SI, Leow A, Papendrecht-van der Voort EAM, Remans PHJ et al.:Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid T lymphocytes in rheumatoid arthritis. J. Immunol. 164:2170-2179, 2000.
 
24) Thomis DC, Aramburu J, Berg LJ:The Jak family tyrosine kinase Jak3 is required for IL-2 synthesis by native/resting CD4+T cells. J. Immunol. 163:5411-5417, 1999.
 
25) Murata Y, Yamashita A, Saito T, Sugamura K, Hamuro J:The conversion of intracellular redox status of peritoneal macrophages during pathological progression of spontaneous inflammatory bowel disease in JAK3-/-and IL-2Rγ-/-mice. Int. Immunol, 16:1-10, 2002.
 
26) Murata Y, Shimamura T, Hamuro J:The polarization of Th1/Th2 balance is dependent on the intracellular thiol redox status of macrophages due to the distinctive cytokine production. Int. Immunol l4:201-212, 2002.
 
27) van Gool SW, Ceuppens JL, Walter H, de Boer M:Synergy between cyclosporin A and a monoclonal antibody to B7 in blocking alloantigen-induced T cell activation. Blood 83:176-183, 1994.
 
28) He X, Stuart JM:Prostaglandin E2 selectively inhibits human CD4+ T cells secreting low amounts of both IL-2 and IL-4. J. Immunol. 163:6173-6179, 1999.
PubMed
29) Sarin A, Adams DH, Henkart PA:Protease inhibitors selectively block T cell receptor-triggered programmed cell death in a murine T cell hybridoma and activated peripheral T cells. J. Exp. Med. 178:1693-1700, 1993.
 
30) Hockenbery DM, Oltvali AN, Yin X-M, Milliman CL et al.:Bc-2 functions in an antioxidant pathway to Prevent apoptosis. Cell 75:1241-251, 1993.
 
31) Dai Z, Lakkis FG:The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection. Curr. Opin. Immunol. 11:504-508, 1999.
PubMed
32) Hassan AT, Dai A, Konieczny BT, Ring GH et al.:Regulation of alloantigen-mediated T-cell proliferation by endogenous interferon-γ:implications for long-term allograft acceptance. Transplantation 68:124-129, 1999.
 
33) Sadlack B, Lohier J, Schorle H, Klebb G, Haber H et al:Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 25:3053-3059. 1995.
 
34) Sadlack B, Merz H, Schorle H, Schimp1 A et al.:Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75:253-261, 1993.
PubMed
35) Suzuki H, Kundig TM, Furlonger C, Wakeham A et al.:Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor B. Science 268:1472-1476, 1995.
PubMed
36) Willerford DM, Chen J, Ferry JA, Davidson L et al.:Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3:521-530, 1995.
PubMed
37) van Parijs L, Biuckians A, Ibragimov A, Alt FW et al.:Functional responses and apoptosis of CD25 (IL-2Ra)-deficient T cells expressing a transgenic antigen receptor. J. Immunol. 158:3738-3745, 1997.
 
38) Refaeli Y, van Parijs L, Londong CA, Tschopp J et al.:Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8:615-623, 1998.
 
39) van Paarijs L, Refaeli Y, Lord JD, BeIson BH et al.:Uncoupling IL-2 signaIs that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity ll:281-288, 1999.
 
40) Lord JD, McIntosh BC, Greenberg PD, BeIson BH:The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J. Immunol. 164:2533-2541, 2000.
 
41) Lord JD, McIntosh BC, Greenberg PD, NeIson BH:The IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell viability through the adapter molecule She. J. Immunol 161:4627-4633, 1998.
 
42) Dai Z, Arakelov A, Wagener M, Konieczny BT et al.:The role of the common cytokine receptor γ chain in regulating IL-2-dependent, activation-induced CD8+T cell death. J. Immunol 163:3131-3137, 1999.
 
43) Suzuki H, Zhou YW, Kato M, Mak TW et al.:Normal regulatory aB T cells effectively eliminate abnormally activated T cells lacking the interleukin 2 receptor B in vivo. J. Exp. Med. 190:1561-1571, 1999,
 
44) Takahashi T, Kuniyasu, Y, Toda M, Sakaguchi N, Itoh Met al.:Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells:induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10:1969-1980. 1998.
 
45) Thornton A, Shevach E:CD4+CD25+immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin-2 production. J. Exp. Med. 188:287-296, 1998.
PubMed
46) Waldmann TA, O'Shea J:The use of antibodies against the IL-2 receptor in transplantation. Curr. Opin. in Immunol. 10:507-512, 1998.
 
47) Eicher DM, Waldmann TA:IL-2R a on one cell can present IL-2 to IL-2Rbg on another cell to augment IL-2 signaling. J. Immunol 161:5430-5437, 1998.
PubMed
48) La Flamme AC, Pearce EJ:The absence of IL-6 does not affect Th2 cell development in vivo, but does lead to impaired proliferation, IL-2 receptor expression, and B cell responses. J. Immunol. 162:5829-5837, 1999.
 
49) Wrenshall LE, Platt JL:Regulation of T cell homeostasis by heparan sulfate-bound IL-2. J. Immunol. 163:3793-3800, 1999.
PubMed
50) Zheng XX, Steele AW, Hancock WA, Kawamoto K et al.:IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J. Immunol. 163:4041-4048, 1999.
 
51) Papiernik M, de Moraes ML, Pontoux C, Vasseur F et al.:Regulatory CD4 T cells:expression of IL-2Ra chain, resistance to clonal deletion and IL-2 dependency. Int, Immunol. 10:371-378, 1998.
 
52) Ludviksson BR, Strober W, Nishikomori R, Hasan WK et al.:Administration of mAb against aEb7 prevents and ameliorates immunization-induced colitis in IL-2-/-mice. J. Immunol. 162:4975-4982, 1999
 
53) Yamada K, Kimura Y, Nishimura H, Namii Y et al.:Characterization of CD4+CD8aa and CD4-CD8aa intestinal intraepithelial lymphocytes in rats. Int. Immunol 11:21-28, 1999.
 
54) Schultz O, Sewell HE, Shakib F:Proteolytic cleavage of CD25, the a subunit of the human T cell interleukin 2 receptor, by Der p 1, a major mite allergen with cysteine protease activity. J. Exp. Med. 187:271-275, 1998.
 
55) De Paoli P, Zanussi S, Simonelli C, Bortolin MT et al.:Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J. Clin. Invest. 100:2737-2743, 1997.
 
56) Ochoa JB, Curti AB, Peitzman AB, Simmons RL et al.:Increased circulating nitrogen oxides after human tumor immunotherapy:correlation with toxic hemodynamic changes. J. Natl. Cancer Inst. 84:864-867, 1992.
 
57) Rafi-Janajreh AQ, Chen D, Schmits R, Mak TW et al.:Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. J. Immunol 163:1619-1627, 1999.
PubMed
58) Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES:Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Medical Science 96:3957-3962, 1999.
 
59) Shrikant P, Khoruts A, Mescher MF:CTLA-4 blockade reverses CD8+T cell tolerance to tumor by a CD4+T cell-and IL-2 dependent mechanism. Immunity 11:483-493, 1999.
PubMed
60) Rosenberg SA, Lotze MT, Yang, JC, Topalian SL et al.:Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85:622-632, 1993.
PubMed
61) Sznol M, Clark JW, Smith II JW, Steis RG et al.:Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J. Natl. Cancer Inst. 84:929-937, 1992.
 
62) Rosenberg SA, Yannelli JR, Yang JC, Topalian SL et al.:Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159-1166, 1994.
PubMed
63) Belldegrun A, Tso C-L, Sakata T, Duckett T et al.:Human renal carcinoma line transfected with interleukin-2 and/or interferon a genes:imp1ications for live cancer vaccines. J. Natl Cancer Inst. 85:207-216, 1993.
PubMed
64) Bowman L, Grossmann M, Rill D, Brown M et al.:IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 92:1941-1949, 1998.
PubMed
65) Wigginton JM, Komschlies KL, Back TC, Franco JL et al.:Administration of interleukin 12 with puIse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst. 88:38-43, 1996.
 
66) Shimizu K, Fields RC, Giedlin M, Mule JJ:Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA 96:2268-2273, 1999.
PubMed
P.111 掲載の参考文献
1) Yokota T, Lee F, Rennick D et al.:Isolati6on and characterization of a mouse cDNA clone that expresses mast cell growth-factor activity in monkey cells. Proc. Natl. Acad. Sci. USA 81:1070-1073, 1984.
PubMed
2) Ihle JN, Keller J, Oroszlan S et al.:Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, P cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. J. Immunol. 131:282-287, 1983.
PubMed
3) Fung MC, Hapel AJ, Ymer S et al.:Molecular cloning of cDNA for murine interleukin-3. Nature 307:233-237, 1984.
PubMed
4) Yang YC, Ciarletta AB, Temple PA et al.:Human IL-3 (Multi-CSF):identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 47:3-10, 1986.
PubMed
5) Feng Y, Klein BK, McWherter CA:Three-dimensional solution structure and backbone dynamics of a variant of human interleukin-3. J. Mol. Biol 259:524-541, 1996.
PubMed
6) Itoh N, Yonehara S, Schreurs J et al.:Cloning of an interleukin-3 receptor gene:a member of a distinct receptor gene family. Science 247:324-327, 1990.
PubMed
7) Hayashida K, Kitamura T, Gorman DM et al.:Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colorly-stimUlating factor (GM-CSF):reconstitution of a high-affinity GM-CSF receptor. Proc. Natl. Acad. Sci. USA 87:9655-9659, 1990.
PubMed
8) Kitamura T, Sato N, Arai K et al.:Expression cloning of the human IL-3 receptor cDNA reveaIs a shared beta subunit for the human IL-3 and GM-CSF receptors. Cell 66:1165-1174, 1991.
PubMed
9) Hara T, Miyajima A:Two distinct functional high affinity receptors for mouse interleukin-3 (IL-3) . EMBO J. 11:1875-1884, 1992.
PubMed
10) Miyatake S, Yokota T, Lee F et al.:Structure of the chromosomal gene for murine interleukin-3. Proc. Natl. Acad. Sci. USA 82:316-320, 1985.
PubMed
11) Cockerill PN, Shannon MF, Bert AG et al.:The granulocyte-macrophage colony-stimulating factor/interleukin 3 locus is regulated by an inducible cyclosporin A-sensitive enhancer, Proc. Natl. Acad. Sci. USA 90:2466-2470, 1993.
PubMed
12) Hawwari A, Burrows J, Vadas MA et al.:The human IL-3 locus is regulated cooperatively by two NFAT-dependent enhancers that have distinct tissue-specific activities. J. Immunol. 169:1876-1886, 2002.
PubMed
13) Duncliffe KN, Bert AG, Vadas MA et al.:A T cell specific enhancer in the interleukin-3 locus is activated cooperatively by Oct and NFAT elements within a DNase I-hypersensitive site. Immunity 6:175-185, 1997.
 
14) Koyano-Nakagawa N, Nishida J, Baldwin D et al.:Molecular cloning of a novel human cDNA encoding a zinc finger protein that binds to the interleukin-3 promoter. Mol. Cell. Biol. 14:5099-5107, 1994.
 
15) Zhang W, Zhang J, Kornuc M et al.:Molecular cloning and characterization of NF-IL-3A, a transcriptional activator of the human interleukin-3 promoter. Mol. Cell. Biol. 15:6055-6063, 1995.
 
16) Shaw G, Kamen R:A conserved AU sequence from the 3'untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46:659-667, 1986.
PubMed
17) Nishinakamura R, Nakayama N, Hirabayashi Y et al.:Mice deficient for the IL-3/GM-CSF/IL-5 B c receptor exhibit lung pathology and impaired immune response, while BIL-3 receptor-deficient mice are normal. Immunity 2:211-222, 1995.
 
18) Robb L, Drinkwater CC, Metcalf D et al.:Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5. Proc. Natl. Acad. Sci. USA 92:9565-9569, 1995.
 
19) Nishinakamura R, Miyajima A, Mee PJ et al.:Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleikin-3/interleukin-5 functions. Blood 88:2458-2464, 1996.
 
20) Lantz CS, Boesiger J, Song CH et al.:Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature 392:90-93, 1998.
PubMed
P.125 掲載の参考文献
1) Howard M, Farrar J, Hilfiker M et al.:Identification of aT cell-derived B cell growth factor distinct from interleukin 2. J. Exp. Med. 155:914-923, 1982.
PubMed
2) Isakson PC, Pure E, Vitetta ES et al.:T cell-derived B cell differentiation factor(s) . Effect on the isotype switch of murine B cells. J. Exp. Med. 155:734-748, 1982.
PubMed
3) Vitetta ES, Ohara J, Myers CD et al.:Serological, biochemical, and functional identity of B cell-stimulatory factor 1 and B cell differentiation factor for IgG 1. J. Exp. Med. 162:1726-1731, 1985.
 
4) Noma Y, Sideras P, Naito T et al.:Cloning of cDNA encoding the murine IgGI induction factor by a novel strategy using SP6 promoter. Nature 319:640-646, 1986.
 
5) Lee F, Yokota T, Otsuka T et al.:Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell-and mast-cell-stimulating activities. Proc. Natl. Acad. Sci. USA 83:2061-2065, 1986.
 
6) Paul WE, Ohara J:B-cell stimulatory factor-1/interleukin 4. Annu. Rev. Immunol. 5:429-459, 1987.
 
7) Yokota T, Otsuka T, Mosmann T et al.:Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell-and T-cell-stimulating activities. Proc. Natl. Acad. Sci. USA 83:5894-5898, 1986.
 
8) Powers R, Garrett DS, March CJ et al.:Three-dimensional solution structure of human interleukin-4by multidimensional heteronuclear magnetic resonance spectroscopy. Science 256:1673-1677, 1992.
 
9) Marsh DG, Neely JD, Breazeale DR et al.:Linkage analysis of IL-4 and other chromosome 5q31. 1 markers and total serum immunoglobulin E concentrarion. Science 264:1152-1156, 1994.
 
10) Harada N, Castle BE, Gorman DM et al.:Expression cloning of a cDNA encoding the murine unterleukin 4 receptor based on ligand binding. Proc. Natl. Acad. Sci. USA 87:857-860, 1990.
PubMed
11) Idzerda RL, March CJ, Mpsley B et al.:Human interleukin 4 receptor confers biological responsiveness and difines a novel receptor superfamily. J. Exp. Med. 171:861-877, 1990.
 
12) Takeshita T, Asano H, Ohtani K et al.:Cloning of the γ chain of the human IL-2 receptor. Science 257:379-382, 1992.
 
13) Kondo M, Takeshita T, Ishii N et al.:Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science 262:1874-1877, 1993.
PubMed
14) Noguchi M, Nakamura Y, Russell SM et al.:Interleukin-2 receptor gamma chain:a functional component of the interleukin-7 receptor. Science 262:1877-1880, 1993.
PubMed
15) Sugamura K, Asao H, Kondo M et al.:The interleukin-2receptor gamma chain:its role in the multiple cytokine receptor complexes and T cell development in XSCID. Ann. Rev. Immunol. 14:179-205, 1996.
 
16) Noguchi M, Yi H, Rosenblatt HM et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73:147-157, 1993.
 
17) Punnonen J, Aversa G, Cocks BG et al.:Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc. Nat. Acad. Sci. USA 90:3735-3739, 1993.
 
18) Hilton DJ, Zhang J-G, Metcalf D et al.:Cloning and characterization of a biding subunit of the interleukin 13receptor that is aIso a component of the interleukin 4receptor. Proc. Acad. Sci. USA 93:497-501, 1996.
 
19) Nelms K, Huang H, Ryan J et al.:Interleukin-4 receptor signalling mechanisms and their biological significance. Adv. Exp. Med. Biol. 452:37-43, 1998.
PubMed
20) Wang LM, Keegan AD, Li W et al.:Common elements in interleukin 4 and insulin signaling pathways in factor-dependent hematopoietic cells. Proc. Natl. Acad. Sci. USA 90:4032-4036, 1993.
PubMed
21) Keegan AD, Nelms K, White M et al.:An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth. Cell 76:811-820, 1994.
 
22) Izuhara K, Feldman RA, Greer P et al.:Interaction of the c-fes proto-oncogene product with the interleukin-4 receptor. J. Biol. Chem. 269:18623-18629, 1994.
 
23) Takeda K, Tanaka T, Shi W et al.:Essential role of Stat6 in IL-4 signalling. Nature 380:627-630, 1996.
PubMed
24) Shimoda K, van Deursen J, Sangster MY et al.:Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380:630-633, 1996.
PubMed
25) Ouyang W, Lohning M, Gao Z et al.:Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 12:27-37, 2000.
PubMed
26) Finkelman FD, Morris SC, Orekhova T et al.:Stat6 regulation of in vivo IL-4 responses. J. Immunol. 164:2303-2310, 2000.
PubMed
27) Grogan JL, Mohrs M, Harmon B et al. Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immunity 14:205-215, 2001.
PubMed
28) Zheng W, Flavell RA:The transcription factor GATA-3is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89:587-596, 1997.
 
29) Kurata H, Lee HJ, O'Garra A et al.:Ectopic expression of activated Stat6 induces the expression of Th2-specific cytokines and transcription factors in developing Th1 cells. Immunity 11:677-688, 1999.
PubMed
30) Ouyang W, Ranganath SH, Weindel K et al.:Inhibition of Th1 developmental mediated by GATA-3 through an IL-4 independent mechanism. Immunity 9:745-755, 1998.
 
31) Takemoto N, Kamogawa Y, Jun Lee H et al.:Cutting edge:chromatin remodeling at the IL-4/IL-13 intergenic regulatory region for Th2-specific cytokine gene cluster. J. Immunol. 165:6687-6691, 2000.
PubMed
32) Loots GG, Locksley RM, Blankespoor CM et al.:Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons. Science 288:136-140, 2000.
PubMed
33) Mohrs M, Blankespoor CM, Wang ZE et al.:Deletion of a coordinate regulator of type 2 cytokine expression in mice. Nat. Immunol. 2:827-842, 2001.
 
34) Hayashi N, Liu D, Min B et al.:Antigen challenge leads to in vivo activation and elimination of highly polarized THI memory T cells. Proc. Natl. Acad, Sci. USA 99:6187-6191, 2002.
 
35) Plaut M, Pierce JH, Watson CJ et al.:Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. Nature 339:64-67, 1989,
PubMed
36) Seder RA, Boulay JL, Finkelman F et al.:CD8+ T cells can be primed in vitro produce IL-4. J. Immunol. 148:1652-1656, 1992.
PubMed
37) Ferrick DA, Schrenzel MD, Mulvania T et al.:Differential production of IFN-γand IL-4 in response to Th1 and Th2-stimulating pathogens by γσ T cells invivo. Nature 373:255-257, 1995.
 
38) Bendelac A:Mouse NKI+Tcells. Curr. Opin. Immunol. 7:367-374, 1995.
 
39) Yoshimoto T, Bendelac A, Watson C et al.:Role of NK1. 1+T cells in a TH2 response and immunoglobulin E production. Science 270:1845-1847, 1995.
 
40) Noben-Trauth N, Hu-Li J, Paul WE:Conventional, naive CD4+T cells provide an initial source of IL-4 during TH2 differentiation. J. Immunol. 165:3620-3625, 2000.
PubMed
41) Noelle R, Krammer PH, Ohara J et al.:Increased expression of la antigens on resting B cells:an additional role for B-cell growth factor. Proc. Natl. Acad. Sci. USA 81:6149-6153, 1984.
 
42) Nakanishi K, Hirose S, Yoshimoto T et al.:Role and regulation of interleukin (IL)-2 receptor alpha and beta chains in IL-2-driven B-cell growth. Proc, Natl Acad. Sci. USA 89:3551-3555, 1992.
PubMed
43) Nakanishi K, Howard M, Muraguchi A et al. Soluble factors involved in B cell differentiation:Identification of two distinct T cell replacing factors (TRFs). J. Immunol 130:2219-2224, 1983.
 
44) Nakanishi K, Malek TR, Smith KA et al.:Both Interleukin-2 (IL-2) and a second T cell derived factor in EL-4 supernatant have activity as differentiation factors in IgM synthesis. J. Exp. Med. 160:1605-1621, 1984.
 
45) Coffman RL, Ohara J, Bond MW et al.:B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J. Immunol. 136:4538-4541, 1986.
PubMed
46) Armitage RJ, Fanslow WC, Strockbine L et al.:Molecular and Biological characterization of a murine ligand for CD40. Nature 357:80-82, 1992.
PubMed
47) Nakanishi K, Matsui K, Kashiwamura S-I et al.:IL-4 and anti-CD40 protect against Fas-mediated B cell apoptosis and induce B cell growth and differentiation. Int. Immunol. 8:791-798, 1996.
 
48) Jabara HH, Fu SM, Geha RS et al.:CD40 and IgE:Synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J. Exp. Med. 172:1861-1864, 1990.
 
49) Gascan H, Gauchat JF, Aversa G et al.:Anti-CD40 monoclonal antibodies or CD4+Tcell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways. J. Immunol 147:8-13, 1991.
 
50) Nakanishi K, Yoshimoto T, Chu CC et al.:IL-2 inhibits IL-4-dependent IgE and IgGI production in vitro and in vivo. Int. Immunol 7:259-268, 1995.
 
51) Yoshida K, Matsuoka M, Usuda S et al.:Immunoglobulin swith circular DNA in the mouse infected with Nippostrongylus brasiliensis:Evidence for successive class switching from μ to ε via γl. Proc. Natl. Acad. Sci. USA 87:7829-7833, 1990.
 
52) Mosmann TR, Coffman RL:THI and TH2 cells:different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173, 1989.
 
53) Seder RA, Paul WE, Davis MM et al.:The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+Tcells from Tcell receptor transgenic mice. J. Exp. Med, 176:1091-1098, 1992.
 
54) Seder RA, Gazzinelli R, Sher A et al.:IL-12 acts directly on CD4+Tcells to enhance priming for IFNγ production and diminishes IL-4 inhibition of such priming. Proc. Natl. Acad. Sci. USA 90:10188-10192, 1993.
 
55) Paul WE, Seder RA:Lymphokine responses and cytokines. Cell 76:241-251, 1994.
PubMed
56) Seder RA, Paul WE:Acquisition of lymphokine-producing phenotype by CD4+Tcells. Annu. Rev. Immunol. 12:635-673, 1994.
 
57) Nakanishi K, Yoshimoto T, Tsutsui H et al.:Interleukin-18 regulates both Th1 and Th2 responces. Annu. Rev. Immunol. 19:423-474, 2001.
 
58) Ma X, Chow JM, Gri G et al.:The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med. 183:147-157, 1996.
 
59) Szabo SJ, Sullivan BM, Peng SL et al.:Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol. 21:713-758, 2003.
PubMed
60) Kim JI, Ho IC, Grusby MJ et al.:The transcription factor c-Maf controIs the production of interleukin-4 but not other Th2 cytokines. Immunity 10:745-751, 1999.
 
61) Biedermann T, Zimmermann S, Himmelrich H et al.:IL-4 instructs Th1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. 2:1054-1060, 2001.
PubMed
62) Finkelman FD, Katona IM, Urban JJ et al.:Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. Proc. Natl. Acad. Sci. USA 83:9675-9678, 1986.
 
63) Tepper RI, Levinson DA, Stanger BZ et al.:IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell 62:457-467, 1990.
PubMed
64) Noben-Trauth N, Shultz LD, Brombacher F et al.:An interleukin 4 (IL-4)-independent pathway for CD4+T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc. Natl. Acad. Sci. USA 94:10838-10843, 1997.
PubMed
65) Morawetz RA, Gabriele L, Rizzo LV et al.:Interleukin-4-independent immunoglobulin class switch to immunoglobulin (lg) E in the mouse. J. Exp. Med, 184:1651-1661, 1996.
 
66) Reiner SL, Locksley RM:The regulation of immunity to Leishmania major. Ann. Rev. Immunol. 13:151-177, 1995.
 
67) Sadick MD, Heinzel FP, Holaday BJ et al.:Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell dependent, interferon gamma-independent mechanism. J. Exp. Med. 171:115-127, 1990.
 
68) Ohkusu K, Yoshimoto T, Takeda K et al.:Potentiality of interleukin-18 as a useful reagent for the treatment and prevention of Leishmania major infection. Infect. Immun. 68:2449-2456, 2000.
PubMed
69) Belosevic M, Finbloom DS, van der Meide PH:Administration of monoclonal anti-IFNγ antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Exp. Med. 177:1505-1509, 1989.
 
70) Noben-Trauth N, Kroph P, Muller I:Susceptibnity to Leishimnania major infection in interleukin-4-deficient mice. Science 271:987-990, 1996.
 
71) Kopf M, Le GG, Bachmann M et al.:Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362(6417):245-248, 1993.
 
72) Yoshimoto T, Paul WE:CD4POS, NK1. 1POS T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179:1285-1295, 1994.
PubMed
73) Yoshimoto T, Min B, Sugimoto T et al.:Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4+T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice. J. Exp. Med. 197:997-1005, 2003.
PubMed
74) Tepper RI, Pattengalle PK, Leder P:Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503-512, 1989.
 
75) Tepper RI, Coffman R, Leder P:An eosinophile-dependent mechanism for the antitumor effect ofinterleukin-4. Science 257:548-551, 1992.
 
76) D'Andrea A, Ma X, Aste-Amezaga M et al.:Stimulatory and inhibitory effects of interleukin(IL)-4and IL-13 on the production of cytokines by human peripheral blood mononuclear cells:priming for IL-12 and tumor necrosis factor alpha production. J. Exp. Med. 181:537-546, 1995.
 
77) Racke MK, Bonomo A, Scott DE et al.:Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1961-1966, 1994.
PubMed
78) Rapoport MJ, Jaramillo A, Zipris D et al.:Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J. Exp. Med. 178:87-99, 1993.
PubMed
79) Hammond KJ, Poulton LD, Palmisano LJ et al.:Alpha/beta-T cell receptor (TCR)+CD4 CD8 (NKT) thymocytes prevent insulin dependent diabetes mellitus in nonobese diabetic (NOD) /Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187:1047-1056, 1998.
PubMed
80) Wierenga EA, Snoek M, De GC et al.:Evidence for compartmentalization of functional subsets of CD4+T lymphocytes in atopic patients. J. Immunol 144:4651-4656, 1990.
 
81) Masinovsky B, Urdal D, Gallatin WM:IL-4 acts synergistically with IL-1beta to promote lymphocyte adhesion to microvascular endothelium by induction of vascular cell adhesion molecule-1. J. Immunol. 145:2886-2895, 1990.
PubMed
P.138 掲載の参考文献
1) 高津聖志:IL-5とそのレセプター. 医学のあゆみ 156:612-616, 1991
Medical*Online
2) Takatsu K, Dickason R, Huston D:Interleukin-5. Growth Factors and Cytokines in Health and Disease. Volume IIA. (ed. LeRoith) , 1997, p143-200.
 
3) Takatsu K:Interleukin-5 and its Receptor:From Genes to Diseases. Springer-Verlag, New York, 1995, p1-157.
 
4) Takatsu K, Tominaga A, Hamaoka T:Antigen-induced T cell-replacing factor (TRF). I . Functional characterization of a TRF producing helper T cell subset and genetic studies on TRF production. J. Immunol. 123:2414-2422, 1980.
 
5) Takatsu K, Tanaka K, Tominaga A et al.:Antigen-induced T cell-replacing factor (TRF). III. Establishment of T cell hybrid clone continuously producing TRF and functional analysis of released TRF. J. Immunol. 125:2646-2653, 1980.
PubMed
6) Harada N, Takahashi T, Takatsu K et al.:Production of a monoclonal antibody useful in the molecular characterization of murine T-cell-replacing factor/B-cell growth factor II. Proc. Natl. Acad. Sci. USA 84:4581-4585, 1987.
 
7) Kinashi T, Harada N, Severinson E et al.:Cloning of complementary DNA for T-cell replacing factor and identity with B-cell growth factor II. Nature 32:70-73, 1986.
 
8) Takatsu K, Tominaga A, Harada N et al.:T cell-replacing factor (TRF)/interleukin 5(IL-5):Molecular and functional properties. Immunol Rev. 102:107-135, 1988.
PubMed
9) Yamaguchi N, Hitoshi Y, Mita S et al.:Characterization of the murine interleukin 5 receptor by using a monoclonal antibody. Int. Immunol. 2:181-187, 1990.
PubMed
10) Hitoshi Y, Yamaguchi N, Mita S et al.:Distribution of IL-5 receptor-positive B cells. Expression of IL-5 receptor on Ly-1(CD5) +B cells. J. Immunol. 144:4218-4225, 1990.
 
11) Takaki S, Tominaga A, Hitoshi Y et al.:Molecular cloning and expression of the murine interleukin 5 receptor. EMBO J. 9:4367-4374, 1990.
PubMed
12) Tominaga A, Takaki S, Koyama N et al.:Transgenic mice expressing a B cell growth and differentiation factor gene (interleukin 5) develop eosinophilia and autoantibody production. J. Exp. Med. 173:429-438, 1991.
 
13) Yoshida T, Ikuta I, Sugaya H et al.:Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5Rα deficient mice. Immunity 4:483-494, 1996.
 
14) Tominaga A, Takahashi T, Kikuchi Y et al.:Role of carbohydrate moiety of IL-5. Effect of tunicamycin on the glycosylation of IL-5 and the biologic activity of deglycosylated IL-5. J. Immunol. 144:1345-1352, 1990.
PubMed
15) Milburn MV, Hassell AM, Lambert MH, Jordan SR, Proudfoot AE, Graber P, WelIs TN:A novel dimer configuration revealed by the crystal structure at 2. 4 A resolution of human interleukin-5. Nature 363:172-176, 1993.
 
16) Dickason RR, Huston DP:Creation of a biologically active interleukin-5 monomer. Nature 379:652-655, 1996.
PubMed
17) Chaikan IM, Proudfoot A:Structure of IL-5. Interleukin-5:from molecule to drug target for asthma. (eds. Sanderson CJ, Dekker M), New York, 2009, p167-189.
 
18) Mita S, Harada N, Naomi S et al.:Receptors for T cell-replacing factor/interleukin 5. Specificity, quantitation and its imp1ication. J. Exp. Med. 168:863-878, 1988.
 
19) Mita S, Tominaga A, Hitoshi Y et al.:Characterization of high-affinity receptors for interleukin-5 on interleukin 5 dependent cell lines. Proc. Natl. Acad. Sci. USA 86:2311-2315, 1989.
PubMed
20) Hitoshi Y, Yamaguchi N, Korenaga M, Mita M et al.:In vivo administration of antibody to murine IL-5 receptor inhibits eosinophilia of IL-5 transgenic mice. Int. Immunol. 3:135-139, 1991.
 
21) Hitoshi Y, Sonoda E, Kikuchi Y et al.:Interleukin-5 receptor positive B cells, but not eosinophiIs are functionally and numerically influenced in the mice carried with X-linked immunodeficiency. Int. Immunol 9:1183-1190, 1993.
 
22) Murata Y, Takaki S, Migita M et al.:Molecular cloning and expression of the human interleukin 5 receptor. J. Exp. Med. 175:341-351, 1992.
PubMed
23) Tavernier J, Devos R, Cornelis S et al.:A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific a chain and a B chain shared with the receptor for GM-CSF. Cell 66:1175-1184, 1991.
 
24) Tarvernier J, Van de Heyden J, Verhee A et al.:Interleukin-5 regulates the isoform expression of its own receptor a-subunit. Blood 95:1600-1607, 2000.
 
25) Gregory B, Kirchem A, Phipps S et al.:Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor a-chain expression by cytokines:IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor expression. J. Immunol. 170:5359-5366, 2003.
PubMed
26) Takaki S, Mita S, Kitamura T et al.:Identification of the second subunit of the murine interleukin 5 receptor:interleukin-3 receptor-like protein, AIC2B is a component of the high affinity interleukin-5receptor. EMBO J. 10:2833-2838, 1991.
 
27) Kitamura T, Sato N, Arai K et al.:Expression cloning of the human IL-3 receptor cDNA reveaIs a shared B subunit for human IL-3 and GM-CSF receptors. Cell 66:1165-1174, 1991.
 
28) Takaki S, Murata Y, Kitamura T et al.:Reconstitution of the functional receptors for murine and human interleukin 5. J. Exp. Med. 177:1523-1529, 1993.
PubMed
29) Iwama A, Pan J, Zhang P et al.:Dimeric RFX proteins contribute to the activity and lineage specificity of the interleukin-5 receptor promoter through activation and repression domains. Mol. Cell. Boil. 19:3940-3950, 1999.
 
30) Takaki S, Kanazawa H, Shiiba M et al.:Critical cytoplasmic domain of the IL-5R a chain and its function in IL-5-mediated growth signal transduction. Mol. Cell. Biol. 12:7404-7413, 1994.
 
31) Ogata N, Kouro T T, Yamada A et al.:JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor alpha and betar subunit, respectively, and are activated upon IL-5 stimulation. Blood 91:2264-2271, 1998.
 
32) Takatsu K:Interleukin-5. Curr. Opin. Immunol. 4:299-306, 1992.
PubMed
33) Pazdrak K, Schreiber D, Forsythe P et al.:The intracelleular signal transduction mechanism of interleukin 5 in eosinophiIs:the involvement of lyntyrosine kinase and the Ras-Raf-1-MEK-microtuble associated protein kinase pathway. J. Exp. Med. 181:1827-1833, 1995.
 
34) Kouro T, Kikuchi Y, Kanazawa H et al.:Critical proline residues of the cytoplasmic domain of the IL-5 receptor alpha chain and its function in IL-5 mediated activation of JAK kinase and STAT5. Int. Immunol 8:237-246, 1996.
PubMed
35) Mui AL-F, Wakao H, O'Farrell A-M et al.:Interleukin-3, granulocyte-macrophage colony-stimulating factor and interleukin-5 transduce signaIs through two STAT5 homologues. EMBO J. 14:1166-1172, 1995.
 
36) Kagami S, Nakajima, H, Kumano K et al.:Both Stat5a and Stat5b are required for antigen-induced eosinophil and T cell recruitment into the inflammatory tissue. Blood 95:1370-1377, 2000.
 
37) Horikawa K, Kaku H, Nakajima H et al.:Essential role of signal transducer and activator of transcription (Stat) 5 for interleukin-5-dependent IgH switch recombination in mouse B cells. J. Immunol 167:5018-5026, 2001.
 
38) 等 靖道, 高津聖志:無ガンマグロブリネミア症とチロシンキナーゼ. 細胞工学 13:239-245, 1994.
 
39) Appleby MW, Kerner JD, Chien S et al.:Involvement of p59fyn T in interleukin-5 receptor signaling. J. Exp. Med. 182:811-820, 1995.
PubMed
40) Satoh S, Katagiri T, Takaki S et al.:IL-5 receptor-mediated tyrosine phosphorylation of SH2/SH3-containing proteins and activation of Bruton's tyrosine and JAK2 kinases. J. Exp. Med. 180:2101-2111, 1994.
 
41) Li T, Tsukada S, Satterthwaite A et al.:Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity 2:451-460, 1995.
PubMed
42) Kikuchi Y, Hirano M, Seto M et al.:Identification and characterization of a molecule, BAM11, that associates with the PH-domain of mouse Btk. Int. Immunol. 12:1397-1408, 2000.
 
43) Kikuchi Y, Yasue T, Yamashita Y et al.:CD38 ligation induces Btk activation and enhanced expression of IL-5 receptor a chain. Proc. Natl. Acad. Sci. USA 92:10879-10883, 1995.
 
44) Turner CA, Mack DH, Davis MM:Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 77:297-306, 1994.
PubMed
45) Honjo T, Takatsu K:Interleukin 5. In Peptide Growth Factors and Their Receptor (Handbook of Experimental Pharmacology, Vol/1) (eds. Sporn MB, Roberts AB) , Springer-Verlag, 1990, p609-632.
 
46) Mosmann TR, Coffman RL:TH1 and TH2 cells:Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173, 1989.
PubMed
47) Takatsu K, Takaki S, Hitoshi Y:Interleukin 5 and its receptor system:Imp1ication in the immune system and inflammation. Adv. Immunol. 57:145-190, 1994.
PubMed
48) Sanderson CJ:Interleukin-5, eosinophiIs, and disease. Blood 79:3101-3109, 1992.
PubMed
49) Kay AB, Hamid Q, Robinson DS et al.:Asthma, eosinophiIs, and interleukin-5. EosinophiIs in Allergy and Inflammation (eds. Gleich GJ, Kay AB), Dekker, 1994, p395-406.
 
50) Desreumaux P, Jamin A, Dubucquoi S et al.:Synthesis of interleukin-5 by activated eosinophiIs in patients with eosinophilic heart diseases. Blood 82:1553-1560, 1993.
 
51) Tominaga A, Matsumoto M, Harada N et al.:Molecular properties and regulation of mRNA expression for murine T cell-replacing factor/IL-5. J. Immunol. 140:1175-1181, 1988.
PubMed
52) Hiroi T, Yanagida M, Iijima H et al. Deficiency of IL-5 receptor alpha-chain selectively influences the development of the common mucosal immune system independent IgA-producing B-1 cell in mucosa-associated tissues. J. Immunol. 162:821-828, 1999.
 
53) Kopf M, Brombacher F, Hodgkin PD et al.:IL-5 deficient mice have a developmental defect in CD5+B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 4:15-24, 1996.
PubMed
54) Mizoguchi C, Uehara, S, Akira S et al.:Interleukin-5 induces IgG1 isotype switch recombination in mouse CD38-activated sIgD-positive B lymphocytes. J. Immunol. 162:2812-2819, 1999.
 
55) Huston MM, Moore JP, Mettes H et al.:Human B cells express IL-5 receptor messenger ribonucleic acid and respond to IL-5 with enhanced IgM production after mitogenic stimulation with Moraxella catarrhalis. J. Immunol. 156:1392-1401, 1996.
 
56) Honjo T, Kinoshita K, Muramatsu M:Molecular mechanism of class switch recombination:Linkage with somatic hypermutation. Annu. Rev. Immunol 20:165-196, 2002.
PubMed
57) Matsumoto R, Matsumoto M, Mita S et al.:Interleukin 5 induces maturation but not class-switching of surface IgA-positive B cells into IgA-secreting cells. Immunology 66:32-38, 1989.
PubMed
58) Sonoda E, Matsumoto R, Hitoshi Y et al.:Transforming growth factor B and interleukin 5 acts additively for IgA production. J. Exp. Med. 170:1415-1420, 1989.
PubMed
59) Yamaguchi Y, Hayashi Y, Sugama Y et al.:Highly purified murine interleukin-5 (IL-5) stimulates eosinophil function and prolongs in vitro survival:IL-5 as an eosinophil chemotactic factor. J. Exp. Med. 167:1737-1742, 1988.
PubMed
60) Sehmi R, Wardlaw AJ, Cromwell O et al.:Interleukin-5 selectively enhances the chemotactic responsivenessof eosinophiIs obtained from noraml but not eosinophilic subjects. Blood 79:2952-2959, 1992.
 
61) WaIsh GM, Hartnell A, Wardlaw AJ et al.:IL-5enhances the in vivo adhesion of human eosinophiIs, but not neutrophiIs, in a leukocyte integrin (CDI1/18)-dependent manner. Immunology 71:258-265, 1990.
 
62) Loughnan MS, Takatsu K, Harada N et al.:T-cellreplacing factor (interleukin 5) induces expression ofinterleukin 2 receptors on murine splenic B cells. Proc. Natl. Acad. Sci. USA 84:5399-5403, 1987.
 
63) Takatsu K, Kikuchi Y, Matsumoto M et al.:Interleukin5, aT-cell-derived B-cell differentiation factor aIsoinduces cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 84:4234-4238, 1987.
 
64) Corrigan CJ, Haczku A, Gemou-Engesaeth V et al.:CD4-T lymphocyte activation in asthma is accompaniedby increased serurn concentrations of interleukin-5:Effect of glucocorticoid therapy. Am Rev Respir Dis147:540-547, 1993.
 
65) Nakajima H, Iwamoto I, Tomoe S et al.:CD4+T lymphocytes and interleukin-5 mediate antigeninduced eosinophil infiltration into the rnouse trachea. Am. Rev, Respir. Dis. 146:374-377, 1992.
PubMed
66) Iwamoto T, Takatsu K:Evaluation of airwayhyperreactivity in IL-5 transgenic mice. Int. Arch. Allergy Immunol. 108 (suppl 1):28-30, 1995.
 
67) Foster PS, Hogan SP, Ramsay AJ et al.:Interleukin-5deficiency abolishes eosinophilia, airway hyperreactivity, and lung damage in a mouse asthma model J. Exp. Med. 183:195-201, 1996.
 
68) Mould AW, Matthaei KI, Young IG et al.:Relationshipbetween interleukin-5 and eotaxin in regulating bloodand tissue eosinophilia in mice. J. Clin. Irlvest, 99:1064-1071, 1997.
 
69) Mishra A, Hogan SP, Brandt EB et al.:1L5 promoteseosinophil trafficking to the esophagus. J. Immunol. 168:2464-2469, 2002.
 
70) Zimmermann N, Hershey GK, Foster PS et al.:chemokines in asthma:Cooperative interaction between chemokines and IL-13. J. Allergy Clin. Immunol. 111:1227-242, 2003.
 
71) Korenaga M, Hitoshi Y, Yamaguchi N et al.:The role of interleukin-5 (IL-5) in protective immunity to Strongyloides venezuelensis infection in mice. Immunology 72:502-507, 1991.
PubMed
72) Mauser PJ, Pitman A, Witt A et al.:Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pigmodel of asthma. Am. Rev. Respir. Dis. 148:1623-1627, 1993.
 
73) Akutsu I, Kojima T, Kariyone A et al.:Passive administration of anti-IL-5 antibody into chronically ovalbumin-sensitized guinea pigs induces suppression of eosinophilia and bronchial hyperreactivity. Immunol. Lett. 45:109-116, 1995.
 
74) Mauser PJ, Pitman AM, Fernandez X et al.:Effects of an antibody to IL-5 in a monkey model of asthma. Am. J. Respir. Crit. Care Med. 152:467-4721 995.
 
75) Leckie M, Brinke A, Khan J et al.:Effects of an interleukin-5 blocking monoclonal antibody oneosinophiIs, airway hyper-responsiveness, and late asthmatic response. Lancet 356:2144-2148, 2000.
PubMed
76) Flood-Page PT, Menzeies-Gow AN, Kay AB et al.:Eosinophil's role remains uncertain as antiinterleukin-5 only partially depletes numbers in asthmatic airway. Am. Rev. Crit. Care Med. 167:199-204, 2003.
 
77) Hogan SP, Mishra A, Brandt EB et al.:A pathologicalfunction for eotaxin and eosinophiIs in eosinophilic gastrointestinal inflammation. Nat. Immunol. 2:353-360, 2001.
PubMed
78) Koike M, Takatsu K:IL-5 and its receptor:whichrole do they play role in the immune system? Int. Arch. Allergy Immunol 104:1-9, 1994.
PubMed
P.160 掲載の参考文献
1) Yoshizaki K, Nakagawa T, Fukunaga K et al.:Characterization of human B cell growth factor (BCGF) from cloned T cells or mitogen-stimulated T cells. J. Immunol. 130:1241-1246, 1983.
PubMed
2) Hirano T, Yasukawa K, Harada H et al.:Complementrary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73-76, 1986.
 
3) Yasukawa K, Hirano T, Watanabe Y et al.:Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J. 6:2939-2945, 1987.
 
4) Isshiki H, Akira S, Tanabe O et al.:Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene. Mol. Cell. Biol. 10:2757-2764, 1990.
PubMed
5) Horii Y, Muraguchi A, Suematsu S et al.:Regulation of BSF-2/IL-6 production by human mononuclear cells:Macrophage-dependent synthesis of BSF-2/IL-6by T cells. J. Immunol. 141:1529-1535, 1988.
 
6) Matsuzaki N, SajiF, Kameda T et al.:In vitro and in vivo production of interleukin-6 by fetal mononuclear cells. Clin. Immunol. Immunopathol. 55:305-314, 1990.
PubMed
7) Muraguchi A, Hirano T, Tang B et al.:The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 167:332-344, 1988.
PubMed
8) Koike K, Nakahata T, Takagi M et al.:Synergism of BSF-2/interleukin 6 and interleukin 3 on development of multipotential hemopoietic progenitors in serum-free culture. J. Exp. Med, 168:879-890, 1988.
PubMed
9) Ishibashi T, Kimura H, Uchida T et al.:Human interleukin 6 is a potent thrombopoietic factor in vivo in mice. Blood 74:1241-1244, 1989.
 
10) Yoshizaki K, Nishimoto N, Matsumoto K et al.:Interleukin-6 and expression of its receptor on epidermal keratinocytes. Cytokines 2:381-387, 1990.
PubMed
11) Nishimoto N, Yoshizaki K, Tagoh H et al.:Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation. Clin. Immunol. Immunopathol. 50:399-401, 1989.
PubMed
12) Horii Y, Muraguchi A, lwano M et al.:Involvement of IL-6 in mesangial proliferative glomerulonephritis. J. Immunol 143:3949-3955, 1989.
 
13) Suematsu S, Matsuda T, Aozasa K et al.:IgG1 plasmacytosis in interleukin-6 transgenic mice. Proc. Natl. Acad. Sci. USA 86:7547-7551, 1989.
PubMed
14) Yamazaki K, Taga T, Hirata Y et al.:Cloning and expression of the human interleukin-6(BSF-2/IFN B2) receptor. Science 241:825-828, 1988.
 
15) Hibi M, Murakami M, Saito M et al.:Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149-1157, 1990.
 
16) Taga T, Kishimoto T:Cytokine receptors and signal transduction. FASEB J. 6:3387-3396, 1992.
PubMed
17) Kishimoto T, Tago T, Akira S:Cytokine signal transduction. Cell 76:253-262, 1994.
 
18) Kishimoto T, Akira S, Taga T:Interleukin 6 and its receptor:Aparadigm for cytokines. Science 258:593-597, 1992.
 
19) Patthy L:Homology of a domain of the growth hormone/prolactin receptor family with type III modules of fibronectin. Cell 61:13-14, 1992.
 
20) Bazan JF:Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 87:6934-6938, 1990.
PubMed
21) Bazan JF:Haemopoietic receptors and helical cytokines. Immunol. Today 11:350-354, 1990.
PubMed
22) 田賀哲也:IL-6受容体のユニークな構造. 治療学30:9-13, 1996.
 
23) Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, Taga T, Kishimoto T:IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase, Science 260:1808-1810, 1993.
PubMed
24) Gearing DP, Comeau MR, Friend DJ et al:The IL-6 signal transducer, gp130:an oncostatin M receptor and affinity converter for the LIF receptor. Science 255:1434-1437, 1992.
PubMed
25) Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, Hirabayashi T, Yoneda Y, Tanaka K, Wang W-Z, Mori C, Shiota K, Yoshida N, Kishimoto T:Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. USA 93:407-411, 1996.
PubMed
26) Hilton DJ, Hilton AA, Raicevic A et al.:Cloning of a murine IL-11 receptor a chain:requirement for gp130 for high affinity binding and signal transduction. EMBO J. 13:4765-4775, 1994.
PubMed
27) Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, Nakajima T, Hirano T, Kishimoto T:A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J. 9:1897-1906, 1990.
 
28) Nakajima T, Kinoshita S, Sasagawa T, Sasaki K, Naruto M, Kishimoto T, Akira S:Phosphorylation at threonine 235 by a ras-dependent MAP kinase cascade is essential for transcriptional activation of NF-IL6, Proc. Natl. Acad. Sci. USA 90:2207-2211, 1993.
 
29) Egan SE, Giddings BW, Brooks MW et al.:Association of Sos Ras exchange protein with Grb2 is imp1icated in tyrosine kinase signal transduction and transformation. Nature 363:45-51, 1993.
PubMed
30) Buday L, Downward J:Epidermal growth factor regulates p21 ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 73(3):611-620, 1993.
PubMed
31) 楢崎雅司:IL-6受容体から遺伝子発現までのシグナル伝達経路. 治療学 30:14-18, 1996.
Medical*Online
32) Narazaki M, Witthuhn BA, Yoshida K, Silvennoinen O, Yasukawa K, Ihle JK Kishimoto T, Taga T:Activation of JAK2 kinase mediated by the interleukin-6 signal transducer gp130. Proc. Natl. Acad. Sci. USA 91:2285-2289, 1994.
 
33) Heldin CH:Dimerization of cell surface receptors in signal transduction. Cell 80:213-223, 1995.
PubMed
34) Stahl N, Farruggella TJ, Boulton TG et al:Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267:1349-1353, 1995.
PubMed
35) Klingmuler U, Lorenz U, Cantley LC et al.:Specific recruitment of SH-PTPI to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signaIs. Cell 80:729-738, 1995.
 
36) Akira S, Nishio Y, Inoue M, Wang X, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T:Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 P91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77:63-71, 1994.
 
37) Tanaka T, Akira S, Yoshida K, Umemoto M, Yoneda Y, Shirafuji N, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T:Targeted disruption of the NF-IL6 gerle discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell 80:353-361, 1995.
 
38) 田中貴志:転写因子NF-IL-6-ノックアウトマウス からのレッスン. 治療学 30:27-31, 1996.
Medical*Online
39) Isshiki H, Akira S, Sugita T, Nishio Y, Hashimoto S, Pawlowski T, Suematsu S, Kishimoto T:Reciprocal expression of NF-IL6 and C/EBP in hepatocytes:Possible involvement of NF-IL6 in acute phase protein gene expression. New Biologist. 3:63-70, 1991.
 
40) Ishibashi T, Kimura H, Shikawa Y et al.:Interleukin 6 is a potent thrombopoietic factor in vivo in mice. Blood 74:1241-1244, 1989.
 
41) Ishibashi T, Kimura H, Uchida T et al.:Human interleuking is a direct promoter of maturation of megakaryocytes in vitro. Proc. Natl. Acad. Sci. USA 86:5953-5957, 1987.
 
42) Asano S, Okano A, Ozawa K, Nakahata T, Ishibashi T, Koike K, Kimura H, Tanioka Y, Shibuya A, Hirano T, Kishimoto T, Takaku F, Akiyama Y:In vivo effects of recombinant human interleukin-6 in primates:stimulated production of platelets. Blood 75:1602-1605, 1990.
 
43) Hill RJ, Warren MK, Levin J:Stimulation of thrombopoiesis in mice by human recombinant interleukin-6. J. Clin. Invest. 85:1242-1247, 1990.
PubMed
44) 中畑龍俊:IL-6, gp130と造血幹細胞. 治療学 30:53-58, 1996.
Medical*Online
45) Ogawa M:Differentiation and proliferation of hematopoietic stem cells. Blood 81(11):2844-2853, 1993.
PubMed
46) Koike K, Nakahata I, Takagi M et al.:Synergism of BSF-2/interleukin 6 and interleukin 3 on development of multipotential hemopoietic progenitors in serum-free culture. J. Exp. Med. 168:879-890, 1988.
PubMed
47) Shinohara M, Koike K, Nakahata T:Synergism of interferon-gamma and stem cell factor on the development of murine hematopoietic grogenitors in serum-free culture. Blood 81(6):1435-1441, 1993.
 
48) Sui X, Tsuji K, Tanaka R, Tajima S, Muraoka K, Ebihara Y, Ikebuchi K, Yasukawa K, Taga T, Kishimoto T et al.:gp130 and c-Kit signalings synergize for ex vivo oxpansion of human primitive hemopoietic progenitor cells. Proc. Natl. Acad. Sci. USA 92:2859-2863, 1995.
 
49) 緒方 篤, 西本憲弘, 井上正宏・他:インターロイキン6と疾患. 病態生理 12:12-29, 1993.
 
50) Nordan B, Potter M:a macrophage derived factor required by plasmacytomas for survival and proliferation in vivo. Science 233:566-567, 1986.
 
51) Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T:Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA 89:232-235, 1992.
PubMed
52) Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T:Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83-85, 1988.
 
53) Klein B, Zhang X-G, Jourdan M et al.:Paracrine rather than antocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:517-526, 1989.
 
54) Bataille R, Jourdan M, Zhang X-G et al.:Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J. Clin. Invest. 84:2008-2011, 1989.
PubMed
55) Solay E, Guiguet M, Zeller V et al.:Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumor cell mass parameters in multiple myeloma. Am. J. Hematol. 39:163-171, 1992.
 
56) Bell JB, Montes A, Gooding R et al.:Comparison of interleukin-6 levels in the bone marrow of multiple myeloma patients with disease severity and clonogenicity in vitro. Leukemia 5:958-961, 1991.
PubMed
57) Asaoku H, Kawano M, Iwato K et al.:Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma. Blood 72:429-432, 1988.
PubMed
58) Zhang XG, Bataille R, Widjenes J, Klein B:Interleukin-6dependence of advanced malignant plasma cell dyscrasias. Cancer 69:1373-1376, 1992.
 
59) Yee C, Biondi A, Wang XH et al.:A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 74:798-804, 1989.
PubMed
60) Emilie D, Coumbaras J, Raphael M, Devergne O, Delecluse HJ, Gisselbrecht C, MichieIs JF, Van Damme J, Taga T, Kishimoto T et al:Interleukin-6 production in high-grade B lymphomas:correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. Blood 80:498-504, 1992.
 
61) Jucker M, Abts H, Li W, Schindler R, Merz H, Gunther A, von Kalle C, Schaadt M, Diamantstein T, Feller AC et al:Expression of interleukin-6 and interleukin-6 rerceptor in Hodgkin's disease. Blood 77:2413-2418, 1991.
PubMed
62) Gause A, Scholz R, Klein S et al.:Increased levels of circulating interleukn-6 in patients with Hodgkin's disease. Hematol. Oncol. 9:307-313, 1991.
 
63) Shimizu S, Hirono T, Yoshioka R, Sugai S, Matsuda T, Taga T, Kishimoto T, Konda S:Interleukin 6 (B cell stimulatory factor 2)-dependent growth of a Lennert's lymphoma-derived T cell line (KT-3). Blood 72:1826-1828, 1988.
 
64) Miyaura C, Onozaki K, Akiyama Y et al.:Recombinant human interleukin (B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukernia cells (MI). FEBS Lett. 234:17-21, 1988.
 
65) Givon T, Slavin S, Haran-Ghera N et al.:Antitumor effects of human recombinant interleukin-6 on acute myeloid leukemia in mice and cell cultures. Blood 79:2392-2398, 1992.
PubMed
66) Hoang T, Haman A, Goncalves O, Wong GG, Clark SC:Interleukin-6 enhances growth factor dependent proliferatiorn of the blast cell of acute myeloblastic leukemia. Blood 72(2):823-826, 1988.
PubMed
67) Sawada T, Tsuda H, Takatsuki K:Spontaneous production of interleukin 6 by adult T-cell leukaemia cells. Br. J. Cancer 62:923-924, 1990.
PubMed
68) Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T:Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in real cell carcinomas. FEBS Lett. 250:607-610, 1989.
 
69) Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, Nakayama H, Fujita J, Yoshida O:Enhanced expression of interleukin-6 in primary human renal cell carcinoma. J. Natl. Cancer Inst. 83:1668-1672, 1991.
PubMed
70) Koo AS, Armstrong C, Bochner B, Shimabukuro T, Tso CL, de Kernion JB, Belldegrum A:Interleukin-6 and renal cell cancer:production regulation and growth effects. Cancer Immunol. Immunother. 35:95-105, 1992.
 
71) Blay JY, Negrier S, Combaret V et al.:Serum level of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 52:3317-3332, 1992.
PubMed
72) Watson JM, Sensintaffar JL, Berek JS et al.:Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 50:6959-6965, 1990.
PubMed
73) Berek JS, Chung C, Watson JM, Knox RM, Martinez-Maza O:Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am. J. Obstet. Gynecol. 164:1038-1041; discussion 1042-1043, 1991.
 
74) Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC Jr:Stimulation of ovarian tumor cell proliferation with monocyte products includin interleukin-1, interleukin-6 and tumor necrosis factor-alpha. Am. J. Obstet. Gynecol. 166:997-1007, 1992.
 
75) Chein L, Mory Y, Zilberstein A et al.:Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon B2. Proc. Natl. Acad. Sci. USA 85:8037-8041, 1988.
 
76) Tomm I, Cardinale I, Krueger J et al:Interleukin 6 decreases cell-cell asociation and increases motility of ductal breast carcinoma cells. J. Exp. Med. 170:1649-1669, 1989.
 
77) Rawle, FC, Shields J, Smith SH, Iliescu V, Merkenschlager M, Beverley PC, Callard RE:B cell growth and differentiation induced by supernatants of transformed epithelial cell lines. Eur. J. Immunol. 16:1017-1019, 1986.
PubMed
78) Meyers FJ, Gumerlock PH, Kawasaki ES, Wang AM, deVere White RV, Erlich HA:Bladder cancer. Human leukocyte antigen II, interleukin-6, and interleukin-6 receptor expression determined by the polymerase chain reaction. Cancer 67:2087-2095, 1991.
 
79) Miles SA, Rezai AR Salazar-Gonzalez JF, Myden MV, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T, Martinez-Maza O:AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc. Natl. Acad. Sci. USA 87:4068-4072, 1990.
 
80) Hirano T, Taga T, Yasukawa K, Nakajima K, Nakano N, Takatsuki F, Shimizu M, Murashima A, Tsunasawa S, Sakiyama F, Kishimoto T:Human B cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc. Natl. Acad. Sci. USA 84:228-231, 1987.
 
81) Siegall CB, Schwab G, Nordan RP, FitzGerald DJ, Pastan I:Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res. 50:7786-7788, 1990.
PubMed
82) van Meier E, Sawamura Y, Diserens AC et al.:Human glioblastoma cells release interleukin 6 in vivo and vitro and in vitro. Cancer Res. 50:6683-6688, 1990.
 
83) Stephanou A, Knight RA, Annicchiarico Petruzzelli M, Finazzi Agro A, Lightmann SL, Melino G:Interleukin-1Band interleukin-6 mRNA are expressed in human glioblastoma and neuroblastoma cells respectively. Funct-Neurol. 7:129-133, 1992.
 
84) Suzuki K, Miyashita A, Inoue Y, Iki S, Enomoto H, Takahashi Y, Takemura T:Interleukin-6 producing pheochromocytoma. Acta Haematol 85:217-219, 1991.
PubMed
85) Matsuguchi T, Okamura S, Kawasaki C, Shimoda K, Omori F, Hayashi S, Kimura N, Niho Y:Constitutive production of granulocyte colony-stimulating factor and interleukin-6 by a human lung cancer cell hne, KSNY:gene amp1ification and increased mRNA stability. Eur. J. Haematol. 47:128-133, 1991.
 
86) Baffet G, Braciak TA, Fletcher RG, Gauldie J, Fey GH, Northemann W:Autocrine activity of interieukin 6secreted by hepatocarcinoma cell lines. Mol. Biol. Med. 8:141-156, 1991.
 
87) Lu C, Vickers MF, Kerbel RS:Interleukin 6:A fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc. Natl. Acad. Sci. USA 89:9215-9219, 1992.
 
88) Jourdan M, Zhang X-G, Portier M et al.:Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rhem. 33:398-402, 1990.
 
89) Saji T, Yanagawa E, Matsuura H et al.:Increased serum interleukin-6 in cardiac myxoma. Am. Heart J. 122:579-580, 1990.
 
90) Castleman B, Iverson L, Menendez VP:Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9:822-823, 1956.
PubMed
91) Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto T:Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74:1360-1367, 1989.
 
92) Leger Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, van Damme J, Galanaud P, Diebold J, Emilie D:Interleukin-6 gene expression in Castleman's disease. Blood 78:2923-2930, 1991.
PubMed
93) Dohi K, Iwano M, Muraguchi A, Horii Y, Hirayama T, Ogawa S, Shiiki H, Hirano T, Kishimoto T, Ishikawa H:The prognostic significance of urinary interleukin 6in IgA nephropathy. Clin. Nephrol. 35:1-5, 1991.
 
94) Gordon C, Richards N, Howie AJ, Richardson K, Michael J, Adu D, Emery P:Urinary IL-6:a marker for mesangial proliferative glomerulonephritis? Clin. Exp. Immunol. 86:145-149, 1991.
PubMed
95) Fukatsu A, Matsuo S, Tamai H, Sakamoto N, Matsuda T, Hirano T:Distribution of interleukin-6 in normal and diseased human kidney. Lab. Invest. 65:61-66, 1991.
PubMed
96) Grossman RM, Krueger J, Yourish D et al.:InterleUkin 6is expressed in high levels in psoriasis skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. USA 86:6367-6371, 1989.
 
97) Prens EP, Benne K, van Damme J, Bakkus M, Brakel K, Benner R, van Joost T:Interleukin-1 and interleukin-6 in psoriasis. J. Invest. Dermatol 95 (Suppl. ):121S-124S, 1990.
 
98) Ohta Y, Katayama I, Funato T, Yokozeki H, Nishiyama S, Hirano T, Kishimoto T, Nishioka K:In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis:interleukin-6 involved in formation of psoriatic Iesions. Arch. Dermatol. Res. 283:351-356, 1991.
 
99) Tursen K, Kupper TA, Degenstein L et al.:Interleukin6;insights to its function in skin by overexpression in transgenic mice. Proc. Natl. Acad. Sci. USA 89:5068-5072, 1992.
 
100) Nakajima K, Martinez-Maza O, Hirano T, Breen EC, Nishanian PG, Salazar-Gonzalez JF, Fahey JL, Kishimoto T:Induction of IL-6 (B cell stimulatory factor-2/EFNb2) production by HIV. J. Immunol. 142:531-536, 1989.
 
101) Bree EC, Rezai AR, Nakajima K, Beall GN, Mitsuyasu RT, Hirano T, Kishimoto T, Martinez-Maza O:Infection with HIV is associated with elevated IL-6 levels and production. J. Immunol. 144:480-484, 1990.
 
102) Paya CV, Ten RM, Bessia C, Alcami J, Hay RT, Virelizier JL:NF-kappa B-dependent induction of the NF-kappa B p50 subunit gene promoter underlies self-perpetuation of human immunodeficiency virus transcription in monocytic cells. Proc. Natl. Acad. Sci. USA 89:7826-7830, 1992.
PubMed
103) Lal RB, Rudolph DL:Constitutive production of interleukin-6 and tumor necrosis factor-alpha from spontaneously prohferating T cells in patients withhuman T-cell lymphotropic virus type-1/H. Blood78:571-574, 1991.
 
104) Nishimoto N, Yoshizaki K, Eiraku N, MachigashiraK, Tagoh H, Ogata A, Kuritani T, Osame M, Kishimoto T:Elevated levels of interleukin-6 inserum and cerebrospinal fluid of HTLV-1-associatedmyelopathy/tropical spastic paraparesis. J. NeuroLSci. 97:183-193, 1990.
 
105) Tosato G, Tanner J, Jorles KD et al.:Identification ofinterleukin-6 as arl autocrine growth factor forEpstein-Barr virus-immortalized B cells. J. Virol. 64:3033-3041, 1990.
 
106) Gosselin J, Flamand L, D'Addario M, Hiscott J, Stefanescu I, Ablashi DV, Gallo RC, Menezes J:Modulatory effects of Epstein-Barr herpes simplexand human herpes-6 viral infections and coinfectionon cytokine synthesis. A comparative study. J. Immunol l46:181-187, 1992.
 
107) Ohzato H, Yoshizaki K, Nishimoto N, Ogata A, TagohH, Monden M, Gotoh M, Kishimoto T, Mori T:Interleukin-6 as a new indicator of inflammatorystatus:Detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery 111:201-209, 1992.
 
108) Nijsten MWN, Degroot ER, TenDuis et al.:Serumlevels of interleukin-6 and acute phase responses. Lancet 17:921, 1987.
 
109) Hirano T, Matsuda T, Turner M, Miyasaka N, Bucham G, Tang B, Sato K, Shirnizu M, Maini R, Feldman M, Kishimoto T:Excessive production ofinterleukin 6/B cell stimulatory factor-2 in rheumatoidarthritis. Eur. J. Immunol. 18:1797-1801, 1988.
 
110) 西本憲弘, 緒方 篤, 嶋 良仁・他:サイトカイン, IL-6. 癌と化学療法 21:1707-1716, 1994.
 
111) Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM:Reshaping ahuman antibody to inhibit the interleukin-6-dependent tumor cell growth. Cancer Res. 53:851-856, 1993.
 
112) Nishimoto N, Ogata A, Shima Y, Tani Y, Ogata H, Nakagawa M, Sugiyama H, Yoshizaki K, Kishimoto T:Oncostatin M, leukemia inhibitory factor, andinterleukin-6 induce the proliferation of humanplasmacytoma cells via the common signaltransducer, gp130. J. Exp. Med. 179:1343-1347, 1994.
 
113) 西本憲弘, 吉崎和幸, 嶋 良仁・他:ヒト型抗IL-6 受容体抗体を用いたミエローマ, キャッスルマン病, 慢性関節リウマチの治療. 治療学 30:66-69, 1996.
 
114) Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K:Improvement in Castleman's disease by humanizedanti-interleukin-6 receptor antibody therapy. Blood95:56-61, 2000.
PubMed
115) Nishimoto N, Kishimoto T, Yoshizaki K:Anticytokine therapy in autoimmune diseases. Intern. Med. 38:178-182, 1999.
PubMed
P.171 掲載の参考文献
1) Namen AE, Schmierer AE, March CJ et al.:Bcell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J. Exp. Med. 167:988-1002, 1988.
 
2) Namen AE, Lupton S, Hjerrild K et al.:Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 333(6173):571-573, 1988.
PubMed
3) Goodwin RG, Lupton S, Schmierer A et al.:Human interleukin 7:molecular cloning and growth factor activity on human and murine B-lineage cells. Proc. Natl. Acad. Sci. USA 86:302-306, 1989.
PubMed
4) Noguchi M, Nakamura Y, Russell SM et al.:Interleukin-2 receptor gamma chain:afunctional component of the interleukin-7 receptor. Science 262(5141):1877-1880, 1993.
 
5) Park LS, Martin U, Garka K et al:Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor:Formation of a functional heteromeric complex requires interleukin 7 receptor. J. Exp. Med. 192:659-670, 2000.
PubMed
6) Goodwin RG, Friend D, Ziegler SF et al.:Cloning of the human and murine interleukin-7 receptors:demonstration of a soluble form and homology to a new receptor superfamily. Cel160:941-951, 1990.
PubMed
7) Puel A, Ziegler SF, Buckley RH et al.:Defective IL7R expression in T(-) B(+) NK(+) severe combined immunodeficiency. Nat. Genet. 20:394-397, 1998.
 
8) Lupton SD, Gimpel S, Jerzy R et al.:Characterization of the human and murine IL-7genes. J. Immunol 144:3592-3601, 1990.
 
9) Wiles MV, Ruiz P, Imhof BA:Interleukin-7expression during mouse thymus development. Eur. J. Immunol. 22:1037-1042, 1992
 
10) Heufler C, Topar G, Grasseger A et al.:Interleukin 7 is produced by murine and human keratinocytes. J. Exp. Med. 178:1109-1114, 1993.
PubMed
11) Sorg RV, McLellan AD, Hock BD et al.:Human dendritic cells express functional interleukin-7. Immunobiology 198:514-526, 1998.
PubMed
12) Watanabe M, Ueno Y, Yajima T et al.:Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J. Clin. Invest. 95:2945-2953, 1995.
PubMed
13) Tang J, Nuccie BL, Ritterman I et al.:TGF-beta down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors. J. Immunol 159:117-125, 1997.
 
14) Sudo T, Ito M, Ogawa Y et al.:Interleukin 7 production and function in stromal cell-dependent B cell development. J. Exp. Med. 170:333-338, 1989.
PubMed
15) Ariizumi K, Meng Y, Bergstresser PR et al.:IFN-gamma-dependent IL-7gene regulation in keratinocytes. J. Immunol 154:6031-6039, 1995.
 
16) Aragane Y, Schwarz A, Luger TA et al.:Ultraviolet light suppresses IFN-gamma-induced IL-7 gene expression in murine keratinocytes by interfering with IFN regulatory factors. J. Immunol 158:5393-5399, 1997.
PubMed
17) Takeda S, Gillis S, Palacios R:in vitro effects of recombinant interleukin 7 on growth and differentiation of bone marrow pro-B-and pro-T-lymphocyte clones and fetal thymocyte clones. Proc. Natl. Acad. Sci. USA 86:1634-1638, 1989.
 
18) Chantry D, Turner M, Feldmann M:Interleukin 7 (murine pre-B cell growth factor/lymphopoietin l stimulates thymocyte growth:regulation by transforming growth factor beta) . Eur. J. Immunol l9:783-786, 1989.
 
19) Morrissey PJ, Goodwin RG, Nordan RP et al.:Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. J. Exp. Med. 169:707-716, 1989.
PubMed
20) von Freeden-Jeffry U, Vieira P, Lucian LA et al.:Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 181:1519-1526, 1995.
PubMed
21) Moore TA, von Freeden-Jeffry U, Murray R et al.:Inhibition of gamma delta T cell development and earlythymocyte maturation in IL-7-/-mice. J. Immunol 157:2366-2373, 1996.
PubMed
22) Fisher AG, Burdet C, Bunce C et al.:Lymphoproliferative disorders in IL-7 transgenic mice:expansion of immature B cells which retain macrophage potential. Int. Immunol. 7:415-423, 1995.
PubMed
23) Morrissey PJ, Conlon P, Braddy S et al.:Administration of IL-7 to mice with cyclophosphamide-induced lymphopenia accelerates lyrnphocyte repopulation. J. Immunol. 146:1547-1552, 1991.
PubMed
24) Damia G, Komschlies KL, Faltynek CR et al.:Administration of recombinant human interleukin-7 alters the frequency and number of myeloid progenitor cells in the bone marrow and spleen of mice. Blood 79:1121-1129, 1992.
PubMed
25) Corcoran AE, Riddell A, Krooshoop D et al.:Impaired immunoglobulin gene rearrangement in mice lacking the IL-7receptor. Nature 391(6670):904-907, 1998.
 
26) von Freeden-Jeffry U, Solvason N, Howard M et al:The earliest T lineage-committed cells depend on IL-7 for Bcl-2 expression and normal cell cycle progression. Immunity 7:147-154, 1997.
PubMed
27) Kim K, Lee CK, Sayers TJ et al.:The trophic action of IL-7 on pro-T cells:inhibition of apoptosis of pro-T1, -T2, and-T3 cells correlates with Bcl-2 and Bax levels and is independent of Fas and p53 pathways. J. Immunol 160:5735-5741, 1998.
 
28) Pallard C, Stegmann AP, van Kleffens T et al.:Distinct roles of the phosphatidylinositol 3-kinase and STAT5 pathways in IL-7-mediated development of human thymocyte precursors. Immunity 10:525-535, 1999.
PubMed
29) Ye SK, Agata Y, Lee HC et al.:The IL-7 receptor controIs the accessibility of the TCR gamrna locus by Stat5 and histone acetylation. Immunity 15:813-823, 2001.
 
30) Chazen GD, Pereira GM, LeGros G et al.:Interleukin 7 is a T-cell growth factor. Proc. Natl. Acad. Sci. USA 86:5923-5927, 1989.
 
31) Boise LH, Minn AJ, June CH et al.:Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division. Proc. Natl. Acad. Sci. USA 92:5491-5495, 1995.
PubMed
32) Alderson MR, Sassenfeld HM, Widmer MB:Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J. Exp, Med. 172:577-587, 1990.
 
33) Lynch DH, Namen AE, Miller RE:in vivo. evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur. J. Immunol. 21:2977-2985, 1991.
PubMed
34) Lynch DH, Miller RE:Induction of murine lymphokine-activated killer cells by recombinant IL-7. J. Immunol 145:1983-1990, 1990.
PubMed
35) Tanchot C, Lemorlnier FA, Perarnau B et al.:Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science 276(5321):2057-2062, 1997.
PubMed
36) Murali-Krishna K, Lau LL, Sambhara S et al.:Persistence of memory CD8 T cells in MHC class I deficient mice. Science 286(5443):1377-1381, 1999.
PubMed
37) Tan JT, Dudl E, LeRoy E et al.:IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. USA 98:8732-8737, 2001.
PubMed
38) Tan JT, Ernst B, Kieper WC et al.:Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of rnemory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med. 195:1523-1532, 2002.
 
39) Seddon B, Tomlinson P, Zamoyska R:Interleukin 7 and T cell receptor signaIs regulate homeostasis of CD4 memory cells. Nat. Immunol. 4:680-686, 2003.
 
40) Jameson SC:Maintaining the Norm:T-cell homeostasis. Nat. Rev. Immunol. 2:547-556, 2002.
PubMed
41) Saito H, Kanamori Y, Takemori T et al:Generation of intestinal T cells from progenitors residing in gut cryptopatches. Science 280(5361):275-278, 1998.
PubMed
42) Suzuki K, Oida T, Hamada H et al.:Gut cryptopatches:direct evidence of extrathymic anatomical sites for intestinal T lymphopoiesis. Immunity 13:691-702, 2000.
PubMed
43) Adachi S, Yoshida H, Honda K et al.:Essential role of IL-7 receptor alpha in the formation of Peyer's patch anlage. Int. Immunol 10:1-6, 1998.
PubMed
44) Yoshida H, Naito A, Inoue J et al.:Different cytokines induce surface lymphotoxin-alphabeta on IL-7 receptor-alpha cells that differentially engender lymph rlodes and Peyer's patches. Immunity 17:823-833, 2002.
PubMed
45) Watanabe M, Ueno Y, Yajima T et al.:Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J. Exp. Med. 187:389-402, 1998.
PubMed
46) Yamazaki M, Yajima T, Tanabe M et al.:Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J. Immunol. 171:1556-1563, 2003.
PubMed
47) Dalloul A, Laroche L Bagot M:Interleukin-7 is a growth factor for Sezary lymphoma cells. J. Clin. Invest. 90:1054-1060, 1992.
 
48) Bolotin E, Annett G, Parkman R et al.:Serum levels of IL-7in bone marrow transplant recipients:relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 23:783-788, 1999.
 
49) Fry TJ, Connick E, Falloon J et al.:Apotential role for interleukin-7 in T-cell homeostasis. Blood 97:2983-2990, 2001.
 
50) Napolitano LA, Grant RM, Deeks SG et al.:Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion:implications for T-cell homeostasis. Nat, Med. 7:73-79, 2001.
 
51) Moller P, Sun Y, Dorbic T et al.:Vaccination with IL-7 gene-modified autologous melanorna cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status:aclinical phase I study. Br. J. Cancer 77:1907-1916, 1998.
 
52) Moller P, Moller H, Sun Y et al.:Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells. Cancer Gene Ther. 7:976-984, 2000.
PubMed
53) Carsana M, Tragni G, Nicolini G et al.:Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine. Cancer Gene Ther. 9:243-253, 2002
 
P.185 掲載の参考文献
1) Fiorentino DF, Bond MW, Mosmann TR:Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones. J. Exp. Med. 170:2081-2095, 1989.
 
2) Groux H, O'Garra A, Bigler M et al.:ACD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737-742, 1997.
 
3) van Parijs L, Abbas AK:Homeostasis and self tolerance in the immune system:turning lymphocytes off. Science 280:243-248, 1998.
PubMed
4) Kappler JW, Roebm N, Marrack P:Tcell tolerance by clonal elimination in the thymus. Cell 49:273-280, 1987.
 
5) Kisielow P, Bluthmann H, Staerz UD et al.:Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+CD8+ thymocytes. Nature 333:742-746, 1998.
 
6) Sakaguchi S:Regulatory T cells;key controllers of immunologic self-tolerance. Cell 101:455-458, 2000.
PubMed
7) Mosmann TR:Cytokine secretion patterns and cross-regulation of T cell subsets. Immunol. Res. 10:183-188, 1991.
PubMed
8) Moore KW, Vieira P, Fiorentino D et al.:Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1. Science 248:1230-1234, 1990.
 
9) Vieira P, de Waal-Maleft R, Dang MN et al.:Isolation and expression of human cytokine synthesis inhibitory factor (CSIF/IL-10) cDNA clones:Homology to Epstein-Barr virus open reading frame BCRF1. Proc. Natl. Acad. Sci. USA 88:1172-1176, 1991.
 
10) Kim JM, Brannan CI, Copeland NG et al.:Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J. Immunol. 148:3618-3623, 1992.
 
11) Ho A, Liu Y, Khan TA et al.:Areceptorfor interleukin-10 is related to interferon receptors. Proc. Natl. Acad, Sci. USA 90:11267-11271, 1993.
PubMed
12) Liu Y, Wei S, Ho A et al, :Expression cloning and characterization of a human interleukin-10 receptor. J. Immunol. 152:1821-1829, 1994.
 
13) Kotenko SV, Krause CD, Izotova LS et al.:Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J. 16:5894-5903, 1997.
PubMed
14) Kotenko SV, Izotova LS, Mirochnitchenko OV et al.:Identification of the functional interleukin-22 (IL-22) receptor complex. J. Biol. Chem. 276:2725-2732, 2001.
PubMed
15) Howard M, O'Garra A, Ishida H et al.:Biological properties of interleukin 10. J. Clin. Immunol. 12:239-247, 1992.
 
16) Roncarolo MG, Levings MK:The role of different subsets of T regulatory cells in controlling autoimmunity. Curr. Opin. Immunol. 12:673-683, 2000.
 
17) Barrat FJ, Cua DJ, Boonstra A et al.:In vitro generation of interleukin 10-producing regulatory CD4(+) Tcells is induced by immunosuppressive drugs and inhibited by T helper type 1(Th1)-and Th2-inducing cytokines. J. Exp. Med. 195:603-616, 2002.
 
18) Kemper C, Chan AC, Green JM et al.:Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell l phenotype. Nature 421:388-392, 2003.
 
19) 石田 博:Tr1細胞の分化誘導におけるCD46. 臨床免疫 40:563-571, 2003.
 
20) O'Garra A, Chang R, Go N et al.:Ly-l B (B-1) cells are the main source of B cell-derived interleukin 110. Eur, J. Immunol. 22:711-717, 1992.
 
21) Ishida H, Hastings R, Kearney J et al.:Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. J. Exp. Med. 175:1213-1220, 1992.
 
22) KUhn R, L6hler J, Rennick D et al.:Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263-274, 1993.
 
23) Hsu DH, de Waal-Malefyt R, Fiorentino DF et al.:Expression of IL-10 activity by Epstein-Barr virus protein BCRF1. Science 250:830-832, 1990.
PubMed
24) Ishida H, Hastings R, Snipes L et al:Modified immunological status of anti-IL10 treated mice. Cell Immunol. 148:371-384, 1993.
 
25) Wogensen L, Huang X, Sarvetnick N:Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans. J. Exp Med. 178:175-185, 1993.
PubMed
26) Moritani M, Yoshimoto K, Ii S et al.:Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Thl lymphocytes. A gene therapy model for autoimmune diabetes. J. Clin. Invest. 98:1851-1859, 1996.
 
27) Saito l, Haruta K, Shimuta M et al.:Fas ligand-mediated exocrinopathy resembling Sjogren's syndrome in mice transgenic for IL-10. J. Immunol. 162:2488-2494, 1999.
 
28) Ishida H, Muchamuel T, Sakaguchi S et al.:Continuous administration of anti-IL-10 antibodies delays onset of autoimmunity in NZB/WFI mice. J. Exp. Med. 179:305-310, 1994.
 
29) 石田 博, 柳田英寿:膠原病患者の血清サイトカイン診断. 臨床病理 47:327-334, 1999.
 
30) Nonoyama S, Farrington M, Ishida H et al.:Activated Bcells from patients with common variable immunodeficiency proliferate and synthesize immunoglobulin. J. Clin. Invest. 92:1282-1287, 1993.
 
31) 石田 博, 熊谷俊一, 井村裕夫:細胞内情報伝達系と疾患. SLE. Clin. Neurosci. 9:892-895, 1991.
 
32) Kennedy MK, Torrance DS, Picha KS et al.:Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveaIs that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:2496-2505, 1992.
 
33) Rott O, Fleischer B, Cash E:Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 24:1434-1440, 1994.
PubMed
34) Rosenbaum JT, Angell E:Paradoxical effects of IL-10 in endotoxin-induced uveitis. J. Immunol 155:4090-4094, 1995.
PubMed
35) Meng X, Sawamura D, Tamai K et al.:Keratinocyte gene therapy for systemic diseases. Circulating interleukin 10released from gene-transferred keratinocytes inhibits contact hypersensitivity at distant areas of the skin. J. Clin. Invest. 101:1462-1467, 1998.
PubMed
36) Suzuki A, Hanada T, Mitsuyama K et al.:CIS3/SOCS3/ SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med. 193:471-481, 2001.
 
37) Colombel JF, Rutgeerts P, Malchow H et al.:Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49:42-46, 2001.
PubMed
38) Tilg H, van Montfrans C, van den Ende A et al.:Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 50:191-195, 2002.
PubMed
39) Shand A, Forbes A:Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease:in the shadow of infliximab? Int. J. Colorectal. Dis. 18:1-11, 2003.
PubMed
40) Howard M, Muchamuel T, Andrade S et al.:Interleukin 10 protects mice from lethal endotoxemia. J. Exp. Med. 177:1205-1208, 1990.
 
41) Friedman G, Jankowski S, Marchant A et al.:Bloodinterleukin 10 levels parallel the severity of septic shock. J. Crit. Care 12:183-187, 1997.
PubMed
42) Kato T, Murata A, Ishida H et al.:Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob. Agents Chemother 39:1336-1340, 1995.
PubMed
43) Ikuta S, Ono S, Kinoshita M et al.:Interleukin-18 concentration in the peritoneal fluid correlates with the severity of peritonitis. Am. J. Surg. 185:550-555, 2003.
PubMed
44) Nishio R, Matsumori A, Shioi T et al.:Treatment of experimental viral myocarditis with interleukin-10. Circulation 100:1102-1108, 1999.
PubMed
45) Emilie D, Touitou R, Raphae1 M et al.:In vivo production of interleukin-10 by malignant cells in AIDS lymphomas. Eur. J. Immunol. 22:2937-2942, 1992.
 
46) Benjamin D, Knobloch TJ, Dayton MA:Human B-cell interleukin-10:B-cell lines derived from patiernts with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 80:1289-1298 1992.
 
47) Giomarelli P, Scolletta S, Borrelli E et al.:Myocardial and lung injury after cardiopulmonary bypass:role of interleukin (IL)-10. Ann. Thorac. Surg. 76:117-123, 2003.
PubMed
48) Llorente L, Richaud-Patin Y, Garcia-Padilla C et al:Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43:1790-1800, 2000.
PubMed
49) Huhn R, Radwanski E, O'Connell SM et al.:Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant humarl interleukin-10 in healthy volunteers. Blood 87:699-705, 1996.
PubMed
50) Tilg H, Ulmer H, Kaser A, Weiss G et al.:Role of IL-10 for induction of anemia during inflammation. J. Immunol, 169:2204-2209, 2002
PubMed
P.197 掲載の参考文献
1) Paul SR, Bennet F, Calvetti JA et al.:Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc. Natl. Acad. Sci. 87:7512-7516, 1990.
 
2) Kawashima I, Ohsumi J, Mita-Honjo K et al.:Molecular cloning of cDNA encoding adipogenesis inhibitory factor and identity with interleukin-11. FEBS. 283:199-202, 1991.
PubMed
3) Barton VA, Hall MA, Hudson KR et al.:Interleukin-11 signaIs through the formation of a hexameric receptor complex. J. Biol. Chem. 275:36197-36203, 2000.
PubMed
4) Davidson AJ, Freeman S-A, Crosier KE et al:Expression of murine intereukin 11 and its receptor α-chain in adult and embryonic tissues. Stem Cells 15:119-124, 1997.
 
5) Cherel M, Sorel M, Apiou F et al.:The human interleukin-11 receptoragene (IL11RA):Genomic organization and chromosome mapping. Genomics 32:49-53, 1996.
PubMed
6) Cherel M, Sorel M, Lebeau B et al.:Molecular cloning of two isoforms of a receptor for the human hematopoietic cytokine interleukin-11. Blood 86:2534-2540, 1995.
PubMed
7) Yang Y-C, Yin T:Interleukin-11-mediated signal transduction. Ann. New York Acad. Sci. 762:31-40, 1995.
 
8) Musashi M, Yang Y, Paul SR et al.:Direct and synergistic effects of interleukin-110n murine hemopoiesis in culture. Proc. Natl. Acad. Sci. 88:765-769, 1991.
 
9) Musashi M, Clark SC, Sudo T et al.:Synergistic interactions between interleukin-11 and interleukin-4in support of proliferation of primitive hematopoietic progenitors of mice. Blood 78:1448-1451, 1991.
 
10) Brandt JE, Hoffman R:Interleukin-11 plays a pivital role in the in vitro expansion of human hematopoietic progenitor and stem cells. Blood 82:368a, 1993.
 
11) Neben S, Donaldson D, Sieff C et al.:Synergistic effects of interieukin-11 with other factors on the expansion of murine hematopoietic progenitors and maintenance of stem cells in liquid culture. Exp. Hematol. 22:353-359, 1994.
 
12) Keller DC, Du XX, Srour EF et al.:Inteleukin-11 inhibits adipogenesis and sitmulates myelopoiesis in human long-term marrow cultures. Blood 82:1428-1435, 1993.
 
13) Quesniaux VFI, Clark SC, Turner K et al.:Interleukin-11stimulates multiple phases of erythropoiesis. Blood 80:1218-1223, 1992.
 
14) Burstein SA, Mei RL, Henthorn J et al.:Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J. Cell Physiol. 153:305-312, 1992.
PubMed
15) Teramura M, Kobayashi S, Hoshino S et al.:Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 79:327-331, 1992.
PubMed
16) Hangoc G, Yin T, Cooper S et al.:In vivo effects of recombinant interleukin-11 On myelopoiesis in mice. Blood 81:965-972, 1993.
PubMed
17) Trepicchio WL, Bozza M, Pedneault G:Recombinant human IL-11 attenuates the inflammatory response through downregulation of proinflammatory cytokine release and nitric oxide production. J. Immunol. 157:3627-3634, 1996.
PubMed
18) Redlich CA, Gao X, Rockwell S et al:IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury. J. Immunol. 157:1705-1710, 1996.
PubMed
19) Leng SX, Elias JA:Interleukin-11 inhibits macrophage interleukin-12 production. J. Immunol 159:2161-2168, 1997.
PubMed
20) Anderson KC, Morimoto C, Paul SR et al.:Interleukin-11promotes accessory cell-dependent B-cell differentiation in humans. Blood 80:2797-2804, 1992.
PubMed
21) Schwertschlag US, Trepicchio WL, Dykstra KH et al.:Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 13:1307-1315, 1999.
PubMed
22) Mehler MF, Rozental R, Dougherty M et al.:Cytokine regulation of neuronal differentiation of hippocampal progenitor cells. Nature 362:62-65, 1993.
PubMed
23) Fann M-J, Patterson PH:Neuropoietic cytokines and activin A differentially regulate the phenotype of cultured sympathetic neurons. Proc. Natl. Acad. Sci. USA 91:43-47, 1994.
PubMed
24) Hughes FJ, HowelIs GL:Interleukin-11 inhibits bone formation in vitro. Calcif. Tissue Int. 53:362-364, 1993.
 
25) Girasole G, Passeri G, Jika RL et al.:Interleukin-11:Anew cytokine critical for osteoclast development. J. Clin. Invest. 93:1516-1524, 1994.
 
26) Takeuchi Y, WataRabe S, Ishii G et al.:Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J. Biochem. Chem. 277:49011-49018, 2002.
 
27) Maier R, Ganu V, Lotz M:Interleukin-11, an inducible cytokine in human articular chondrocytes and synoviocytes, stimulates the production of tissue inhibitor of metalloproteinases. J. Biol. Chem. 268:21527-21532, 1993.
PubMed
28) Zimmerman MA, Selzman CH, Reznikov LL et al.: Interleukin-11 attenuates human vascular smooth muscle cell proliferation. Am. J. Physiol 283:H175-180, 2002.
 
29) Baumann H, Schendel P:Interleukin-11regulates the hepatic expression of the same plasma protein genes as interleukin-6. J. Biol. Chem. 226:20424-20427, 1991
 
30) Pennica D, King, KL, Shaw KJ et al.:Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc. Natl. Acad. Aci. USA 92:1142-1146, 1995.
 
31) Karpovich N, Chobotova K, Carver J et al:Expression and function of interleukin-11 and its receptor alpha in the human endometrium. Molec. Hum. Reproduc. 9:75-80, 2003.
 
32) Yamaguchi M, Taga T, Kishimoto T et al:Cytokines that use gp130 as a signal transducer stimulate mouse placental lactogen-I (mPL-I) but inhibit mPL-II production in vitro. Biol. Reproduc. 53:399-406, 1995.
 
33) Du X, Everett ET, Wang G et al.:Murine interleukin-11 (IL-11) is expressed at high levels in the hippocampus and expression is developmentally regulated in the testis. J. Cell Physiol. 168:362-372, 1996.
PubMed
34) Robb L, Li R, Hartley L et al.:Infertility in female micelacking the receptor for interleukin 11 is due to adefective uterine response to imp1antation. NatureMed. 4:303-308, 1998.
 
35) Baynes RD, Cook JD, Keith J et al.:Interleukin-1lenhances gastrointestinal absorption of iron in rats. Br. J. Haematol 91:230-233, 1995.
PubMed
36) Denis CV, Kwack K, Saffaripour S et al.:Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII wild type and von Willebrand disease mouse modeIs. Blood 97:462-472, 2001.
 
37) Hu JP, Cesano A, Santoli D et al:Effects of interleukin-11 on the proliferation and cell cycle status of myeloidleukemic cells. Blood 81:1586-1592, 1993.
 
38) Kobayashi S, Teramura M, Sugawara I et al.:Interleukin-11 acts as an autocrine growth factor formegakaryoblastic cell lines. Blood 81:889-893, 1993.
PubMed
39) Zhang X-G, Gu J-J, Lu Z-Y et al.:Ciliary neurotropic factor, interleukin 11, leukernia inhibitory factor, andoncostatin M are growth factors for human myelomacell lines using the interleukin 6 signal transducer GP130. J. Exp. Med. 177:1337-1342, 1994.
 
40) Paul SR, Barut A, Bennett F et al.:Lack of a role of interleukin 11 in the growth of multiple myeloma. Leuk. Res. 16:247-252, 1992.
 
41) Nishimoto N, Ogata A, Shima Y et al.:Oncostatin M, leukemia inhibitory factor, and interleukin 6 inducethe proliferarition of human plasmacytoma cells viathe common signal transducer, GP130. J. Exp. Med. 179:1343-1347, 1994.
 
42) Du XX, Doerschuk, CM, Orazi A et al.:Abone marrowstromal-cell drived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cellsafter cytoablative therapy. Blood 83:33-37, 1994.
 
43) Lentsch AB, Crouch LD, Jordan JA et al:Regulatory effects of interleukin-11 during acute lunginflammatory injury. J. Leukocyte. Biol 66:151-157, 1999.
 
44) Einarsson O, Geba GP, Zhu Z et al.:Interleukin-11:Stimulation in vivo abd in vitro by respiratoryviruses and induction of airways hyperresponsiveness. J. Clin. Invest. 97:915-924, 1996.
 
45) Gordon MS, McCaskill-Stevens WJ, Battiato LA et al.:Aphase 1 trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women withbreast cancer receiving chemotherapy. Blood 87:3615-3674, 1996.
 
46) Tepler I, Elias L, Smith JW 2nd et al.:A randomized placebo-controlled trial of recombinant humaninter leukin-11 in cancer patients with sever ethrombocytopenia due to chemotherapy. Blood 87:3607-3614, 1996.
 
47) Isaacs C, Robert NJ, Bailey FA et al.:Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer recieving dose-intensive cyclo phosphamide and doxorubicin. J. Clin. Onclol. 15:3368-3377, 1997.
 
48) Vredenburgh JJ, Hussein A, Fisher D et al.:A randomized trial of recombinant human interluekin-11 following autologous bone marrow transplantation with peripheral blood cell support in patients with breast cancer. Biol. Blood Marrow Transplant. 4:134-141, 1998.
 
49) Ghalib R, Levine C, Hassan M et al.:Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology 37:1165-1171, 2003.
PubMed
50) Du XX, Doerschuk CM, Orazi A et al.:A bone marrow stromal-cell derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 83:33-37, 1994.
PubMed
51) Orazi A, Du X, Yang Z et al.:Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab. Invest. 75:33-42, 1996.
PubMed
52) Peterson RL, Bozza MM, Dorner AJ et al.:Interleukin-11 induced intestinal epithelial cell growth arrest through effects on retinoblastoma protein phosphorylation. Am. J. Phathol. 149:895-902, 1996.
 
53) Elis M, Zwaan F, Hedstrom U et al.:Recombinant human interleukin-11 and bacterial infection in patients with haematological malignant disease under going chemotherapy:adouble-blind randomized trial. Lancet 361:275-280, 2003.
 
54) Opal SM, Keith JC Jr, Jhung J et al.:Orally administered recombinant human interleukin-11 is protective in experimental neurtopenic sepsis. J. Infect. Dis. 187:70-76, 2003.
PubMed
55) Opal SM, Jhung J, Keith JC Jr et al.:Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis. Blood 93:3467-3472, 1997.
 
56) Liu Q, Du XX, Schindel DT et al.:Trophic effects of interleukin-11 in rats with experimental short bowel syndrome. J. Pediatr. Surg. 31:1047-1050, 1996.
PubMed
57) Qiu BS, Pfeiffer CJ, Keith JC Jr:Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Digest. Dis. Sci. 41:1625-1630, 1996.
PubMed
58) Castagliuolo I, Kelly CP, Qiu BS et al:IL-11 inhibits clostridium difficile toxin A enterotoxicity in rat ileurn, Am. J. Physiol. 273:G333-341, 1997.
 
59) Sands BE, Winston BD, Salzberg B et al.:Randomized, controlled trial of recombinant human interleukin-11 in patients with active Chron's disease. Alimentary Pharmacol. Ther. 16:399-406, 2002.
 
60) Schindel D, Maze R, Liu Q et al.:Interleukin-11 improves survival and reduces bacterial translocation and bone marrow suppression in burned mice. J. Pediatr. Surg. 32:312-315, 1997.
PubMed
61) Moreland L, Gugliotti R, King K et al.:Results of a Phase I/II randomized, masked, plasebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res. 3:247-252, 2001.
 
62) Shimizu T, Shiratori K, Sawada T et al.:Recombinant human interleukin-11 decreases severity of acute necrotizing pancreatitis in mice. Pancreas 21:134-140, 2000.
PubMed
63) Sonis ST, Peterson RL, Edward LJ et al.:Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol. 36:373-381, 2000.
 
64) Scordi IA, Nassiri M, Hanly AJ et al.:Interleukin-11 reduces apoptosis in USB-irradiated mouse skin. Dermatology 199:296-301, 1999.
 
65) Hill GR, Cooke KR, Teshima T et al.:Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102:115-123, 1998.
PubMed
66) Teshima T, Hill GR, Pan L et al:IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J. Clin. Invest. 104:317-325, 1999.
PubMed
67) Antin JH, Lee SJ, Neuberg D et al.:Aphase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation, Bone Marrow Translant. 29:373-377, 2002.
 
P.209 掲載の参考文献
1) Kobayashi M, Fitz L, Ryan M et al.:Identification and purification of natural killer stimulatory factor (NKSF) , acytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827-845, 1989.
 
2) Wolf SF, Temple PA, Kobayashi M et al.:Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol 146:3074-3081, 1991.
 
3) Hsieh CS, Macatonia SE, Tripp CS et al.:Development of THI CD4-T cells through IL-12 produced by Listeria-induced macrophages. Science 23(260):547-549, 1993.
 
4) Stern AS, Podlaski FJ, Hulmes JD et al.:Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 87:6808-6812, 1990.
 
5) Manetti R, Parronchi P, Giudizi MG et al.:Natural killer cell stimulatory factor (interleukin 12[IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199-1204, 1993.
 
6) D'Andrea A, Rengaraju M, Valiante NM et al.:Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J. Exp. Med. 176:1387-1398, 1992.
PubMed
7) Macatonia SE, Hosken NA, Litton M et al.:Dendritic cells produce IL-12 and direct the development of Thl cells from naive CD4+ T cells. J. Immunol 154:5071-5079, 1995.
 
8) Merberg DM, Wolf SF, Clark SC:Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol. Today 13:77-78, 1992.
PubMed
9) Ma X, Trinchieri G:Regulation of interleukin-12 production in antigen-presenting cells. Adv. Immunol 79:55-92, 2001.
PubMed
10) Trinchieri G:Interleukin-12:acytokine at the interface of inflammation and immunity. Adv. Immunol. 70:83-243, 1998.
 
11) Oppmann B, Lesley R, Blom B et al.:Novel plg protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715-725, 2000.
 
12) Pflanz S, Timans JC, Cheung J et al.:IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16:779-790, 2002.
PubMed
13) Trinchieri G:Interleukin-12:aproinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol 13:251-276, 1995.
PubMed
14) Ma X, Chow JM, Gri G et al.:The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med 183:147-157, 1996.
 
15) Wagner H:Toll meets bacterial CpG-DNA. Immunity 14:499-502, 2001.
PubMed
16) Kawano T, Cui J, Koezuka Y et al.:CDId-restricted and TCR-mediated activation of valphal4 NKT cells by glycosylceramides. Science 278(5343):1626-1629, 1997.
 
17) Mosmann TR, Sad S:The expanding universe of T-cell subsets:Th1, Th2 and more. Immunol. Today 17:138-146, 1996.
PubMed
18) Tsuchiya Y, Igarashi M, Suzuki R et al.:Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. J. Immunol l41:699-708, 1988.
 
19) Takeda K, Hatakeyama K, Tsuchiya Y et al.:A correlation between GM-CSF gene expression and metastases in murine tumors. Int. J. Cancer 47:413-420, 1991.
PubMed
20) Takeda K, Fujii N, Nitta Y et al:Murine tumor cells metastasizing selectively in the liver:ability to produce hepatocyte-activating cytokines interleukin-1and/or-6. JPn. J. Cancer Res. 82:1299-1308, 1991.
PubMed
21) Hashimoto W, Takeda K, Anzai R et al.:Cytotoxic NK1. 1 Ag-alpha beta T cells with intermediate TCR induced in the liver of mice by IL12. J. Immunol 154:4333-4340, 1995.
 
22) Takeda K, Seki S, Ogasawara K et al.:Liver NK1. 1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J. Immunol 156:3366-3373, 1996.
 
23) Kumagai K, Takeda K, Hashimoto W et al:Interleukin-12as an inducer of cytotoxic effectors in anti-tumor immunity. International Reviews of Immunology 14:229-256, 1997.
 
24) Takahashi M, Ogasawara K, Takeda K et al.:LPS induces NK1. 1+ alpha beta T cells with potent cytotoxicity in the liver of mice via production of IL 12 from Kupffer cells. J. Immunol 156:2436-2442, 1996.
 
25) Lieberman MD, Sigal RK, Williams NN 2nd et al.:Natural killer cell stimulatory factor (NKSF) augments natural killer cell and antibody-dependent tumoricidal response against colon carcinoma cell lines. J. Surg. Res. 50:410-415, 1991.
PubMed
26) Rossi AR, Pericle F, Rashleigh S et al:Lysis of neuroblastoma cell lines by human natural kiiler cells activated by interleukin-2 and interleukin 1-12. Blood 83(5):1323-1328, 1994.
 
27) Soiffer RJ, Robertson MJ, Murray C et al.:Interleukin-12augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 82:2790-2796, 1993.
PubMed
28) Andrews JV, Schoof DD, Bertagnolli MM et al.:Immunomodulatory effects of interleukin-12 on human tumor-infiltrating lymphocytes. J. Immunother. 14:1-10, 1993.
 
29) Tahara H, Zeh HJ 3rd, Storkus WJ et al.:Fibroblasts genetically engineered to secrete interleukin l2 cansuppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54:182-189, 1994.
 
30) Brunda MJ, Luistro L, Warrier RR et al.:Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223-1230, 1993,
PubMed
31) Gately MK, Warrier RR, Honasoge S et al.:Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int. Immunol. 6:157-167, 1994.
PubMed
32) Zeh HJ 3rd, Hurd S, Storkus WJ et al.:Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors:imp1ications for the immuno-therapy of cancer. J. Immunother. 14:155-161, 1993.
 
33) Nastala CL, Edington HD, McKinney TG et al.:Recombinant IL12 administration induces tumor regression in association with IFN-gamma production. J. Immunol. 153:1697-1706, 1994.
PubMed
34) Zou Jp, Yamamoto N, Fujii T et al.:Systemic administration of rIL-12 induces complete tumor regression and protective immunity:response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int. Immunol. 7:1135-1145, 1995.
PubMed
35) Banks RE, Patel PM, Selby PJ et al.:Interleukin 12:a new clinical player in cytokine therapy. Br. J. Cancer 71:655-659, 1995.
PubMed
36) Gazzinelli RT, Hieny S, Wynn TA et al.:Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc. Natl. Acad. Sci. USA 90:6115-6119, 1993.
 
37) Fallarino F, Uyttenhove C, Boon T et al:Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156:1095-1100, 1996.
PubMed
38) Smyth MJ, Thia KY, Street SE et al.:Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191:661-668, 2000.
PubMed
39) Trinchieri G:Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol 3:133-146, 2003.
PubMed
40) Nanni P, Nicoletti G, De Giovanni C et al.:Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogerlesis in HER-2/neu transgenic mice. J. Exp. Med. 194:1195-1205, 2001.
PubMed
41) Colombo MP, Trinchieri G:Interleukin-12 in antitumor immunity and immunotherapy. CytokineGrowth Factor Rev. 13:155-168, 2002.
 
42) Voest EE, Kenyon BM, O'Reilly MS et al.:Inhibitionof angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87:581-586, 1995.
 
43) Yao L, Pike SE, Setsuda J et al:Effective targeting oftumor vasculature by the angiogenesis inhibitorsvasostatin and interleukin-12. Blood 96:1900-1905, 2000.
 
44) Gee MS, Saunders HM, Lee JC et al:Dopplerultrasound imaging detects changes in tumorperfusion during antivascular therapy associated withvascular anatomic alterations. Cancer Res. 61:2974-2982, 2001.
 
45) Quaglino E, Rovero S, Cavallo F et al:Immunologicalprevention of spontaneous tumors:anew prospect?Immunol. Lett. 80:75-79, 2002.
 
46) Yang YF, Tomura M, Ono S et al.:Requirement forIFN-gamma in IL-12 production induced bycollaboration between v(alpha) 14(+) NKT cellsand antigen-presenting cells. Int. Immurlol. 12:1669-1675, 2000.
 
47) Nakahira M, Tomura M, Iwasaki M et al.:An absoluterequirement for STAT4 and a role for IFN-gamma asan amp1ifying factor in IL-12 induction of thefunctional IL-18 receptor complex. J. Immunol 167:1306-1312, 2001.
 
48) Uekusa Y, Yu WG, Mukai T et al.:Apivotal role forCC chemokine receptor 5 in T-cell migration totumor sites induced by interleukin 12 treatment intumor-bearing mice. Cancer Res. 62:3751-3758, 2002.
 
49) Sypek Jp, Chung CL, Mayor SE et al.:Resolution ofcutaneous leishmaniasis:interleukin 12 initiates aprotective T helper type 1 immune response. J. Exp. Med. 177:1797-1802, 1993.
 
50) Reiner SL, Zheng S, Wang ZE et al.:Leishmaniapromastigotes evade interleukin 12 (IL-12) inductionby rnacrophages and stimulate a broad range ofcytokines from CD4+ T cells during initiation ofinfection. J. Exp. Med. 179:447-456, 1994.
 
51) Murray HW, Hariprashad J et al.:Interleukin 12 iseffective treatment for an established systemicintracellular infection:experimental visceralleishmaniasis. J. Exp. Med. 181:387-391, 1995.
 
52) Scharton-Kersten T, Afonso LC, Wysocka M et al.:IL-12 is required for natural killer cell activation andsubsequent T helper l cell development inexperimental leishmaniasis. J. Immunol. 154:5320-5330, 1995.
 
53) Gazzinelli RT, Wysocka M, Hayashi S et al.:Parasiteinduced IL-12 stimulates early IFN-gammasynthesis and resistance during acute infection with Toxoplasmagondii. J. Immunol. 153:2533-2543, 1994.
 
54) Gazzinelli RT, Bala S, Stevens R et al:HIV infectionsuppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but faiIs to inhibit the synthesis of other parasite-induced monokines. J. Immunol 155:1565-1574, 1995.
 
55) Stevenson MM, Tam MF, Wolf SF et al.:IL-12-induced protection against blood-stage Plasmodiumchabaudi AS requires IFN-gamma and TNF-alphaand occurs via a nitric oxide-dependent mechanism. J. Immunol. 155:2545-2556, 1995.
 
56) Sedegah M, Finkelman F, Hoffman SL et al:Interleukin 12 induction of interferon gammadependent protection against malaria. Proc. Natl. Acad. Sci. USA 91:10700-10702, 1994.
PubMed
57) King CL, Hakimi J, Shata MT et al.:IL-12 regulationof parasite antigen-driven IgE production in humanhelminth infections. J. Immunol. 155:454-461, 1995.
 
58) Orange JS, Wolf SF, Biron CA:Effects of IL-120n the response and susceptibility to experimental viral infections. J. Immunol. 152:1253-1264, 1994.
 
59) Gazzinelli RT, Giese NA, Morse HC 3rd l In. vivotreatment with interleukin 12 protects mice fromimmune abnormalities observed during murineacquired immunodeficiency syndrome (MAIDS) . J. Exp. Med, 180:2199-2208, 1994.
 
60) Milich DR, Wolf SF, Hughes JL et al.:Interleukin 12 suppresses autoantibody production by reversinghelper T-cell phenotype in hepatitis B e antigentransgenic mice. Proc. Natl. Acad. Sci. USA 92:6847-6851, 1995.
 
61) Schijns VE, Haagmans BL, Horzinek MC:IL12 stimulates an antiviral type 1 cytokine response butlacks adjuvant activity in IFN-gamma-receptordeficient mice. J. Immunol. 155:2525-2532, 1995.
 
62) Orange JS, Wang B, Terhorst C, Biron CA:Requirement for natural kHler cell-producedinterferon gamma in defense against murinecytomegalovirus infection and enhancement of thisdefense pathway by interleukin 12 administration. J. Exp. Med. 182:1045-1056, 1995.
 
63) Geng Y, Berencsi K, Gyulai Z et al.:Roles ofinterleukin-12 and gamma interferon in murine Chlamydia pneumoniae infection. Infect. Immun. 68:2245-2253, 2000.
 
64) Carter LL, Murphy KM:Lineage-specific requirement for signal transducer and activator oftranscription (Stat) 4 in interferon gamma productionfrom CD4(+) versus CD8(+) Tcells. J. Exp. Med. 189:1355-1360, 1999.
 
65) Szabo SJ, Sullivan BM, Stemmann C et al.:Distincteffects of T-bet in THI lineage commitment and IFNgamma production in CD4 and CD8 T cells. Science 295(5553):338-342, 2002.
 
66) Gately MK, Wolitzky AG, Quinn PM et al.:Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol. 143:127-142, 1992.
PubMed
67) Tripp CS, Kanagawa O, Unanue ER:Secondary response to Listeria infection requires IFN-gamma but is partially independent of IL-12. J. Immunol 155:3427-3432, 1995.
PubMed
68) Sieling PA, Wang XH, Gately MK et al.:IL-12 regulates T helper type 1 cytokine responses in human infectious disease. J. Immunol. 153:3639-3647, 1994.
PubMed
69) Flynn JL, Goldstein MM, Triebold KJ et al.:IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosisinfection. J. Immmol. 155:2515-2524, 1995.
 
70) Flesch IE, Hess JH, Huang S et al.:Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferorl gamma and tumor necrosis factor alpha. J. Exp. Med. 181:1615-1621, 1995.
PubMed
71) Castro AG, Silva RA, Appelberg R:Endogenously produced IL-12 is required for the induction of protective T cells during mycobacterizemavium infections in mice. J. Immunol. 155:2013-2019, 1995.
PubMed
72) Romani L, Mencacci A, Tonnetti L et al.:IL-12 is both required and prognostic in vitro for T helper type 1 differentiation in murine candidiasis. J. Immunol. 153:5167-5175, 1994.
 
73) Bost KL, Clements JD:In vivo induction of interleukin-12mRNA expression after oral immunization with Salmonella dzeblin or the B subunit of Escherichia coli heat-labile enterotoxin. Infect. Immun. 63:1076-1083, 1995.
 
74) Zhan Y, Cheers C:Endogenous interleukin-12 is involved in resistance to Brucella abortus infection. Infect. Immun. 63:1387-1390, 1995.
PubMed
75) Seder RA, KeIsall BL, Jankovic D:Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease. J. Immunol. 157:2745-2748, 1996.
 
76) Yap G, Pesin M, Sher A:Cutting edge:IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxopplasma. Immunol 165:628-631, 2000.
 
77) Park AY, Hondowicz BD, Scott P:IL-12 is required to maintain a Th1 response during Leishmania major infection. J. Immunol. 165:896-902, 2000.
PubMed
P.218 掲載の参考文献
1) Mosmann TR, Coffman RL:THI and TH2 cells:different patterns of lyrnphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173, 1989.
 
2) McKenzie AN, Culpepper JA, de Waal Malefyt R et al.:Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc. Natl. Acad. Sci. USA 90:3735-3739, 1993.
 
3) Minty A, Chalon P, Derocq J-M et al.:Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362:248-250, 1993.
PubMed
4) Morgan JG, Dolganov GM, Robbins SE et al.:The selective isolation of novel cDNAs encoded by the regions surrounding the human interleukin 4 and 5 genes. Nucleic Acids Res. 20:5173-5179, 1992.
PubMed
5) Minty A, Asselin S, Bensussan A et al.:The related cytokines interleukin-13 and interleukin-4 are distinguished by differentiai production and differential effects on T lymphocytes. Eur. Cytokine Netw. 8:203-213, 1997.
 
6) Bazan JF:Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 87:6934-6938, 1990.
PubMed
7) Moy FJ, Diblasio E, Wilhelm J et al.:Solution structure of human IL-13 and implicatiorl for receptor binding. J. Mol. Biol. 310:219-230, 2001.
 
8) Eisenmesser EZ, Horita DA, Altieri AS et al.:Solution structure of interleukin-13 and insights into receptor engagement. J. Mol. Biol. 310:231-241, 2001.
PubMed
9) Oshima Y, Puri RK:Characterization of a powerful high affinity antagonist that inhibits biological activities of human interleukin-13. J. Biol Chem. 276:15185-15191, 2001.
PubMed
10) Shirakawa T, Deichmann KA, Izuhara K et al:Atopy and asthma:genetic variants of IL-4 and IL-13 signalling. Immunol. Today 21:60-64, 2000
 
11) Arima K, Umeshita-Suyama R, Sakata Y et al.:Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma. J. Allergy Clin. Immunol. 109:980-987, 2002.
PubMed
12) Nelms K, Keegan AD, Zamorano J et al.:The IL-4 receptor:signaling mechanisms and biologic functions. Annu. Rev. Immunol. 17:701-738, 1999.
PubMed
13) lzuhara K, Umeshita-Suyama R, Akaiwa M et al:Recent advances in understanding how interleukin-13 signaIs are involved in the pathogenesis of bronchial asthma. Arch. Immunol. Ther. Exp. 48:505-512, 2000.
 
14) McKenzie GJ, Fallon PG, Emson CL et al.:Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J, Exp. Med. 189:1565-1572, 1999.
 
15) Mohrs M, Ledermann B, K6hler G et al.:Differences between IL-4-and IL-4 receptora-deficient mice in chronic leishmaniasis reveal a protective role for IL-13receptor signaling. J. Immunol. 162:7302-7308, 1999.
 
16) Izuhara K, Shirakawa T:The signal transduction via the interleukin-4 receptor and its correlation with atopy. Int. J. Mol. Med. 3:3-10, 1999.
PubMed
17) Heinzmann A, Mao XQ, Akaiwa M et al.:Genetic variants of IL-13 signalling and human asthma and atopy. Hum. Mol. Genet. 9:549-559, 2000.
PubMed
18) Orchansky PL, Kwan R, Lee F et al.:Characterization of the cytoplasmic domain of interleukin-13 receptor-a. J. Biol. Chem. 274:20818-20825, 1999.
 
19) Umeshita-Suyama R, Sugimoto R, Akaiwa M et al.:Characterization of IL-4 and IL-13 signaIs dependenton the human IL-13 receptorachain 1:redundancy of requirement of tyrosine residue for STAT 3activation. Int. Immunol. 12:1499-1509, 2000.
 
20) Ogata H, Ford D, Kouttab N et al.:Regulation ofinterleukin-13 receptor constituents on maturehuman B lymphocytes. J. Biol. Chem. 273:9864-9871, 1998.
 
21) Kawakami K, Taguchi J, Murata T et al.:Theinterleukin-13 recepto ra2 chain:an essentialcomponent for binding and internalization but not forinterleukin-13-induced signal transduction throughthe STAT6 pathway. Blood 97:2673-2679, 2001.
 
22) Bernard J, Treton D, Vermot-Desroches C et al.:Expression of interleukin 13 receptor in glioma andrenal cell carcinoma:ILI3Ra2as a decoy receptorfor IL13. Lab. Invest. 81:1223-1231, 2001.
 
23) Chiaramonte MG, Mentink-Kane M, Jacobson BA etal.:Regulation and function of the interleukin 13 receptora2duringaThelper cell type 2-dominantimmune response. J. Exp. Med. 197:687-701, 2003.
PubMed
24) Zheng T, Zhu Z, Liu W et al.:Cytokine regulation of IL-13Rα2 and IL-13Rα1 in vivo and in vitro. J. Allergy Clin. Immunol 111:720-728, 2003.
 
25) Zurawski G, de Vries JE:Interleukin 13, aninterleukin 14-like cytokine that acts on rnonocytesand B cells, but not on T cells. Immunol. Today 15:19-26, 1994.
 
26) Loots GG, Locksley RM, Blankespoor CM et al.:Identification of a coordinate regulator of interleulkins 4, 13, and 5 by cross-species sequence comparisons. Science 288:136-140, 2000.
 
27) WilIs-Karp M, Chiaramonte M:Interleukin-13 inasthma. Curr. Opin. Pulm. Med. 9:21-27, 2003.
 
28) Woerly G, Lacy P, Younes AB et al.:Human eosinophiIsexpress and release IL-13 following CD28-dependentactivation. J. Leukocyte Biol 72:769-779, 2002,
 
29) Zhang DH, Yang L, Cohn L et al:Inhibition of allergic inflammation in a murine model of asthma byexpression of a dominant-negative mutant of GATA-3. Immunity 11:473-482, 1999.
 
30) Yamashita M, Ukai-Tadenuma M, Kimura M et al.:Identification of a conserved GATA3 responseelement upstream proximal from the interleukin-13gene locus. J. Biol. Chem. 277:42399-42408, 2002.
 
31) Das J, Chen CH, Yang L et al:Acritical role for NF-κB in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat. Immunol. 2:45-50, 2001.
 
32) Kim JI, Ho IC, Grusby MJ et al.:The transcription factor c-Maf controIs the production of interleukin-4 but not other Th2 cytokines. Immunity 10:745-751, 1999.
 
33) Macian F, Garcia-Rodriguez C, Rao A:Gene expressionelicited by NFAT in the presence or absence ofcooperative recruitment of Fos and Jun. EMBO J, 19:4783-4795, 2000.
PubMed
34) Richter A, Puddicombe SM, Lordan JL et al.:The contribution of interleukin (IL)-4 and IL-13 to theepithelial-mesenchymal trophic unit in asthma. Am. J. Respir. Cell Mol. Biol. 25:385-391, 2001.
 
35) Wen FQ, Kohyama T, Liu X et al.:Interleukin-4-and interleukin-13-enhanced transforming growth factor-B2 production in cultured human bronchial epithelial cells is attenuated by interferon-γ. Am. J. Respir. Cell Mol. Biol. 26:484-490, 2002.
 
36) Banwell ME, Tolley NS, Williams TJ et al.:Regulation of human eotaxin-3/CCL26 expression:modulation by cytokines and glucocorticoids. Cytokine 17:317-323, 2002.
PubMed
37) Zhou Y, Dong Q, Louahed J et al.:Characterization of acalcium-activated chloride channel as a shared target of Th2 cytokine pathways and its potential involvement in asthma. Am. J. Respir. Cell Mol. Biol. 25:486-491, 2001.
 
38) Zuhdi Alimam M, Piazza FM, Selby DM et al.:Muc-5/5ac mucin messenger RNA and protein expression is a marker of goblet cell metaplasia in murine airways. Am. J. Respir. Cell Mol. Biol. 22:253-260, 2000.
PubMed
39) Hoeck J, Woisetschlager M:STAT6 mediates eotaxin-lexpression in IL-40r TNF-α-induced fibroblasts. J. Immunol 166:4507-4515, 2001.
 
40) Doucet C, Brouty-Boy6 D, Pottin-Clemenceau C et al.:IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int. Immunol 10:1421-1433, 1998.
 
41) Kraft M, Lewis C, Pham D et al.:IL-4, IL-13, and dexamethasone augment fibroblast proliferation in asthma. J. Allergy Clin. Immunol 107:602-606, 2001.
PubMed
42) Moore PE, Church TL, Chism DD et al.:IL-13 and IL-4cause eotaxin release in human airway smooth muscle cells:arole for ERK. Am. J. Physiol. Lung Cell Mol. Physiol, 282:L847-853, 2002.
 
43) Hirst SJ, HalIsworth MP, Peng Q et al, :Selective induction of eotaxin release by interleukin-130r interleukin-4 in human airway smooth muscle cells is synergistic with interleukin-1Band is mediated by the interleukin-4 receptora-chain. Am. J. Respir. Crit. Care Med. 165:1161-1171, 2002.
 
44) Laporte JC, Moore PE, Baraldo S et al.:Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. Am. J. Respir. Crit. Care Med. 164:141-148, 2001.
PubMed
45) Grunstein MM, Hakonarson H, Leiter J et al.:IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle. Am. J. Physiol. Lung Cell Mol. Physiol. 282:L520-528, 2002.
PubMed
46) Bancroft AJ, McKenzie ANJ, Grencis RK:Acritical role for IL-13 in resistence to intestinal nematode infection. J. Immunol. 160:3453-3461, 1998.
 
47) GrUnig G, Warnock M, Wakil AE et al.:Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282:2261-2263, 1998.
PubMed
48) WilIs-Karp M, Luyimbazi J, Xu X et al.:Interleukin-13:central mediator of allergic asthma. Science 282:2258-2261, 1998.
 
49) Zhu Z, Homer RJ, Wang Z et al.:Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103:779-788, 1999.
PubMed
50) Kuperman DA, Huang X, Koth LL et al.:Direct effects of interleukin-130n epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat. Med. 8:885-889, 2002.
 
51) WilIs-Karp M:IL-12/IL-13 axis in allergic asthma. J. Allergy Clin. Immunol. 107:9-18, 2001.
 
52) Izuhara K, Arima K, Yasunaga S:IL-4 and IL-13:their pathological roles in allergic diseases and their potential in developing new therapies. Current Drug Targetslnflamm Allergy 1:263-269, 2002.
 
53) Morse B, Sypek JP, Donaldson DD et al.:Effects of IL-130n airway responses in the guinea pig. Am. J. Physiol. Lung Cell Mol. Physiol. 282:L44-49, 2002,
 
54) Kruse N, Tony H-P, Sebald W:Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J. 11:3237-3244, 1992.
PubMed
55) Tony HP, Shen BJ, Reusch P et al:Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Eur. J. Immunol 225:659-665, 1994.
 
56) Husain SR, Puri RK:Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy:from bench to bedside. J. Neurooncol 65:37-48, 2003.
PubMed
P.229 掲載の参考文献
1) Grabstein KH, Eisenman J, Shanebeck K et al.:Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264:965-968, 1994.
 
2) Bamford RN, Grant AJ, Burton JD et al:The interleukin (IL) 2receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells Proc. Natl. Acad. Sci. USA 91:4940-4944, 1994.
 
3) Pettit DK, Bonnert TP, Eisenman J et al.:Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. J. Biol. Chem. 272:2312-2318, 1997.
PubMed
4) Waldmann TA, Tagaya Y:The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17:19-49, 1999.
 
5) Fehniger TA, Caligiuri MA:Interleukin 15:biology and relevance to human disease. Blood 97:14-32, 2001.
PubMed
6) Giri JG, Kumaki S, Ahdieh M et al:Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 14:3654-3663, 1995.
 
7) Anderson DM, Kumaki S, Ahdieh M et al.:Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of ILI5RA and IL2RA genes. J. Biol. Chem. 270:29862-29869, 1995.
 
8) Bulanova E, Budagian V, Pohl T et al.:The IL-15R alpha chain signaIs through association with Syk in human B cells. J. Immunol. 167:6292-6302, 2001.
 
9) Dubois S, Magrangeas F, Lehours P et al.:Natural splicing of exon 2 of human interleukin-15 receptor alpha-chain mRNA resuits in a shortened form with a distinct pattern of expression. J. Biol. Chem. 274:26978-26984, 1999.
 
10) Tagaya Y, Burton JD, Miyamoto Y et al.:Identification of a novel receptor/signal transduction pathway for IL-15/T in mast cells. EMBO J. 15:4928-4939, 1996.
PubMed
11) Bulanova E, Budagian V, Orinska Z et al.:Mast cells express novel functional IL-15 receptor alphaisoforms. J. Immunol. 170:5045-5055, 2003.
 
12) Masuda A, Matsuguchi T, Yamaki K et al.:Interleukin-15 prevents mouse mast cells from apoptosis through STAT6-mediated Bcl-xL Expression J. Biol. Chem. 276:26107-26113, 2001.
PubMed
13) Anderson DM, Johnson L, Glaccum MB et al:Chromosomal assignment and genomic structure of IL-15. Genomics 25:701-706, 1995.
PubMed
14) Krause H, Jandrig B, Wernicke C, Bulfone-Paus S et al.:Genornic structure and chromosomal localization of the human interleukin 15 gene (IL-15) . Cytokinev 8:667-674, 1996.
 
15) Nishimura H, Washizu J, Nakamura N et al.:Translational efficiency is up-regulated by alternative exon in murine IL-15 mRNA. J. Immunol 160:936-942, 1998.
PubMed
16) Bamford RN, DeFilippis AP, Azimi N et al.:The 5'untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. J. Immunol 160:4418-4426, 1998.
PubMed
17) Onu A, Pohl T, Krause H, Bulfone-Paus S:Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms. J. Immunol. 158:255-262, 1997.
PubMed
18) Tagaya Y, Kurys G, Thies TA et al.:Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. Proc, Natl. Acad. Sci. USA 94:14444-14449, 1997.
PubMed
19) Washizu J, Nishimura H, Nakamura N et al.:NF-κB binding site is essential for transcriptional activation of IL-15. Immunogenetics 48:1-7, 1997.
 
20) Azimi N, Tagaya Y, Mariner J et al.:Viral activation of interlukin 15:Characterization of a virus-inducible element in the IL-15 promoter region. J. Virol. 74:7338-7348, 2000.
 
21) Bamford RN, DeFilippis AP, Azimi N et al, :The 5'untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. J. Immunol. 160:4418-4426, 1998.
PubMed
22) Nishimura H, Yajima T, Naiki Y et al:Differential roles of interleukin 15 mRNA isoforms generated by alternative splicing in immune responses in vivo. J. Exp. Med. 191:157, 2000.
PubMed
23) Kurys G, tagaya Y, Bamford R et al.:The long signal peptide isoform and its alternative processing direct the intracellular traficking of interleukin 15. J. Biol. Chem. 275:30653-30659, 2000.
 
24) Lodolce JP, Boone DL, Chai S et al.:IL-15 recepter maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9:669-675, 1998.
 
25) Kennedy MK, Glaccum M, Brown SN et al.:Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191:771-778, 2000.
PubMed
26) Colucci F, Caligiuri MA, Di Santo Jp:What does it take to make a natural killer? Nat. Rev. Immunol. 3:413-425, 2003.
PubMed
27) Lodolce JP, Burkett PR, Koka RM et al.:Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev. 13:429-439, 2002.
PubMed
28) Koka R, Burkett PR, Chien M et al.:Interleukin (IL)-15R［alpha］-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice. J. Exp. Med. 197:977-984, 2003.
 
29) Ohteki T, Suzue K, Maki C, Ota T, Koyasu S:Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response. Nat. Immunol. 2:1138-1143, 2001.
PubMed
30) Marks-Konczalik J, Dubois S, Losi JM et al, :IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. USA 97:11445-11450, 2000.
PubMed
31) Fehniger TA, Suzuki K, Ponnappan A et al.:Fatal leukemia in interleukin 15 transgenic mice follows early expansion in natural killer and memory phenotype CD8+ T cells. J. Exp. Med. 193:219-231, 2001
PubMed
32) Prlic M, Lefrancois L, Jameson SC:Multiple choices: regulation of memory CD8 T cell generation and homeostasis by interleukin (IL)-7 and IL-15. J. Exp. Med. 195:F49-52, 2002.
PubMed
33) Tan JT, Ernst B, Kieper WC et al.:Interleukin (IL)-15 and IL-7jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med. 195:1523-1532, 2002.
 
34) Goldrath AW, Sivakumar PV, Glaccum M et al.:Cytokine requirements for acute and Basal homeostatic proliferation of naive arld memory CD8+ T cells. J. Exp. Med. 195:1515-1522, 2002.
 
35) Yoshikai Y, Nishimura H:The role of interleukin 15 in mounting an immune response against microbial infections. Microbes Infect. 4:381-389, 2000.
PubMed
36) Yajima T, Nishimura H, Ishimitsu R et al.:Memory phenotype CD8-Tcells increased in IL-15 transgenic mice are involved in early protection against a primary infection with Listeriamonocytogenes. Eur. J. Immunol 31:757-766, 2001.
 
37) Sprent J:Turnover of memory-phenotype CD8+ T cells. Microbes Infect. 5:227-231, 2003.
PubMed
38) Judge AD, Zhang X, Fujii H et al.:Interleukin 15 controIs both proliferation and survival of a subset of memory-phenotype CD8(+) Tcells. J. Exp. Med. 196:935-946, 2002.
 
39) Yajima T, Nishimura H, Ishimitsu R et al.:Overexpression of IL-15 in vivo increases antigendriven memory CD8+T cells following a microbe exposure. J. Immunol. 168:1198-1203, 2002.
PubMed
40) Umemura M, Nishimura H, Hirose K et al, :Overexpression of IL-15 in vivo induces a predominant Tcl response in mice inoculated with Mycobacterium bovis Bacille Calmette-Guerin infection. J. Immunol. 167:946-956, 2001.
 
41) Ishimitsu R, Nishimura H, Yajima T et al.:Overexpression of interleukin-15 in vivo enhances Tcl response which inhibits allergic inflammation in a murine model of asthma. J. Immunol 166:1991-2001.
 
42) Umemura M, Nishimura H, Yajima T et al.:Overexpression of interleukin 15 prevents the development of murine retrovirus-induced acquired immunodeficiency syndrome. FASEB J. 16:1755-1763, 2002.
PubMed
43) Khan IA, Moretto M, Wei XQ, Williams M, Schwartzman JD, Liew FY:Treatment with soluble interleukin-15R alpha exacerbates intracellular parasitic infection by blocking the development of memory CD8+ T cell response. J. Exp. Med. 195:1463-1470, 2002.
 
44) Mclnnes IB, al-Mughales J, Field M et al.:The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. 2:175-182, 1996.
 
45) Oh S, Berzofsky JA, Burke DS, et al.:Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. USA 100:3392-3397, 2003.
 
46) Becknell B, Caligiuri MA:Cancer T cell therapy expands. Nat. Med. 9:257-258, 2003.
PubMed
47) Taylor PC:Antibody therapy for rheumatoid arthritis. Curr. Opin. Pharmacol. 3:323-328, 2003.
PubMed
P.239 掲載の参考文献
1) Center DM, Cruikshank WW:Modulation of lymphocyte migration by human lymphokines, 1. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J. Immunol. 128:2563-2568, 1982.
 
2) Cruikshank WW, Center DM:Modulation of lymphocyte migration by human lymphokines. II. Purification of lymphocyte chemoattractant factor (LCF) . J. Immunol 128:2569-2574, 1982.
 
3) Cruikshank WW, Center DM, Nisar N et al.:Molecular and functional analysis of a lymphocyte chemoattractant factor:Association of biologic function with CD4 expression. Proc. Natl. Acad. Sci. USA 91:5109-5113, 1994.
PubMed
4) Baier M, Bannert N, Werner A et al.:Molecular cloning, sequence, expression, and processing of the interleukin 16 precurser. Proc. Natl. Acad. Sci. USA 94:5273-5277, 1997.
 
5) Zhang Y, Center DM, Wu D et al.:Processing and activation of pro-interleukin-16 by caspase-3. J. Biol. Chem. 273:1144-1149, 1998.
PubMed
6) Nicoll J, Cruikshank WW, Brazer W et al.:Identification of domains in IL-16 critical for biological activity. J. Immunol. 163:1827-1832, 1999.
PubMed
7) Laberge S, Cruikshank WW, Kornfeld H et al.:Chemoattractant factor from CD8+ T cells is independent of transcription and translation evidence for constitutive protein synthesis and storage. J. Immunol. 155:2902-2906, 1995.
PubMed
8) Laberge S, Cruikshank WW, Beer DJ et al.:Secretion of IL-16 (lymphocyte chemoattractant factor) from serotonin-stimulated CD8+ T cells 71n仇汐o. J. Immunol. 156:310-315, 1996.
 
9) Bellini A, Yoshimura H, Vittori E et al.:Bronchial epithelial cells of patients with asthma release chemoattractant factors for T lymphocyte. J. Allergy Clin. Immunol. 92:412-424, 1993.
 
10) Chupp GL, Wright EA, Wu D et al.:Tissue and T cell distribution of precursor and mature IL-16. J. Immunol. 161:3114-3119, 1998.
 
11) Lim KG, Wan HC, Bozza PT et al.:Human eosinophiIs elaborate IL-16 (lymphocyte chemoattractant factor) and RANTES. J. Immunol. 156:2566-2570, 1996.
PubMed
12) Kaser A, Dunzendorfer S, Offner FA et al.:B lymphocyte-derived IL-16 attracts dendritic cells and Th cells. J. Immunol. 165:2474-2480, 2000.
 
13) Rumsaeng V, Cruikshank WW, Foster B et al:Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16. J. Immunol. 159:2904-2910, 1997.
PubMed
14) Kaser A, Durlzondorfer S, Offner FA et al.:Arole for IL-16 in the cross-talk between dendritic cells and T cells. J. Immunol. 163:3232-3238, 1999.
 
15) Juang T, Shauer U, Hensset C et al.:Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods 159:197-205, 1993.
 
16) Wu D, Zhang Y, Parada NA et al.:Processing and release of IL-16 from CD4+ but not CD8+ T cells is activation dependent. J. Immunol. 162:1287-1293, 1999.
 
17) Cruikshank WW, Greenstein JL, Theodore AC et al.:Lymphocyte chemoattractant factor induces CD4-dependent intracytoplasmic signaling in lymphocytes. J. Immunol. 146:2928-2934, 1991.
PubMed
18) Parada NA, Center DM, Kornfeld H et al.:Synergistic activation of CD4+ T cells by IL-16 and IL-2. J. Immunol 160:2115-2120, 1998.
PubMed
19) Theodore AC, Center DM, Nicoll J et al.:CD41igand IL-16 inhibits the mixed lymphocyte reaction. J. Immunol 157:1958-1964, 1996.
PubMed
20) Baier M, Werner A, Bannert N et al.:HIV suppression by interleukin-16. Nature 378:563, 1995.
PubMed
21) Maciaszek JW, Parada NA, Cruikshank WW et al.:IL-16represses HIV-1 promoter activity. J. Immunol 158:5-8, 1997.
PubMed
22) Franz JK, Kolb SA, Hummel KM et al.:Interleukin-16, produced by snovial fibroblasts, mediates chemoattraction for CD4+ T lymphocytes in rheumatoid arthritis. Eur. J. Immunol. 28:2661-2671, 1998.
 
23) Klimiuk PA, Goronzy JJ, Weyand CM:IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J. Immunol. 162:4293-4299, 1999.
PubMed
24) Parrorichi P, Romagnani P, Annunziato F et al.:Type lT-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. J, Pathol. 150:823-832, 1997.
 
25) Pizarro TT, Michie MH, Bentz M et al.:IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease:expression and localization in intestinal mucosal cells. J. Immmul. 162:6829-6835, 1999.
 
26) Raab Y, Fredens K, Gerdin B et al.:Eosinophil activation in ulcerative colitis. studies on mucosal release and localization of eosinophil granule constitutents. Dig. Dis. Sci. 43:1061-1070, 1998.
 
27) Keates AC, Castagliuolo L, Cruikshank WW et al.:Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology 119:972-982, 2000.
 
28) Wierenga EA, Snock M, de Groot GC et al.:Evidence for compartmentalization of functional subsets of CD4 Tlymphocytes in atopic patients. J. Immunol 144:4651-4656, 1990.
 
29) Reich K, Heine A, Hugo S et al.:Engagement of the FcεRI stimulates the production of IL-16 in Langerhans cell-like dendritic cells. J. Immunol. 167:6321-6329, 2001.
 
30) Cruikshank WW, Long A, Tarpy RE et al.:Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1-alpha (MIP 1-alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am. J. Respir. Cell Mol. Biol. 13:738-747, 1995.
 
31) Hessel EM, Cruikshank WW, van Ark I et al:Involvement of IL-16 in the induction of airway hyperresponsiveness and up-regulation of IgE in a murine model of allergic asthma. J. Immunol. 160:2998-3005, 1998.
 
P.248 掲載の参考文献
1) Yao Z, Fanslow WC, Seldin MF et al.:Human IL-17, a novel cytokine derived from T cells. J. Immunol. 155:5483-5486, 1995.
 
2) Fossiez F, Banchereau J, Murray R et al.:T-cell IL-17 induces stromal cells to produces proinflammatory and hematopoietic cytokines. J. Exp. Med. 183:2593-2603, 1996.
 
3) Aarvak T, Chabaud M, Miossec P et al.:IL-17 is produced by pro-inflammatory Th1/ThO cells but not by Th2 cells. J. Immunol. 162:1246-1251, 1999.
 
4) Teunissen MBM, Koomen CW, de Waal Malefyt R et al.:Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 111:645-649, 1998.
 
5) Infante-Duarte C, Horton HE, Byrne MC et al.:Microbial lipopeptides induce the production of IL-17. J. Immunol. 165:6107-6115, 2000.
 
6) Ferretti S, Bonneau Q, Dubois GR et al.:IL-17, produced by lymphocytes and neutrophiIs, is necessary for lipopolysaccharide-induced airway neutrophilia:IL-15 as a possible trigger. J. Immunol. 170:2106-2112, 2003.
 
7) Happel KI, Zheng M, Young E et al.:Cutting edge:Roles of Toll-like receptor 4 and IL-23 in IL-17 expresslon In response to Klebsiella pneumoniae infection. J. Immunol. 170:4432-4436, 2003.
PubMed
8) Yao Z, Fanslow WC, Seldin MF et al.:Herpesvirus Samiri encodes a new cytokine, IL-17, which binds to anovel cytokine receptor. Immunity 8:811-821, 1995.
 
9) Javanovic DV, Di Battista JA, Martel-Pelletier J et al.:IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α, by human macrophages. J. Immunol 160:3513-3521, 1998.
 
10) Laan M, Cui ZH, Hoshino H et al.:Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways, J, Immunol. 162:2347-2352, 1999.
 
11) Schwarzenberger P, La Russa V, Miller A et al.:IL-17 stimulates granulopoiesis in mice:Use of an alternate, novel gene therapy-derived method for in vitro elevation of cytokines. J. Immunol. 161:6383-6389, 1998.
PubMed
12) Schwarzenberger P, Huang W, Ye P et al.:Requirement of endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis. J. Immunol. 164:4783-4789, 2000.
PubMed
13) Ye P, Rodriguez FH, Kanaly S et al:Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defence. J. Exp. Med. 194:519-527, 2001.
PubMed
14) Miyamoto M, Prause Q, Sjostrand M et al.:Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J. Immunol. 170:4665-4672, 2003.
 
15) Matusevicius D, Kivisakk P, Kostulas N et al.:Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Multiple Sclerosis 5:101-104, 1999.
PubMed
16) Van Kooten C, Boonstra JG, Paape ME et al.:Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J. Am. Soc. Nephrol. 9:1526-1534, 1998.
PubMed
17) Ziolkowska M, Koc A, Luszczykiewicz G et al.:High levels of IL-17 in rheumatoid arthritis patients:IL-15 triggers in vitro. IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol 164:2832-2838, 2000.
PubMed
18) Quayle AJ, Chomarat Jp, Miossec P et al.:Rheumatoid inflammatory T-cell clones express mostly Thl but aIso Th2 and mixed (ThO-like) cytokine patterns. Scan. J. Immunol. 38:75-82, 1993.
 
19) Chabaud M, Durand JM, Buchs N et al.:Human interleukin-17:ATcell-derived cytokine produced by rheumatoid synovium. Arthritis Rheum. 42:963-970, 1999.
 
20) Gravallese EM, Harada Y, Wang JT et al.:Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152:943-951, 1998.
PubMed
21) Jimi E, Akiyama S, Tsurukai T et al.:Osteoclast differentiation factor act as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163:434-449, 1999.
 
22) Kotake S, Udagawa N, Takahashi N et al.:IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103:1345-1352, 1999.
PubMed
23) Chabaud M, Lubberts E, Joosten L et al.:IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 3:168-177, 2001.
PubMed
24) Nocker RET, Schoonbrood DFM, van de Graaf EA et al.:Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease. Int. Arch. Allergy Immunol. 109:183-191, 1996.
 
25) Nakajima H, Iwamoto I, Tomoe S et al:CD4+ T lymphocytes and interleulkin-5 mediate antigen-induced eosinophil infiltration into the mouse trachea. Am. J. Respir. Dis. 146:374-377, 1992.
 
26) Gavett SH, Chen X, Finkelman F et al.:Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hypereactivity and pulmonary eosinophilia. Am. J. Respir. Cell Mol. Biol. 10:587-593, 1994.
 
27) Linden A, Hoshino M, Laan M:Airway neutrophiIs and interleukin-17. Eur. Respir. J. 15:973-977, 2000.
 
28) Schlaak JF, Buslau M, Jochuin W et al.:T cells involved in psoriasis vulgaris belong to the Thl subset. J. Invest. Dermatol. 126:351-355, 1990.
 
29) Fierlbeck G, Rassner G, Muller C:Psoriasis induced at the injection site of recombinant interferon gamma. Arch. Dermatol. 102:145-149, 1994.
 
30) Taub DD, Anver M, Oppenheim JJ et al.:T lymphocyte recruitment by interleukin-8 (IL-8) . IL-8-induced degranulation of neutrophiIs releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J. Clin. Invest. 97:1931-1941, 1996.
 
31) Santamaria Babi LF, Moser M, Perez Soler M et al.:The interleukin-8 receptor B and CXC chemokines can mediate transendothelial migration of human skin homing T cells. Eur. J. Immunol 26:2056-2061, 1996.
 
32) Albanesi C, Cavani A, Girolomoni G et al.:IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes:synergistic or antagonist effects with IFN-γand TNF-a. J. Immunol. 162:494-502, 1999.
 
33) Niemialtowski MG, Rouse BT:Predominance of Thl cells in ocular tissue during herpetic stromal keratitis. J. Immunol. 149:3035-3041, 1992.
 
34) Maertzdorf J, Osterhaus ADME, Verlans MGM:IL-17 expression in human herpetic stromal keratitis:Modulatory effects on chemokine production by corneal fibroblasts. J. Immunol. 169:5897-5903, 2002.
 
35) Thomas J, Gangappa S, Kanangat S et al.:On the essential involvement of neutrophiIs in the immunopathologic disease:Herpetic stromal keratitis. J. Immunol 158:1383-1390, 1997.
 
36) Adams MD, Kelley JM, Gocayne JD et al.:Complementary DNA sequencing:Expressed sequence tags and human genome project. Science 252:1651-1656, 1991.
PubMed
37) Shi Y, Ulrich S, Zhang J et al.:Anovel cytokine receptor-ligand pair:Identification, molecular characterization, and in vivo. immunomodulatory activity. J. Biol. Chem. 275:19167-19176, 2000.
 
38) Li H, Chen J, Huang A et al.:Cloning and characterization of IL-17 B and IL-17C, two new members of the IL-17 cytokine family. Proc. Natl. Acad. Sci. USA 97:773-778, 2000.
 
39) Lee J, Ho WH, Maruoka M et al.:IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17 Rh 1. J. Biol. Chem. 276:1660-1664, 2001.
 
40) Pan G, French D, Mao W et al:Forced expression of murine IL-17E induces growth retardation, jaundice, aTh-2-biased response, and multiorgan inflammation in mice. J. Immunol. 167:6559-6567, 2001.
 
41) Starnes T, Robertson MJ, Sledge G et al.:1L17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J. Immunol. 167:4137-4140, 2001.
 
P.265 掲載の参考文献
1) Imler JL, Hoffman JA:Toll receptors in Drosophila:a family of molecules regulating development and immunity. Curr. Top. Microbiol. Immunol. 270:63-79, 2002.
 
2) Medzhitov R, Preston-Hurburt P, Janeway CAJr:Innage immunity:the virtues of a nonclonal system of recognition. Cell 91:295-298, 1998.
 
3) Janeway CAJr, Medzhitov R:Innate immune recognition. Annu. Rev. Immunol. 20:197-216, 2002.
 
4) O'Neill LAJ, Dinarello CA:The IL-1 receptor/toll-like receptor superfamily:critical receptors for inflammation and host defense. Immunol. Today 21:206-209, 2000.
 
5) Akira S, Takeda K, Kaisho T:Toll-like receptors:critical proteins linking innate and acquired immunity. Nat. Immunol. 2:675-680, 2001.
PubMed
6) Takeda K, Kaisho T, Akira S:Toll-like receptors. Annu. Rev. Immunol. 21:335-376, 2003.
PubMed
7) Okamura H, Tsutsui H, Komatsu T et al.:Cloning of a new cytokine that induces IFN-γ production by Tcells. Nature 378:88-91, 1995.
 
8) Nakanishi K, Yoshimoto T, Tsutsui H et al.:Interleukin-18 regulates both Thl and Th2 responses. Annu. Rev. Immunol 19:423-474, 2001.
 
9) Tsutsui H, Yoshimoto T, Okamura H et al:IL-18 and IL-18 rceptor knockout mouse. Cyotokine Knockouts Second Edition. (ed. Funtuzzi G) , Humana Press, Totowa, NJ, USA, 2003, p303-322.
 
10) Tsutsui H, Adachi K, Seki E et al:Cytokine-induced inflammatory liver injuries. Curr. Mol. Med. 3:545-559, 2003.
PubMed
11) Dinarello CA, Fantuzzi G:Interleukin-18 and host defense against infection. J. Infect. Dis. 187:S370-S384, 2003.
PubMed
12) Gu Y, Kuida K, Tsutsui H et al.:Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 275:206-209, 1997.
 
13) Tsutsui H, Kayagaki N, Kuida K et al:Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 11:359-367, 1999.
PubMed
14) Kim YM, Kang HS, Paik SG et al.:Roles of IFN consensus sequence binding protein and PU. 1in regulating IL-18 gene expression. J. Imrnunol. 1631 2000-2007, 1999.
 
15) Takeda N, Arima M, Tsuruoka N et al.:Bc16 is a transcriptional repressor for the IL-18 gene. J. Immunol. 171:426-431, 2003.
 
16) Novick D, Kim S-H, Fantuzzi G et al:Interleukin-18 binding protein:anovel modulator of the Thl cytokine response. Irnmunity 10:127-136, 1999.
 
17) Kim S-H, Eisenstein M, Reznikov L et al:Structural requirements of six naturally occurring isoformx of the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad. Sci. USA 97:1190-1195, 2000.
 
18) Hoshino K, Tsutsui H, Kawai T et al.:Generation of IL-18 receptor-deficient mice:evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J. Immunol. 162:5041-5044, 1999.
PubMed
19) Adachi O, Kawai T, Takeda K et al:Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9:143-150, 1998.
PubMed
20) Kanakaraj P, Ngo K, Wu Y et al.:Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J. Exp. Med. 189:1129-1138, 1999.
 
21) Suzuki N, Chen N-J, Miller DG et al.:IRAK-4 is essential for interleukin-18-mediated natural killer and T helper cell type 1 response. J. Immunol. 170:4031-4035, 2003.
 
22) Suzuki N, Suzuki S, Duncan GS et al.:Severe impairment of interleukin-1 arld Toll-like receptor signaling in mice lacking IRAK-4. Nature 416:750-754, 2002.
 
23) Yamamoto M, Sato S, Hemmi H et al.:Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 420:324-329, 2002.
PubMed
24) Yamamoto M, Sato H, Hemmi H et al.:Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301:640-643, 2003.
 
25) Kobayashi K, Hernandez ID, Galan JE et al.:IRAK-M is a negative regullator of Toll-like receptor signaling. Cell 110:191-202, 2002.
 
26) Kinjyo I, Hanada T, Inagaki-Ohara K et al.:SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 17:538-591, 2002.
 
27) Nakagawa R, Naka T, Tsutsui H et al:SOCS-1 participates in negative regulation of LPS response. Immunity 17:677-687, 2002.
PubMed
28) Shimoda K, Tsutsui H, Aoki K et al.:Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood 99:2094-2099, 2002.
PubMed
29) Alnemri ES, Livingston DJ, NichoIson DW et al.:Human ICE/CED-3 protease nomenclature. Cell 87:171, 1996.
 
30) Seki E, Tsutsui H, Nakano H et al.:LPS-induced IL-18 secretion from murine Kupffer cells independently of MyD88 that is critically involved in induction of production of IL-12 and IL-1B. J. Immunol 166:2651-2657, 2001,
 
31) Tschopp J, Martinon F, Burns K:NALPs:Anovel protein family involved in inflammation. Nat. Rev. 4:95-104, 2003.
 
32) Takeda A, Hamano S, Yamanaka A et al.:Role of IL-27/WSW-l signaling for induction of T-bet through activation of STATI during initial Thl commitment. J. Immunol 170:4886-4890, 2003.
 
33) Takeda K, Tsutsui H, Yoshimoto T et al.:Defective NK cell activity and Thl response in IL-18-deficient mice. Immunity 8:383-390, 1998.
 
34) aeary AM, Tu W, Enright A et al:Impaired accumulation and fuction of memoryh CD4 T cells in human IL-12 receptorBldeficiency. J. Immunol. 170:597-603, 2003.
 
35) Yang J, Zhu H, Murphy TL et al.:1L18-stimulated GADD45Brequired in cytokine-induced, but not TCR-induced, IFN-γproduction. Nat. Immunol. 2:157-164, 2001.
 
36) Lu B, Yu H, Chow C et al.:GADD45γmediates the activation of the p38 and JNK MAP kinase pathways and cytokine production in effector Thl cells. Immunity 14:583-590, 2001.
 
37) Itoi H, Fujimori Y, Tsutsui H:Fas ligand-induced caspase-1-dependent accumulation of interleukin (IL)-18 in mice with acute graft-versus-host disease. Blood 98:235-237, 2001.
PubMed
38) Yoshimoto T, Mizutani H, Tsutsui H:IL-18 induction of lgE:Dependence on CD4+ T cells, IL-4 and STAT6. Nat. Immunol 1:132-137, 2000.
 
39) Konishi H, Tsutsui H, Murakami T:IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc. Natl. Acad. Sci. USA 99111340-11345, 2002.
 
40) Yoshimoto T, Nim B, Stlgimoto T:Nonredundant roles for CDld-restricted natural killer T cells and conventional CD4斗Tcells in the induction of immunoglobulin E antibodies in response to interleukin-18 treatment of mice. J. Exp. Med. 197:997-1005, 2003.
 
41) Seki E, Tsutsui H, Tsuji NM et al.:Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogebes in mice. J. Immunol. 169:3863-3868, 2002.
PubMed
42) Way SS, Kollmann TR, Hajjar AM et al.:Protective cell-mediated immunity to Listeria monocytoenes in the absence of myeloid differentiation factor 88. J. Immunol. 171:533-537, 2003.
 
43) Neighbors M, Xu X, Barrat F et al.:ACritical role for interleukin 18 in primary and memory effector responses to Listeria monocytoenes that extends beyond its effects on interferon γ production. J. Exp. Med. 194:343-354, 2001.
 
44) Kanai T, Watanabe M, Akazawa A et al.:Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenteorol 121:875-888, 2001.
 
45) Tsutsui H, Matsui K, Okamura H et al.:Pathophysiological roles of interleukin-18 for inflammatory liver diseases. Immunol. Rev. 174:192-209, 2000.
PubMed
46) Libby P, Ridker PM, Maseri A:Inflammation and atherosclerosis. Circulation 105:1135-1143, 2002.
PubMed
47) Whitan SC, Ravisakar P, Daugherty A:Interleukin-18 enhances atherosclerosis in apolipoprotein E -/- mice through release of interferon-γ. Cir. Res. 90:e34-e38, 2002.
 
48) Jawien ER, Rudling M, Ljunggren HG et al.:Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 591234-240, 2003.
 
49) Kretowski A, KinaIska I:Serum levels of interleukin-18-apotential marker of cardiovascular death-could be determined by genetic predisposition. Circulation107:e206-e207, 2003.
 
50) Kiechi S, Lorenz E, Reindl M et al:Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347:185-192, 2002.
 
51) Hanifi-Moghaddam P, Schloot NC, Kappler S et al.:An association of autoantibody status and serum cytokinelevels in tyep l diabetes. Diabetes 52:1137-1142, 2003.
 
52) Kretowski A, Miroczuk K, Karpinska A et al:Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes 51:3347-3349, 2002.
 
53) Cannetti CA, Leung BP, Cuschaw S et al.:IL-18 enhances collagen-induced arthritis by recruiting neutrophiIs via TNF-aand leukotriene B4. J. Immunol. 171:1009-1015, 2003,
 
54) Kruse S, Kuehr J, Moseler M et al.:Polymorphisms in the IL-18 gene are associated with specific sensitization to common allergens and allergic rhinitis. J. Allergy Clin. Immunol 111:117-122, 2003.
PubMed
55) Chikano S, Sawada K. Shimoyama T et al.:IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-γ-dependent manner. Gut 47:779-786, 2000
 
P.277 掲載の参考文献
1) Isaacs A, Lindenmann J:Virus interference I. The interferon. Proc. R. Soc. London Ser. B l47:339-349, 1957.
 
2) Nagano Y, Kojima Y:Inhibition de I'infection vaccinale par le virus homologue. C. R. Seances Soc. Biol Fil. 152:1627-1630, 1958.
 
3) Davis G, Zhou R, Pin J et al.:Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Eng1. J. Med. 339:1493-1499, 1998.
 
4) Takaoka A, Taniguchi T:New aspects of IFN-a/B signaling in immunity, ongogenesis and bone metabolism. Cancer Sci. 94:405-411, 2003.
 
5) Hata N, Sato M, Takaoka A et al.:Constitutive IFN a/ Bsignal for efficient IFN-a/Bgene induction by virus. BBRC 285:518-525, 2001.
 
6) Bevialacqua PC, Cech T:Minor groove recognition of double stranded RNA-binding domain from the RNA activated protein kinase PKR. Biochemistry 35:9983-9994, 1996.
 
7) Manchie L, Green SR, Schmedt C et al.:Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol. Cell, Biol. 12:5238-5248, 1992.
 
8) Cattaneo R, Scmid A, Eschle D et al.:Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell 55:225-265, 1988.
 
9) Kochs G, Haller O:GTP-bound human MxA GTPase interacts with the nucleocapsids of Thogoto virus (Orthomyxoviridae) . J. Biol. Chem. 274:4370-4376, 1999.
PubMed
10) Nathan C:Inducible nitric oxide synthase:what difference does it make? J. Clin. Invest. 100:2417-2423, 1997.
 
11) Biron CA, Sen GC:Interferons and other cytokines. (eds. Knipe DM, Howley PM, Griffin DE, Martin M, Roizman B, Straus SE) , Fields virology, 4th ed, Lippincott-Raven, Philadelphia, Pa. , 2001, p321-351.
 
12) Samuel CE:Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 183:1-11, 1991.
PubMed
13) Smith GL, Symons JA, Alcami A:Poxviruses:interfering with interferon. Semin. Virol 8:409-418, 1998.
 
14) Leonard GT, Sen GC:Restoration of interferorl responses of adenovirus EIA-expressing HT1080 ell lines by overexpression of p48 proteinJ. Virol. 71:5095-5101, 1997.
 
15) Ronco LV, Karpova AY, Vidal M et al.:Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor 3 and inhibits its transcriptional activity. Genes Dev. 12:2061-2072, 1998.
PubMed
16) Gao SJ, Boshoff C, Jayachandra C et al.:KSHV ORF K9 (vlRF) is an oncogene which inhibit the interferon signaling pathway. Oncogene 15:1979-1985, 1997.
 
17) Abendroth A, Slobedman B, Lee EE et al.:Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J. Virol. 74:1900-1907, 2000.
 
18) Miller DM, Rahill BM, Boss JM et al.:Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J. Exp. Med. 187:675-683, 1998.
PubMed
19) Basler CF, Wang XY, Muhlberger E et al.:The Ebola virus VP35 protein functions as a type IIFN antagonist. Proc. Natl. Acad. Sci. USA 97:12289-12294, 2000.
 
20) Clemens MJ, Elia A:The double-stranded RNA-dependent protein kinase PKR:structure and function. J. Interferon Cytokine Res. 17:503-524, 1997.
PubMed
21) Samuel CE:The elF-2aprotein kinases, regulators of translation in eukaryotes from yeasts to humans. J. Biol Chem. 268:7603-7606, 1993.
 
22) Lu Y, Wambach M, Katze MG et al.:Binding of the influenza virus NSl protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor. Virology 214:222-228, 1995.
 
23) Mathews MB, Shenk T:Adenovirus virus-associated RNA and translational control. J. Virol. 65:5657-5662, 1991.
PubMed
24) Black TL, Barber GN, Katze MG:Degradation of the interferon-induced 68, 000 Mr protein kinase by poliovirus requires RNA. J. Virol. 67:791-800, 1993.
PubMed
25) Bass B L:Double-stranded RNA as a temp1ate for gene silencing. Cell 101:235-238, 2000.
PubMed
26) He B, Gross M, Roizman R:The gamma (1) 34. 5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA 94:843-848, 1997.
 
27) Gale M Jr, Blakely CM, Kwieciszewski G et al.:Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein:molecular mechanisms of kinase regulation. Mol. Cell. Biol. 18:5208-5218, 1998.
 
28) Taylor DR, Shi ST, Romano PR et al.:Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285:107-110, 1999.
PubMed
29) Foy E, Li K, Wang C et al.:Regulation of interferon regulatory factor 3 by the hepatitis C virus serine protease. Science 16:300(5622):1145-1148, 2003.
 
30) Ogasawara K, Hida S, Weng Y et al.:Requirement of the IFN-a/B-induced CXCR3 chemokine signaling for CD8+ T cell activation. Genes Cell 7:309-320, 2002.
 
31) Fantuzzi GD, Reed A, Dinarello CA:IL-12-induced IFN gamma is dependent on caspase-1processing of the IL-18 precursor. J. Clin. Invest. 104:761-767, 1999.
 
32) Xing Z, Zganiacz A, Wang JM et al.:IL-12 independent Th1-type immune responses to respiratory viral infection:requirement of IL-18 for IFN-gamma release in the lung but not for the differentiation of vira+reactive Th1-type 1ymphocytes. J. Immunol. 164:2575-2584, 2000.
 
33) Takaoka A, Hayakawa S, Yanai H et al.:Integration of interferon-a/Bsignalling to p53 responses in tumour suppression and antiviral defence. Nature 424:516-523, 2003.
 
34) Lacey DL, Timm E, Tan HL et al.:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998.
 
35) Yasuda H, Shima N, Nakagawa N et al.:Osteoclast differentiation factor is identical to TRANCE/ RANKL. PNAS 95:3597-3602, 1998.
PubMed
36) Kong YY, Yoshida H, Sarosi I et al.:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999.
PubMed
37) Hoofnagle JH, Mullen KD, Jones DB et al.:Treatment of chronic non-A, non-B hepatitis with recombinant human alfa interferon. A preliminary report. N. Erlgl. J. Med. 315:1575-1578, 1986.
 
38) Davis GL, Balart LA, Schiff ER et al.:Treatment of chronic hepatitis C with recombinant interferon alfa. Amulticenter randomized, controlled trial. N. Engl. J. Med. 321:1501-1506, 1989.
 
39) Di Bisceglie AM, Martin P, Kassianides C et al.:Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 321:1506-1510, 1989.
 
40) Nishiguchi S, Shiomi S, Nakatani S et al.:Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357:196-197, 2001.
 
41) Kohara M, Tanaka T, Kohara K-T et al.:Hepatitis C virus genotype 1 and 2 respond to interferon-awith different virologic kinetics. J. Infect. Dis. 172:934-938, 1995.
 
42) Honda M, Kaneko S, Matsushita E et al.:Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation. Gastroenterology 118:152-162, 2000.
PubMed
43) Lau JYN, Davis GL, Knniffen J et al:Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501-1504, 1993.
 
44) Orito E, Mizokami M, Tanaka T et al.:Quantification of serum hepatitis C virus core protein level in patients chronically infected with different hepatitis C virus genotype. Gut 39:876-880, 1996.
PubMed
45) Tanaka T, Yoshioka J, Abe A et al.:An application of new algorithm for efficacy prediction of IFN-ribavirin combination therapy using a low-density cDNA microarray. 11th Viral Hepatitis and Liver Disease, 2003.
 
46) Koyama H, Arakawa T, Adachi A:Comparison of an antiviral activity of recombinant consensus interferon with recombinant interferon-a2b. Micobes Infect. 1:1073-1077, 1999.
 
47) Myron JT, Rajender R, William ML et al.:Treatment of chronic hepatitis C virus with consensus interferon:A multicenter, randomized, controlled trial. Hepatology 26:747-754, 1997.
 
48) Jessner W, Stauber R, Hackl F et al:Ealy viral kinetics on treatment with pegylated interferon-α-2a in chronic hepatitis C virus genotype 1 infection. J. Viral Hepatitis 10:37-42, 2003.
 
49) Poynard T, Marcellin P, Lee SS et al.:Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferona2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432, 1998.
 
50) McHutchison JG, Gordon SC, Schiff ER et al.:Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 329:1485-1492, 1998.
PubMed
51) Inoue K, Sekiyama K, Yamada M et al.:Combined interferon a2b and cyclosporine A in the treatment of chronic hepatitis C:controlled trial. J. Gatroenterol 38:567-572, 2003.
 
P.297 掲載の参考文献
1) Carswell EA, Old LJ et al.:An endotoxin-induced serum factor that causes necrosis of tumor. Proc. Natl. Aca. Sci. USA 72:3666-3670, 1975.
 
2) Beutler B, Greenwald D et al.:Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552-554, 1985.
PubMed
3) 山崎正利:tumor necrosis factorと炎症サーキット. 炎症 10:163-170, 1990.
Medical*Online
4) Granger GA, Shack SJ et al.:Lymphocyte in vitro cytotoxicity:specific release of lymphotoxin-like materiaIs from tuberculin-sensitive lymphoid cells. Nature 221:1155-1157, 1969.
 
5) Schlondorff J, Blobel CP:Metalloprotease-disintegrins:modular proteins capable of promoting cell-cell interactions and triggering signaIs by protein-ectodomain shedding. J. Cell Sci. 112:3603-3617, 1999.
PubMed
6) Aggarwal BB:Structure, Mechanism of Action, Role in Disease and Therapy. (eds. Bonavida G, Granger G) , Karger, Base1, 1990, p49-54.
 
7) Jones EY, Stuart DI, Walker NPC:Structure of tumour necrosis factor. Nature 338:225-228, 1989.
 
8) Eck MJ, Sprang SR:The structure of tumor necrosis fa ct or-a at 2. 6 eA resolution. Imp1ications for receptor binding. J. Biol. Chem. 246:17595-17605, 1989.
 
9) Browning JL, Ngam-ek A, Lawton P et al.:LymphotoxinB, a novei member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72:847-856, 1993.
 
10) Lopez-Fraga M, Fernandez R et al.:Biologically active APRIL is secreted followlng intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep. 2:945-951, 2001.
 
11) Lucas R, Magez S, Leys RD et al:Mapping the lectin-like activity of tumor necrosis factor. Science 263:814-817, 1994.
 
12) 佐藤元信, 山崎正利:腫瘍壊死因子(TNF-a)による生体防御. Biotherapy 7:1-12, 1993.
 
13) MacEwan DJ:TNF ligands and receptor-a matter of life and death. Br. J. Pharm. 135:855-875, 2002.
 
14) Banner DW, D'Arcy A et al.:Crystal structure of the soluble human 55kd TNF receptor-human TNFβ complex:implications for TNF receptor action. Cell. 73:431-435, 1993.
 
15) Chan FK-M, Chun HJ, Zheng L et al.:Adomain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288:2351-2354, 2000.
 
16) Aganna E, Aksentijevich I, Hitman GA et al.:Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Dutch family:evidence for a TNFRSFIA mutation with reduced penetrance. Europ. J. Hum. Genet. 9:63-66, 2001.
 
17) Cleveland JL, Ihle JN:Contenders in FasL/TNF death signaling. Cell. 81:479-482, 1995.
PubMed
18) Rothe M, Wong SC, Henzel WJ, Goeddel DV:Anovel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78:681-692, 1994.
 
19) Chung JY, Park YC, Ye H, Wu H:All TRAFs are not created equal:common and distinct molecular mechanisms of TRAF-mediated signal transduction. J. Cell Sci. 115:679-688, 2002.
 
20) Vaux DL:CED-4 The third horseman of apoptosis. Cell 90:389-390, 1997.
PubMed
21) Oberholzer C, Oberholzer A, Clare-Salzler M, Moldawer LL:Apoptosis in sepsis:anew target for therapeutic exploration. FASEB J. 15:879-892, 2001.
 
22) Micheau O, Tschopp J:Induction of TNF receptor 1-mediated apoptosis via two sequential signaling complexes. Cell 114:181-190, 2003.
PubMed
23) Garcia-Ruiz C, Colell A, Mari M et al.:Defective TNF-a-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J. Clin. Invest. 111:197-208, 2003.
PubMed
24) MacEwan DJ:TNF ligands and receptors-a matter of life and death.:Br. J. Pharmacol. 135:855-875, 2002.
PubMed
25) Yao J, Mackman N, Edgington TS, Fan S:Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-κb transcription factors. J. Biol. Chem. 272:17795-17801, 1997.
 
26) Quasney MW, Zhang Q, Sargent S et al.:Increased frequency of the tumor necrosis factor-α-308 A allele in adults with human immunodeficiency virus dementia. Ann. Neurol 50:157-162, 2001.
 
27) RuuIs SR, Sedgwick JD:Unlinking tumor necrosis factor biology from the major histocompatibility complex:lessons from human genetics and animal modeIs. Am. J. Hum. Genet. 65:294-301, 1999.
 
28) Locksley RM, Killeen N, Lenardo MJ:The TNF and TNF receptor superfamilies:Integrating mammalian biology. Cell 104:487-501, 2001.
PubMed
29) McDermott MF, Aksentijevich I, Galon J et al.:Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndrornes. Cell 97:133-144, 1999.
 
30) Henricson BE, Benjamin WR, Vogel SN:Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect. Immun. 58:2429-2437, 1990.
PubMed
31) Gordon S:Pattern recognition receptors:doubling up for the innate immune response. Cell 111:927-930, 2002.
PubMed
32) Kaisho T, Akira S:Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta. 1589:1-13, 2002.
PubMed
33) Lee EG, Boone DL, Chai S et al.:Failure to regulate TNF-induced NF-κBand cell death responses in A20-deficient mice. Science 289:2350-2354, 2000.
 
34) Sosic D, Richardson JA, Yu K et al.:Twist regulates cytokine gene expression through a negative feedback loop that represses NF-κBactivity. OIson EN. Cell 112:169-180, 2003.
 
35) Dumitru CD, Ceci JD, Tsatsanis C et al:TNF-induction by LPS is regulated posttranscriptionally via aTp12/ERK-dependent pathway. Cell 103:1071-1083, 2000.
 
36) Lai WS, Carballo E, Strum JR, et al.:Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol. Cell Biol. 19:4311-4323, 1999.
 
37) Taylor GA, Carballo E, Lee DM et al.:Apathogenetic role for TNFain the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 4:445-454, 1996.
 
38) Rothe J, Lesslauer W, Lotscher H et al.:Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798-802, 1993
 
39) Pfeffer K, Matsuyama T, Kundig TM et al:Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457-467, 1993.
 
40) Bruce AJ, Boling W, Kindy MS et al.:Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nature Med. 2:788-794, 1996.
PubMed
41) Alimzhanov MB, Kuprash DV, Kosco-Vilbois MH et al.:Abnormal development of secondary lymphoid tissues in lymphotoxin β-deficient mice. Proc. Natl. Acad. Sci. USA 94:9302-9307, 1997.
 
42) Bucay N, Sarosi I, Dunstan CR et al.:Osteoprotegerin-deficient rnice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260-1268, 1998.
PubMed
43) Headon DJ, Overbeek PA:Involvement of a novel TNF receptor homologue in hair follicle induction. Nature Genet. 22:370-374, 1999.
PubMed
44) Pasparakis M, Alexopoulou L, Episkopou V, Kollias G:Immune and inflammatory responses in TNFa-deficient mice:Acritical requirement for TNFain the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184:1397-1411, 1996.
 
45) Marino MW, Dunn A, Grail D et al.:Characterization of tumor necrosis factor-deficient mice. Proc. Nat. Acad. Sci. USA 94:8093-8098, 1997.
PubMed
46) Flynn RM, Palladino MA:TNF and TGF-B:The opposite sides of the avenue? Tumor Necrosis Factors. (ed. Beutler B) , Raven Press, New York, 1992, p131-144.
 
47) Abe S, Yamamoto T, Iihara S et al.:Apossible role of glucocorticoids:An intrinsic inhibitor of the cytotoxic activity of tumor necrosis factor. JPn. J. Cancer Res. 79:305-308, 1988.
 
48) 小川道雄:侵襲に対する生体反応の分子機構. 医学のあゆみ 205:535-540, 2003.
Medical*Online
49) van Der Veen AH, ten Hagen TL, de Wilt JH et al.:An overview on the use of TNF-a:our experience with regiona administration and developments towards new opportunities for systemic application. Anticancer Res. 20:3467-3474, 2000.
 
50) Satoh M, Tsurumaki K, Kagehara H, Yamazaki M:Induction of intratumoral tumor necrosis factor by a synthetic lipid A analog, ONO-4007 with less tolerance in repeated administration and its implication in potent antitumor effects with low toxicity. Cancer Immun. Immunother. 50:653-662, 2002.
 
51) Long R, Gardam M:Tumour necrosis factor-a inhibitors and the reactivation of latent tuberculosis infection. Canad. Med. Assoc. J. 168:1153-1156, 2003.
 
P.303 掲載の参考文献
1) Miyazono K, ten Dijke P, Ichijo H, Heldin C-H:Receptors for transforming growth factor-B. Adv. Immunol. 55:181-220, 1994.
 
2) Miyazono K, ten Dijke P, Heldin C-H:TGF-B signaling by Smad proteins. Adv. Immunol. 75:115-157, 2000.
PubMed
3) Heldin C-H, Miyazono K, ten Dijke P:TGF-B signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465-471, 1997.
PubMed
4) Daopin S, Piez KA, Ogawa Y, Davies DR:Crystal structure of transforming growth factor-β2. An unusual fold for the superfamily. Scierlce 257:369-373, 1992.
 
5) Kawabata M, Imamura T, Miyazono K:Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev. 9:49-61, 1998,
PubMed
6) Lin HY, Wang X-F, Ng-Eaton E, Weinberg RA Lodish HF:Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/ threonine kinase. Cell 68:775-785, 1992.
 
7) Franz6n P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin C-H, Miyazono K:Cloning of a TGF-B type I receptor that forms a heteromeric complex with the TGF-β type II receptor. Cell 75:781-792, 1993.
 
8) Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang X-F, Massague J:TGFβ signaIs through a heteromeric protein kinase receptor complex. Cell 71:1003-1014, 1992.
 
9) Wrana JL, Attisano L, Wieser R, Ventura F, Massague J:Mechanism of activation of the TGF 19 receptor. Nature 370:341-347, 1994.
 
10) Shi Y, Massague J:Mechanisms of TGF-Bsignaling from cell membrane to the nucleus. Cell 113:685-700, 2003.
 
11) Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K:Two major Smad pathways in TGF-β superfamny signalling. Genes Cells 7:1191-1204, 2002.
 
12) Miyazono K, Ichijo H, Heldin C-H:Transforming growth Factor-β:Latent forms, binding proteins and receptors. Growth Factors 8:11-22, 1993.
 
13) McAllister KA, Gro99 KM, Johnson Dw, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, McCormick MK, Perical-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA:Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type I. Nat. Genet. 8:345-351, 1994.
 
14) Johnson DW, Berg JN, Baldwin MA et al.:Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet. 13:189-195, 1996.
PubMed
15) Kanzaki T, Olofsson A, Moren A, Wernstedt C, Hellman U, Miyazono K, Cleasson-WeIsh L, Heldin C-H:TGF-β1 binding protein:Acomporlent of the large latent complex of TGF-B1with multiple repeat sequences. Cell 61:1051-1061, 1990.
 
16) Annes Jp, Munger JS, Rifkin DB:Making sense of latent TGFBactivation. J. Cell Sci. 116:217-224, 2003.
 
17) Massague J:The transforming growth factor-β family. Annu. Rev. Cell Biol 6:597-641, 1990.
 
18) Roberts AB, Sporn MB:The transforming growth factor-B s. Peptide Growth Factors and Their Receptors, part I. (eds. Sporn, M. B. , Roberts, A. B. ) , Springer-Verlag, Berlin, 1990, p419-472.
 
19) Piek E, Moustakas A, Kurisaki A et al.:TGF-β type I receptor/ALK-5 and Smad proteins mediate epitheli. al to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J. Cell Sci. 112:4557-4568, 1999.
 
20) Shull MM, Ormsboy I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T:Targeted disruption of the mouse transforming growth factor-Blgene results in multifocal inflammatory disease. Nature 359:693-699, 1992.
 
21) Sanford LP, Ormsby I, Gittenberger-de Groot AC et al.:TGFB 2 knockout mice have multiple developmental defects that are non-overlapping with other TGFBknockout phenotypes. Development 124:2659-2670, 1997.
 
22) Proetzel G, Pawlowski SA, Wiles MV et al.:Transforming growth factor-β3 is required forsecondary palate fusion. Nat. Genet. 11:409-414, 1995.
 
23) Tsukazaki T, Chiang TA, Davison AF et al.:SARA, a FY'VE domain protein that recruits Smad2 to the TGFB receptor. Cell 11:779-791, 1998.
 
24) Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, VogeIstein B, Brattain M, WilIson JKV:Inactivation of the type II TGFB receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338, 1995.
 
25) Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE:DPC4, a candidate tumor suppressor gene at human chromosome 188q21. 1. Science 271:350-353, 1996.
 
26) Howe JR, Roth S, Ringold JC et al.:Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280:1086-1088, 1998.
PubMed
27) Lane KB, Machado RD, Pauciulo MW et al:Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat. Genet. 26:81-84, 2000.
 
28) Blobe GC, Schiemann WP, Lodish HF:Role of transforming growth factor-Bin human disease. N. Engl. J. Med. 342:1350-1358, 2000.
 
29) Inman GJ, Nicolas FJ, Callahan JF et al:SB-431542 is apotent and specific inhibitor of transforming growth factor-Bsuperfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62:65-74, 2002.
 
P.313 掲載の参考文献
1) Nicola NA, Metcalf D, Johnson GR et al.:Separation of functionally distinct human granulocyte-macrophage colony-stimulating factors. Blood 54:614-627, 1979.
PubMed
2) Nicola NA, Metcalf D, Matsumoto M et al.:Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells:identification as granulocyte colony-stimulating factor (G-CSF) . J. Biol. Chem, 258:9017-9023, 1983.
PubMed
3) Asano S, Urabe A, Okabe T et al.:Demonstration ofgranulopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissues. Blood 49:845-852, 1977.
 
4) Nomura H, Imazeki l, Oheda M et al:Purification and characterization of human granulocyte colony-stimulating factor (G-CSF) . EMBO J. 5:871-876, 1986.
 
5) Nagata S, Tsuchiya M, Asano S et al.:Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 319:415-418, 1986.
PubMed
6) Asano S:Human granulocyte colony-stimulating factor:its basic aspects and clinical applications. Am. L. Ped. Hematol/Oncol. 13:400-413, 1991.
 
7) Lieshke GW, Burgess AW:Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1) . N. Eng. J. Med. 327:28-35, 1992.
 
8) Lieshke GW, Burgess AW:Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2) . N. Eng. J. Med. 327:99-106, 1992.
 
9) Nagata T, Tsuchiya M, Asano S et al.:The chromosomal gerle structure and two mRN. As for human granulocyte colony-stimulating factor. EMBO J. 6:611-616, 1986.
 
10) Oheda M, Hasegawa N Hattori N et al.:O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J. Biol Chem. 265:11432-11435, 1990.
 
11) Kishita M, Motojima H, Oheda M et al.:Stability of granulocyte colony-stimulating factor (G-CSF) in serum. Clinical Report 26:221-226, 1992.
 
12) Lovejoy B, Cascio D, Eisenberg D et al.:Crystal structure of granulocyte colony-stimulating factor (G-CSF) . J Mol. Biol. 234:640-653, 1993.
PubMed
13) Motojima H, Kobayashi T, Shimane M et al.:Quantitative enzyme immunoassay for human granulocyte colony-stimulating factor (G-CSF) . J. Immunol. Methods 118:187-192, 1989.
PubMed
14) Fukunaga R, Seto Y, Mizushima S et al.:Three different mRNAs encoding human granulocyte colony-stimullating factor. receptor. Proc. Natl. Acad. Sci. USA 87:8702-8706, 1990.
PubMed
15) Larsen A, Davis T, Curtis BM et al.:Expression cloning of human granulocyte colony-stimulating factor receptor:astructural mosaic of hematopoietin receptor, immunoglobulin, and fibronectin domain. J. Exp Med. 172:1559-1570, 1990.
 
16) Fukunaga R, Ishizaka-lkeda E, Nagata S:Growth and differentiation signaIs mediated by different regions in the cytoplasmic domain of granulocyte colony-stimulating factor. Cell 74:1079-1087, 1993.
 
17) Dong F, Brynes RK, Tidow N et al.:Mutations in the gene for the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. Eng. J. Med. 333:487-493, 1995.
 
18) Matsuda S, Shirafuj i N, Asano S:Human granulocyte colony-stimulating factor specifically binds to murine myeloblastic NFS60 cells and activates their guanine triphosphate binding proteinsu/adenylate cyclase system. Blood 74:2343-2348, 1989.
 
19) NichoIson SE, Novak U, Ziegler SF et al.:Distinct regions of granulocyte colony-stimulating factor receptor are required for tyrosine phosporylation of the signalling molecules JAK2, Stat3, and p42, p44 (MAPK). Blood 86:3698, 1993.
 
20) Tweardy DJ, Wright TM, Zieglar SE et al.:Granulocyte colony-stimulating factor rapidly activates a distinct ATAT-like protein in normal myeloid cells. Blood 86:4409, 1995.
 
21) Lieschke GJ, Grail D, Hodgson G et al.:Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granuiocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84:1737-1746, 1994.
 
22) Watari K, Asano S, Shirajuji N et al:Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as astimated by enzyme immunoassay. Blood 73:117-122, 1989.
 
23) World Health Organization (WHO) BS/92. 1711, International collaborative study for the proposedinternational standards for granulocyte macrophagecolony stimulating factor and granulocyte-colonystimulating factor. 1992.
 
24) Nissen C, Dalle CV, Moser Y et al.:In vivo. comparison of the biological potency of glycosylatedversus non-glycosylated rG-CSF. Drug Invest. 7:346-352, 1994.
 
25) Takahashi S, Okamoto S, Shirafuj i N et al.:Recombinant human glycosylated granulocyte colonystimulating factor (rtG-CSF)-combined regimen forallogeneic bone marrow transplantation in refractoryacute myeloid leukemia. BMT 13:239-245, 1994.
 
26) Ozer H, Armitage JO, Bennet CL, et al:2000 Update of recommeudation for the use of bematopoieticcolony-stimulating factors:evideuce-based, clinicalpractice guidelines. J. Clin Oncol 18(20) 13558-3585, 2000.
 
P.324 掲載の参考文献
1) Kato T, Ogami K, Shimada Y et al.:Purification and characterization of thrombopoietin. J, Biochem. 118:229-236, 1995.
PubMed
2) Miyazaki H, Horie K, Shimada Y et al.:A simple and quantitative liquid culture system to measure megakaryocyte growth using highly purified CFU-MK. Exp. Hematol. 23:1224-1228, 1995.
PubMed
3) Shimada Y, Kato T, Ogami K et al.:Production of thrombopoietin (TPO) by rat hepatocytes and hepatoma cemines. Exp. Hematol. 23:1388-1396, 1995.
 
4) Ogami K, Shimada Y, Sohma Y et al.:The sequence of arat cDNA encoding thrombopoietin. Gene 158:309-310, 1995.
 
5) Sohma Y, Akahori H, Seki N et al.:Molecular cloning arld chromosomal localization of the human thrombopoietin gene. FEBS Lett. 353:57-61, 1994.
 
6) Kuter DJ, Beeler DL, Rosenberg RD:The purification of megapoietin:aphysiological regulator of megakaryocyte growth and platelet production. Proc. Natl. Acad. Sci. USA 91:11104-11108, 1994.
 
7) Vigon I, Mornon Jp, Cocault L et al.:Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene:identification of a member of the hematopoietic growth factor receptor superfamily. Proc. Natl. Acad. Sci. USA 89:5640-5644, 1992.
 
8) de Sauvage FJ, Hass PE, Spencer SD et al.:Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369:533-538, 1994.
 
9) Bartley TD, Bogenberger J, Hunt P et al.:Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor MpL Cell 77:1117-1124, 1994.
PubMed
10) Lok S, Kaushansky K, Holly RD et al:Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369:565-568, 1994.
PubMed
11) Kaushansky K, Lok S, Holly RD et al:Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369:568-571, 1994.
 
12) Muto T, Feese MD, Shimada Y et al.:Functional analysis of the C-terminal region of recombinant human thrombopoietin. J. Biol. Chem. 276:12090-12094, 2000.
 
13) Matsumoto A, Tahara T, Morita H et al.:Characterization of native human thrombopoietin in the blood of normal individuaIs and of patients with haematologic disorders. Thromb. Haemost. 82:24-29, 1999.
 
14) Kaushansky K, Drackman JD:The molecular and cellular biology of thrombopioietin:the primary regulator of platelet production. Oncogene 21:3359-3367, 2002.
 
15) Miyakawa Y, Oda A, Druker BJ et al.:Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood 86:23-27, 1995.
PubMed
16) Miyakawa Y, Oda A, Druker BJ et al.:Thrombopoietin induces tyrosine phosphorylation of Stat 3 and Stat 5 in human blood platelets. Blood 87:439-446, 1996.
 
17) Komatsu N, Kunitama M, Yamada M et al, :Establishment and characterization of the thrombopoietir1-dependent megakaryocytic cell line, UT-7/TPO. Blood 87:4552-4560, 1996.
PubMed
18) Matsumura I, Ishikawa J, Nakajima K et al.:Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21 (WAF1/Cipl) by STAT5. Mol. Cell. Biol. 17:2933-2943, 1997.
 
19) Takatoku M, Kametaka M, Shimizu R et al.:Identification of functional dornains of the human thrombopoietin receptor required for growth and differentiation of megakaryocytic cells. J. Biol. Chem. 272:7259-7263, 1997.
 
20) Morita H, Tahara T, Matsumoto A et al.:Functional analysis of the cytoplasmic domain of the human Mpl receptor for tyrosine-phosphorylation, proliferation and differentiation. FEBS Lett. 395:228-234, 1996.
PubMed
21) Mignotte V, Vigon 1, Boucher de Crevecoeur E et al.:Structure and transcription of the human c-mpl gene (MPL) . Genomics 20:5-12, 1994.
 
22) Stoffel R, Wiestner A, Skoda RC:Thrombopoietin in thrombocytopenic mice:evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 87:567-573, 1996.
PubMed
23) Sasaki Y, Takahashi T, Miyazaki H et al.:Production of thrombopoietin by human carcinomas and its novel isoforms. Blood 94:1952-1960, 1999.
PubMed
24) Nomura S, Ogami K, Kawamura K et al:Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp. Hematol. 25:565-572, 1997.
PubMed
25) Ulich TR, del Castillo J, Yin S et al.:Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 86:971-976, 1995.
PubMed
26) Tahara T, Usuki K, Sato H et al.:Asensitive sandwich ELISA for measuring thrombopoietin in human serum:serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br. J. Haematol. 93:783-788, 1996.
 
27) Usuki K, Tahara T, Iki S et al.:Serum thrombopoietin level in various hematological diseases. Stem Cells 14:558-565, 1996.
PubMed
28) Nichol JL, Hokorn MM, Hornkohl A et al.:Megakaryocyte growth and development factor:analyses in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapyinduced thrombocytopenia. J. Clin. Invet. 95:2973-2978, 1995.
 
29) Fielder PJ, Gurney AL, Stefanich E et al.:Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 87:2154-2161, 1996.
 
30) Kuwaki T, Hagiwara T, Yuki C et al.:Quantitative analysis of thrombopoietin receptors on human megakaryocytes. FEBS Lett. 427:46-50, 1998.
PubMed
31) Horikawa Y, Matsumura I, Hashimoto K et al.:Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 90:4031-4038, 1997.
PubMed
32) Shimodaira S, Ishida F, Ichikawa N et al.:Serum thrombopoietin (c-mpl ligand) levels in patients with liver cirrhosis. Thromb. Haemost. 76:545-548, 1996.
PubMed
33) Ishikawa T, Ichida T, Matsuda Y et al:Reduced expression of thrombopoietin is involved in thrombocytopenia in human and rat liver cirrhosis. J. Gastroenterol. Hepatol. 13:907-913, 1998.
PubMed
34) Kato T, Oda A, Inagaki Y et al:Thrombin cleaves recombinant human thrombopoietin:one of the proteolytic events that generates truncated forms of thrombopoietin. Proc. Natl. Acad. Sci. USA 94:4669-4674, 1997.
PubMed
35) Cazzola M, Skoda RC:Translational pathophysiology:a novel molecular mechanism of human disease. Blood 95:3280-3288, 2000.
PubMed
36) Kondo T, Okabe M, Sanada M et al.:Familial essential thrombocythemia associated with one-base deletion in the 5-'untranslated region of the thrombopoietin gene. Blood 92:1091-1096, 1998.
PubMed
37) Ihara K, Ishii E, Eguchi M et al.:Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc. Natl. Acad. Sci. USA 96:3132-3136, 1999.
 
38) Shiozaki H, Miyawaki S, Kuwaki T et al:Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura. Blood 95:2187-2188, 2000.
 
39) Broudy VC, Lin NL, Kaushansky K:Thrornbopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in bioro. Blood 85:1719-1726, 1995.
 
40) Kato T, Horie K, Hagiwara T et al:Gpllb/IIIa+ subpopulation of rat megakaryocyte progenitor cells exhibits high responsiveness to hurnan thrombopoietin (TPO) . Exp. Hematol. 24:1209-1214, 1996.
 
41) Nishihira H, Toyoda Y, Miyazaki H et al.:Growth of macroscopic human megakaryocyte colonies from cord blood in culture with recombinant human thrombopoietin (c-mpl ligand) and the effects of gestational age on frequency of colonies, Br. J. Haematol 92:23-28, 1996.
PubMed
42) Hagiwara T, Kodama I, Horie K et al:Proliferative properties of human umbilical cord blood megakaryocyte progenitor cells to human thrombopoietin. Exp. Hematol. 26:228-235, 1998.
PubMed
43) Kaushansky K, Broudy VC, Lin N et al.:Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development, Proc. Natl. Acad. Sci. USA 92:3234-3238, 1995.
PubMed
44) Choi ES, Hokom MM, Bartley T et al.:Recombinant human megakaryocyte growth and development factor (rHuMGDF) , aligand for c-Mpl, produces functional human platelets in vitro. Stem CelIs 13:317-322, 1995.
 
45) Horie K, Miyazaki H, Hagiwara T et al.:Action of thrombopoietin at the megakaryocyte progenitor level is critical for the subsequent proplatelet production. Exp. Hematol. 25:169-176, 1997. Erratum in:Exp. Hematol 25:270, 1997.
 
46) Kobayashi M, LaverJH, Kato T et al.:Thrombopoietin supports proliferation of human primitive hematopoietic ceIs in synergy with steel factor and/or interleukin 3. Blood 88:429-436, 1996.
PubMed
47) Itoh R, Katayama N, Kato T et al.:Activity of the ligand for c-mpl, thrombopoietin, in early haematopoiesis, Br, J. Haematol. 94:228-235, 1996.
PubMed
48) Solar GP, Kerr WG, Zeigler FC et al.:Role of c-mpl in early hematopoiesis. Blood 92:4-10, 1998.
PubMed
49) Kimura S, Roberts AW, Metcalf D et al.:Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc. Natl. Acad. Sci, USA 95:1195-200, 1998.
PubMed
50) Kobayashi M, Laver JH, Kato T et al:Recombinant human thrombopoietin (Mpl ligand) enhances proliferation of erythroid progenitors. Blood 86:2494-2499, 1995.
PubMed
51) Matsumura I, Kanakura Y, Kato T et al:Growth response of acute myeloblastic leukemia cells to recombinant human thrombopoietin. Blood 86:703-709, 1995.
PubMed
52) Matsumura I, Kanakura Y, Ikeda H et al.:Coexpression of thrombopoietin and c-mpl genes in human acute myeloblastic leukemia cells. Leukemia 10:91-94, 1996.
 
53) Oda A, Miyakawa Y, Drucker BJ et al.:Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 87:4664-4670, 1996
 
54) Nishiyama U, Morita H, Torii Y et al.:Platelets exposed to elevated levels of endogenous thrombopoiet in vivo have a reduced response to megakaryocyte growth and development factor in vitro. Thromb. Haemost. 85:152-159, 2001.
 
55) Bunting S, Widmer R, Lipari T et al.:Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. Blood 90:3423-3429, 1997.
PubMed
56) Kabaya K, Akahori H, Shibuya K et al:In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. Stem Cells 14:651-660, 1996.
PubMed
57) Torii Y, Nitta Y, Akahori H et al.:Mobilization of primitive haemopoietic progenitor cells and stem cells with long-term repopulating ability into peripheralblood in mice by pegylated recombinant humanmegakaryocyte growth and development factor. Br. J. Haematol. 103:1172-1180, 1998.
 
58) Hokom MM, Lacey D, Kinstler OB et al.:Pegylatedmegakaryocyte growth and development factorabrogates the lethal thrombocytopenia associatedwith carboplatin and irradiation in mice. Blood 86:4486-4492, 1995.
 
59) Akahori H, Shibuya K, Ozai M et al:Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia inducedby a new myelosuppressive chemotherapy regimen inmice. Stem CelIs 14:678-689, 1996.
 
60) Kabaya K, Shibuya K, Torii Y et al:Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth arld development factor in mice. Bone Marrow Transplant, 18:1035-1041, 1996. Erratum in:Bone Marrow Transplant. 20:619-620, 1997.
 
61) Shibuya K, Akahori H, Takahashi K et al.:Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice. Blood 91:37-45, 1998.
PubMed
62) Akahori H, Ozai M, Ida M et al.:Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice. Ther. Apher. 2:58-64, 1998.
PubMed
63) Pestina TI, Cleveland JL, Yang C et al. l Mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis. Blood 98:2084-2090, 2001.
 
64) Akahori H, Shibuya K, Obuchi M et al.:Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br. J. Haematol. 94:722-728, 1996.
PubMed
65) Archimbaud E, Ottmann OG, Yin JA et al.:A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 94:3694-3701, 1999.
PubMed
66) Nomura S, Dan K, Hotta T et al.:Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 100:728-730, 2002.
PubMed
67) Shibuya K, Kuwaki T, Tahara E et al.:Marked improvement of thrombocytopenia in a murine model of idiopathic thrombocytopenic purpura by pegylated recombinant human megakaryocyte growth and development factor. Exp. Hematol. 30:1185-1192, 2002.
 
68) Li J, Yang C, Xia Y et al:Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241-3248, 2001.
 
69) Kato T, Miyazaki H:Therapeutically-induced auto antibodies in patients treated with recombinant hematopoietic growth factors:a brief summarry. Curr. Pharm. Des. 9:1129-1132, 2003.
 
P.333 掲載の参考文献
1) 浦部晶夫:エリスロポエチン. ライフ・サイエンス, 1991.
 
2) Carnot P, Deflandre C:Sur l'activite hemopoietique du serum au cours de la regeneration du sang. Compt. Rend. Acad. Sci. 143:384-386, 1906.
 
3) Carnot P, Deflandre C:Sur l'activite hemopoietique des differents organes au cours de la regeneration du sang. Compt. Rend. Acad. Sci. 143:432-435, 1906.
 
4) Erslev A:Humoral regulation of red cell production. Blood 8:349-357, 1953.
PubMed
5) 浦部贔夫:血液細胞の分化と増殖. メジカルビュー, 1991.
 
6) Lacombe C et al.:Peritubular cells are the site of erythropoietin synthesis in the murine kidney. J. Clin. Invest. 81:620-623, 1988.
 
7) Miyake T et al.:Purification of human erythropoietin. J. Biol Chem. 252:5558-5564, 1977.
PubMed
8) 宮家隆次:エリスロポエチンの精製. 血液・免疫・腫瘍 8:67-69, 2003.
Medical*Online
9) Jacobs K et al:Isolation and characterizatin of genomic and cDNA clones of human erythropoietin. Nature 313:806-810, 1985.
 
10) Lin F-K et al:Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA 82:7580-7584. 1985.
PubMed
11) Law ML et al.:Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism. Proc. Matl. Acad. Sci, USA 83:6920-6924, 1986.
 
12) D'Andrea AD et al.:Expression cloning of the murine erythropoietin receptor. Cell 57:277-285, 1989.
PubMed
13) D'Andrea AD et al.:The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory dornains. Mol. Cell. Biol. 11:1980-1987, 1991.
PubMed
14) de la Chapelle A et al.:Truncated erythropoietin receptor causes dominantly inherited benign humanerythrocytosis. Proc. Natl. Acad. Sci. USA 90:4495-4499, 1993.
PubMed
15) 小松則夫:家族性多血症. 血液・腫瘍科 30:241- 246, 1995.
 
16) Del Mastro L et al.:Chemotherapy of non-small-cell lung cancer:Role of erythropoietin in the management of anemia. Ann. Oncol. 10 (Suppl. 5):S91-S94, 1999.
 
17) Casadevall N et al:Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N, Engl. J. Med. 346:469-475, 2002.
PubMed
18) Gershon SK et al.:Pure red-cell aplasia and reconbinant erythropoietin. N. Engl. J. Med. 346:1584-1585, 2002,
 
P.342 掲載の参考文献
1) Theill LE, Boyle WJ, Penninger JM:RANK-L and RANK:Tcells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20:795-823, 2002.
 
2) Kobayashi Y, Takahashi N:Regulatory mechanism of bone resorption:roles of bone remodeling-regulatory cytokines 'osteokines' in osteoclast differentiation and function. Nippon Rinsho 61:200-206, 2003.
PubMed
3) Takayanagi H, Kim S, Taniguchi T:Signaling cross talk between RANKL and interferons in osteoclast differentiation. Arthritis Res. 4 (Suppl. 3):S227-232, 2002.
 
4) Takahashi N, Akatsu T, Udagawa N et al.:Osteoblastic cells are involved in osteoclast formation. Endo-crinology 123:2600-2602, 1988.
 
5) Suda T, Takahashi N, Udagawa N et al.:Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357, 1999.
PubMed
6) Tsuda E, Goto M, Mochizuki S et al.:Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234:137-142, 1997.
PubMed
7) Simonet WS, Lacey DL, Dunstan CR et al.:Osteo-protegerin:anovel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997.
 
8) The American Society for Bone and Mineral Research President's Committee on Nomenclature:Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. J. Bone Miner. Res. 15:2293-2296, 2000.
PubMed
9) Yasuda H, Shima N, Nakagawa N et al:Identity of osteoclastogenesis inhibitory factor (OCIF) and osteo-protegerin (OPG):amechanism by which OPG/OCIF inhibits osteoclastogenesis in vivo. Endocrinology 139:1329-1337, 1998.
 
10) Mizuno A, Amizuka N, Irie K et al.:Severe osteo-porosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem, Biophys. Res. Commun. 247:610-615, 1998.
 
11) Bucay N, Sarosi I, Dunstan CR et al.:Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260-1268, 1998.
PubMed
12) Yasuda H, Shima N, Nakagawa N et al.:Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95:3597-3602, 1998.
PubMed
13) Wong BR, Rho J, Arron J et al.:TRANCE is a novel ligand of the tumor necrosis factor receptor family that activate c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272:25190-25194, 1997.
 
14) Anderson DM, Maraskovsky E, Billingsley WL et al.:A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179, 1997.
PubMed
15) Lacey DL, Timms E, Tan HL et al.:Osteoprotegerin ligand is a cytokine taht regulates osteoclast differentiation and activation. Cell 93:165-176, 1998.
 
16) Nakagawa N, Kinosaki M, Yamaguchi K et al.:RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253:395-400, 1998.
PubMed
17) Lam J, NeIsorl CA, Ross FP et al:Crystal structure of the TRANCE/RANKL cytokine reveaIs determinants of receptor-ligand specificity. J. Clin. Invest. 108:971-979, 2001.
PubMed
18) Kong YY, Feige U, Sarosi I et al:Activated T cells regulate bone loss and joint destruction in adjacent arthritis through osteoprotegerin ligand. Nature 402:304-309, 1999.
 
19) Horwood NJ, Kartsogiannis V, Quinn JM et al.:Bio-chem. Biophys. Res. Commun. 265:144-150, 1999.
 
20) Kotake S, Udagawa N, Hakoda M et al.:Activated human T cells directly induce osteoclastogenesis from human monocytes:Possible role of T cells on bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 44:1003-1012, 2001.
 
21) Gravallese EM, Manning C, Tsay A et al:Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43:250-258, 2000.
PubMed
22) Takayanagi H, Iizuka H, Juji T et al.:Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 43:259-269, 2000,
PubMed
23) Takamoto M, Tsuji K, Yamashita T et al.:Hedgehog signaling enhances core-binding factoraand receptor activator of nuclear factor-kappaB ligand (RANKL) gene expression in chondrocytes. J. Endocrinol. 177:413-421, 2003.
PubMed
24) Crotti TN, Smith MD, Weedon H et al.:Receptor acti-vator NF-kappaB ligand (RANKL) expression in syn-ovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients:semiquantitative and quantitative analysis. Ann. Rheum. Dis. 61:1047-1054, 2002.
 
25) Zhao S, Zhang YK, Harris S et al.:MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J. Bone Miner Res. 17:2068-2079, 2002.
PubMed
26) Hofbauer LC, Kluger S, Kuhne CA et al.:Detection and characterization of RANK ligand and osteoprote-gerin in the thyroid gland. J. Cell. Biochem. 86:642-650, 2002.
 
27) Takami M, Takahashi N, Udagawa N et al.:Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Endocrinology 141:4711-4719, 2000.
PubMed
28) Kotake S, Udagawa N, Takahashi N et al:IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103:1345-1352, 1999.
PubMed
29) Lomaga MA, Yeh WC, Sarosi I et al.:TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13:1015-1024, 1999.
PubMed
30) Naito A, Azuma S, Tanaka S et al:Severe osteopetrosis, defective interleukin-1signalling and lymph node organogenesis in TRAF6-deficient mice. Genes CelIs. 4:353-362, 1999.
 
31) Wong BR, Besser D, Kim N et al.:TRANCE, a TNF family member, activates Akt/PKB through a signaling complex invoMng TRAF6 and c-Src. Mol. Cell. 4:1041-1049, 1999.
 
32) Li X, Udagawa N, Itoh K, et al.:p38 MAPK-mediated signaIs are required for inducing osteoclast differenti-ation but not for osteoclast function. Endocrinology 143:3105-3113, 2002.
 
33) Lee ZH, Kim HH:Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 305:211-214, 2003.
PubMed
34) Takayanagi H, Kim S, Koga T et al.:Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell. 3:889-901, 2002.
PubMed
35) Ishida N, Hayashi K, Hoshijima M et al:Large scale gene expression analysis of osteoclastogenesis i7z vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 277:41147-41156, 2002.
PubMed
36) Takayanagi H, Ogasawara K, Hida S et al.:T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408:600-605, 2000.
 
37) Takayanagi H, Kim S, Matsuo K et al.:RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416:744-749, 2002.
PubMed
38) Jimi E, Akiyama S, Tsurukai T et al:Osteoclast differentiation factor (ODF) acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163:434-442, 1999.
PubMed
39) Kong YY, Yoshida H, Sarosi I et al.:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999.
PubMed
40) Dougall WC, Glaccum M, Charrier K et al.:RANK is essential for osteoclast and lymph node development. Genes Dev. 13:2412-2424, 1999.
PubMed
41) Li J, Sarosi I, Yan XQ et al.:RANK is the intrinsic hematopoietic cell surface receptor that controIs osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97:1566-1571, 2000.
 
42) Hughes AE, RaIston SH, Marken J et al.:Mutations in TNFRSFllA, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genet. 24:45-48, 2000.
 
43) Udagawa N, Kotake S, Kamatani N et al:. The molecular mechanism of osteoclastogenesis inrheumatoid arthritis. Arthritis Res. 4:281-289, 2002.
 
44) Kotake S, Kamatani N:The role of IL-17 in joint destruction. Drug News Perspect. 15:17-23, 2002.
PubMed
45) Kotake S, Nanke Y, Ichikawa N et al.:Interferongamma producing human T cells directly induce osteoclastogenesis from huma monocytes via the expression of RANKL:possible role of Thl cells in bone resorption. First joint meeting of IBMS-JBMR. s157 abstract, 2003.
 
46) Kobayashi K et al.:Tumor necrosis factor a stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191:275-285, 2000.
PubMed
47) Azuma Y, Kaji K, Katogi R et al.:Tumor necrosis factoralpha induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275:4858-4864, 2000.
PubMed
48) Kotake S, Schumacher HR Jr, Yarboro CH et al.:In vivo gene expression of type 1 and type 2 cytokines in synovial tissues from patients in early stages of rheumatoid, reactive, and undifferentiated arthritis. Proc. Assoc. Am. Physicians. 109:286-301, 1997.
PubMed
49) Zhang YH, HeuIsmann A, Tondravi MM et al.:Tumor necrosis factor-alpha (TNF) stimulates RANKLinduced osteoclastogenesis via coupling of TNF type 1receptor and RANK signaling pathways. J. Biol Chem. 276:563-568, 2001.
 
50) Lam J, Takeshita S, Barker JE et al.:TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106:1481-1488, 2000.
PubMed
51) 市川奈緒美, 小竹 茂, 南家由紀・他:可溶性RANKL とTNF-aは相乗的にヒト破骨細胞の形成を促進する. リウマチ 43:382(抄録), 2003.
 
52) Sezer O, Heider U, Zavrski I et al.:RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101:2094-2098, 2003.
PubMed
53) Terpos E, Szydlo R, Apperley JF et al.:Soluble receptor activator of nuclear factor {kappa} B ligandosteoprotegerin ratio predicts survival in multiple myeloma:proposal for a novel prognostic index. Blood 102:1064-1069, 2003.
PubMed
54) Eghbali-Fatourechi G, Khosla S, Sanyal A et al.:Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111:1221-1230, 2003.
PubMed
55) Bekker PJ, Holloway D, Nakanishi A et al, :The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner Res. 16:348-360, 2001.
PubMed
56) Body JJ, Greipp P, Coleman RE et al.:Aphase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (Suppl. 3):887-892, 2003.
 

ケモカイン受容体とそれらのリガンド

P.353 掲載の参考文献
1) Yoshimura T, Matsushima K, Tanaka S et al.:Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc. Natl. Acad. Sci. USA 84:9233-9237, 1987.
 
2) Matsushima K, Morishita K, Yoshimura T et al.:Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin l and tumor necrosis factor. J. Exp. Med. 167:1883-1893, 1988.
 
3) Larsen CG, Anderson AO, Appella E et al.:The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 243:1464-1466, 1989.
 
4) Holmes WE, Lee J, Kuang WJ et al.:Structure and functional expression of a human interleukin-8 receptor. Science 253:1278-1280, 1991.
 
5) Murphy PM, Tiffany HL:Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 253:1280-1283, 1991.
 
6) Murphy PM:The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12:593-633, 1994.
PubMed
7) Roth I, Hebert C:CXCRI and CXCR2. Cytokine Reference Vol. 1 (ed. Oppenheim JJ, Feldman M) , Academic Press, San Diego, 2001, p1981-2002.
 
8) Iizasa H, Matsushima K:IL-8. Cytokine Reference Vol. 1 (ed. Oppenheim JJ, Feldman M) , Academic Press, San Diego, 2001, p1061-1067.
 
9) Oppenheim JJ, Howard OMZ, Goetzel E:Chemotactic factors, neuropeptides, and other ligands for seven transmembrane receptors. Cytokine Reference Vol. 1 (ed. Oppenheim JJ, Feldman M) , Academic Press, San Diego, 2001, p985-1021.
 
10) Wilkinson NC, Navarro J:PU. 1 regulates the CXCR1 promoter. J. Biol. Chem. 274:438-443, 1999.
PubMed
11) Baggiolini M, Dewald B, Moser B:Human chemokines:an update. Annu. Rev. Immunol. 15:675-705, 1997
PubMed
12) Khandaker MH, Xu L, Rahimpour R et al.:CXCR1 and CXCR2 are rapidly down-modulated by bacterial endotoxin through a unique agonist-independent, tyrosine kinase-dependent rnechanism. J. Immunol. 161:1930-1938, 1998.
PubMed
13) Asagoe K, Yamamoto K, Takahashi A et al.:Down-regulation of CXCR2 expression on human polymorphonuclear leukocytes by TNF-alpha. J. Immunol. 160:4518-4525, 1998.
PubMed
14) Strieter RM, Polverini PJ, Arenberg D et al.:Role of C-X-Cchemokines as regulators of angiogenesis in lung cancer. J. Leukoc. Biol. 57:752-762, 1995.
 
15) Cacalano G, Lee J, Kikly K et al.:Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science 265:682-684, 1994. Erratum in:Science 270:365, 1995.
 
16) Bron R, Klasse PJ, Wilkinson D:Promiscuous use of CC and CXC chemokine receptors in cel1-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein. J. Virol 71:8405-8415, 1997.
 
17) Backhed F, Torstensson E, Seguin D et al.:Helicobacter pylori infection induces interleukin-8 receptor expression in the human gastric epithelium. Infect. Immun. 71:3357-3360, 2003.
PubMed
18) White JR, Lee JM, Young P et al.:Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem. 273:10095-10098, 1998.
PubMed
19) Catusse J, Liotard A, Loillier B et al:Characterization of the molecular interactions of interleukin-8 (CXCL8) , growth related oncogen alpha (CXCLI) and anon-peptide antagonist (SB 225002) with the human CXCR2. Biochem. Pharmacol. 65:813-821, 2003.
 
P.360 掲載の参考文献
1) Loetscher M, Gerber B, Loetscher P et al.:Chemokine receptor specific for IP10 and Mig l structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184:963-969, 1996.
 
2) Tamaru M, Tominaga Y, Yatsunami K et al.:Cloning of the murine interferon-inducible protein 10(IP-10) receptor and its specific expression in lymphoid organs. Biochem. Biophys. Res. Commun. 251:41-48, 1998.
PubMed
3) Tamaru M, Nishioj i K, Kobayashi Y et al.:Liver-infiltrating lymphocytes are attracted selectively by IFN-inducible protein-10. Cytokine 12:299-308, 2000.
 
4) Cole KE, Strick CA, Paradis TJ et al.:Interferon-inducible T cell alpha chemoattractant (1-TAC):a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 187:2009-2021, 1998.
PubMed
5) Bonecchi R, Bianchi G, Bordignon PP et al.:Differential expression of chemokine receptors and chemotactic responsiveness of Type 1 T helper cells (Th1s) and Th2 cells. J. Exp. Med. 187:129-134, 1998.
PubMed
6) Sallusto F, Lenig D, Mackay CR et al.:Flexible programs of chemokine receptor expression on human polarized T helper l and T helper 21ymphocytes. J. Exp. Med. 187:875-883, 1998.
 
7) Meyer M, Hensbergen PJ, van der Raaij-Helmer EMH et al:Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection. Eur. J. Immunol. 31:2521-2527, 2001.
 
8) Khan IA, MacLean JA, Lee FS et al.:IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 12:483-494, 2000.
PubMed
9) Liu MT, Chen BP, Oertel P et al.:Cutting edge:the Tcell chemoattractant IFN-inducible protein 10 (IP-10) is essential in host defense against viral-induced neurologic disease. J. Immunol 165:2327-2330, 2000.
 
10) Liu MT, Armstrong D, Hamilton TA et al.:Expression of Mig (monokine induced by interferon-γ) is important in T lymphocyte recruitment and host defense following viral infection of the central nervous system. J. Immunol, 166:1790-1795, 2001.
 
11) Watarai Y, Koga S, Paolone DR et al.:Intraallograft chemokine RNA and protein during rejection of MHC-matched/multiple minor histocompatibmty-disparate skin grafts. J. Immunol. 164:6027-6033, 2000.
PubMed
12) Hancock WW, Lu B, Gao W et al.:Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J. Exp. Med. 192:1515-1520, 2000.
PubMed
13) Hancock WW, Gao W, Csizmadia V et al.:Donor-derived IP-10 initiates development of acute allograft relection. J. Exp. Med. 193:975-980, 2001.
 
14) Narumi S, Kaburaki T, Yoneyama H et al.:Neutralization of IFN-inducible protein 1O/CXCL10 exacerbates experimental autoimmune encephalo-myelitis. Eur. J. Immunol 32:1784-1791, 2002.
 
15) Yoneyama H, Narumi S, Zhang Y et al.:Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J, Exp. Med. 195:1257-1266, 2002.
PubMed
16) Romagnani P, Annunziato F, Lasagni L et al.:Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest. 107:53-63, 2001.
PubMed
17) Lasagni L, Francalanci M, Annunziato F et al.:An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 197:1537-1549, 2003.
PubMed
18) Sasaki S, Yoneyama H, Suzuki K et al:Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival Eur. J. Immunol, 32:3197-3205, 2002.
PubMed
19) Luster AD, Unkeless JC, Ravetch JV:γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315:672-676, 1985.
 
20) Ohmori Y, Hamilton TA:Amacrophage LPS-inducible early gene encodes the murine homologtle of IP-10. Biochem. Biophys. Res. Commun. 168:1261-1267, 1990.
 
21) Farber JM:Acollection of mRNA species that are inducible in the RAW264. 7 mouse macrophage cell line byγinterferon and other agents. Mol. Cell Biol 12:1535-1545, 1992.
 
22) Cole KE, Strick CA, Paradis TJ et al.:Interferon-inducible T cell alpha chemoattractant (1-TAC):a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 187:2009-2021, 1998.
PubMed
23) Rani MRS, Foster, GR, Leung S et al.:Characterization ofB-Rl, a gene that is selectively induced by interferon β (IFN-β) compared with IFN-a. J. Biol Chem. 271:22878-22884, 1996.
 
24) Jacobs KA, Collins-Racie LA, Colbert M et al:A genetic selection for isolating cDNAs encoding secreted proteins. Gene 198:289-296, 1997.
PubMed
25) Tensen CP, Flier J, van der Raaij-Helmer EMH et al.:Human IP-9:a keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3) . J. Invest. Dermatol. 112:716-722, 1999.
 
26) Narumi S, Hamilton TA:Inducible expression of murine IP-10 mRNA varies with the state of macrophage inflammation activity. J. Immunol. 146:3038-3044, 1991.
 
27) Gasperini S, Matchi M, Calzetti F et al.:Gene expression and production of the monokine induced by IFN-γ (MIG) , IFN-inducible T cellachemoattractant (1-TAC) , and IFN-γ-inducible protein-10 (IP-10) chemokines by human neutrophiIs. J. Immunol. 162:4928-4937, 1999.
 
28) Janatpour MJ, Hudak S, Sathe M et al l Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. J. Exp. Med. 193:1375-1384, 2001.
 
29) Amichay D, Gazzinelli RT, Karupiah G et al.:Genes for chemokines MuMig and Crg-2 are induced in protozoan and viral infections in response to IFN-γ with patterns of tissue expression that suggest nonredundant roles in vivo. J. Immunol 157:4511-4520, 1996.
 
30) Narumi S, Tominaga Y, Tamaru M et al:Expression of IFN-inducible protein-10 in chronic hepatitis. J. Immunol. 158:5536-5544, 1997.
PubMed
31) Tamaru M, Nishioji K, Kobayashi Y et al.:Liver-infiltrating T lymphocytes are attracted selectively by IFN-inducible protein-10. Cytokine 12:299-308, 2000.
PubMed
32) Mohan K, Ding Z, Hanly J et al.:IFN-γ-inducible T cellachemoattractant is a potent stimulator of normal human blood T lymphocyte transendothelial migration:differential regulation by IFN-γand TNF-a. J. Immunol. 168:6420-6428, 2002.
 
33) Heinemeyer T, Wingender E, Reuter I et al.:Databases on transcriptional regulation:TRANSFAC, TRRD and COMPEL. Nucleic Acids Res. 26:362-367, 1998.
PubMed
34) Luster AD, Ravetch JV:Genomic characterization of a λ-interferon-inducible gene (IP-10) and identification of an interferon-inducible hypersensitive site. Mol. Cell. Biol 7:3723-3731, 1987.
 
35) Ohmori Y, Hamilton T A:Cooperative interaction between interferon (IFN) stimulus response eiement andκB sequence motifs controIs IFN-γ-and lipopoiysaccharide-stimulated transcription from the murine IP-10 promoter. J. Biol. Chem. 268:6677-6688, 1993.
 
36) Wright TM, Farber JM:5'Regulatory region of a novel cytokine gene mediates selective activation by interferonγ. J. Exp. Med. 173:417-422, 1991.
 
37) Wong P, Severns CW, Guyer NB et al.:Aunique paiindromic element mediates gamma interferon induction of mig gene expression. Mol. Cell. Biol. 14:914-922, 1994.
 
38) Tensen CP, Flier J, Rampersad SS et al.:Genomic organization, sequence and transcriptional regulation of the human CXCLIl gene. Biochim. Biophys. Acta 1446:167-172, 1999.
PubMed
39) Majumder S, Zhou LZ-H, Chaturvedi P et al.:p48/ STAT-1a-containing complexes play a predominant role in induction of IFN-γ-inducible protein, 10 kDa (IP-10) by IFN-γalone or in synergy with TNFa. J. Immunol. 161:4736-4744, 1998.
 
40) Guyer NB, Severns CW, Wong P et al.:IFN-γinduces ap91/STATIa-related transcription factor with distinct activation and binding properties. J. Immunol 155:3472-3480, 1995.
 
41) Shuai K, Schindler C, Prezioso VR et al.:Activation of transcription by IFN-γ:tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258:1808-1812, 1992.
 
42) Shuai K, Stark C, Kerr IM et al.:Asingle phosphotyrosine residue of Stat91 required for gene activation by interferon-γ. Science 261:1744-1746, 1993.
 
43) Decker T, Lew DJ, Darnell JE Jr:Two distinct alpha-interferon-dependent signal transduction pathways may contribute to activation of transcription of the guanylate-binding protein gene. Mol. Cell. Biol. 11:5147-5153, 1991.
PubMed
44) Horton MR, McKee CM, Bao C et al.:Hyaluronan fragments synergize with interferon-γto induce the C-X-Cchemokines Mig and interferon-γ-inducible protein-10 in mouse macrophages. J. Bio. Chem. 273:35088-35094, 1998.
 
45) Narumi S, Yoneyama H, Inadera H et al.:TNF-ais a potent inducer for IFN-inducible protein-10 in hepatocytes and unaffected by GM-CSF in vivo, in contrast to IL-1Band IFN-γ. Cytokine 12:1007-1016, 2000.
 
46) Hamilton N H R, Banyer J L, Hapel A J et al.:IFN-γregulates murine interferon-inducible T cell alphallines and during experimental autoimmuneencephalomyelitis (EAE) . Scand. J. Immunol. 55:171-177, 2002.
 
47) Gautam S, Tebo JM, Hamilton TA:IL-4 suppresses cytokine gene expression induced by IFN-γand/orIL-2 in murine peritoneal macrophages. J. Immunol. 148:1725-1730, 1992.
 
48) Deng W, Ohmori Y, Hamilton TA:Mechanisms of IL4-mediated suppression of IP-10 gene expression inmurine macrophages. J. Immunol. 153:2130-2136, 1994.
PubMed
49) Ito S, Ansari P, Sakatsume M et al.:Interleukin-10 inhibits expression of both interferona-and interferonγ-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93:1456-1463, 1999.
 
50) Albanesi C, Scarponi C, Sebastiani S et al. l IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines. J. Immunol. 165:1395-1402, 2000.
 
51) Fort MM, Lesley R, Davidson NJ et al.:IL-4 exacerbates disease in a Thl cell transfer model of colitis. J. Immunol. 166:2793-2800, 2001.
 
52) Finbloom DS, Larner AC, Nakagawa Y et al:Culture of human monocytes with granulocyte-macrophage colony-stimulating factor results in enhancement of IFN-γreceptors but suppression of IFN-γinduced expression of the gene IP-10. J. Immunol. 150:2383-2390, 1993.
 
53) Langenkamp A, Nagata K, Murphy K et al.:Kinetics and expression patterns of chernokine receptors in human CD4+T lymphocytes primed by myeloid or plasmacytoid dendritic cells. Eur. J. Immunol 33:474-482, 2003.
PubMed
54) Sarris AH, Broxmeyer HE, Wirthmueller HE et al.:Human interferon-inducible protein 10:expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors. J. Exp. Med. 178:1127-1132, 1993.
 
55) Cole AM, Ganz T, Liese AM et al.:Cutting edge:IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. J. Immunol. 167:623-627, 2001.
PubMed
56) Juffermans NP, Verbon A, van Deventer SJH et al:Elevated chemokine concentrations in sera of human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients with tuberculosis:apossible role for myrcobacterial lipoarabinomannan. Infec. Immu. 67:4295-4297, 1999.
 
57) Shimada A, Morimoto J, Kodama K et al.:Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 24:510-515, 2001.
PubMed
58) Narumi S, Takeuchi T, Kobayashi Y et al.:Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine12:1561-1565, 2000.
 
59) Patel DD, Zachariah JP, Whichard LP:CXCR3 and CCR51igands in rheumatoid arthritis synovium. Clin. Immunol. 98:39-45, 2001.
PubMed
60) Garcia-Lopez MA, Sancho D, Sanchez-Madrid F et al.:Thyrocytes from autoimmune thyroid disorders produce the chemokine IP-10 and Mig and attract CXCR3+lymphocytes. J. Clin. Endocrinol. Metab. 86:5008-5016, 2001.
PubMed
61) Ogawa N, Ping L, Zhenjun L et al.:Involvement of the interferon-γ-induced T cell-attracting chemokines, interferon-γ-inducibie 10-kd protein (CXCL10) and monokine induced by interferon-γ (CXCL9) in the salivary gland lesions of patients with Sjogren's syndrome. Arthritis Rheum. 46:2730-2741, 2002.
 
62) Agostini C, Cassatella M, Zambello R et al.:Involvement of the IP-10 chemokine in sarcoidgranulomatous reactions. J. Immunol 161:6413-6420, 1998.
PubMed
63) Nakae S, Komiyama Y, Narumi S et al.:IL-1-induced TNF aelicits inflammatory cell infiltration in the skinby inducing IFN-γ-inducible protein 10 in theelicitation phase of the contact hypersensitivity response. Int. Immunol. 15:251-260, 2003.
 
64) Cameron MJ Arreaza GA, Grattan M et al.:Differential expression of CC chemokines and theCCR5 receptor in the pancreas is associated withprogression to type I diabetes. J. Immunol. 165:1102-1110, 2000.
 
65) Han GD, Koike H, Nakatsue T et al.:IFN-γ-inducibleprotein 10 (IP-10) /CXCL10 has a differential role invole podocyte during Thy 1. 1 glomerulonephritis. J. Am. Soc. Nenprol. 14:3111-3126, 2003.
 
P.366 掲載の参考文献
1) Tashiro K et al:Science 261:600-603, 1993.
PubMed
2) Nagasawa T et al.:Proc. Natl. Acad. Sci. USA 91:2305-2309, 1994.
PubMed
3) Crump M et al.:EMBO J. 16:6996-7000, 1997.
PubMed
4) Feng Y et al.:Sceince 261:872-877, 1996.
 
5) Bleul CC et al.:Nature 382:829-833, 1996.
PubMed
6) Oberlin E et al.:Nature 382:833-835, 1996.
PubMed
7) Nagasawa T et al.:Nature 382:635-683, 1996.
PubMed
8) Tachibana K et al.:Nature 393:591-594, 1998.
PubMed
9) Zou Y-Ret al.:Nature 393:595-599, 1998.
 
10) Shirozu M et al.:Genomics 28:495-500, 1995.
PubMed
11) McGrath KE et al.:Dev, Biol. 213:442-456, 1999.
PubMed
12) Ara T et al.:Immunity 19:257-267, 2003.
 
13) Nagasawa T et al.:Adv. Immunol. 71:211, 1999.
PubMed
14) Egawa T et al.:Immunity 15:323-334, 2001.
PubMed
15) Nanki T et al.:J. Immunol. 164:5010, 2000.
PubMed
16) Ara T et al.:J. Immunol 170:4649-4655, 2003.
 
17) Ara T et al.:Proc. Natl. Acad. Sci. USA 100:5319-5323, 2003.
PubMed
18) Doitsidonu M et al.:Cell 111:647-659, 2002.
 
19) Knaut H et al.:Nature 421:279-282, 2003.
PubMed
20) Okada T et al.:J. Exp. Med. 196:65-75, 2002.
PubMed
21) Peled A et al.:Science 283:845-848, 1999.
PubMed
22) Muller A et al.:Nature 410:50-56, 2001.
PubMed
23) Burger JA, Kipps TJ:Leuk. Lymp. 43:461-466, 2002.
 
24) Hernandez PA et al.:Nat. Genet. 34:70-74, 2003.
PubMed
25) Clercq ED:Nature Rev. Drug Discovery 2:581-587, 2003.
 
26) Tamamura H et al.:BBRC 253:877-882, 1998.
PubMed
P.373 掲載の参考文献
1) Gunn MD, Ngo VN, Ansel KM et al.:AB-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 391:799-803, 1998.
PubMed
2) Legler DF, Loetscher M, Roos RS et al:Bcell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLRI/CXCR5. J. Exp. Med. 187:655-660, 1998.
 
3) Forster R, Mathis AE, Kremmer E et al.:Aputative chemikine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87:1037-1047, 1996.
 
4) Ishikawa S, Sato T, Abe M et al:Aberrant high expression of B lymphocyte chemokine (BLC/ CXCL13) by CD11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of BI cells towards BLC. J. Exp. Med. 193:1393-1402, 2001.
PubMed
5) Ishikawa S, Nagai S, Sato T et al.:Increased circulating CD11b+CD11c+ dendritic cells in aged BWFI mice which can be matured by TNF-ainto BLC/CXCLI3 producing dendritic cells. Eur. J. Immmulnol. 32:1881-1887, 2002.
 
6) Vissers JL, Hartgers FC, Lindout E et al.:BLC (CXCL139) is expressed by differerlt dendritic cell subsets in vitro and in vivo. Eur. J. Immunol. 31:1544-1549, 2001.
 
7) Ansel KM, Ruth B, Harris S et al.:CXCL13 is required for BI cell homing, natural antibody production, and body cavity immunity. Immunity 16:67-76, 2002.
 
8) Mazzucchelli L, Blaser A, Kappler A et al.:BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J. Clin. Invest. 104:R49-54, 1999.
 
9) Smith JR, Braziel RM, Paoletti S et al:Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101:815-821, 2003.
PubMed
10) Okada T, Ngo VN, Ekland EH et al.:Chemokine requirement for B cell entry to lymph nodes and Peyer's patches. J. Exp. Med. 196:65-75, 2002.
PubMed
11) Ansel M, McHeyzer-Williams LJ, Ngo VN et al.:In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. J. Exp. Med. 190:1123-1134, 1999.
 
12) Schaerli P, Willmann K, Lang AB et al.:CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 192:1553-1562, 2000.
 
13) Wu MT, Hwang ST:CXCR5-transduced bone marrow-derived dendritic cells traffic to B cell zone of iymph nodes and modify antigen-specific immune responses. J. Immunol 168:5096-5102, 2002.
 
14) Lisignoh G, Toneguzzi S, Piacentini A et al.:Human osteoblasts express functional CXC chemokine receptors 3 and 5:activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N-acetylhexosamidase release. J. Cell. Physiol 194:71-79, 2003.
 
15) Voigt IV, Camacho SA, Boer BA et al.:CXCR5-deficient mice develop functional germinal centers in the splenic T cell zone. Eur. J. Immunol. 30:560-567, 2000.
 
16) Luther SA et al.:BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 12:471-481, 2000.
PubMed
17) Adachi S, Yoshida H, Honda K et al.:Essential role of IL-7 receptorain the formation of Peyer's patch anlage. Int. Immunol, 10:1-6, 1998.
PubMed
18) Honda K, Nakano H, Yoshida H et al.:Molecular basis for hematopoietic/mesenchymal interaction during initiation of Peyer's patch organogenesis. J. Exp. Med. 193:621-630, 2001.
PubMed
19) Ansel KM, Ngo VN, Hyman PL et al.:A chemokine-driven positive feedback loop organizes lyrnphoid follicles. Nature 406:309-314, 2000.
PubMed
20) Finke D, Acha-Orbea H, Mathis A et al.:CD4-CD3 cells induce Peyer's patch development:Role ofa4Bl integrin activation by CXCR5. Irnmunity 17:363-373, 2002.
 
21) Luther SA, Ansel KM, Cyster JG:Overlapping roles of CXCL13, interleukin 7 receptora, and CCR71igands in lymph node development. J. Exp. Med. 197:1191-1198, 2003.
 
22) Kong YY, Yoshida H, Sarosi I et al.:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature 397:315-323, 1999.
PubMed
23) Yoshida H, Naito A, Inoue J et al.:Different cytokines induce surface lymphotoxinaBon IL-7 receptor-a cells that differentially engender lymph node and Peyer's patches. Immunity 17:823-833, 2002.
PubMed
24) Herzenberg LA:The Ly-1 B cell lineage. Immunol. Rev. 93:81-102, 1986.
PubMed
25) Shi K, Hayashida K, Kaneko M et al. ;Lymphoid chemikine B cell-attracting chemokine-1 (CXCLI3) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J. Immunol. 166:650-655, 2001.
 
26) Amft N, Curnow SJ, Scheel-Toellner D et al.:Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sj6gren's syndrome. Arth. Rheum. 44:2633-2641, 2001.
 
27) Salomonsson S, Larsson P, Tengner P et al.:Expression of the B-cell attracting chemokine CXCLI3 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sj6gren's syndrome. Scand. J. Immunol. 55:336-342, 2002.
 
28) Theofilopoulos AN:Murine modeIs of systemic lupus erythematosus. Adv. Immunol. 37:269-390, 1985.
 
29) Shirai T et al:Immunology and immunopathology of the autoimmune disease of NZB arld related mouse strains. Immunological Disorders in Mice. (eds. Rihova EB, Vetvicka V) , CRC Press Inc, 1991, p95-136.
 
30) Mclntyre TM, Strober W:Gut associated lymphoid tissue:Regulation of IgA B cell development (eds. Ogra P et al. ) , Mucosal Immunology. San Diego, CA, Academic Press, 1999, p319-356.
 
31) Husband AJ, Beagley KW, McGhee JR et al.:Mucosal cytokines. Mucosal Immunology. (eds. Ogra P et al. ) , San Diego, CA, Academic Press. 1999, p541-557.
 
32) Phillips-Quagliata JM, Lamm ME:Lymphocyte homing to mucosal effector sites. Handbook of Mucosal Immunology. (eds. Ogra P et al) , San Diego, CA, Academic Press:1999, p319-356.
 
33) Kroese FG et al.:Many of the IgA producing plasma cells in murine gut are derived from self-replenishing precursors in the peritoneal cavity. Int. Immunol. 1:75-84, 1989.
PubMed
34) Kroese FG et al.:Evidence that intestinal IgA plasma cells in/t, κtransgerlic mice are derived from B-1 (Ly-1B) cells. Int. Immunol. 5:1317-1327, 1993.
 
35) Fagarasan S et al.:in vitro. class switching and differentiation to IgA-prpoducing cells in the gut lamina propria. Nature 413:639-643, 2001.
PubMed
36) Gong J-H, Clark-Lewis I:Antagonism of monocyte chemoattractant protein 1 identified by modification of dunctionally critical NH2-terminal residues. J. Exp. Med. 181:631-640, 1995.
 
37) Arenzana-Seisdedos F, Virelizier J-L, Rousset D et al.:HIV blocked by chemokine antagonist. Nature 383:400-403, 1996.
PubMed
38) Shimizu H, Maruyama S, Yuzawa Y et al.:Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overloaded proteinuria. J. Am. Soc. Nephrol. 14:1496-505, 2003.
PubMed
P.379 掲載の参考文献
1) Liao F, Alkhatib G, Peden KW et al.:STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J. Exp. Med. 185:2015-2023, 1997.
 
2) Deng H, Unutmaz D, KewalRamarli VN et al.:Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388:296-300, 1997.
 
3) Loetscher M, Amara A, Oberlin E et al.:TYMSTR, a putative chemokine receptor selectively expressed in activated T cells, exhibits HIV-1 coreceptor function. Curr. Biol. 7:652-660, 1997.
PubMed
4) Unutmaz D, Xiang W, Sunshine MJ et al.:The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse. J. Immunol. 165:3284-3292, 2000.
PubMed
5) Kim CH, Kunkel EJ, Boisvert J et al.:Borlzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J. Clin. Invest. 107:595-601, 2001.
PubMed
6) Motsinger A, Haas DW, Stanic AK et al.:CDId-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J. Exp. Med. 195:869-879, 2002.
 
7) Kim CH, Rott L, Butcher EC et al:Rules of chemokine receptor association with T cell polarization in vivo. J. Clin. Invest. 108:1331-1339, 2001.
 
8) Shimaoka T, Kume N, Minami M et al.:Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J. Biol. Chem. 275:40663-40666, 2000.
PubMed
9) Matloubian M, David A, Engel S et al.:A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. Immunol. 1:298-304, 2000.
 
10) Shimaoka T, Nakayama T, Kume N et al:Cutting edge:SR-PSOX/CXC chemokine ligand 16 mediates bacterial phagocytosis by APCs through its chemokine domain. J. Immunol. 171:1647-1651, 2003.
PubMed
11) Wilbanks A, Zondio SC, Briskin, M et al.:Expression cloning of the STRL33/BONZO/TYMSTRIigand reveaIs elements of CC, CXC, and CX3C chemokines. J. Immunol. 166:5145-5154, 2001.
 
12) Nakayama T, Hieshima K, Izawa D et al.:Cutting edge:profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J. Immunol 170:1136-1140, 2003.
PubMed
13) Murphy PM:International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol. Rev. 54:227-229, 2002.
PubMed
14) 稗島州雄:CXCR6. ケモカインハンドブック. (義江 修・他編), 秀潤社, 東京, 2000, p173-175.
 
15) Sharron M, Pohlmann S, Price K et al:Expressionand coreceptor activity of STRL33/Bonzo on primaryperipheral blood lymphocytes. Blood 96:41-49, 2000.
 
16) Croitoru-Lamoury J, Guillemin GJ, Boussin FD et al.:Expression of chemokines and their receptors inhuman and simian astrocytes:evidence for a centralrole of TNF alpha and IFN gamma in CXCR4 andCCR5 modulation. Glia 41:354-370, 2003.
 
17) Langenkamp A, Nagata K, Murphy K et al.:Kineticsand expression patterns of chemokine receptors inhuman CD4+T lymphocytes primed by myeloid orplasmacytoid dendritic cells. Eur. J. Immunol. 33:474-482, 2003.
 
18) Duggal P, Beaty TH, Strathdee SA et al.:Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans. Genes Immunity 4:245-250, 2003.
PubMed
19) Boisvert J, Kunkel EJ, Campbell JJ et al.:Liver-infiltrating lymphocytes in end-stage hepatitis C virus:Subsets, activation status, and chemokine receptor phenotypes. J. Hepatol. 38:67-75, 2003.
PubMed
20) Dong H, Toyoda N, Yoneyama H et al.:Gene expression profile analysis of the mouse liver during bacteria-induced fulminant hepatitis by a cDNA microarray system. Biochem. Biophys. Res. Commun. 298:675-686, 2002.
PubMed
P.387 掲載の参考文献
1) Neote K, DiGregorio D, Mak JY et al.:Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 72:415-425, 1993.
 
2) Gao JL, Kuhns DB, Tiffany HL et al.:Structure and functional expression of the human macrophage inflammatory protein l alpha/RANTES receptor. J. Exp. Med. 177:1421-1427, 1993.
 
3) Nomura H, NieIsen BW, Matsushima K:Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. Int. Immunol. 5:1239-1249, 1993.
 
4) Gao JL, Wynn TA, Chang Y et al.:Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J. Exp. Med. 185:1959-1968, 1997.
PubMed
5) Gao W, Topham PS, King JA et al.:Targeting of the chemokine receptor CCRI suppresses development of acute and chronic cardiac allograft rejection. J. Clin. Invest. 105:35-44, 2000.
 
6) Broxmeyer HE, Kim CH:Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities. Exp. Hematol. 27:1113-1123, 1999.
 
7) Clemons MJ, Marshall E, Durig J et al.:Arandomized phase-Hstudy of BB-10010 (macrophage inflammatory protein-1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy. Blood 92:1532-1540, 1998.
 
8) Samson M, Labbe O, Mollereau C et al.:Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35:3362-3367, 1996.
PubMed
9) Combadiere C, Ahuja SK, Tiffany HL et al:Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1 (aipha) , MIP-1 (beta) , and RANTES. J. Leukoc. Biol. 60:147-152, 1996.
 
10) Alkhatib G, Combadiere C, Broder CC et al.:CC CKR5:aRANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958, 1996.
 
11) Deng H, Liu R, Ellmeier W, Choe S et al.:Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666, 1996.
 
12) Dragic T, Litwin V, Allaway GP et al.:HIV-1 entry into CD4+cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673, 1996.
PubMed
13) Liu R, Paxton WA, Choe S et al.:Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuaIs to HIV-1 infection. Cell 86:367-377, 1996.
 
14) Huang Y, Paxton WA, Wolinsky SM et al.:The role of amutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240-1243, 1996.
 
15) Martin MP, Dean M, Smith MW et al.:Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282:1907-1911, 1998.
PubMed
16) 山村昌弘:RAにおけるCXCR3, CCR4, CCR5の発現. リウマチ科 29:14-20, 2003.
 
17) Murai M, Yoneyama H, Harada A et al.:Active participation of CCR5(+) CD8(+) Tlymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J. Clin. Invest. 104:49-57, 1999.
 
18) Obaru K, Fukuda M, Maeda S et al.:AcDNA clone used to study mRNA inducible in human tonsillar lymphocytes by a tumor promoter. J. Biochem. 99:885-894, 1986.
 
19) Lipes MA, Napolitano M, Jeang KT et al.:Identification, cloning, and characterization of an immune activationgene. Proc. Natl. Acad. Sci. USA 85:9704-9708, 1988.
 
20) Wolpe SD, Davatelis G, Sherry B et al.:Macrophagessecrete a novel heparin-binding protein withinflammatory and neutrophil chemokinetic properties, J. Exp. Med. 167:570-581, 1988.
 
21) Davatelis G, Tekamp-OIson P, Wolpe SD et al.:Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP) , anovelmonokine with inflammatory and chemokineticproperties. J. Exp. Med. 167:1939-1944, 1988.
 
22) Sherry B, Tekamp-OIson P, Gallegos C et al.: Resolution of the two components of macrophageinflammatory protein 1, and cloning and characterizationof one of those components, macrophage inflammatoryprotein l beta. J. Exp. Med. 168:2251-2259, 1988.
 
23) Schall TJ, Jongstra J, Dyer BJ et al.:Ahuman T cellspecific molecule is a member of a new gene family. J. Immunol. 141:1018-1025, 1988.
 
24) Schall TJ, Bacon K, Toy KJ et al.:Selective attractionof monocytes and T lymphocytes of the memoryphenotype by cytokine RANTES. Nature 347:669-671, 1990.
 
25) 前田洋助, 野見山尚之, 茆原順一・他:ケモカインハ ンドブック. 秀潤社, 東京, 2000, p82-95, p176-178, p189-192.
 
26) Murphy PM, Baggiolini M, Charo IF et al.:International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52:145-176, 2000.
PubMed
27) Shaffer AL, Yu X, He Y et al:BCL-6 represses genesthat function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13:199-212, 2000.
 
28) Toney LM, Cattoretti G, Graf JA et al.:BCL-6regulates chemokine gene transcription in macrophages. Nat. Immunol. 1:214-220, 2000.
PubMed
29) NeIson PJ, Ortiz BD, Pattison JM et al.:Identificationof a novel regulatory region critical for expression of the RANTES chemokine in activated T lymphocytes. J. Immunol 157:1139-1148, 1996.
 
30) Song A, Chen YF, Thamatrakoln K et al.:RFLAT-11Anew zinc finger transcription factor that activatesRANTES gene expression in T lymphocytes. Immunity 10:93-103, 1999.
 
31) Swanson BJ, Murakami M, Mitchell TC et al.:RANTES production by memory pherlotype T cells iscontrolled by a posttranscriptional, TCR-dependentprocess, Immunity 17:605-615, 2002.
 
32) Tanaka Y, Adams DH, Hubscher S et al.:T-celladhesion induced by proteoglycan-immobilizedcytokine MIP-1 beta. Nature 361:79-82, 1993.
 
33) Kawai T, Seki M, Hiromatsu K et al.:Selectivediapedesis of Thl cells induced by endothelial cellRANTES. J. Immunol. 163:3269-3278, 1999.
 
34) Cook DN, Beck MA, Coffman TM et al.:Requirementof MIP-1 alpha for an inflammatory response to viralinfection. Science 269:1583-1585, 1995.
 
35) Kameyoshi Y, Dorschner A, Mallet AI et al.:Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J. Exp. Med. 176:587-592, 1992.
PubMed
36) 齋藤紀先, 茆原順一:ケモカイン(RANTES, eotaxin など). 日本臨床 59:1900-1905, 2001.
Medical*Online
37) Taub DD, Anver M, Oppenheim JJ et al:T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophiIs releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J. Clin. Invest. 97:1931-1941, 1996.
 
38) Karpus WJ, Lukacs NW, Kennedy KJ et al:Differential CC chemokine-induced enhancement of Thelper cell cytokine production. J. Immunol. 158:4129-4136, 1997.
 
39) Zhou Y, Kurihara T, Ryseck RP et al.:Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J. Immunol. 160:4018-4025, 1998.
PubMed
40) Huffnagle GB, McNeil LK, McDonald RA et al.:Role of C-C chemokine receptor 5 in organ-specific and innate immunity to cryptococozes neoformans. J. Immunol. 163:4642-4646, 1999.
PubMed
41) Sato N, Kuziel WA, Melby PC et al.:Defects in the generation of IFN-gamma are overcome to control infection with Leishmaniadonovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice. J. Immunoi. 163:5519-5525, 1999.
 
42) Cocchi F, DeVico AL, Garzino-Demo A et al.:Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+Tcells. Science 270:1811-1815, 1995.
 
43) Lee B, Sharron M, Blanpain C et al.:Epitope mapping of CCR5 reveaIs multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274:9617-9626, 1999.
PubMed
44) Karpus WJ, Kennedy KJ:MIP-1 alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th21ymphocyte differentiation. J. Leukoc. Biol. 62:681-687, 1997.
 
45) Murai M, Yoneyama H, Ezaki T et al.:Peyer's patch isthe essential site in initiating murine acute and lethalgraft-versus-host reaction. Nat Immunol. 4:154-160, 2003. Erratum in:Nat. Immunol. 4:497, 2003.
 
46) Gao W, Faia KL, Csizmadia V et al.:Beneficial effects of targeting CCR5 inεallograft recipients. Transplantation 72:1199-1205, 2001.
 
47) Pattison J, NeIson PJ, Huie P et al.:RANTES chemokine expression in cell-mediated transplantrejection of the kidney. Lancet 343:209-211, 1994.
 
48) Fischereder M, Luckow B, Hocher B et al.:CC chemokine receptor 5 and renal-transplant survival. Lancet 357:1758-1761, 2001.
PubMed
49) Kimata H, Yoshida A, Ishioka C et al.:RANTES and macrophage inflammatory protein l aipha selectively enhance immunoglobulin (IgE) and lgG4 production by human B cells. J. Exp. Med. 183:2397-2402, 1996.
 
50) Arenzana-Seisdedos F, Virelizier JL, Rousset D et al.:HIV blocked by chemokine antagonist. Nature 383:400, 1996.
PubMed
51) Simmons G, Clapham PR, Picard L et al.:Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276-279, 1997.
PubMed
52) Proudfoot AE, Power CA, Hoogewerf AJ et al.:Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol, Chem. 271:2599-2603, 1996.
PubMed
53) 上田博嗣:ケモカイン阻害剤. Molecular Medicine 38:184-193, 2001.
 
54) Hunter MG, Bawden L, Brotherton D et al.:BB-10010:an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties. Blood 86:4400-4408, 1995.
PubMed
55) Ng HP, May K, Bauman JG et al.:Discovery of novel non-peptide CCRI receptor antagonists. J. Med. Chem. 42:4680-4694, 1999.
 
56) Baba M, Nishimura O, Kanzaki N et al.:A small molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl. Acad. Sci. USA 96:5698-5703, 1999.
PubMed
P.399 掲載の参考文献
1) Matsushima K, Larsen CG DuBois GC et al.:Purification and characterization of a novel monocyte chemotactic arld activating factor produced by a human myelomonocytic cell line. J. Exp. Med. 169:1485-1490, 1989.
 
2) Yoshimura T, Robinson EA, Tanaka S et al.:Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohe-magglutinin-stimulated human blood mononuclear leukocytes. J. Immunol 142:1956-1962, 1989.
 
3) Furutani Y, Nomura H, Notake M et al.:Cloning and sequencing of the cDNA for human monocyte chemotactic arld activating factor (MCAF) . Biochem. Biophys. Res. Commun. 159:249-255, 1989.
 
4) Yoshimura T, Yuhki N, Moore SK et al.:Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett. 244:487-493, 1989.
PubMed
5) Charo IF, Myeers SJ, Herman A et al:Molecular cloning and functional expression of two monocyte chemoattractant protein l receptors reveaIs alternative splicing of the carboxyl-terminal taiIs. Proc. Natl. Acad. Sci. USA gl:2752-2756, 1994.
 
6) Wong LM, Myers SJ, Tsou CL et al.:Organization and differential expression of the human monocyte chemoattractant protein l receptor gene:Evidence for the role of the carboxyl-terminal tail in receptor trafficking. J. Biol. Chem. 272:1038-1045, 1997.
 
7) Viedt C, Dechend R, Fei J et al:MCP-1 induces inflammatory activation of human tubular epithelial cells:involvement of the transcription factors, nuclear factor-kappaB and activating protein-1. J. Am. Soc. Nephrol 13:1534-1547, 2002.
PubMed
8) Charo IF:CCR2:from cloning to the creation of knockout mice. Chem Immunol. 72:30-41, 1999.
 
9) Murphy PM, Baggiolini M, Charo IF et al.:International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52:145-176, 2002.
 
10) Rollins BJ, Morrison ED, Stiles CD:Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc. Natl. Acad. Sci. USA 85:3738-3742, 1988.
 
11) Ueda A, Okuda K, Ohno S et al.:NF-kappa B and Spl regulate transcription of the human monocyte chemoattractant protein-1 gene. Immunology 153:2052-2063, 1994.
 
12) Ueda A, Ishigatsubo Y, Okubo T et al:Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J. Biol. Chem. 272:31092-31099, 1997.
PubMed
13) Sridhar P, Liu Y, Chin LD et al:Platelet-derived growth factor-stimulated expression of the MCP-1 immediate-early gene involves an inhibitory multiprotein complex. Mol. Cell. Biol. 19:4219-4230, 1999.
 
14) 向田直史:ケモカイン遺伝子発現の制御機構. 血液・腫瘍科 45:356-362, 2002.
 
15) Toney LM, Cattoretti G, Graf JA et al.:BCL-6 regulates chemokine gene transcription in macrophages. Nat. Immunol. 1:214-220, 2000.
PubMed
16) Furuichi K, Wada T, Iwata Y et al.:CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J. Am. Soc. Nephrol. 14:2503-2515, 2003.
 
17) Ashida N, Arai H, Yamasaki M et al. I Distinct signaling pathways for MCP-1-dependent integrin activation and chemotaxis. J. Biol Chem. 276:16555-16560, 2001.
PubMed
18) Arai H, Tsou CL, Charo IF:Chemotaxis in a lymphocyte cell line transfected with C-C chemokine receptor 2B:that directed migration is mediated by betagamma dimers released by activation of Galphai-coupled receptors. Proc. Natl. Acad. Sci. USA 94:14495-14499, 1997.
 
19) Ono K, Matsumori A, Furukawa Y et al.:Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab. Invest. 79:195-203, 1999.
PubMed
20) Koyanagi M, Egashira K, Kitamoto S et al.:Role of monocyte chemoattractant protein-1 in cardiovascular rernodeling induced by chronic blockade of nitric oxide synthesis. Circulation 102:2243-2248, 2000.
PubMed
21) Furukawa Y, Matsumori A, Ohashi N et al.:Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ. Res. 84:306-314, 1999.
PubMed
22) Salcedo R, Ponce ML, Young HA et al.:Human endothelial cells express CCR2 and respond to MCP-1:direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34-40, 2000.
PubMed
23) Gordon JR:Monocyte chemoattractant peptide-1 expression during cutaneous allergic reactions in mice is mast cell dependent and largely mediates the monocyte recruitment response. J. Allergy Clin. Immunol. 106:110-116, 2000.
PubMed
24) Karpus WJ, Kennedy KJ:MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 1ymphocyte differentiation. J. Leukoc. Biol. 62:681-687, 1997.
 
25) Zou LP, Pelidou SH, Abbas N et al.:Dynamics of production of MIP-lalpha, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats. J. Neuroimmunol. 98:168-175, 1999.
 
26) Ogata H, Takeya M, Yoshimura T et al.:The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J. Pathol. 182:106-114, 1997.
PubMed
27) Ichiyasu H, Suga M, Matsukawa A et al.:Functional roles of MCP-1 in Propionibacterium acnes-induced, T cell-mediated pulmonary granulomatosis in in rabbits. J. Leukoc. Biol. 65:482-491, 1999.
PubMed
28) Kimura H, Kasahara Y, Kurosu K et al.:Alleviation ofmonocrotaline-induced pulmonary hypertension byantibodies to monocyte chemotactic and activatingfactor/monocyte chemoattractant protein-1. Lab. Invest. 781571-581, 1998.
 
29) Wada T, Yokoyama H, Furuichi K et al.:Intervention of crescentic glomerulonephritis by antibodies tomonocyte chemotactic and activating factor (MCAF/MCP-1) . FASEB J. 10:1418-1425, 1996.
 
30) Gu L, Okada Y, Clinton SK et al:Absence ofmonocyte chemoattractant protein-1 reducesatherosclerosis in low density lipoprotein receptordeficient mice. Mol. Cell, 2:275-281, 1998.
 
31) Gosiing J, Slaymaker S, Gu L et al.:MCP-1deficiencyreduces susceptibility to atherosclerosis in mice thatoverexpress human apolipoprotein B. J. Clin. Invest. 103:773-778, 1999.
PubMed
32) Boring L, Gosling J, Cleary M et al.:Decresed lesionformation in CCR2 ' mice reveaIs a role forchemokines in the initiatiorl of atherosclerosis. Nature 394:894-897, 1998.
 
33) Moore BB, Paine R 3rd, Christensen PJ et al.:Protection from pulmonary fibrosis in the absence of CCR2 signaling. J. Immunol. 15:4368-4377, 2001.
 
34) Kawakami K, Kinjo Y, Uezu K et al.:Monocytechemoattractant protein-1-dependent increase of Valpha 14 NKT cells in lungs and their roles in Thlresponse and host defence in cryptococcal infection. J. Immunol. 167:6525-6532, 2001.
 
35) Kim Y, Sung Ss, Kuziel WA et al.:Enhanced airway Th2 response after allergen challenge in micedeficient in CC chemokine receptor-2 (CCR2) . J. Immunol. 166:5183-5192, 2001.
 
36) Boring L, Gosling J, Chensue SW et al.:Impairedmonocyte migration and reduced type 1 (Th1) cytokineresponses in C-C chemokine receptor 2 knockoutmice. J, Clin. Invest, 100:2552-2561, 1997.
 
37) Dambach DM, Watson LM, Gray KR et al.:Role ofCCR2 in macrophage migration into the liver duringacetaminophen-induced hepatotoxicity in the mouse. Hepatology 35:1093-1103, 2002.
 
38) Izikson L, Klein RS, Charo IF et al.:Resistance toexperimental autoimmune encephalomyelitis in micelacking the CC chemokine receptor (CCR) 2. J. Exp. Med. 192:1075-1080, 2000.
 
39) Gonnella PA, Kodai D, Weiner HL:Induction of lowdose oral tolerance in monocyte chemoattractantprotein-1-and CCR2-deficient mice. J Immunol. 170:2316-2322, 2003.
 
40) Tesch GH, Maifert S, Schwarting A et al.:Monocytechemoattractant protein 1-dependent leukocyteinfiltrates are responsible for autoimmune disease inMRL-Fas lpr mice. J. Exp. Med. 190:1813-1824, 1999.
 
41) Tesch GH, Schwarting A, Kinoshita K et al.:Monocyte chemoattractant protein-l promotesmacrophage-mediated tubular injury, but notglomerular injury, in nephrotoxic serum nephritis. J. Clin. Invest. 103:73-80, 1999.
 
42) Gerszten RE, Garcia-Zepeda EA, Lim YC et al.:MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398:718-723, 1999.
PubMed
43) Gu L, Tseng S, Horner RM et al.:Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404:407-411, 2000.
PubMed
44) Smith MW, Dean M, Carrington M et al.:Contrasting genetic influence of CCR2 and CCR5 variants on HIV-linfection and disease progression. Hemophilia Growth and Development Study (HGDS) , Multicenter AIDS Cohort Study (MACS) , Multicenter Hemophilia Cohort Study (MHCS) , San Francisco City Cohort (SFCC) , ALIVE Study. Science 277:959-965, 1997.
 
45) Damon I, Murphy PM, Moss B:Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. Proc. Natl. Acad. Sci. USA 95: 6403-6407, 1998.
PubMed
46) Wang H, Nemoto-Sasaki Y, Kondo T et al.:Potential involvement of monocyte chemoattractant protein (MCP)-1/CCL2 in IL-4-mediated tumor immunity through inducing dendritic cell migration into the draining lymph nodes. Int, Immunopharmacol. 3:627-642, 2003.
PubMed
47) Sakai Y, Kaneko S, Nakamoto Y et al.:Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-l in hepatocellular carcinoma. Cancer Gene Ther. 8:695-704, 2001.
 
48) Ross R:Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340:115-126, 1999.
PubMed
49) Egashira K:rnolecular mechanisms mediating inflammation in vascular disease. Hypertension 41:834-841, 2003.
PubMed
50) Wada T, Yokoyama H, Matsushima K et al.:Chemokines in renal diseases. Int. Immunopharmacol. 1:637-645, 2001.
PubMed
51) Wada T, Matsushima K, Yokoyama H:Chemokines as the therapeutic targets for renal diseases. Curr. Med. Chem. Anti-lnflammatory & Anti-Allergy 2:175-190, 2003.
 
52) Akahoshi T, Wada C, Endo H et al.:Expression ofmonocyte chemotactic and activating factor inrheumatoid arthritis. Regulation of its production insynovial cells by interleukin-l and tumor necrosisfactor. Arthritis Rheum. 36:762-771, 1993.
 
53) Katschke KJ Jr, Rottman JB, Ruth JH et al.:Differential expression of chemokine receptors onperipheral blood, synovial fluid, and synovial tissuemonocytes/macrophages in rheumatoid arthritis. Arthritis Rheum. 44:1022-1032, 2001.
 
54) Gong JH, Ratkay LG, Waterfield JD et al.:An antagonist of morlocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mousemodel. J. Exp. Med. 186:131-137, 1997.
 
55) Taylor PC, Peters AM, Paleolog E et al.:Reduction ofchemokine levels and leukocyte traffic to joints bytumor necrosis factor alpha blockade in patients withrheumatoid arthritis. Arthritis Rheum. 43:38-47, 2000.
 
56) Conti P, Digioacchino M:MCP-1 and RANTES are mediators of acute and chronic inflammation. AllergyAsthma Proc. 22:133-137, 2001.
 
57) Iyonaga K, Takeya M, Saita N et al.:Monocytechemoattractant protein-1 in idiopathic pulmonaryfibrosis and other interstitial lung diseases. Hum. Pathol. 25:455-463, 1994.
 
58) Proudfoot AEI:Chemokine receptors:multifaceted therapeutic targets. Nat. Rev. Irnmunol 2:106-115, 2002.
PubMed
59) Mizadegan T, Diehl F, Ebi B et al.:Identification ofthe binding site for a rlovel class of CCR2b chemokinereceptor antagonists:binding to a commonchemokine receptor motif within the helical burldle. J. Biol. Chem. 275:25562-25571, 2000.
 
60) Yokochi S, Hashimoto H, Ishiwata Y et al:An antiinflammatory drug, propagermanium, may target GPIanchored proteins associated with a MCP-1 receptor, CCR2. J. Interferon Cytokine Res. 21:389-398, 2001.
PubMed
P.406 掲載の参考文献
1) Jose pJ, Adcock IM, Griffiths-Johnson DA et al.:Eotaxin:cloning of an eosinophil chemoattractant cytokine and increased mRNA expression in allergen-challenged guinea-pig lungs. Biochem. Biophys. Res. Commun. 205:788-794, 1994.
PubMed
2) Jose PJ, Griffiths-Johnson DA, Collins PD et al.:Eotaxin:apotent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J. Exp. Med. 179:881-887, 1994.
 
3) Garcia-Zepeda EA, Rothenberg ME, Ownbey RT et al.:Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nature Med. 2:449-456, 1996.
PubMed
4) Ganzalo JA, Jia GQ, Aguirre V et al.:Mouse eotaxin expression paralleIs eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response. Immunity 4:1-14, 1996.
 
5) Ishi Y, Shirato M, Nomura A et al.:Cloning of rat eotaxin:Ozone inhalation increases mRNA and protein expression in lungs of brown Norway rats. Am. J. Physiol. 274 (1Pt 1):L171-176, 1998.
 
6) Forssmann U, Uguccioni M, Loetscher P et al.:Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on hurnan eosinophil and basophil leukocytes. J. Exp. Med. 185:2171-2176, 1997.
 
7) Patel VP, Kreider BL, Li Y et al.:Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J. Exp. Med. 185:1163-1172, 1997.
 
8) Kitaura M, Suzuki N, Imai T et al.:Molecular cloning of a novel hurrlan CC chemokine (Eotaxin-3) that is a functiorlal ligand of CC chemokine receptor 3. J. Biol. Chem. 274:27975-27980, 1999.
PubMed
9) Shinkai A, Yoshisue H, Koike M et al.:Anovel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophiIs. J. Immunol. 163:1602-1610, 1999.
 
10) Ponath PD, Qin S, Post TW et al.:Molecular cloning and characterization of a hurnan eotaxin receptor expressed selectively on eosinophiIs. J. Exp. Med. 183:2437-2448, 1996.
 
11) Post TW, Bozic CR, Rothenberg ME et al.:Molecular characterization of two murine eosinophil beta chemokine receptors. J. Immunol. 155:5299-5305, 1995.
PubMed
12) Sabroe I, Conroy DM, Gerard NP et al.:Cloning and characterization of the guinea pig eosinophil eotaxin receptor, C-C chemokine receptor-3:blockade using a monoclonal antibody in vivo. J. Immunol. 161:6139-6147, 1998.
PubMed
13) Kampen GT, Stafford S, Adachi T et al.:Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood 95:1911-1917, 2000.
PubMed
14) Adachi T, Vita R, Sannohe S et al.:The functional role of rho and rho-associated coiled-coil forming protein kinase in eotaxin signaling of eosinophiIs. J. Immunol. 167:4609-4615, 2001.
PubMed
15) Heath H, Qin S, Rao P et al.:Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J. Clin. Invest. 99:178-184, 1997.
PubMed
16) Yamada H, Hirai K, Miyamasu M et al.:Eotaxin is a potent chemotaxin for human basophiIs. Biochem. Biophys. Res. Commun. 231:365-368, 1997.
PubMed
17) Uguccioni M, Mackay CR, Ochensberger B et al.:High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J. Clin. Invest. 100: 1137-1143, 1997.
PubMed
18) Iikura M, Miyamasu M, Yamaguchi M et al.:Chemokine receptors in human basophils:inducibleexpression of functional CXCR4. J. Leukoc. Biol. 70:113-120, 2001.
 
19) Sallusto F, Mackay CR, Lanzavecchia A:Selective expression of the eotaxin receptor CCR3 by human Thelper 2 cells. Science 277(5334):2005-2007, 1997.
 
20) Sallusto F, Lanzavecchia A, Mackay CR:Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today 19:568-574, 1998.
 
21) Romagnani P, De Paulis A, Beltrame C et al.:Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am. J. Pathol 155:1195-1204, 1999.
PubMed
22) Beaulieu S, Robbiani DF, Du X et al.:Expression of afunctional eotaxin (CC chemokine ligand 11) receptorCCR3 by human dendritic cells. J. Immunol. 169:2925-2936, 2002.
 
23) Stellato C, Brummet ME, Plitt JR et al.:Expression of the C-C chemokine receptor CCR3 in human airwayepithelial cells. J. Immunol. 166:1457-1461, 2001.
 
24) Matthews AN, Friend DS, Zimmermann N et al.:Eotaxin is required for the baseline level of tissu leeosinophils. Proc. Natl. Acad. Sci. USA 95:6273-6278, 1998.
 
25) Lilly CM, Nakamura H, Belostotsky OI et al.:Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. Am. J. Respir. Crit. CareMed. 163:1669-1675, 2001.
 
26) Rothenberg ME, Luster AD, Lilly CM et al.:Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung. J. Exp. Med. 181:1211-1216, 1995.
 
27) Humbles AA, Conroy DM, Marleau S et al.:Kinetics of eotaxin generation and its relationship to eosinophil accumulation in allergic airways disease:analysis in a guinea pig model in vivo. J. Exp. Med. 186:601-612, 1997.
 
28) Chensue SW, Warmington K, Ruth JH et al.:Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-gamma and IL-4 knockout mice:analysis of local and regional cytokine and chemokine networks. J. Immunol. 159:3565-3573, 1997.
PubMed
29) Mochizuki M, BarteIs J, Mallet AI et al.:IL-4 induces eotaxin:apossible mechanism of selective eosinophil recruitment in helminth infection and atopy. J. Immunol. 160:60-68, 1998.
 
30) Miyamasu M, Nakajima T, Misaki Y et al.:Dermal fibroblasts represent a potent major source of human eotaxin:in vitro production and cytokine-mediated regulation. Cytokine 11:751-758, 1999.
PubMed
31) Matsukura S, Stellato C, Plitt JR et al.:Activation of eotaxin gene transcription by NF-kappa B andSTAT6 in human airway epithelial cells. J. Immunol. 163:6876-6883, 1999.
PubMed
32) Miyamasu M, Yamaguchi M, Nakajima T et al.:Thlderived cytokine interferon-gamma is a potent inhibitor of human eotaxin synthesis in vitro. Int. Immunol. 11:1001-1004, 1999.
PubMed
33) Matsukura S, Kokubu F, Kuga H et al.:Differential regullation of eotaxin expression by IFN-gamma in airway epithelial cells. J. Allergy Clin. Immunol. 111:1337-1344, 2003.
PubMed
34) Komiya A, Nagase H, Yamada H et al.:Concerted expression of eotaxin-1, eotaxin-2 and eotaxin-3 in human bronchial epithelial cells, Cell Immunol.:in press. 2003.
 
35) Stellato C, Beck LA, Gorgone GA et al.:Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. J. Immunol. 155:410-418, 1995.
PubMed
36) Lilly CM, Nakamura H, Kesselman H et al.:Expression of eotaxin by human lung epithelial cells:induction by cytokines and inhibition by glucocorticoids. J. Clin. Invest. 99:1767-1773, 1997.
PubMed
37) Fujisawa T, Kato Y, Atsuta J et al.:Chemokine production from the BEAS-2B human bronchial epithelial cells:Differential regulation of eotaxin and IL-8 by TH2 cytokines. J. Allergy Clin. Immunol. 105:126-133, 2000.
PubMed
38) Watanabe K, Jose PJ, Rankin SM:Eotaxin-2 generation is differentially regulated by lipopoly-saccharide and IL-4 in monocytes and macrophages. J. Immunol. 168:1911-1918, 2002.
 
39) Cuvelier SL, Patel KD:Shear-dependent eosinophil transmigration on interleukin 4-stimulated endothelial cells:arole for endothelium-associated eotaxin-3. J. Exp. Med. 194:1699-1709, 2001.
 
40) Nagase H, Kudo K, Izumi S et al.:Chemokine receptor expression profile of eosinophiIs at inflamed tissue sites:decreased CCR3 and increased CXCR4 expression by lung eosinophiIs. J. Allergy Clin. Immunol. 108:563-569, 2001.
PubMed
41) Dulkys Y, Kluthe C, Buschermohle T et al.:IL-3 induces down-regulation of CCR3 protein and mRNA in human eosinophiIs. J. Imrnunol. 167:3443-3453, 2001.
PubMed
42) Bonecchi R, Polentarutti N, Luini W et al:Up-regulation of CCRI and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophiIs. J. Imrnunol. 162:474-479, 1999.
 
43) Collins PD, Marleau S, Griffiths-Johnson DA et al.:Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J. Exp. Med. 182:1169-1174, 1995.
PubMed
44) Nagase H, Yamaguchi M, Jibiki S et al.:Eosinophil chemotaxis by chemokines:astudy by a simple photometric assay. Allergy 54:944-950, 1999.
 
45) Tenscher K, Metzner B, Schopf E et al.:Recombinant human eotaxin induces oxygen radical production, Ca (2+)-mobilization, actin reorganization, and CD11b upregulation in human eosinophiIs via a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein. Blood 88:3195-3199, 1996.
 
46) Kitayama J, Mackay CR, Ponath PD et al.:The C-C chemokine receptor CCR3 participates in stimulation of eosinophil arrest on inflammatory endothelium in shear flow. J. Clin. Invest. 101:2017-2024, 1998.
 
47) Shahabuddin S, Ponath P, Schleimer RP:Migration ofeosinophiIs across endothelial cell monolayers:interactions among IL-5, endothelial-activatingcytokines, and C-C chemokines. J. Immunol. 164:3847-3854, 2000.
 
48) EIsner J, Hochstetter R, Kimmig D et al.:Human eotaxin represents a potent activator of therespiratory burst of human eosinophiIs. Eur. J. Immunol. 26:1919-1925, 1996.
 
49) Fujisawa T, Kato Y, Nagase H et al.:Chemokines induce eosinophil degranulation through CCR3. J. Allergy Clin. Immunol. 106:507-513, 2000.
PubMed
50) Lloyd CM, Delaney T, Nguyen T et al.:CC chemokine receptor (CCR) 3/eotaxin is followed by CCR4/monocytederived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J. Exp. Med. 191:265-274, 2000.
PubMed
51) Quackenbush EJ, Wershil BK, Aguirre V et al.:Eotaxin modulates myelopoiesis and mast cell development from embryonic hematopoietic progenitors. Blood 92:1887-1897, 1998.
PubMed
52) Ma W, Bryce PJ, Humbles AA et al.:CCR3 is essentialfor skin eosinophilia and airway hyperresponsivenessin a murine model of allergic skin inflammation. J. Clin. Invest. 109:621-628, 2002.
 
53) Choe H, Farzan M, Sun Y et al.:The beta-chemokinereceptors CCR3 and CCR5 facilitate infection byprimary HIV-1 isolates. Cell 85:1135-1148, 1996.
 
54) Minshall EM, Cameron L, Lavigne F et al.:Eotaxin mRNA and protein expression in chronic sinusitis andallergen-induced nasal responses in seasonal allergicrhinitis. Am. J. Respir. Cell Mol. Biol. 17:683-690, 1997.
 
55) Ying S, Robinson DS, Meng Q et al.:Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur. J. Immunol. 27:3507-3516, 1997.
PubMed
56) Ying S, Meng Q, Zeibecoglou K et al.:Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3) , and MCP-4) , and C-C chemokine receptor 3 expression in bronchial biopsies fromatopic and nonatopic (Intrinsic) asthmatics. J. Immunol 163:6321-6329, 1999.
 
57) Nakamura H, Weiss ST, Israel E et al.:Eotaxin and impaired lung function in asthma. Am. J. Respir. Crit. Care Med. 160:1952-1956, 1999.
PubMed
58) Yamada H, Yamaguchi M, Nakajima T et al.:Eotaxin in induced sputum of asthmatics:relationship with eosinophiIs and eosinophil cationic protein in sputum. Allergy 55:1-6, 2000.
PubMed
59) Lamkhioued B, Renzi PM, Abi-Younes S et al.:Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophiIs to the site of inflammation. J. Immunol. 159:4593-4601, 1997.
 
60) Katoh S, Matsumoto N, Fukushima K et al.:Elevated chemokine levels in bronchoalveolar lavage fluid ofpatients with eosinophilic pneumonia. J, Allergy Clin 1. Immunol. 106:730-736, 2000.
 
61) Lilly CM, Woodruff PG, Camargo CA Jr et al.:Elevated plasma eotaxin levels in patients with acute asthma. J. Allergy Clin. Immunol 104 (4 Pt 1):786-790, 1999.
 
62) Kato H, Tsuchiya N, Izumi S et al.:New variations of human CC-chemokine receptors CCR3 and CCR4. Genes Immun. 1:97-104, 1999.
PubMed
63) Miyamasu M, Sekiya T, Ohta K et al.:Variations in human CC chemokine eotaxin gene. Genes Immun. 2:461-463, 2001.
PubMed
64) Nakamura H, Luster AD, Nakamura T et al:Variant eotaxin:its effects on the asthma phenotype. J. Allergy Clin. Immunol. 108:946-953, 2001.
PubMed
65) Zimmermann N, Bernstein JA, Rothenberg ME:Polymorphisms in the human CC chemokine receptor-3 gene. Biochim. Biophys. Acta 1442:170-176, 1998.
PubMed
66) Fukunaga K, Asano K, Mao XQ et al.:Genetic polymorphisms of CC chemokine receptor 3 in Japanese and British asthmatics. Eur. Respir. J. 17:59-63, 2001.
PubMed
67) Rothenberg ME, MacLean JA, Pearlman E et al.:Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J. Exp. Med. 185:785-790, 1997.
PubMed
68) Yang Y, Loy J, Ryseck RP et al:Antigen-induced eosinophilic lung inflammation develops in mice deficient in chemokine eotaxin. Blood 92:3912-3923, 1998.
PubMed
69) Ying S, Robinson DS, Meng Q et al.:C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects:association of eotaxin with early 6-hour eosinophiIs, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophiIs and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES) . J. Immunol. 163:3976-3984, 1999.
 
70) Berkman N, Ohnona S, Chung FK et al.:Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am. J. Respir. Cell Mol. Biol. 24:682-687, 2001.
 
71) Zhu J, Qiu YS, Majumdar S et al.:Exacerbations of bronchitis:bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chernoattractants. Am. J. Respir. Crit. Care Med. 164:109-116, 2001.
 
72) EIsner J, Petering H, Kimmig D et al.:The CC chemokine receptor antagonist met-RANTES inhibits eosinophil effector functions. Int. Arch. Allergy Immunol. 118:462-465, 1999.
 
73) Simmons G, Clapham PR, Picard L et al.:Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276(5310):276-279, 1997.
PubMed
74) EIsner J, Mack M, Bruhl H et al.:Differential activation of CC chemokine receptors by AOP-RANTES. J. Biol. Chem. 275:7787-7794, 2000.
 
75) Nibbs RJ, Salcedo TW, Campbell JD et al.:C-C chemokine receptor 3 antagonism by the beta-chemokine macrophage inflammatory protein 4, a property strongly enhanced by an amino-terminal alanine-methionine swap. J. Immunol. 164:1488-1497, 2000.
PubMed
76) Sabroe I, Peck MJ, Van Keulen BJ et al.:Asmall molecule antagonist of chemokine receptors CCRl and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J. Biol. Chem. 275:25985-25992, 2000.
 
77) White JR, Lee JM, Dede K et al.:Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J. Biol Chem. 275:36626-36631, 2000.
PubMed
P.417 掲載の参考文献
1) Mosmann TR, Cherwinski H, Bond MW et al.:Two types of murine helper T cell clone. 1. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348-2357, 1986.
PubMed
2) Sallusto F, Lenig D, Mackay CR et al:Flexible programs of chemokine receptor expression on human polarized T helper l and 21ymphocytes. J. Exp. Med. 187:875-883, 1998.
 
3) Imai T, Nagira M, Takagi S et al.:Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int. Immunol l1:81-88, 1999.
 
4) Sallusto F, Kremmer E, Palermo B et al.:Switch in chemokine receptor expression upon TCR stimulation reveaIs novel homing potential for recently activated Tcells. Eur. J. Immunol. 29:2037-2045, 1999.
 
5) Lloyd CM, Delaney T, Nguyen T et al.:CC chemokine receptor (CCR) 3/eotaxin is followed by CCR4/ monocyte-derived chemokine in mediating pulmonary Thelper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J. Exp. Med. 191:265-274, 2000.
 
6) Kawasaki S, Takizawa H, Yoneyama H et al.:Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice. J. Immunol 166:2055-2062, 2001.
PubMed
7) Sekiya T, Yamada H, Yamaguchi M et al.:Increased levels of a TH2-type CC chemokine thymus and activatlon-regulated chemokine (TARC) in serum and induced sputum of asthmatics. Allergy 57:173-177, 2002.
PubMed
8) Sekiya T, Miyamasu M, Imanishi M et al.:Inducible expression of a Th2-type CC chemokine thymus-and activation-regulated chemokine by human bronchial epithelial cells. J. Immunol 165:2205-2213, 2000.
PubMed
9) Kakinuma T, Nakamura K, Wakugawa M et al.:Thymus and activation-regulated chemokine in atopic dermatitis:Serum thymus and activation-regulated chemokine level is closely related with disease activity. J. Allergy Clin. Immunol. 107:535-541, 2001.
PubMed
10) Kakinuma T, Nakamura K, Wakugawa M et al.:Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin. Exp. Immunol. 127:270-273, 2002.
PubMed
11) Power CA, Meyer A, Nemeth K et al.:Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human basophilic cell line. J. Biol. Chem. 270:19495-19500, 1995.
PubMed
12) Imai T, Baba M, Nishimura M et al:The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J. Biol Chem. 272:15036-15042, 1997.
 
13) Imai T, Chantry D, Raport CJ et al.:Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J. Biol. Chem. 273:1764-1768, 1998.
 
14) Stine JT, Wood C, Hill M et al.:KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 95:1151-1157, 2000.
PubMed
15) Napolitano M, Santoni A:Structure and function of the CC chemokine receptor (CCR) 8. Forum (Genova) 9:315-324, 1999.
 
16) Tiffany HL, Lautens LL, Gao JL et al.:Identification of CCR8:ahuman monocyte and thymus receptor for the CC chemokine I-309. J. Exp. Med. 186:165-170, 1997.
 
17) Roos RS, Loetscher M, Legler DF et al.:Identification of CCR8, the receptor for the human CC chemokine I-309. J. Biol. Chem. 272:17251-17254, 1997.
PubMed
18) Goya I, Gutierrez J, Varona R et al.:Identification of CCR8 as the specific receptor for the human beta-chemokine I-309:cloning and molecular characterization of murine CCR8 as the receptor for TCA-3. J. Immunol. 160:1975-1981, 1998.
PubMed
19) Imai T, Yoshida T, Baba M et al.:Molecular cloning of anovel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector. J. Biol. Chem. 271:21514-21521, 1996.
 
20) Godiska R, Chantry D, Raport CJ et al.:Human macrophage-derived chemokine (MDC) , anovel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J. Exp. Med. 185:1595-1604, 1997.
 
21) Miller MD, Hata S, De Waal Malefyt R et al.:Anovel polypeptide secreted by activated human T lymphocytes. J. Immunol. 143:2907-2916, 1989.
 
22) Kato H, Tsuchiya N, Izumi S et al, :New variations of human CC-chemokine receptors CCR3 and CCR4. Genes Imrnun. 1:97-104, 1999.
PubMed
23) Sekiya T, Tsunemi Y, Miyamasu M et al.:Variations in the human Th2-specific chemokine TARC gene. Immunogenetics 54:742-745, 2003.
PubMed
24) Zingoni A, Soto H, Hedrick JA et al.:The chemokine receptor CCR8 is preferentially expressed in Th2 but not Thl cells. J. Immunol. 161:547-551, 1998.
PubMed
25) Andrew DP, Chang MS, McNinch J et al.:STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th21ymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J. Immulnol. 161:5027-5038, 1998.
PubMed
26) Vulcano M, Albanesi C, Stoppacciaro A et al.:Dendritic cells as a major source of macrophagederived chemokine/CCL22 in vitro and in vivo. Eur. J. Immunol. 31:812-822, 2001.
 
27) Oliveira SH, Lukacs NW:Stem cell factor and IgEstimulated murine mast cells produce chemokines (CCL2, CCL17, CCL22)and express chemokinereceptors. Inflamm. Res. 50:168-174, 2001.
 
28) D'Ambrosio D, Iellem A, Bonecchi R et al.:Selectiveup-regulation of chemokine receptors CCR4 andCCR8 upon activation of polarized human type 2 Thcells. J. Immunol. 161:5111-5115, 1998.
 
29) Kumagai N, Fukuda K, Nishida T:Synergistic effectof TNF-alpha and IL-4 on the expression of thymusand activation-regulated chemokine in humancorneal fibroblasts. Biochem. Biophys. Res. Commun. 279:1-5, 2000.
 
30) Vestergaard C, Bang K, Gesser B et al.:ATh2 chernokine, TARC, produced by keratinocytes mayrecruit CLA+CCR4+ lymphocytes into lesional atopicdermatitis skin. J. Invest. Dermatol. 115:640-646, 2000.
 
31) Horikawa T, Nakayama T, Hikita I et al.:IFN-gamma-inducible expression of thymus and activationregulated chemokine/CCL17 and macrophagederived chemokine/CCL22 in epidermal keratinocytesand their roles in atopic dermatitis. Int. Immunol. 14:767-773, 2002.
 
32) Albanesi C, Scarponi C, Sebastiani S et al.:A cytokineto-chemokine axis between T lymphocytes and keratinocytes can favor Th1 cell accumulation inchronic inflammatory skin diseases. J. Leukoc. Biol. 70:617-623, 2001.
 
33) Kakinuma T, Nakamura K, Wakugawa M et al.:IL-4, but not IL-13, modulates TARC (thymus and activation-regulated chemokine) /CCL17 and IP-10 (interferon-induced protein of 10kDA) /CXCL10 release by TNF-alpha and IFN-gamma in HaCaT cell line. Cytokine 20:1-6, 2002.
 
34) Selvan RS, Butterfield JH, Krangel MS:Expression of multiple chemokine genes by a human mast cell leukemia. J. Biol. Chem. 269:13893-13898, 1994.
PubMed
35) Selvan RS, Zhou LJ, Krangel MS:Regulation of I-309 gene expression in human monocytes by endogenous interleukin-1. Eur. J. Immunol. 27:687-694, 1997.
PubMed
36) Nakajima T, Inagaki N, Tanaka H et al.:Marked increase in CC chemokine gene expression in both human and mouse mast cell transcriptomes following Fcepsilon receptor I cross-linking:an interspecies comparison. Blood 100:3861-3868, 2002.
PubMed
37) Galli G, Charltry D, Annunziato F et al.:Macrophagederived chemokine production by activated human T cells in vitro abd in vivo:preferential association with the production of type 2 cytokines. Eur. J. Immunol. 30:204-210, 2000.
 
38) Nakatani T, Kaburagi Y, Shimada Y et al.:CCR4 memory CD4+T lymphocytes are increased in peripheral blood and lesional skin from patients with atopic dermatitis. J. Allergy Clin. Immunol. 107:353-358, 2001.
PubMed
39) Panina-Bordignon P, Papi A, Mariani M et al.:The C-Cchemokine receptors CCR4 and CCR8 identify airway T celis of allergen-chailenged atopic asthmat ics. J. Clin. Invest. 107:1357-1364, 2001.
 
40) Kurashima K, Fujimura M, Myou S et al.:Effects of oral steroids on blood CXCR3+and CCR4-Tcells in patients with bronchial asthma. Am. J. Respir. Crit. Care Med. 164:754-758, 2001,
PubMed
41) Dairaghi DJ, Fan RA, McMaster BE et al.:HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J. Biol. Chem. 274:21569-21574, 1999.
PubMed
42) Endres MJ, Garlisi CG, Xiao H et al.:The Kaposi's sarcoma-related herpesvirus (KSHV)-encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor (CCR)8. J. Exp. Med. 189:1993-1998, 1999.
 
43) Luttichau HR, Stine J, Boesen TP et al.:Ahighly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosum. J. Exp. Med. 191:171-180, 2000.
 
44) Horuk R, Hesselgesser J, Zhou Y et al:The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1strains. J. Biol Chem. 273:386-391, 1998.
 
45) Chung CD, Kuo F, Kumer J et al.:CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease. J. Immunol. 170:581-587, 2003.
PubMed
46) Yoneyama H, Harada A, Imai T et al.:Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in rnice. J. Clin. Invest. 102:1933-1941, 1998.
PubMed
47) Kakinuma T, Wakugawa M, Nakamura K et al.:High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid. Br. J. Dermatol. 148:203-210, 2003.
PubMed
48) Kakinuma T, Sugaya M, Nakamura K et al.:Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides:serum TARC levels reflect the disease activity of mycosis fungoides. J. Am. Acad. Dermatol. 48:23-30, 2003.
PubMed
49) Spinetti G, Bernardini G, Camarda G et al.:The chemokine receptor CCR8 mediates rescue from dexamethasone-induced apoptosis via an ERKdependent pathway. J. Leukoc. Biol. 73:201-207, 2003.
PubMed
P.429 掲載の参考文献
1) Hieshima K, Imai T, Opdenakker G et al.:Molecular cloning of a novel hurnan CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J. Biol. Chem. 272:5846-5853, 1997.
 
2) Rossi DL, Vicari AP, Franz-Bacon K et al.:Identification through bioinformatics of two new macrophage proinflammatory human chemokines:MIP-3 alpha and MIP-3 beta. J. Immunol. 158:1033-1036, 1997.
 
3) Hromas R, Kim CH, Klemsz M et al:Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension. J. Immunol. 159:2554-2558, 1997.
 
4) Zlotnik A, Yoshie O:Chemokines:anewclassification system and their role in immunity. Immunity 12:121-127, 2000.
PubMed
5) Baba M, Imai T, Nishimura M et al.:Identification of CCR6, the specific receptor for a novel lymphocytedirected CC chemokine LARC. J. Biol. Chem. 272:14893-14898, 1997.
PubMed
6) Liao F, Alderson R, Su J et al.:STRL22 is a receptor for the CC chemokine MIP-3 alpha. Biochem. Biophys. Res. Commun. 236:212-217, 1997.
 
7) Power CA, Church DJ, Meyer A et al.:Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3 alpha from lung dendritic cells. J. Exp. Med. 186:825-835, 1997.
PubMed
8) Schutyser E, Struyf S, Menten P et al.:Regulated production and molecular diversity of human liver and activation-regulated chemokine/macrophage inflammatory protein-3 alpha from normal and transformed cells. J. Immunol. 165:4470-4477, 2000.
 
9) Yang D, Chertov O, Bykovskaia SN et al.:Betadefensins:linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286:525-528, 1999.
 
10) Perez-Canadillas JM, Zaballos A, Gutierrez J et al.:NMR solution structure of murine CCL20/MIP-3 alpha, a chemokine that specifically chemoattracts immature dendritic cells and lymphocytes through its highly specific interaction with the beta-chemokine receptor CCR6. J. Biol. Chem. 276:28372-28379, 2001.
PubMed
11) Liao F, Rabin RL, Smith CS et al:CC-chemokine receptor 6 is expressed on diverse memory subsets ofT cells and determines responsiveness to macrophage inflammatory protein 3 alpha. J. Immunol 162:186-194, 1999.
 
12) Bowman EP, Campbell JJ, Soler D et al.:Developmental switches in chemokine response profiles during B cell differentiation and maturation. J. Exp. Med. 191:1303-1318, 2000.
 
13) Krzysiek R, Lefevre EA, Bernard J et al:Regulation of CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory protein-3 alpha/CCL20 in human B cells. Blood 96:2338-2345, 2000.
 
14) Greaves DR, Wang W, Dairaghi DJ et al.:CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3 alpha and is highly expressed in human dendritic cells. J. Exp. Med. 186:837-844, 1997.
 
15) Yang D, Howard OM, Chen Q et al.:Cutting edge:immature dendritic cells generated from monocytes in the presence of TGF-beta 1 express functional C-C chemokine receptor 6. J. Immunol. 163:1737-1741, 1999.
PubMed
16) Charbonnier AS, Kohrgruber N, Kriehuber E et al.:Macrophage inflammatory protein 3 alpha is involved in the constitutive trafficking of epidermal Langerhans cells. J. Exp. Med. 190:1755-1768, 1999.
PubMed
17) Iwasaki A, Kelsall BL:Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3 alpha, MIP-3 beta, and secondary lymphoid organ chemokine. J. Exp. Med. 191:1381-1394, 2000.
 
18) Kim CH, Johnston B, Butcher EC:Trafficking machinery of NKT cells:shared and differential chemokine receptor expression among V alpha 24(+) Vbeta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 100:11-16, 2002.
 
19) Yamashiro S, Wang JM, Yang D et al.:Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood 96:3958-3963, 2000.
PubMed
20) Kleeff J, Kusama T, Rossi DL et al.:Detection and localization of Mip-3 alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 81:650-657, 1999.
PubMed
21) Imaizumi Y, Sugita S, Yamamoto K et al.:Human Tcell leukemia virus type-I Tax activates human macrophage inflammatory protein-3 alpha/CCL20 gene transcription via the NF-kappa B pathway. Int. Immunol l4:147-155, 2002.
 
22) Tanaka Y, Imai T, Baba M et al.:Selective expression of liver and activation-regulated chemokine (LARC) in intestinal epithelium in mice and humans. Eur. J. Immunol. 29:633-642, 1999.
PubMed
23) Nakayama T, Fujisawa R, Yamada H et al.:Inducible expression of a CC chemokine liver-and activationregulated chemokine (LARC) /macrophage inflammatory protein (MIP)-3 alpha/CCL20 by epidermal keratinocytes and its role in atopic dermatitis. Int. Immunol 13:95-103, 2001.
PubMed
24) Dieu-Nosjean MC, Massacrier C, Homey B et al:Macrophage inflammatory protein 3 alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Larngerhans cell precursors. J. Exp. Med. 192:705-718, 2000.
PubMed
25) Casamayor-Palleja M, Mondiere P, Amara A et al.:Expression of macrophage inflamrrlatory protein-3 alpha, stromal cell-derived factor-1, and B-cell-attracting chemokine-1 identifies the tonsil crypt as an attractive site for B cells. Blood 97:3992-3994, 2001.
 
26) Kriehuber E, Breiteneder-Geleff S, Groeger M et al.:Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J. Exp. Med. 194:797-808, 2001.
PubMed
27) Scapini P, Laudanna C, Pinardi C et al.:NeutrophiIs produce biologically active macrophage inflammatory protein-3 alpha (MIP-3 alpha) /CCL20 and MIP-3 beta/CCL19. Eur. J. Immunol. 31:1981-1988, 2001.
 
28) Matsui T, Akahoshi T, Namai R et al.:Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis. Clin. Exp. Immunol. 125:155-161, 2001.
PubMed
29) Chabaud M, Page G, Miossec P:Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3 alpha production in rheurnatoid arthritis:regulation by soluble receptors and Th2 cytokines. J. Immunol, 167:6015-6020, 2001.
PubMed
30) Shimizu Y, Murata H, Kashii Y et al.:CC-chemokine receptor 6 and its ligand macrophage inflammatory protein 3 alpha might be involved in the amplification of local necroinflammatory response in the liver. Hepatology 34:311-319, 2001.
PubMed
31) Sun B, Nasu K, Fukuda J et al.:Expression of macrophage inflammatory protein-3 alpha in an endometrial epithelial cell ine, HHUA, and cultured human endometrial stromal cells. Mol. Hum. Reprod. 8:930-933, 2002.
 
32) Lin TJ, Maher LH, Gomi K et al.:Selective early production of CCL20, or macrophage inflammatory protein 3 alpha, by human mast cells in response to Pseudomonas aeruginosa. Infect. Immun. 71:365-373, 2003.
PubMed
33) Abiko Y, Nishimura M, Kusano K et al.:Expression of MIP-3 alpha/CCL20, a macrophage inflammatory protein in oral squamous cell carcinoma. Arch. Oral Biol 48:171-175, 2003.
PubMed
34) Reibman J, Hsu Y, Chen LC et al.:Airway epithelial cells release MIP-3 alpha/CCL20 in response to cytokines and ambient particulate matter. Am. J. Respir. Cell. Mol. Biol. 28:648-654, 2003.
 
35) Dieu MC, Vanbervliet B, Vicari A et al.:Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188:373-386, 1998.
 
36) Sallusto F, Schaerli P, Loetscher P et al:Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 28:2760-2769, 1998.
PubMed
37) Sato K, Kawasaki H, Nagayama H et al.:TGF-beta 1 reciprocally controIs chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokinereceptors. J. Immunol. 164:2285-2295, 2000.
 
38) Cook DN, Prosser DM, Forster R et al.:CCR6 mediates dendritic cell localization, lymphocyte homeostasis, arld immune responses in mucosal tissue. Immunity 12:495-503, 2000.
 
39) Homey B, Dieu-Nosjean MC, Wiesenborn A et al.:Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164:6621-6632, 2000.
PubMed
40) Fitzhugh DJ, Naik S, Caughman SW et al.:Cutting edge:C-C chernokine receptor 6 is essential for arrest of a subset of memory T cells on activated dermal microvascular endothelial cells underphysiologic flow conditions in vitro. J. Immunol. 165:6677-6681, 2000
 
41) Kucharzik T, Hudson JT 3rd, Waikel RL et al.:CCR6 expression distinguishes mouse myeloid and lymphoid dendritic cell subsets:demonstration using a CCR6 EGFP knock-in mouse. Eur. J. Immunol. 32:104-112, 2002.
PubMed
42) Fujiie S, Hieshima K, Izawa D et al.:Proinflammatory cytokines induce liver and activation-regulated chemokine/macrophage inflammatory protein-3alpha/CCL20 in mucosal epithelial cells through NFkappaB [correction of NK-kappaB]. Int. Immunol. 13:1255-1263, 2001.
PubMed
43) Harant H, Eldershaw SA, Lindley IJ:Human macrophage inflammatory protein-3 alpha/CCL20/LARC/Exodus/SCYA20 is transcriptionally upregulated by tumor necrosis factor-alpha via a non-standard NF-kappaB site. FEBS Lett. 509:439-445, 2001.
 
44) Sugita S, Kohno T, Yamamoto K et al.:Induction ofmacrophage-inflammatory protein-3 alpha gene expression by TNF-dependent NF-kappaB activation. J. Immunol. 168:5621-5628, 2002.
 
45) Kwon JH, Keates S, Simeonidis S et al.:ESE-1, an enterocyte-specific Ets transcription factor, regulates MIP-3 alpha gene expression in Caco-2 human colonic epithelial cells. J. Biol. Chem. 278:875-884, 2003.
PubMed
46) Oettgen P, Alani RM, Barcinski MA et al.:Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family. Mol. Cell. Bicl. 17:4419-4433, 1997.
 
47) Izadpanah A, Dwinell MB, Eckmann L et al.:Regulated MIP-3 alpha/CCL20 production by human intestinal epithelium:mechanism for modulating mucosal immunity. Am J physiol Gastrointest. Liver Physiol. 280:G710-719, 2001.
PubMed
48) Sierro F, Dubois B, Coste A et al.:Flagellin stimulation of intestinal epithelial cells triggers CCL20-mediated migration of dendritic cells. Proc. Natl. Acad. Sci. USA 98:13722-13727, 2001.
PubMed
49) Lukacs NW, Prosser DM, Wiekowski M et al.: Requirement for the chemokine receptor CCR6 in allergic pulmonary inflammation. J. Exp. Med. 194:551-555, 2001.
PubMed
50) NeIson RT, Boyd J, Gladue RP et al.:Genomic organization of the CC chemokine mip-3 alpha/CCL20/larc/exodus/SCYA20, showing gene structure, splice variants, and chromosome localization. Genomics 73:28-37, 2001.
 
51) Serafini B, Columba-Cabezas S, Di Rosa F et al.:Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am. J. Pathol 157:1991-2002, 2000.
PubMed
52) Ambrosini E, Columba-Cabezas S, Serafini B et al.: Astrocytes are the major intracerebral source of macrophage inflammatory protein-3 alpha/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro. Glia 41:290-300, 2003.
PubMed
53) Kohler RE, Caon AC, Willenborg DO et al.:A role for macrophage inflammatory protein-3 alpha/CC chemokine ligand 20 in immune priming during T cellmediated inflammation of the central nervous system. J. Immunol. 170:6298-6306, 2003.
 
54) Page G, Lebecque S, Miossec P:Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ:correlation with selective chemokine expression in rheumatoid synovium. J. Immunol. 168:5333-5341, 2002.
 
55) Schmuth M, Neyer S, Rainer C et al.:Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp. Dermatol. 11:135-142, 2002.
 
56) Varona R, Villares R, Carramolino L et al.:CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hyPersensitivity responses. J. Clin. Invest. 107:R37-45, 2001.
PubMed
57) Kwon J H, Keates S, Bassani L et al.:Colonic epithelial cells are a major site of macrophage inflammatory protein 3 alpha (MIP-3 alpha) production in normal colon and inflammatory bowel disease. Gut 51:818-826, 2002.
 
58) Fushimi T, Kojima A, Moore MA et al.:Macrophage inflammatory protein 3 alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105:1383-1393, 2000.
PubMed
P.438 掲載の参考文献
1) Vicari AP, Figueroa DJ, Hedrick JA et al.:TECK:a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity 7:291-301, 1997.
 
2) Zlotnik A, Yoshie O:Chemokines:anew classification system and their role in immunity. Immunity 12:121-127, 2000.
 
3) Zaballos A, Gutierrez J, Varona R et al.:Cutting edge:identification of the orphan chemokine receptor GPR-9-6as CCR9, the receptor for the chemokine TECK. J. Immunol. 162:5671-5675, 1999.
 
4) Youn BS, Kim CH, Smith FO et al.:TECK, an efficacious chemoattractant for human thymocytes, uses GPR-9-6/CCRg as a specific receptor. Blood 94:2533-2536, 1999.
 
5) Norment AM, Bogatzki LY, Gantner BN et al.:Murine CCR9, a chemokine receptor for thymus-expressed chemokine that is up-regulated following pre-TCR signaling. J. Immunol. 164:639-648, 2000.
PubMed
6) Yu CR, Peden KW, Zaitseva MB et al.:CCRgA and CCRgB:two receptors for the chemokine CCL25/ TECK/Ck beta-15 that differ in their sensitivities to Hgand. J. Immunol. 164:1293-1305, 2000.
 
7) Wurbel MA, Philippe JM, Nguyen C et al.:The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double-and single-positive thymocytes expressing the TECK receptor CCR9. Eur. J. Immunol. 30:262-271, 2000.
 
8) Carramolino L, Zaballos A, Kremer L et al.: Expression of CCR9 beta-chemokine receptor is modulated in thymocyte differentiation and is selectively maintained in CD8(+) Tcells from secondary lymphoid organs. Blood 97:850-857, 2001.
 
9) Zabel BA, Agace WW, Campbell JJ et al.:Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J. Exp. Med. 190:1241-1256, 1999.
 
10) Bowman EP, Kuklin NA, Youngman KR et al.:The intestinal chemokine thymus-expressed chemokine (CCL25) attracts IgA antibody-secreting cells. J. Exp. Med. 195:269-275, 2002.
 
11) Bowman EP, Campbell JJ, Soler D et al.:Developmental switches in chemokine response profiles during B cell differentiation and maturation. J. Exp. Med. 191:1303-1318, 2000.
 
12) Onai N, Kitabatake M, Zhang YY et al.:Pivotal role of CCL25(TECK)-CCR9 in the formation of gut cryptopatches and consequent appearance of intestinal intraepithelial T lymphocytes. Int. Immunol. 14:687-694, 2002.
PubMed
13) Papadakis KA, Prehn J, NeIson V et al.:The role of thymus-expressed chernokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J. Immunol. 165:5069-5076, 2000.
 
14) Otten K, Dragoo J, Wang HC et al.:Antigen-inducedchemokine activation in mouse buccal epithelium. Biochem. Biophys. Res. Commun. 304:36-40, 2003.
PubMed
15) Campbell JJ, Pan J, Butcher EC:Cutting edge:developmental switches in chemokine responsesduring T cell maturation. J. Immunol 163:2353-2357, 1999.
 
16) Bleul CC, Boehm T:Chemokines define distinct microenvironments in the developing thymus. Eur. J. Immunol. 30:3371-3379, 2000.
PubMed
17) Wurbel MA, Malissen M, Guy-Grand D et al.:Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T-and B-cell development and a reduction in T-cell receptor gammadelta(+) gut intraepithelial Imphocytes. Blood 98:2626-2632, 2001.
 
18) Uehara S, Grinberg A, Farber JM et al.:Arole for CCR9 in T lymphocyte development and migration. J. Irnmunol. 168:2811-2819, 2002.
 
19) Wilkinson B, Owen JJ, Jenkinson EJ:Factors regulating stem cell recruitment to the fetal thymus. J. Immunol. 162:3873-3881, 1999.
 
20) Kunkel EJ, Campbell JJ, Haraldsen G et al:Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal imrnune compartment:Epithelial expression of tissue-specific chemokines as an organizing Principle in regional immunity. J. Exp. Med. 192:761-768, 2000.
PubMed
21) Svensson M, Marsal J, Ericsson A et al.:CCL25 mediates the localization of recently activated CD8 alphabeta(+) lymphocytes to the small-intestinal mucosa. J. Clin. Invest. 110:1113-1121, 2002.
 
22) Lazarus NH, Kunkel EJ, Johnston B et al.:A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J. Immunol. 170:3799-3805, 2003.
 
23) Youn BS, Kim YJ, Mantel C et al.:Blocking of c-FLIP (L)-independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction, Blood 98:925-933, 2001.
PubMed
24) Papadakis KA, Prehn J, Moreno ST et al.:CCR9-positive lymphocytes arld thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 121:246-254, 2001.
 
25) Papadakis KA, Landers C, Prehn J et al.:CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Thl or T-regulatory l cytokine profile. J. Immunol. 171:159-165, 2003.
 
P.449 掲載の参考文献
1) Airkenbach M, Josefsen K, Yalamanchili, R, LenoirG, Kieff E:Epstein-Barr virus-induced genes:first lymphocyte-specific G protein-coupled peptide receptors. J. Virol. 67:2209-2220, 1993.
 
2) Burgstahler R, Kempkes B, Steube K, Lipp M:Expression of the chemokine receptor BLR2/EBI1 is specifically transactivated by Epstein-Barr virus nuclear antigen 2. Biochem. Biophys. Res. Commun. 215:737-743, 1995.
PubMed
3) Yoshida R, Imai T, Hieshima K, Kusuda J, Baba M, Kitaura M, Nishimura M, Kakizaki M, Nomiyama H, Yoshie O:Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. J. Biol Chem. 272:13803-13809, 1997.
PubMed
4) Nagira M, Imai T, Hieshima K, Kusuda J, Ridanpaa M, Takagi S, Nishimura M, Kakizaki M, Norniyarna H, Yoshie O:Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome gp13, J. Biol. Chem. 272:19518-19524, 1997.
 
5) Vassileva G, Soto H, Zlotnik A, Nakano H, Kakiuchi T, Hedrick JA, Lira SA:The reduced expression of 6Ckine in the plt mouse results from the deletion of one of two 6Ckine genes. J. Exp. Med. 190:1183-1188, 1999.
 
6) Soto H, Wang W, Strieter RM, Copeland NG, Gilbert DJ, Jenkins NA, Hedrick J, Zlotnik A:The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc. Natl. Acad. Sci. USA 95:8205-8210, 1998.
 
7) Schweickart VL, Raport CJ, Godiska R, Byers MG, Eddy RL, Shows Jr TB, Gray PW:Cloning of humanand mouse EBI1, a lymphoid-specific G-protein-coupled receptor encoded on human chromosome 17q12-q21. 2. Genomics 23:643-650, 1994.
 
8) Yoshida R, Nagira M, Kitaura M, Imagawa N, Imai T, Yoshie O:Secondary lymphoid-tissue chemokine is a furlctional ligand for the CC chemokine receptor CCR7. J. Biol. Chem. 273:7118-7122, 1998.
 
9) Nakano H, Mori S, Yonekawa H, Nariuchi H, Matsuzawa A, Kakiuchi T:Anovel mutant gene involved in T-lymphocyte-specific horning into peripheral lymphoid organs on mouse chromosome 4. Blood 91:2886-2895, 1998.
 
10) Nakano H, Gunn MD:Gene duplications at the chemokine locus on mouse chromosome 4:multiple strain-specific haplotypes and the deletion of secondary lymphoid-organ chemokine and EBI-1ligand chemokine genes in the plt mutation. J. Immurlol 166:361-369, 2001.
 
11) Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT:Achemokine expressed in lymphoid high endothelial venules promotes the adhesion andchemotaxis of naive T lymphocytes. Proc. Natl. Acad. Sci. USA 95:258-263, 1998.
 
12) Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A:Two subsets of memory T lymphocytes with distinct homing potentiaIs and effector functions. Nature 401:708-712, 1998.
 
13) Randolph DA, Huang G, Carruthers CJ, Bromley LE, Chaplin DD:The role of CCR7 in THl and TH2 cell localization and delivery of B cell help in vivo. Science 286:2159-2162, 1999.
 
14) Okada T, Ngo VN, Ekland EH, Forster R, Lipp M, Littman DR, Cyster JG:Chemokine requirements for Bcell entry to lymph nodes and Peyer's patches. J. Exp. Med. 196:65-75, 2002.
 
15) Reif K, Ekland EH, Ohl L, Nakano H, Lipp M, ForsterR, Cyster JG:Balanced responsiveness to chemoattractants from adjacent zones determines Bcell position. Nature 416:94-99, 2002.
PubMed
16) Sallusto F, Mackay CR, Lanzavecchia A:The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18:593-620, 2000.
PubMed
17) Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K:Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-811, 2000.
PubMed
18) Ngo VN, Korner H, Gunn MD, Schmidt KN, Riminton DS, Cooper MD, Browning JL, Sedgwick JD, Cyster JG:Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med. 189:403-412, 1999.
 
19) Luther SA, Tang HL, Hyman PL, Farr AG, Cyster JG:Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse. Proc. Natl. Acad. Sci. USA 97:12694-12699, 2000.
 
20) Gunn MD, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams LT, Nakano H:Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189:451-460, 1999.
PubMed
21) Ngo VN, Tang HL, Cyster JG:Epstein-Barr virusinduced molecule l ligand chemokine is expressed by dendritic cells in lyrnphoid tissues and strongly attracts naive T cells and activated B cells. J. Exp. Med. 188:181-191, 1998.
PubMed
22) Stein JV, Rot A, Luo Y, Narasimhaswamy M, NakanoH, Gunn MD, Matsuzawa A, Quackenbush EJ, DorfME, von Andrian UH:The CC chemokine thymusderived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen Lrnediated arrest of rolling T lyrnphocytes in perip止ierallymph node high endothelial venules. J. Exp. Med. 191:61-76, 2000.
 
23) Hopken UE, Foss HD, Meyer D, Hinz M, Leder K, Stein H, Lipp M:Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 99:1109-1116, 2002.
 
24) Ito A, Matejuk A, Hopke C, Drought H, Dwyer J, Zamora A, Subramanian S, Vandenbark AA, Offner H:Transfer of severe experimental autoimmune encephalomyelitis by IL-12-and IL-18-potentiated Tcells is estrogen sensitive. J. Immunol. 170:4802-4809, 2003.
 
25) Muta H, Boise LH, Fang L, Podack ER:CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J. Immurlol. 165:5105-5111, 2000.
PubMed
26) Bardi G, Lipp M, Baggiolini M, Loetscher P:The T cell chemokine receptor CCR7 is internalized on stimulation with ELC, but not with SLC. Eur J. Immunol. 31:3291-3297, 2001.
 
27) Zanin-Zhorov A, Nussbaum G, Franitza S, Cohen IR, Lider, O:Tcells respond to heat shock protein 60 via TLR2:activation of adhesion and inhibition of chemokine receptors. Faseb J. 17:1567-1569, 2003.
 
28) Ato M, Stager S, Engwerda CR, Kaye PM:Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis. Nat. Immunol. 3:1185-1191, 2002.
 
29) Wong MM, Fish EN:Chemokines:attractive mediators of the immune response. Semin. Immunol 15:5-14, 2003.
PubMed
30) Bardi G, Niggh V, Loetscher P:Rho kinase is required for CCR7-mediated polarization and chemotaxis of T lymphocytes. FEBS Lett. 542:79-83, 2003.
 
31) Fukui Y, Hashimoto O, Sanui T, Oono T, Koga H, Abe M, Inayoshi A, Noda M, Oike M, Shirai T, Sasazuki T:Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 412:826-831, 2001.
PubMed
32) Yanagawa Y, Onoe K:CCR71igands induce rapid endocytosis in mature dendritic cells with concomitant up-regulation of Cdc42 and Rac activities. Blood 101:4923-4929, 2003.
 
33) Tangemann K, Gunn MD, Giblin P, Rosen SD:A high endothelial cell-derived chemokine induces rapid, efficient, and subset-selective arrest of rolling Tlymphocytes on a reconstituted endothelial substrate. J. Immunol. 161:6330-6337, 1998.
 
34) Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M:CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23-33, 1999.
 
35) Ueno T, Hara K, Willis MS, Malin MA, Hopken UE, Gray DH, Matsushima K, Lipp M, Springer TA, Boyd RL, Yoshie O, Takahama Y:Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus. Immunity 16:205-218, 2002.
PubMed
36) Ohl L, Henning G, Krautwald S, Lipp M, Hardtke S, Bernhardt G, PabstO, Forster R:Cooperating mechanisms of CXCR5 and CCR7 in development and organization of secondary lymphoid organs. J. Exp. Med. 197:1199-1204, 2003.
PubMed
37) Luther S. A, Ansel KM, Cyster JG:Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands in lymph node development. J. Exp, Med. 197:1191-1198, 2003.
PubMed
38) Fan L, Reilly CR, Luo Y, Dorf ME, Lo D:Cutting edge:ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J. Immunol 164:3955-3959, 2000.
PubMed
39) Luther SA, Bidgol A, Hargreaves DC, Schrnidt A, Xu Y, Paniyadi J, Matloubian M, Cyster JG:Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. Immunol. 169:424-433, 2002.
PubMed
40) Crowley MT, Reilly CR, Lo D:Influence of lymphocytes on the presence and organization ofdendritic cell subsets in the spleen. J. Immunol. 163:4894-4900, 1999.
 
41) Kriehuber E, Breiteneder-Geleff S, Groeger M, Soleiman A, Schoppmann SF, Stingl G, Kerjaschki D, Maurer D:Isolation and characterization of dermallymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J. Exp. Med. 194:797-808, 2001.
 
42) Ploix C, Lo D, Carson MJ:Aligand for the chemokine receptor CCR7 can influence the homeostatic proliferation of CD4 T cells and progression ofautoimmunity. J. Immunol. 167:6724-6730, 2001.
 
43) Mori S, Nakano H, Aritomi K, Wang CR, Gunn MD, Kakiuchi T:Mice lacking expression of the chemokines CCL21-ser and CCL19 (plt mice) demonstrate delayed but enhanced T cell immune responses. J. Exp. Med. 193:207-218, 2001.
PubMed
44) Alt C, Laschinger M, Engelhardt B:Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggeststheir involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 32:2133-2144, 2002.
 
45) Columba-Cabezas S, Serafini B, Ambrosini E, Aloisi F:Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis:imp1ications for the maintenance of chronic neuroinflammation. Brain Pathol. 13:38-51, 2003.
PubMed
46) Pashenkov M, Soderstrom M, Link H:Secondary lymphoid organ chemokines are elevated in the cerebrospinal fluid during central nervous system inf/ammation. J. Neuroimmunol. 135:154-160, 2003.
 
47) Christopherson KW, 2nd, Hood AF, Travers JB, Ramsey H, Hromas RA:Endothelial induction of the T-cell chemokine CCL21 in T-cell autoimmunediseases. Blood 101:801-806, 2003.
 
48) Weninger W, CarIsen HS, Goodarzi M, Moazed F, Crowley MA, Baekkevold ES, Cavanagh LL, Von Andrian UH:Naive T cell recruitment to nonlymphoid tissues:Arole for endothelium-expressed CC chemokine ligand 21 in autoimmune disease and lylnphoid neogenesis. J. Immunol. 170:4638-4648, 2003.
 
49) Grant AJ, Goddard S, Ahmed-Choudhury J, Reynolds G, Jackson DG, Briskin M, Wu L, Hubscher SG, Adams DH:Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am. J. Pathol 160:1445-1455, 2002.
PubMed
50) Armengol MP, Cardoso-Schmidt CB, Fernandez M, Ferrer X, Pujol-Borrell R, Juan M:Chemokines determine local lymphoneogenesis and a reduction of circulating CXCR4 (+) Tand CCR7 B and T lymphocytes in thyroid autoimmune diseases. J. Immunol. 170:6320-6328, 2003.
 
51) Hammad H, Lambrecht BN, Pochard P, Gosset P, Marquillies P, Tonnel AB, Pestel J:Monocyte-derived dendritic cells induce a house dust mite-specific Th2 allergic inflammation in the lung of humanized SCID mice:involvement of CCR7. J. Immunol 169:1524-1534, 2002.
PubMed
52) Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A:Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56, 2001.
PubMed
53) Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST:Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl. Cancer Inst. 93:1638-1643, 2001.
PubMed
54) Till KJ, Lin K, Zuzel M, Cawley JC:The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 99:2977-2984, 2002.
PubMed
55) Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, Inoue H, Mori M:Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 62:2937-2941, 2002.
PubMed
56) Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, Batra RK, Dubinett SM:Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. 164:4558-4563, 2000.
PubMed
57) Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C:Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165:1992-2000, 2000.
PubMed
58) Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, Chamberlain JS, GiedDn M, Aukerman L, Mule JJ:T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine:augmentation of dendritic cell-based immunotherapy. Cancer Res. 61:2062-2070, 2001.
 
59) Junt T, Nakano H, Dumrese T, Kakiuchi T, Odermatt, B, Zinkernagel RM, Hengartner H, Ludewig B:Antiviral immune responses in the absence of organized lymphoid T cell zones in plt/plt Mice. J. Immunol 168:6032-6040, 2002.
PubMed
60) Jensen KK, Chen SC, Hipkin RW, Wiekowski MT, Schwarz MA, Chou CC, Simas JP, Alcami A, Lira SA:Disruption of CCL21-induced chemotaxis in vitro and in vivo by M3, a chemokine-binding protein encoded by murine gammaherpesvirus 68. J. Virol. 77:624-630, 2003.
PubMed
61) Mandala S, Haldu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H:Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296:346-349, 2002.
 
62) Honig SM, Fu S, Mao X, Yopp A, Gunn MD, Randolph, GJ, Bromberg JS:FTY720 stimulates multidrug transporter-and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J. Clin. Invest. 111:627-637, 2003.
 
63) Henning G, Ohl L, Junt T, Reiterer P, Brinkmann V, Nakano H, Hohenberger W, Lipp M, Forster R:CC chemokine receptor 7-dependent and-independent pathways for lymphocyte homing:modulation by FTY720. J. Exp. Med. 194:1875-1881, 2001.
PubMed
64) Sasaki M, Hasegawa H, Kohno M, Inoue A, Ito MR, Fujita S:Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice. J. Immunol. 170:588-596, 2003.
PubMed
P.457 掲載の参考文献
1) Morales J, Homey B, Vicari AP et al.:CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc. Natl. Acad. Sci. USA 96:14470-14475, 1999.
PubMed
2) lchihashi-Mochizuki l, Kitaura M, Baba M et al.:Molcecular cloning of a novel CC chemokine, interleukin-11 receptor a-locus chemokine (ILC) , which is located on chromosome 9p13 and a potential homologue of a CC chemokine encoded by molluscum contagiosum virus. FEBS Lett. 460:544-548, 1999.
 
3) Hromas R, Broxmeyer HE, Kim C et al:Isolation of ALP, a novel divergent murine CC chemokine with a unique carboxy terminal extension. Biochem. Biophys. Res. Commun. 258:737-740, 1999.
 
4) Baird SW, Nibbs RJB, Komai-Koma M et al.:Eskine, a novel B-chemokine, is differentially spliced to produce secretable and nuclear targeted isoforms. J. Biol. Chem. 274:33496-33503, 1999.
 
5) Homey B, Wang W, Soto H et al.:The orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC) . J. Immunol. 164:3465-3470, 2000.
PubMed
6) Gortz A, Nibbs RJ, McLean P et al.:The chemokine ESkine/CCL27 displays novel modes of intracrine and paracrine function. J. Immnuol. 169:1387-1394, 2002.
PubMed
7) Nibbs RJ, Graham GJ:CCL27/PESKY:anovel paradigm for chemokine function. Exp. Opin. Biol. Ther. 3:15-22, 2003.
 
8) Marchese A, Docherty JM, Nguyen T et al.:Cloning of human genes encoding novel G protein-coupled receptors. Genomics 23:609-618, 1994.
 
9) Homey B, Alenius H, Muller A et al.:CCL27-CCR1O interactions regulate T cell-mediated skin inflammation. Nat. Med. 8:157-165, 2002.
PubMed
10) Jarmin DI, Rits M, Bota D et al.:Identification of the orphan receptor G-protein-coupled receptor 2 as CCR10, a specific receptor for the chemokine ESkine. J. Immunol. 164:3460-3464, 2000.
PubMed
11) Wang W, Soto H, Oldham ER et al.:Identification of a novel chemokine (CCL28) , which binds CCR10 (GPR2) . J. Biol. Chem. 275:22313-22323, 2000.
PubMed
12) Pan J, Kunkel EJ, Gosslar U et al.:Anovel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J. Immunol. 165:2943-2949, 2000.
 
13) Nakayama T, Hieshima K, Izawa D et al.:Profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J. Immunol. 170:1136-1140, 2003.
PubMed
14) Senkevich TG, Bugert JJ, Sister JR et al.:Genome sequence of a human tumorigenic poxvirus:prediction of specific host response-evasion genes. Science 273:813-816, 1996.
 
15) Hudak S, Hagen M, Liu Y et al.:Immune surveillance and effector functions of CCR10 (+) skin homing T cells. J. Immunol. 169:1189-1196, 2002.
PubMed
16) Dorf ME, Berman MA, Tanabe S et al.:Astrocytes express functional chemokine receptors. J. Neuroimmunol. 1;111(1-2):109-121, 2000.
 
17) Payne AS, Cornelius LA:The role of chemokines in melanoma tumor growth arld metastasis. J. Invest. Dermatol, 118:915-922, 2002.
 
18) Huber TB, Reinhardt HC, Exner M et al:Expression of functional CCR and CXCR chemokine receptors in podocytes. J. Immunol. 168:6244-6252, 2002.
PubMed
19) Nakayama T, Fuj isawa R, Izawa D et al.:Human B cells immortalized with Epstein-Barr virus upregulate CCR6 and CCR1O and downregulate CXCR4 and CXCR5. J. Virol. 76:3072-3077, 2002.
 
20) Reiss Y, Proudfoot AE, Power CA et al.:CC chemokine receptor (CCR) 4and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J. Exp. Med. 194:1541-1547, 2001.
 
21) Kunkel EJ, Kim CH, Lazarus NH, Vierra MA, Soler D, Bowman EP, Butcher EC:CCR1O expression is a common feature of circullating and mucosal epithelial tissue IgA Ab-secreting cells. J. Clin. Invest. 111:1001-1010, 2003.
 
22) Kunkel EJ, Campbell DJ, Butcher EC:Chemokines in Iymphocyte trafficking and intestinal immunity. Microcirculation 10:313-323, 2003.
 
23) Cyster JG:Homing of antibody secreting cells. Immunol. Rev. 194:48-60, 2003.
PubMed
24) Hieshima K, Ohtani H, Shibano M et al.:CCL28 has dual roles in mucosal immunity as a chemokine with broad-spectrum antimicrobial activity. J. Immunol. 170:1452-1461, 2003.
PubMed
25) Kakinuma T, Saeki II, Tsunemi Y et al:Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J. Allergy Clin. Immunol. 111:592-597, 2003.
 
26) Soler D, Humphreys TL, Spinola SM et al.:CCR4 versus CCRIO in human cutaneous TH lymphocyte trafficking. Blood 101:1677-1682, 2003.
 
27) Muller A, Homey B, Soto H et al:Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50-56, 2001.
PubMed
P.467 掲載の参考文献
1) Bazan JF, Bacon KB, Hardiman G et al:Anew class of membrane-bound chemokine with a CX3C motif. Nature 385:640-644, 1997.
 
2) Pan Y, Lloyd C, Zhou H et al.:Neurotactin, amembrane-anchored chemokine upregulated in braininflammation. Nature 387:611-617, 1997.
 
3) Kelner GS, Kennedy J, Bacon KB et al:Lyrnphotactin:acytokine that represents a new class of chemokine. Science 266:1395-1399, 1994.
 
4) Yoshida T, Imai T, Kakizaki M et al.:Molecularcloning of a novel C or gamma type chemokine, SCM-1. FEBS Lett. 360:155-159, 1995.
PubMed
5) Muller S, Dorner B, Korthauer U et al.:Cloning of ATAC, an activation-induced, chemokine-relatedmolecule exclusively expressed in CD8+. Tlymphocytes. Eur. J. Immunol. 25:1744-1748, 1995.
 
6) Fong AM, Erickson HP, Zachariah JP et al.:Ultrastructure and function of the fractalkine mucindomain in CX (3) Cchemokine domain presentation. J. Biol. Chem. 275:3781-3786, 2000.
 
7) Tsou CL, Haskell CA, Charo IF:Tumor necrosis factoralpha-converting enzyme mediates the induciblecleavage of fractalkine. J. Biol. Chem. 276:44622-44626, 2001.
 
8) Garton KJ, Gough PJ, Blobel CP et al.:Tumor necrosisfactor-alpha-converting enzyme (ADAM17) mediatesthe cleavage and shedding of fractalkine (CX3CL1) . J. Biol. Chem. 276:37993-38001, 2001.
 
9) Kuloglu ES, McCaslin DR, Markley JL et al.:Structural rearrangement of human lymphotactin, a Cchemokine, under physiological solution conditions. J. Biol. Chem. 277:17863-17870, 2002.
 
10) Hedrick JA, Saylor V, Figueroa D et al.:Lymphotactinis produced by NK cells and attracts both NK cells and T cells in vivo J. Immunol. 158:1533-1540, 1997.
 
11) Yoshie O, Imai T, Nomiyama H:Chemokines inimmunity. Adv. Immunol. 78:57-110, 2001.
PubMed
12) Imai T, Hieshima K, Haskell C et al.:Identificationand molecular characterization of fractalkine receptorCX3CR1, which mediates both leukocyte migrationand adhesion. Cell 91:521-530, 1997.
 
13) Yoshida T, Imai T, Kakizaki M et al.:Identification ofsingle C motif-1/lymphotactin receptor XCR1. J. BiolChem. 273:16551-16554, 1998.
 
14) Shan L, Qiao X, Oldham E et al.:Identification of viralmacrophage inflammatory protein (vMIP)-II as aligand for GPR5/XCR1. Biochem. Biophys. Res. Commun. 268:938-941, 2000.
 
15) van Berkel V, Barrett J, Tiffany HL et al:Identificationof a gammaherpesvirus selective chemokine bindingprotein that inhibits chemokine action. J. Virol. 74:6741-6747, 2000.
 
16) Casarosa P, Bakker RA, Verzijl D et al:Constitutivesignahng of the human cytomegalovirus-encodedchemokine receptor US28. J. Biol. Chem. 276:1133-1137, 2001.
PubMed
17) Tripp RA, Jones LP, Haynes LM et al:CX3Cchemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2:732-738, 2001.
 
18) DeVries ME, Cao H, Wang J et al.:Genomicorganization and evolution of the CX3CR1/CCR8chemokine receptor locus. J. Biol. Chem. 278:11985-11994, 2003.
PubMed
19) Faure S, Meyer L, Costagliola D et al.:Rapid progression to AIDS in HIV+individuals with a structural variant of the chemokine receptor CX3CR1. Science 287:2274-2277, 2000.
PubMed
20) Moatti D, Faure S, Fumeron F et al.:Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97:1925-1928, 2001.
PubMed
21) Fraticelli P, Sironi M, Bianchi G et al.:Fractalkine (CX3CL1) as an amp1ification circuit of polarized Th1 responses. J. Clin. Invest. 107:1173-1181, 2001.
PubMed
22) Nishimura M, Umehara H, Nakayama T et al.:Dual functions of fractalkine/CX3C hg and I in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CRI expression. J. Immunol. 168:6173-6180, 2002.
 
23) Boismenu R, Feng L, Xia YY et al.:Chemokine expression by intraepithelial gamma delta T cells. Implications for the recruitment of inflammatory cells to damaged epithelia. J. Immunol. 157:985-992, 1996.
PubMed
24) Dorner BG, Scheffold A, Rolph MS et al.:MIP-1alpha, MIP-1beta, RANTES, and ATAC/ lymphotactin function together with IFN-gamma as type 1 cytokines. Proc. Natl. Acad. Sci, USA 99:6181-6186, 2002.
PubMed
25) Cairns CM, Gordon JR, Li F et al.:Lymphotactin expression by engineered myeloma cells drives tumor regression:mediation by CD4+ and CD8+ T cells and neutrophiIs expressing XCRI receptor. J. Immunol. 167:57-65, 2001.
 
26) Shiraishi K, Fukuda S, Mori T et al.:Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53. Cancer Res. 60:3722-3726, 2000.
PubMed
27) Hautamaa D, Merica R, Chen Z et al.:Murine lymphotactin:gene structure, post-translational modification and inhibition of expression by CD28 costimulation. Cytokine 9:375-382, 1997.
PubMed
28) Yoshida T, Ishikawa I, Ono Y et al.:An activation-responsive element in single C motif-1/lymphotactin promoter is a site of constitutive and inducible DNA-Protein interactions involving nuclear factor of activated T cell. J. Immunol. 163:3295-3303, 1999.
PubMed
29) Middel P, Thelen P, Blaschke S et al.:Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's disease. Am. J. Pathol. 159:1751-1761, 2001.
 
30) Cipriani B, Borsellino G, Poccia F et al.:Activation of C-Cbeta-chemokines in human peripheral blood gammadelta T cells by isopentenyl pyrophosphate and regulation by cytokines. Blood 95:39-47, 2000.
 
31) Ortaldo JR, Bere EW, Hodge D et al.:Activating Ly-49NK receptors:central role in cytokine and chemokine production. J. Immunol. 166:4994-4999, 2001.
PubMed
32) Rumsaeng V, Vliagoftis H, Oh CK et al.:Lymphotactin gene expression in mast cells following Fc (epsilon) receptor I aggregation:modulation by TGF-beta, IL-4, dexamethasone, and cyclosporin A. J. Immunol. 158:1353-1360, 1997.
PubMed
33) Adachi S, Nakano T, Vliagoftis H et al.:Receptor-mediated modulation of murine mast cell function by alpha-melanocyte stimulating hormone. J. Immunol. 163:3363-3368, 1999.
PubMed
34) Hanna J, Wald O, Goldman-Wohl D et al.:CXCL12 expression by invasive trophoblasts induces the specific migration of CDI6 negative human natural killer cells. Blood 102:1569-1577, 2003.
 
35) 今井俊夫:ケモカインと接着分子のハイブリッド fractalkine. Annual Review 免疫 2000:186-192, 1999.
 
36) Umehara H, Bloom E, Okazaki T et al.:Fractalkine and vascular injury. Trends Immunol. 22:602-607, 2001.
PubMed
37) Goda S, Imai T, Yoshie O et al.:CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and-independent mechanisms. J. Immunol. 164:4313-4320, 2000.
PubMed
38) Hundhausen C, Misztela D, Berkhout TA et al.:The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102:1186-1195, 2003.
PubMed
39) Fong AM, Robinson LA, Steeber DA et al.:Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp. Med. 188:1413-1419, 1998.
 
40) Fong AM, Alam SM, Imai T et al.:CX3CR1 tyrosine sullfation enhances fractalkine-induced cell adhesion. J. Biol. Chem. 277:19418-19423, 2002.
PubMed
41) Lillard JW, Jr, Boyaka PN, Hedrick JA et al.:Lymphotactin acts as an innate mucosal adjuvant. J. Immunol 162:1959-1965, 1999.
PubMed
42) Yoneda O, Imai T, Goda S et al.:Fractalkine-mediated endothelial cell injury by NK cells. J. Immunol. 164:4055-4062, 2000.
PubMed
43) Yoneda O, Imai T, Nishimura M et al.:Membrane-bound form of fractalkine induces IFN-gamma production by NK cells. Eur. J. Immunol 33:53-58, 2003.
PubMed
44) Lesnik P, Haskell CA, Charo IF:Decreased atherosclerosis in CX3CR1+mice reveaIs a role for fractalkine in atherogenesis. J. Clin. Invest. 111:333-340, 2003.
PubMed
45) Combadiere C, Potteaux S, Gao JL et al.:Decreased atherosclerotic lesion formation in CX3CR1/ apolipoprotein E double knockout mice. Circulation 107:1009-1016, 2003.
PubMed
46) Greaves DR, Hakkinen T, Lucas AD et al.:Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus-and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 21:923-929, 2001.
PubMed
47) Robinson LA, Nataraj C, Thomas DW et al.:Arole for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J. Immunol. 165:6067-6072, 2000.
 
48) Haskell CA, Hancock WW, Salant DJ et al.:Targeted deletion of CX (3) CR1 reveaIs a role for fractalkine in cardiac allograft rejection. J. Clin. Invest. 108:679-688, 2001.
PubMed
49) Yun JJ, Fischbein MP, Laks H et al.:Early and latechemokine production correlates with cellularrecruitment in cardiac allograft vasculopathy, Transplantation 69:2515-2524, 2000.
PubMed
50) Segerer S, Hughes E, Hudkins KL et al.:Expressionof the fractalkine receptor (CX3CR1) in human kidneydiseases. Kidney Int. 62:488-495, 2002.
 
51) Feng L, Chen S, Garcia GE et al.:Prevention ofcrescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapidcommunication. Kidney Int. 56:612-620, 1999.
 
52) Ou ZL, Hotta O, Natori Y et al.:Enhanced expressionof C chemokine lymphotactin in IgA nephropathy. Nephron 91:262-269, 2002.
 
53) Natori Y, Ou ZL, Yamamoto-Shuda Y:Expression oflymphotactin mRNA in experimental crescenticglomerulonephritis. Clin. Exp. Immunol. 113:265-268, 1998.
 
54) Nanki T, Imai T, Nagasaka K et al.:Migration ofCX3CR1-positive T cells producing type 1 cytokinesand cytotoxic molecules into the synovium of patientswith rheumatoid arthritis. Arthritis Rheum. 46:2878-2883, 2002.
 
55) Ruth JH, Volin MV, Haines GK 3rd et al.:Fractalkine, anovel chemokine in rheumatoid arthritis and in ratadj uvant-induced arthritis. Arthritis Rheum. 44:1568-1581, 2001.
 
56) Volin MV, Woods JM, Amin MA et al.:Fractalkine:anovel angiogenic chemokine in rheumatoid arthritis. Am. J. Pathol. 159:1521-1530, 2001.
 
57) Blaschke S, Middel P, Dorner BG et al.:Expression ofactivation-induced, T cell-derived, and chemokinerelated cytokine/lymphotactin and its functional rolein rheumatoid arthritis. Arthritis Rheum. 48:1858-1872, 2003.
 
58) Muehlhoefer A, Saubermann LJ, Gu X et al.:Fractalkine is an epithelial and endothelial cellderived chemoattractant for intraepitheliallymphocytes in the small intestinal mucosa. J. Immunol. 164:3368-3376, 2000.
PubMed
59) Lucas AD, Chadwick N, Warren BF et al.:The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am. J. Pathol. 158:855-866, 2001.
PubMed
60) Scheerens H, Hessel E, de Waal-Malefyt R et al.:Characterization of chemokines and chemokine receptors in two murine modeis of inflammatory bowel disease:IL-10-/-mice and Rag-2-/-mice reconstituted with CD4+CD45RBhigh T cells. Eur. J. Immunol. 31:1465-1474, 2001.
 
61) Guo J, Zhang M, Wang B et al.:Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int. J. Cancer 103:212-220, 2003.
PubMed
62) Huang H, Li F, Gordon JR et al.:Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+and CD8+T cells and intratumoral lymphotactin transgene expression. Cancer Res, 62:2043-2051, 2002.
 
63) Xia DJ, Zhang WP, Zheng S et al.:Lymphotactinco transfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Gene Ther. 9:592-601, 2002.
PubMed
64) Dilloo D, Bacon K, Holden W et al:Combined chemokine and cytokine gene transfer enhancesantitumor immunity. Nat. Med. 2:1090-1095, 1996.
PubMed
65) Emtage PC, Wan Y, Hitt M et al.:Adenoviral vectorsexpressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer modeIs. Hum. Gene Ther. 10:697-709, 1999.
 
66) Rousseau RF, Haight AE, Hirschmann-Jax C et al.:Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastorna. Blood 101:1718-1726, 2003.
PubMed
67) Foussat A, Bouchet-Delbos L, Berrebi D et al.:Deregulation of the expression of the fractalkine/ fractalkine receptor complex in HIV-1-infected patients. Blood 98:1678-1686, 2001.
PubMed
68) Ancuta P, Rao R, Moses A et al, :Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J. Exp. Med. 197:1701-1707, 2003.
PubMed
69) Geissmann F, Jung S, Littman DR:Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19:71-82, 2003.
 

サイトカインの細胞内情報伝達機構

P.483 掲載の参考文献
1) Bazan JF:Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 87:6934-6938, 1990.
PubMed
2) Abdel-Meguid SS, Shieh W, Dayringer HE, Violand BN, Bentle LA:Three dimensiorlal structure of a genetically engineered variant of porcine growth hormone. Proc. Natl. Acad. Sci. USA 84:6434-6437, 1990.
 
3) Sprang SR, Bazan JF:Cytokine structural taxonomy and mechanisms of receptor engagement. Curr. Opin, Struct. Biol. 3:815-821, 1993.
 
4) de Vos AM, Ultsch M, Kossiakoff AA:Human growth hormone and extracellular domain of its receptor. Crystal structure of the complex. Science 255:306-312, 1992.
PubMed
5) Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK et al.:Functional mimicry of a protein hormone by a peptide agonist:the EPO receptor complex at 2. 8A. Science 273:464-471, 1996.
PubMed
6) Livnah O, Stura EA, Johnson DL, Middleton SA, Jolliffe LK, WiIson IA:Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283:987-990, 1999.
 
7) Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD et al.:Efficiency of signaHing through cytokine receptors depends critically on receptor orientation. Nature 395:511-516, 1998.
PubMed
8) Josephson K, Logsdon NJ, Walter MR:Crystal structure of the IL-10/IL-10R1 complex reveaIs a shared receptor bonding site. Immunity 14:35-46, 2001.
 
9) Chow D-C, He X-1, Snow, AL, Rose-John S, Garcia KC:Structure of an extracellular gP130 cytokine receptor signaling complex. Science 291:2150-2155, 2001.
 
10) Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, et al.:Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715-725, 2000.
 
11) Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H:The interleukin-10 family of cytokines. Trends Immunol. 23:89-96, 2002.
PubMed
12) Gadina M, Hilton D, Johnston JA, Morinobu A, Lighvani A, Zhou YJ, Visconti R, O'Shea JJ:Signaling by type I and II cytokine receptors:ten years after. Curr. Opin. Immunol. 13:363-373, 2001.
PubMed
13) Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, AdeIstein S, Modi WS, McBride OW, Leonard WJ:Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 73:147-157, 1993.
 
14) Cao X, Shores EW, Hu-Li J, Anver MR, KeIsall BL et al.:Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 2:223-238, 1995.
PubMed
15) Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O'Shea JJ et al.:Mutations of JAK-3 gene in patients with autosomal severe combined immune deficiency (SCID) . Nature 377:65-68, 1995
PubMed
16) Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH et al.:Mutation of JAK3 in a patient with SCID:essential role of JAK3 in lymphoid development. Science 270:797-800, 1995.
 
17) Park SY, Saijo K, Takahashi T, Osawa M, Arase H et al.:Developmental defects of lymphoid cells in JAK3 kinase-deficient mice. Immunity 3:771-782, 1995.
PubMed
18) Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ:Defects in B lymphocyte maturation and T cell activation in mice lacking JAK3. Science 270:794-797, 1995.
 
19) Nosaka T, van Deursen JMA, Tripp RA, Thierfelder WE, Witthuln BA et al.:Defective lymphoid development in mice lacking JAK3. Science 270:800-802, 1995.
 
20) Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KC, Yin L, Pennica D, Johnson EM Jr, Schreiber RD:Disruption of the JAKl gene demonstrates obligatory and nonredundant roles of the JAKS in cytokine-induced biologic responses. Cell. 93:373-383, 1998.
 
21) Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G, Ihle JN: JAK2 is essential for signaling through a variety of cytokine receptors. Cell. 93:385-395, 1998.
PubMed
22) Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K:JAK2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 93:397-409, 1998.
PubMed
23) Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H, McCoy B, Bogdan C, Decker T, Brem G, Pfeffer K, Muller M:Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13:549-560, 2000.
PubMed
24) Shimoda K, Kato K, Aoki K, Matsuda T, Miyamoto A, Shibamori M, Yamashita M, Numata A, Takase K, Kobayashi S, Shibata S, Asano Y, Gondo H, Sekiguchi K, Nakayama K, Nakayama T, Okamura T, Okamura S, Niho Y, Nakayama K:Tyk2 plays a restricted role in IFN alpha signahng, although it is required for IL-12-mediated T cell function. Immunity 13:561-571, 2000.
 
25) Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD:Targeted disruption of the Statl gene in mice reveaIs unexpected physiologic specificity in the JAK-STAT signaling Pathway. Cel1. 84:431-442, 1996.
 
26) Durbin JE, Hackenmiller R, Simon MC, Levy DE:Targeted disruption of the mouse Statl gene results in compromised innate immunity to viral disease. Cell. 84:443-450, 1996.
 
27) Bluyssen AR, Durbin JE, Levy DE:ISGF3 gamma p48, aspecificity switch for interferon activated transcription factors. Cytokine Growth Factor Rev. 7:11-17, 1996.
 
28) Park C, Li S, Cha E, Schindler C:Immune response in Stat2 knockout mice. Immunity 13:795-804, 2000.
PubMed
29) Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S:Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. U S A 94:3801-3804, 1997.
PubMed
30) Akira S:Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 19:2607-2611, 2000.
 
31) Kaplan MH, Sun YL, Hoey T, Grusby MJ:Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382:174-177, 1996.
PubMed
32) Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN:Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382:171-174, 1996.
 
33) Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L:Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 11:179-186, 1997.
PubMed
34) Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW:Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc. Natl. Acad. Sci. U S A 94:7239-7244, 1997.
PubMed
35) Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN:Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 93:841-850, 1998.
PubMed
36) Kaplan MH, Schindler U, Smiley ST, Grusby MJ:Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4:313-319, 1996.
PubMed
37) Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignali DA, Doherty PC, Grosveld G, Paul WE, Ihle JN:Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380:630-633, 1996.
PubMed
38) Levy DE, Darnell JE Jr:Stats:transcriptional control and biological impact. Nat. Rev. Mol. Cell. Biol. 3:651-662, 2002.
PubMed
39) Bodmer JL, Schneider P, Tschopp J:The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27:19-26, 2002.
 
40) Locksley RM, Killeen N, Lenardo MJ:The TNF and TNF receptor superfamilies:integrating mammalian biology. Cell. 104:487-501, 2001.
PubMed
41) Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W:Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex:imp1ications for TNF recePtor activation. Cell. 73:431-445, 1993.
PubMed
42) Ni CZ, WeIsh K, Leo E, Chiou CK, Wu H, Reed JC, Ely KR:In PMC Molecular basis for CD40 signaling mediated by TRAF3. Proc. Natl. Acad. Sci. U S A 97:10395-10399, 2000.
 
43) Park YC, Ye H, Hsia C, Segal D, Rich RL, Liou HC, Myszka DG, Wu H:Anovel mechanism of TRAF signaling revealed by structural and functional analyses of the TRADD-TRAF2 interaction. Cell. 101:777-787, 2000.
 
44) Chung JY, Park YC, Ye H, Wu H:Full Text All TRAFs are not created equal:common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci. 115:679-688, 2002.
 
45) Tsitsikov EN, Laouini D, Dunn IF, Sannikova TY, Davidson L, Alt FW, Geha RS:TRAFl is a negative regulator of TNF signaling. enhanced TNF signaling in TRAF1-deficient mice. Immunity 15:647-657, 2001.
 
46) Yeh WC, Shahinian A, Speiser D, Kraunus J, BiHia F, Wakeham A, de la Pompa JL, Ferrick D, Hum B, Iscove N, Ohashi P, Rothe M, Goeddel DV, Mak TW:Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7:715-725, 1997.
 
47) Xu Y, Cheng G, Baltimore D:Targeted disruption of TRAF3leads to postnatal lethality and defective T-dependent immune responses. Immunity 5:407-415, 1996.
 
48) ShieIs H, Li X, Schumacker PT, Maltepe E, Padrid PA, Sperling A, Thompson CB, Lindsten T:Full Text TRAF4 deficiency leads to tracheal malformation with resulting alterations in air flow to the lungs. Am. J. Pathol 157:679-688, 2000.
 
49) Nakano H, Sakon S, Koseki H, Takemori T, Tada K, Matsumoto M, Munechika E, Sakai T, Shirasawa T, Akiba H, Kobata T, Santee SM, Ware CF, Rennert PD, Taniguchi M, Yagita H, Okumura K:In PMC targeted disruption of Traf5 gene causes defects in CD40-and CD27-mediated lymphocyte activation. Proc. Natl. Acad. Sci. U S A 96:9803-9808, 1999.
 
50) Lomaga MA, Henderson JT, Elia AJ, Robertson J, Noyce RS, Yeh WC, Mak TW:Full Text tumor necrosis factor receptor-associated factor 6 (TRAF6) deficiency results in exencephaly and is required for apoptosis within the developing CNS. J. Neurosci. 20:7384-7393, 2000.
 
51) Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, Katsuki M, Yamamoto T, Inoue J:Severe osteopetrosis, defective interleukin-1 signalling and lymph node organo-genesis in TRAF6-deficient mice. Genes CelIs. 4:353-362, 1999.
 
52) Ke1Uher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P:The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8:297-303, 1998.
 
53) Yeh WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, El-Deiry WS, Lowe SW, Goeddel DV, Mak TW:FADD:essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 279:1954-1958, 1998.
 
54) Finzel BC, Clancy LL, Holland DR, Muchmore SW, Watenpaugh KD, Einspahr HM:Crystal structure of recombinant human interleukin-l beta at 2. 0 A resolution. J. Mol. Biol. 209:779-791, 1989.
 
55) Priestle JP, Schar HP, Grutter MG:Crystallographic refinement of interleukin l beta at 2. 0 A resolution. Proc. Natl. Acad. Sci. U S A 86:9667-9671, 1989.
 
56) Vigers GP, Anderson LJ, Caffes P, Brandhuber BJ:Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Nature 386:190-194, 1997.
PubMed
57) Schreuder H, Tardif C, Trump-Kalimeyer S, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Barrett RW:Anew cytokine-receptor binding mode revealed by the crystal structuare of the IL-1receptor with an antagonist. Nature 386:194-200, 1997.
 
58) Kawai T, Adachi O, Ogawa T, Takeda K, Akira S:Unresponsiveness of MyD88-deficient mice toendotoxin. Immunity 11:115-122, 1999.
PubMed
59) Adachi O, Kawai T, Takeda K, Matsumoto M, TsutsuiH, Sakagami M, Nakanishi K, Akira S:Targeteddisruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 9:143-150, 1998.
 
60) Kanakaraj P, Ngo K, Wu Y, Angulo A, Ghazal P, HarrisCA, Siekierka JJ, Peterson PA, Fung-Leung WP:FullText defective interleukin (IL-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J. Exp. Med. 189:1129-1138, 1999.
 
P.492 掲載の参考文献
1) Szabo SJ, Kim ST, Costa GL et al.:Anovel transcription factor, T-bet, directs Thl lineage commitment. Cell 100:655-669, 2000.
 
2) Mullen AC, High FA, Hutchins AS et al.:Role of T-bet in commitment of THI cells before IL-12-dependent selection. Science 292:19. 07-1910, 2001.
 
3) Afkarian M, Sedy JR, Yang J et al.:T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+T cells. Nat. Immunol, 3:549-557, 2002.
 
4) Szabo SJ, Sullivan BM, Stemmann C et al.:Distinct effects of T-bet in THI lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 295:338-342, 2002.
 
5) Peng SL, Gerth AJ, Ranger AM et al:NFATcl and NFATc2 together control both T and B cell activation and differentiation. Immunity 14:13-20, 2001.
 
6) Mullen AC, Hutchins AS, High FA et al.:Hlx is induced by and genetically interacts with T-bet to promote heritable T (H) 1 gene induction. Nat. Immunol. 3:652-658, 2002.
 
7) Szabo SJ, Jacobson NG, Dighe AS et al:Developmental commitment to the Th21ineage by extinction of IL-12 signaling. Immunity 2:665-675, 1995.
 
8) Szabo SJ, Dighe AS, Gubler U et al.:Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J. Exp. Med. 185:817-824, 1997.
PubMed
9) Yang J, Zhu H, Murphy TL et al.:IL-18-stimulatedGADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production. Nat. Immunol 2:157-164, 2001.
 
10) Lu B, Yu H, Chow C et al.:GADD45gamma mediates the activation of the p38 and JNK MAP kinase pathways and cytokine production in effector THl cells. Immunity l4:583-590, 2001.
 
11) Taki S, Sato T, Ogasawara K T et al.:Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 6:673-679, 1997.
PubMed
12) Salkowski CA, Thomas KE, Cody MJ et al.:Impaired IFN-gamma production in IFN regulatory factor-1 knockout mice during endotoxemia is secondary to a loss of both IL-12 and IL-12 receptor expression. J. Immunol. 165:3970-3977, 2000.
PubMed
13) Oppmann B, Lesley R, Blom B et al.:Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715-725, 2000.
 
14) Yoshida H, Hamano S, Senaldi G et al.:WSX-1 is required for the initiation of Thl responses and resistance to L. major infection. Immtlnity 15:569-578, 2001.
 
15) Belladonna ML, Renauld JC, Bianchi R et al.:IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J. Immunol. 168:5448-5454, 2002.
PubMed
16) Takeda A, Hamano S, Yamanaka A et al.:Cutting edge:Role of IL-27/WSX-1 signaling for induction of T-bet through activation of STATI during initial Thl commitment. J. Immunol. 170:4886-4890, 2003.
 
17) Rao A, Luo C, Hogan PG:Transcription factors of the NFAT family:regulation and function. Annu. Rev. Immunol. 15:707-747, 1997.
PubMed
18) Hodge MR, Ranger AM, Charles F et al:Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient mice. Immunity 4:397-405, 1996.
 
19) Kiani A, Viola JP, Lichtman AH et al.:Down-regulation of IL-4 gene transcription and control of Th2 cell differentiation by a mechanism involving NFAT1. Immunity 7:849-860, 1997.
PubMed
20) Ranger AM, Oukka M, Rengarajan J et al.:Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. Immunity 9:627-635, 1998.
PubMed
21) Ranger AM, Hodge MR, Gravallese EM et al.:Delayed lymphoid repopulation with defects in IL-4-driven responses produced by inactivation of NF-ATc. Immunity 8:125-134, 1998.
PubMed
22) Yoshida H, Nishina H, Takimoto H et al.:The transcription factor NF-ATcl regulates lymphocyte proliferation and Th2 cytokine production. Immunity 8:115-124, 1998.
 
23) Kubo M, Ransom J, Webb D et al.:T-cell subset-specific expression of the IL-4 gene is regulated by a silencer element and STAT6. Embo. J. 16:4007-4020, 1997.
 
24) Wenner CA, Szabo SJ, Murphy KM:Identification of IL-4 promoter elements conferring Th2-restricted expression during T helper cell subset development. J. Immunol. 158:765-773, 1997.
 
25) Ho IC, Hodge MR, Rooney JW et al.:The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 85:973-983, 1996.
PubMed
26) Kim JI, Ho IC, Grusby MJ et al.:The transcription factor c-Maf controIs the production of interleukin-4 but not other Th2 cytokines. Immunity 10:745-751, 1999.
 
27) Rengarajan J, Mowen KA, McBride KD et al:Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J. Exp. Med. 195:1003-1012, 2002.
PubMed
28) Tominaga N, Ohkusu-Tsukada K, Udono H et al. Development of Thl and not Th2 immune responses in mice lacking IFN-regulatory factor-4. Int. Immunol. 15:1-10, 2003.
 
29) Zheng W, Flavell RA:The transcription factor GATA-3is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89:587-596, 1997.
 
30) Kurata H, Lee HJ, O'Garra A et al:Ectopic expression of activated Stat6 induces the expression of Th2-specific cytokines and transcription factors in developing Thl cells. Immunity 11:677-688, 1999.
 
31) Huang H, Paul WE:Impaired interleukin 4 signaling in T helper type 1 cells. J. Exp. Med. 187:1305-1313, 1998.
 
32) Ouyang W, Lohning M, Gao Z et al.:STAT6-independent GATA-3 autoactivation directs IL-4-independent Th2 devlopment and commitment. Immunity 12:27-37, 2000.
 
33) Lee H-J, Takemoto N, Kurata H et al.:GATA-3 induces T helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Thl cells. J. Exp. Med. 192:105-115, 2000.
 
34) Das J, Chen CH, Yang L et al.:Acritical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat. Immunol. 2:45-50, 2001.
 
35) Kubo M, Yamashita M, Abe R et al.:CD28 costimulation accelerates IL-4 receptor sensitivity and IL-4-mediated Th2 differentiation. J. Immunol 163:2432-2442, 1999.
PubMed
36) Rodriguez-Palmero M, Hara T, Thumbs A et al.:Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo. Eur. J. Immunol. 29:3914-3924, 1999.
PubMed
37) Ranganath S, Murphy KM:Structure and specificity of GATA proteins in Th2 development. Mol. Cell. Biol. 21:2716-2725, 2001.
PubMed
38) Miaw SC, Choi A, Yu E et al.:ROG, repressor of GATA, regulates the expression of cytokine genes. Immunity 12:323-333, 2000.
PubMed
39) Zhou M, Ouyang W, Gong Q et al.:Friend of GATA-1 represses GATA-3-dependent activity in CD41T cells. J. Exp. Med. 194:1461-1471, 2001.
 
40) Kurata H, Lee HJ, McClanahan T et al.:Friend of GATA is expressed in naive Th cells and functions as a repressor of GATA-3-mediated Th2 cell development. J. Immunol. 168:4538-4545, 2002.
PubMed
41) Kimura M, Koseki Y, Yamashita M et al.:Regulation of Th2 cell differentiation by mel-18, a mammalian polycomb group gene. Immunity 15:275-287, 2001.
PubMed
42) Komine O, Hayashi K, Natsume W et al.:The Runxl transcription factor inhibits the differentiation of naive CD4T-cells into the Th2 lineage by repressing GATA3 expression. J. Exp. Med. 198:51-61, 2003.
 
43) Agarwal S, Rao A:Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity 9:765-775, 1998.
 
44) Agarwal S, Avni O, Rao A:Cell-type-restricted binding of the transcription factor NFAT to a distal IL-4 enhancer in vivo. Immunity 12:643-652, 2000.
PubMed
45) Takemoto N, Koyano-Nakagawa N, Yokota T et al.:Th2-specific DNase I-hypersensitive sites in the murine IL-13 and IL-4 intergenic region. Int. Immunol. 10:1981-1985, 1998.
PubMed
46) Loots GG, Locksley RM, Blankespoor CM et al.:Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons. Science 288:136-140, 2000.
PubMed
47) Mohrs M, Blankespoor CM, Wang ZE et al.:Deletion of a coordinate regulator of type 2 cytokine expression in mice. Nat. Immunol. 2:842-847, 2001.
PubMed
48) Solymar DC, Agarwal S, Bassing CH et al.:A3' enhancer in the IL-4 gene regulates cytokine prodしtction by Th2 cells and mast cells. Immunity 17:41-50, 2002.
 
49) Guo L, Hu-Li J, Zhu J et al.:Disrupting IL13 impairs production of IL-4 specified by the linked allele. Nat. Immunol. 2:461-466, 2001.
PubMed
50) Lee GR, Fields PE, Flavell RA:Regulation of IL-4 gene expression by distal regulatory elements and GATA-3 at the chromatin level. Immunity 14:447-459, 2001.
PubMed
51) Lee GR, Fields PE, Griffin TJ et al.:Regulation of the Th2 cytokine locus by a locus control region. Immunity 19:145-153, 2003.
 
52) Avni O, Lee D, Macian F et al.:T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat. Imrnunol. 3:643-651, 2002.
 
53) Yamashita M, Ukai-Tadenuma M, Kimura M et al.:Identification of a conserved GATA3 response element upstream proximal from the interleukin-13 gene locus. J. Biol Chem. 277:42399-42408, 2002.
PubMed
54) Fields PE, Kim ST, Flavell RA:Cutting edge:changes in histone acetylation at the IL-4 and IFN-gamma loci accompany Thl/Th2 differentiation. J. Immunol. 169:647-650, 2002.
 
55) Grogan JL, Mohrs M, Harmon B et al.:Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immunity 14:205-215, 2001.
PubMed
56) Guo L, Hu-Li J, Zhu J et al.:In TH2 cells the IL4 gene has a series of accessibility states associated with distinctive probabilities of IL-4 production. Proc. Natl. Acad. Sci. USA 99:10623-10628, 2002.
 
57) Lee DU, Agarwal S, Rao A:Th2 lineage commitment and efficient IL-4 production involves extended demethylation of the IL-4 gene. Immunity 16:649-660, 2002.
PubMed
58) Santangelo S, Cousins DJ, Winkelmann NE et al.:DNA methylation changes at human Th2 cytokine genes coincide with DNase I hypersensitive site formation during CD4(+) Tcell differentiation. J. Immunol. 169:1893-1903, 2002.
 
59) Hutchins AS, Mullen AC, Lee HW et al:Gene silencing quantitatively controIs the function of a developmental trans-activator. Mol. Cell. 10:81-91, 2002.
 
60) Seki Y, Hayashi K, Matsumoto A et al.:Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc. Natl. Acad. Sci. USA 99:13003-13008, 2002.
PubMed
61) Seki Y, Inoue H, Nagata N et al.:SOCS-3 regulates onset and maintenance of T(H) 2-mediated allergic responses. Nat. Med. 9:1047-1054, 2003.
 
P.502 掲載の参考文献
1) Shultz LD, Schweitzer PA, Rajan TV et al.:Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73:1445-14 54, 1993.
 
2) Kralovics R, Indrak K, Stopka T et al:Two new EPO receptor mutations:Truncated EPO receptors are most frequently asociated with primary familial and congenital polycytherrlias. Blood 90:2057-2061, 1997.
 
3) Klingmuller U, Lorenz U, Cantley, LC et al.:Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signaIs. Cell 80:726-738, 1995.
 
4) Schmitz J, Weissenbach M, Haan S et al.:SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275:12848-12856, 2000.
PubMed
5) Damen JE, Liu L, Rosten P et al.:The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidyhnositol 3, 4, 5-triphosphate 5-phosphatase. Proc. Natl. Acad. Sci. USA 93:1689. -1693, 1996.
 
6) Ono M, Okada H, Bolland S et al.:Deletion of SHIP or SHP-1 reveaIs two distinct pathways for inhibitory signaling. Cell 90:293-301, 1997.
PubMed
7) Ono M, Bolland S, Tempst P et al.:Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc (gamma) RIIB. Nature 383:263-266, 1996.
PubMed
8) Suzuki A, Yamaguchi MT, Ohteki T et al.:Tcell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14:523-534, 2001.
 
9) Yokouchi M, Kondo T, Sanjay A, Houghton A, Yoshimura A, Komiya S, Zhang H, Baron R:Srccatalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins. J. Biol. Chem. 276:35185-35193, 2001.
 
10) Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, Jang IK, Gutkind JS, Shevach E, Gu H:Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403:216-220, 2000.
PubMed
11) Takaki S, Morita H, Tezuka Y, Takatsu K:Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J. Exp. Med. 195:151-160, 2002.
PubMed
12) Kurachi H, Wada Y, Tsukamoto N, Maeda M, Kubota H, Hattori M, Iwai K, Minato N:Human SPA-1gene product selectively expressed in lymphoid tissues is a specific GTPase-activating protein for Rapl and Rap2. Segregate expression profiles from a raplGAP gene product. J. Biol. Chem. 272:28081-28088, 1997.
 
13) Casci T, Vinos J, Freeman M:Sprouty, an intracellular inhibitor of Ras signaling. Cell 96:655-665, 1999.
PubMed
14) Sasaki A, Taketomi T, Wakioka T, Kato R, Yoshimura A:Identification of a dominant negative form of Sproutys that potentiates FGF-but not EGF-induced ERK activation. J. Biol Chem. 276:36804-36808, 2001.
 
15) Sasaki A, Taketomi T, Kato R, Saeki K, Nonami A, Sasaki M, Kuriyama M, Saito N, Shibuya M, Yoshimura A:Mammalian Sprouty 4 suppresses Ras-independent ERK activation by binding to Rafl. Nature Cell. Biol 5:427-432, 2003.
 
16) Wakioka T, Sasaki A, Kato R, Shouda T, Matsumoto A, Miyoshi K, Tsuneoka M, Komiya S, Baron R, Yoshimura A:Spred, a Sprouty-related suppressor of Ras signaling. Nature 412:647-651, 2001.
PubMed
17) Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyaj ima A:Anovel cytokine-inducible gene CIS encodes an SH2-containing Protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors, EMBO J. 14:2816-2826, 1995.
 
18) Endo AT, Masuhara M, Yokouchi M et al:Anew protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921-924, 1997.
 
19) Starr R, WilIson TA, Viney EM et al.:Afamily of cytokine-inducible inhibitors of signaling. Nature 387:917-921, 1997.
 
20) Naka T, Narazaki M, Hirata M et al.:Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924-929, 1997.
PubMed
21) Yasukawa H, Sasaki A, Yoshimura A:Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 18:143-164, 2000.
PubMed
22) Tyers M, Willems AR:One ring to rule a superfamily of E3 ubiquitin ligases. Science 284:601-604, 1999.
 
23) Kamizorlo S, Hanada T, Yasukawa H et al.:The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J. Biol. Chem. 276:12530-12538, 2001.
 
24) Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O:Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol. Cell. Biol. 22:3316-3326, 2002.
PubMed
25) Zhang JG, Metcalf D, Rakar S, Asimakis M, Greenhalgh CJ, WilIson TA, Starr R, NichoIson SE, Carter W, Alexander WS, Hilton DJ, Nicola NA:The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc. Natl. Acad. Sci. U S A 98:13261-13265, 2001.
 
26) Verdier F, Chretien S, Muller O, Varlet P, Yoshimura A, Gisselbrecht S, Lacombe C, Mayeux P:Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein J. Biol. Chem. 273:28185-28190, 1998.
 
27) Zhang JG, Farley A, NichoIson SE et al.:The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. U S A 96:2071-2076, 1999.
 
28) Yasukawa H, Misawa H, Sakamoto H et al.:The JAK-binding Protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1309-1320, 1999.
PubMed
29) Sasaki A, Yasukawa H, Shouda T et al.:CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J. Biol. Chem. 275:29338-29347, 2000.
PubMed
30) NichoIson SE, De Souza D, Fabri LJ et al.:Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. U S A 97:6493-6498, 2000.
 
31) De Souza D, Fabri LJ, Nash A, Hilton DJ, Nicola NA, Baca M:SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry 41:9229-9236, 2002.
PubMed
32) Ram PA, Waxman DJ:SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J. Biol Chem. 274:35553-35561, 1999.
PubMed
33) Matsumoto A, Seki Y, Kubo M et al.:Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein l transgenic mice. Mol. Cell. Biol. 19:6396-6407, 1999.
 
34) Metcalf D, Greenhalgh CJ, Viney E, WilIson TA, Starr R, Nicola NA, Hilton DJ, Alexander WS:Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405:1069-1073, 2000.
 
35) Greenhalgh CJ, Bertolino P, Asa SL, Metcalf D, Corbin JE, Adams TE, Davey HW, Nicola NA, Hilton DJ, Alexander WS:Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b) . Mol Endocrinol. 16:1394-1406, 2002,
PubMed
36) Marine J-C, Topham D J, McKay C et al.:SOCSI deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98:609-616, 1999.
 
37) Alexander WS, Starr R, Fenner JE et al.:SOCSI is a critical inhibitor of interferonγ signaling and p revents the potentially fatal neonatal actions of this cytokine. Cell 98:597-608, 1999.
 
38) Hanada T, Yoshida H, Kato S, Tanaka K, Masutani K, Tsukada J, Nomura Y, Mimata H, Kubo, M Yoshimura A:Suppressor of cytokine signaling-1 (SOCS1) isessential for suppressing dendritic cell activation andsystemic autoimmunity. Immunity (in press).
 
39) Chong MM, Cornish AL, Darwiche R, Stanley EG, Purton JF, Godfrey DI, Hilton DJ, Starr R, AlexanderWS, Kay TW:Suppressor of cytokine signaling-1 is acritical regulator of interleukin-7-dependent CD8+Tcell differentiation. Immunity 18:475-487, 2003.
 
40) Naka T, Tsutsui H, Fujimoto M et al:SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFNgamma and IL-4 signaling in vitro. Immunity 14:535-545, 2001.
 
41) Yoshikawa H, Matsubara K, Qian GS et al.:SOCS-1, anegative regulator of the JAK/STAT pathway, issilenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28:29-35, 2000.
 
42) Kinjyo I, Hanada T, Inagaki-Ohara K, Mori H, Aki D, Ohishi M, Yoshida H, Kubo M, Yoshimura A:SOCSl/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 17:583-591, 2002.
 
43) Nakagawa R, Naka T, Tsutsui H, Fujimoto M, KimuraA, Abe T, Seki E, Sato S, Takeuchi O, Takeda K, AkiraS, Yamanishi K, Kawase I, Nakanishi K, Kishimoto T:SOCS-l participates in negative regulation of LPSresponses. Immunity 17:677-687, 2002.
 
44) Roberts AW et al.:Placental defects and embryoniclethality in mice lacking suppressor of cytokinesignaling 3, Proc. Natl. Acad. Sci. USA 98:9324-9329, 2001.
 
45) Takahashi Y et al:SOCS3:an essential regulator ofLIF receptor signahng in trophoblast giant celldifferentiation. EMBO J. 22:372-384, 2003.
 
46) Seki Y-i, Inoue H, Nagata N, Hayashi K, Fukuyama S, Matsumoto K, Komine O, Hamano S, Himeno K, Inagaki-Ohara K, Cacalano N, O'Garra A, Oshida T, Saito H, Johnston J A, Yoshimura A, Kubo M:SOCS-3regulates onset and maintenance of TH2-mediatedallergic responses Nature Med. 9:1047-1054, 2003.
 
47) Suzuki A, Hanada T, Mitsuyama K et al.:CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3activation and intestinal inflammation. J. Exp. Med. 193:471-482, 2001.
 
48) Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, Komiya S, Kosai K, Hanakawa Y, Hashimoto K, Nagata K, Yoshimura A:Induction ofthe cytokine signal regulator SOCS3/CIS3 as atherapeutic strategy for treating inflammatoryarthritis. J. Clin. Invest. 108:1781-1788, 2001.
 
49) Takeda K, Clausen BE, Kaisho T, Tsujimura T, TeradaN, Forster I, Akira S:Enhanced Thl activity anddevelopment of chronic enterocolitis in mice devoid ofStat3 in macrophages and neutrophiIs. Immunity 10:39-49, 1999.
 
50) Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda K, Akira S, Hoshijima M, Hirano T, Chien KR, Yoshimura A:IL-6 induces an anti-inflammatory response in theabsence of SOCS3 in macrophages. Nature Immunol 4:551-556, 2003.
 
P.513 掲載の参考文献
1) Ward SG, Bacon K, Westwick J:Chemokines and T lyrnphocytes:more than an attraction. Immunity 9:1-11, 1998.
 
2) Thelen M:Dancing to the tune of chemokine. Nat. Immunol 2:129-134, 2001.
 
3) Singer II, Scott S, Kawka DW et al.:CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. J. Virol. 75:3779-3790, 2001.
 
4) Issafran H, Angers S, Bulenger S et al.:Constitutive agonist-independent CCR5 oligomerization and anti-body-mediatedclustering occurring at physiological levels of receptors. J. Biol. Chem. 277:34666-34673, 2002.
 
5) Babcock GJ, Farzan M, Sodroski J:Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. J. Biol. Chem. 278:3378-3385, 2003.
PubMed
6) Jordan BA, Devi LA:G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399:697-700, 1999.
PubMed
7) Abdalla S, Lother H, Quitterer U:ATI-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407:94-98, 2000.
 
8) El-Shazly A, Yamaguchi M, Masuyama, K et al.:Novel association of the Src family kinases, Hck and c-Fgr, with CCR3 receptor stimulation:apossible mechanism for eotaxin-induced human eosinophil chemotaxis. Biochem. Biophys. Res. Commun. 264:163-170, 1999.
 
9) Vila-coro AJ, Rodriguez-Frade JM, Martin De Ana A et al.:The chemokine SDF-1 alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 13:1699-1710, 1999.
PubMed
10) Mellado M, Rodriguez-Frade JM, Aragay A et al.:The chemokine monocyte chemotactic protein l triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. J. Immunol. 161:805-813, 1998.
 
11) Rodriguez-Frade J M Vila-Co A J, Martin De Ana A et al:The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. Proc. Nat. Acad. Sci. USA 96:3628-3633, 1999.
 
12) Gutkind J S:The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J. Biol. Chem. 273:1839-1842, 1998.
 
13) Gilbert C, Levasseur S, Desaulniers P et al.:Chmotacticfactor-induced recruitment and activation of Tec family kinases in human neutrophiIs. II. Effects of LFM-A13, aspecific Btk inhibitor. J. Immunol. 170:5235-5243, 2003.
 
14) Neptune ER, Iiri T, Bourne HR:Gaiis not required for chemotaxis mediated by Gi-coupled receptors. J. Biol. Chem. 274:2824-2828, 1999.
 
15) Arai H, Tsou C-L, Charo IF:Chemotaxis in a lymphocyte cell line transfected with C-C chemokine receptor 2B:evidence that directed migration is mediated by Bγdimmers released by activation of Gai-coupled receptors. Proc. Natl. Acad. Sci. USA 94:14495-14499, 1997.
 
16) Turner L, Ward SG, Westwick J:RANTES-activated human T lymphocytes:arole for phosphoinositide 3-kinase. J. Immunol 155:2437-2444, 1995.
 
17) Knall C, Worthen GS Johnson GL:Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase. Proc. Natl. Acad. Sci. USA 94:3052-3056, 1997.
PubMed
18) Hirsch E, Katanaev VL, Garlanda C et al:Central role for G protein-coupled phosphoinositide 3-kinaseγin inflammation. Science 287:1049-1053, 2000.
 
19) Li Z, Jiang H, Xie W et al:Roles of PLC-B2 and B3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 287:1046-1049, 2000.
 
20) Sasaki T, Sasaki J, Jones RG et al.:Function of PI3Kγin thymocyte development, T cell activation and neutrophil migration. Science 287:1040-1046, 2000.
 
21) Vankaesebroeck B, Jones GE, Allen, WE et al.:Distinct PI (3) Ks mediate mitogenic signaling and cell migration in macrophage. Nat. Cell. Biol. 1:69-71, 1999.
 
22) Franke T F et al.:PI3K:downstream AKT ion blocks apoptosis. Cell 88:435-437, 1997.
 
23) Servant, G, Weiner O D, Herzmark P et al.:Polarization of chemoattractant receptor signaling during neutrophil chernotaxis. Science 287:1037-1040, 2000.
PubMed
24) Barlic J, Andrews JD, Kelvin AA et al.:Regulation of tyrosine kinase activation and granule release through B-arrestin by CXCRI. Nat. Immunol. 1:227-233, 2000.
 
25) Ma Y C, Huang J, Ali S et al.:Src tyrosine kinase is a novel direct effector of G protein. Cell 102:635-646, 2000.
PubMed
26) Barlic J, Khandaker MH, Mahon E et al.:B-arrestins regulate interleukin-8-induced CXCRI interrlalization. J. Biol. Chem. 274:16287-16294, 1999.
 
27) Yang W, Wang D, Richmond A:Role of clathrin-mediated endocytosis in CXCR2 sequestration, and signal transduction. J. Biol Chem. 274:11328-11333, 1999.
PubMed
28) Laudanna, C, Mochly-Rosen, D, Liron T et al.:Evidence of protein kinase C involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis. J. Biol. Chem. 273:30306-30315, 1998.
PubMed
29) Weiner OD, Servant G, Welch MD et al.:Spatial control of actin polymerization during neutrophil chemotaxis. Nat. Cell. Biol. 1:75-81, 1999.
PubMed
30) Miki, H, Yamaguchi, H, Suetsugu S et al.:IRSp53 is an essential intermediate between Rac and WAVE in the regulation of membrane ruffling. Nature 408:732-735, 2000.
PubMed
31) Yayoshi-Yamamoto S, Taniguci I, Watanabe T:FRL, a movel fomin-related protein, binds to Rac and regulates cell motility and survival of macrophages. Mol. Cell. Biol. 20:6872-6881, 2000.
 
32) Fukui Y, Hashimoto O, Sanui T et al.:Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 412:826-831, 2001.
PubMed
33) Ma AD, Metjian A, Bagrodia S et al.:Cytoskeletal reorganization by G protein-coupled receptors is dependent on phosphoinositide 3-kinaseγ, a Rac Guanosine exchange factor, and Rac. Mol. Cell. Biol. 18:4744-4751, 1998.
 
34) Weber KSC, Klickstein LB, Weber PC et al.:Chemokine-induced monocyte transmigration requires cdc42-mediated cytoskeletal changes. Eur. J. Immunol. 28:2245-2251, 1998.
 
35) Roberts A W, Kim C, Zhen L et al.:Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense. Immunity 10:183-196, 1999.
PubMed
36) Symons M, Derry JMJ, Karlak B et al.:Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell 84:723-734, 1996.
 
37) Haddad, E, Zugaza JL, Louache F et al.:The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chem. otaxis. Blood 97:33-38, 2001.
 
38) Rohatgi R, Ma L, Miki H et al.:The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signaIs to actin assembly. Cell 97:221-231, 1999.
PubMed
39) Laudanna, C, Campbell JJ, Butcher EC:Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants. J. Biol. Chem. 272:24141-24144, 1997.
PubMed
40) Hart MJ, Jiang X, Kozasa T et al.:Direct stimulation of the guanine nucleotide exchange activity of p115RhoGEF by Gα13. Science 280:2112-2114, 1998.
 
41) Laudanna C, Campbell JJ, Butcher EC:Role of Rho in chemoattractant-activated leukocyte adhesion through integrins. Science 271:981-983, 1996.
PubMed
42) Bardi G, Niggli V, Loetscher P:Rho kinase is required for CCR7-mediated polarization an chem. otaxis of T lymphocytes. FEBS Lett. 542(1-3):79-83, 2003.
 
43) Campbell JJ, Hedrick J, Zlotnik A et al.:Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 279:381-384, 1998.
PubMed
44) Constantin G, Majeed M, Giagulli C et al.:Chemokines trigger immediate β2 integrin affinity and mobility changes:differential regulation and roles in lymphocyte arrest under flow. Immunity 13:759-769, 2000.
 
45) Shimonaka M, Katagiri K, Nakayama T et al.:Rapl translates chemokine signals to integrin activation, cell polarization and motility across vascular endotheliu under flow. J. Cell. Biol. 161:417-427, 2003.
 
46) Ilic D, Furuta Y, Kanazawa S et al.:Reduced cell motility and erlharlced forcal adhesion contact formation in cells from FAK-deficient mice. Nature 377:539-544, 1995.
 
47) Feniger-Barish R, Yron I, Meshel T et al.:IL-8-induced migratory responses through CXCRI and CXCR2:association with phosphorylation and cellular redistribution of focal adhesion kinase. Biochemistry 42:2874-2886, 2003.
 
48) Davis CB, Dikic I, Unutmaz D et al.:Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. J. Exp. Med. 186:1793-1798, 1997.
PubMed
49) 沖垣光彦:マクロファージの形態および遊走機能におけるPYK2の不可欠な役割. 第23回日本分子生物学会年会講演要旨集, 2000.
 
50) Knall C et al.:Proc. Natl. Acad. Sci. USA 94:3052-3057, 1997.
PubMed
51) Huang C, Rajfur Z, Borchers C et al.:JNK phosphorylates paxillin and regulates cell migration. Nature 424:219-223, 2003.
PubMed
52) Kehrl JH:Heterotrimeric G protein signaling:roles immmune function and fine-tuning by RGS proteins. Immunity 8:1-10, 1998.
 
53) Daub H, Weiss F U, Wallasch C et al:Role of transactivation of the EGF receptor in signaling by G-protein-coupled receptors. Nature 379:557-560, 1996.
PubMed
54) Prenzel N, Zwick E, Daub H et al:EGF receptor transactivation by G-protein-coupled receptors requires methalloproteinase cleavage of proHB-EGF. Nature 402:884-888, 1999.
 
55) Dairaghi DJ, Soo KS, Oldham ER et al:RANTES-induced T cell activation correlates with CD3 expression. J. Immurlol. 160:426-433, 1998.
PubMed
56) Taub DD, Turcovski-Corrales SM, Key ML et al.:Chemokines and T lymphocyte activation. J. Immunol. 156:2095-2103, 1996.
 
57) Nanki T, Lipsky PE:Strornal cell-derived factor-1 is acostimulator for CD4+T cell activation. J. Immunol. 164:5010-5014, 2000.
PubMed
58) Tilton B, Ho L, Oberlin E et al:Signal transduction by CXC chemokine receptor 4:stromal cell-derived factor 1 stimulatesprolonged protein kinase B and extracellular signal regulated kinase 2 activation in T lymphocytes. J. Exp. Med. 192:313-324, 2000.
 
59) Bacon KB, Szabo MC, Yssel H et al.:RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells. J. Exp. Med. 184:873-882, 1996.
 
60) Haino M, Sawanobori Y, Matsushima K:Submitting, 2003.
 
61) Luther SA, Cyster JG:Chemokines as regulators of T cell differentiation. Nat. Immunol. 2:102-107, 2001.
PubMed
62) Gu L, Tseng S, Horner RM et al.:Control of Th2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404:407-411, 2000.
PubMed
63) Karpus WJ, Lukacs NW, Kennedy KJ et al.:Differential CC chemokine-induced enhancement of T helper cell cytokine production. J. Immunol 158:4129-4136, 1997.
PubMed
64) 灰野 誠・他:7回膜貫通型受容体研究の新展開. 医学のあゆみ別冊. 2001, p247-251.
 
P.524 掲載の参考文献
1) Baggiolini M, Dewald B, Moser B:Human chemokines:an update. Annu. Rev. Immunol 15:675-705, 1997.
PubMed
2) Murphy PM, Baggiolini M, Charo IF et al.:International union of pharmacology XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52:145-176, 2000.
PubMed
3) Mukaida N:Interleukin-8:an expanding universe beyond neutrophil chemotaxis and activation. Int. J. Hematol 72:391-398, 2000.
PubMed
4) Xu L, Xie K, Mukaida N et al.:Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res. 59:5822-5829, 1999.
PubMed
5) Kitadai Y, Haruma K, Mukaida N et al.:Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin. Cancer Res. 6:2735-2740, 2000.
PubMed
6) Karin M, Ben-Neriah Y:Phosphorylation meets ubiquitination:the control of NF-κB activity. Annu. Rev. Immunol. 18:621-663, 2000.
 
7) Mukaida N, Morita M, Ishikawa Y et al.:Anovel mechanism of glucocorticoid-mediated gene repression:nuclear factor-κB is the target for glucocorticoid-mediated interleukin-8 gene repression. J. Biol. Chern. 269:13289-13295, 1994.
 
8) Oliveira IC, Mukaida N, Matsushima K et al.:Transcriptional inhibition of interleukin-8 gene by interferon is mediated by the NF-κB site. Mol. Cell. Biol. 14:5300-5308, 1994.
 
9) Barboric M, Nissen RM, Kanazawa S et al.:NF-κB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol. Celi. 8:327-337, 2001.
 
10) Zharlg H, Sheherd AT, Eason DD et al:Retinoblas-toma protein expression leads to reduced Oct-1 and DNA binding activity and enhances interleukin-8 expression. Cell. Growth Differ. 10:457-465, 1999.
 
11) lguchi A, Kitajima l, Yamakuchi M et al.:PEA3 and AP-1 are required for constitutive IL-8 gerle expression in hepatoma cells. Biochem. Biophys. Res. Commun. 279:166-171, 2000.
 
12) Polakis P:Wnt signaling and cancer. Genes Dev. 14:1837-1851, 2000.
PubMed
13) Levy L, Neuveut C, Renard C-A et al.:Transcriptional activation of interleukin-8 byB-catenin-Tcf4. J. Bio. Chem. 277:42386-42393, 2002.
 
14) Anisowicz A, Messineo M, Lee SW et al, :An NF-rc B-like transcription factor mediates IL-1/TNF-ainduction of gro in human fibroblasts. J. Immunol. 147:520-527, 1991.
 
15) Wood LD, Farmer AA, Richmond A:HMGI (Y) and Spl in addition to NF-κB regulate transcription of the MGSA/Groagene. Nucleic. Acid Res. 23:4210-4219, 1995.
 
16) Nirodi C, NagDas S, Gygi SP et al.:Arole for poly (ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activitiy (CXCL1) gerle expression. J. Biol Chem. 276:9366-9374, 2001.
 
17) Devalaraja MN, Wang DZ, Ballard DW et al.:Elevated constitutive IκB kinase activity and lκB-aphospho-rylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-atranscription. Cancer Res. 59:1372-1377, 1999.
 
18) Nirodi C, Hart J, Dhawan P et al:The role of CDP in the negative regulation of CXCLl gene expression. J. Biol. Chem. 276:26122-26131, 2001.
 
19) Luster AD, Unkeless JC, RavetchJV:Gamma-interfer on transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315:672-676, 1985.
 
20) Luster AD, RavetchJV:Genomic characterization of a gamma-interferon-inducible gene (IP-10) and identification of an interferon-inducible hypersensitive site. Mol. Cell. Biol. 7:3723-3731, 1987.
PubMed
21) Majumder S, Zhou LZ, Chaturverdi P et al.:p48/STAT-1α-containing complexes play a predominant role in induction of IFN-γ-inducible protein, 10kDa (IP-10) by IFN-γ alone or in synergy with TNF-a. J. Immunol. 161:4736-4744, 1998.
 
22) Ohmori Y, Hamilton TA:Cooperative interaction between interferon (IFN) stimulus response element andκB sequence motifs controIs IFNγ-and lipopolysac-charide-stimulated transcription from the murine IP-10 promoter. J. Biol. Chem. 268:6677-6688, 1993.
 
23) Wu C, Ohmori Y, Bandyopadhyay S et al.:Interferon-stimulated response element and NF-κB sites to cooperate to regulate double-stranded RNA-induced transcription of the IP-10 gene. J. Interferon Res. 14:357-363, 1994.
 
24) Rollins BJ, Morrison ED, Stiles CD:Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc. Natl. Acad. Sci. USA 85:3738, 1988.
 
25) Rollins BJ, Yoshimura T, Leonard EJ:Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am. J. Pathol. 136:1229-1233, 1990.
PubMed
26) Ueda A, Okuda K, Ohno S et al.:NF-κB and Spl regulates transcription of the human monocyte chemoat-tractant protein-1gene. J. Immunol. 153:2052-2063, 1994.
 
27) Ueda A, Ishigatsubo Y, Ohkubo T et al.:Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. J. Biol. Chem. 272:31092-31099, 1997.
 
28) Mori N, Ueda A, Iseda S et al.:Human T-cell leukemia virus type I Tax activates transcription of the human monocyte chemoattractant protein-1 gene through two nuclear factor-κB sites. Cancer Res. 60:4939-4045, 2000.
 
29) Ueno M, Sonoda Y, Funakoshi M et al:Differential induction of JE/MCP-1 in subclones from a murine macrophage cell line, RAW254. 7:Role ofκB binding site protein. Cytokine 12:207-219, 2000.
 
30) Toney LM, Cattoretti G, Graf JA et al.:BCL-6 regulates chemokine gene transcription in macrophages. Nat. Immunol. 1:214-220, 2000.
PubMed
31) Sridhar P, Liu Y, Chin LD et al.:Platelet-derived growth factor-stimulated expression of the MCP-1 immediate early gene involves an inhibitory multiprotein complex. Mol. Cell. Biol. 19:4219-4230, 1999.
 
32) NeIson PJ, Kim HT, Manning WC et al.:Genomic organization and transcriptional regulation of the RANTES chemokine gene. J. Immunol 151:2601-2612, 1993.
 
33) Boehlk S, Fessele S, Mojaat A et al.:ATF and Jun transcription factors, acting through Ets/CRE promoter module, mediate lipopolysaccharide inducibility of the chemokine RANTES in monocyteic Mono Mac 6 cells. Eur. J. Ilnmunol. 30:1102-1112, 2000.
PubMed
34) NeIson pJ, Ortiz BD, Pattison JM et al.:Identification of a novel regulatory region critical for expression of the RANTES chemokine in activated T lymphocytes. J. Immunol. 157:1139-1148, 1996.
 
35) Song A, Chen Y-F, Thamatrkoln K et al.:RFLAT-1:a new zinc finger transcription factor that activates RANTES gene expression in T lympllocytes. Immunity 10:93-103, 1999.
 
36) Nikolcheva T, Pyrolment S, Chou S et al.:A translational rheostat for RFLAT-1 regulates RANTES expression in T lymphocytes. J. CUn. Invest. 110:119-126, 2002.
 
37) Rankin SM, Conroy DM, Williams TJ:Eotaxin and eosinophil recruitment:imp1ications for humandisease. Mol. Med. Today 6:20-27, 2000.
 
38) Matsukura S, Stellato C, Plitt JR et al.:Activation of eotaxin gene transcription by NF-κB and STAT-6 in human airway epithelial cells. J. Immunol. 163:6876-6883, 1999.
 
39) Huber MA, Denk A, Peter RU et al.:The IKK/1κBa/NF-κB pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in IκBα-deficient mice. J. Biol. Chem. 277:1268-1275, 2002.
 
40) Mathew A, MacLean JA, DeHaan E et al.:Signal transducer and activator of transcription 6 controIs chemokine production and T helper cell trafficking in allergic pulmonary inflammation. J. Exp. Med. 193:1087-1096, 2001.
 
41) Sugita S, Kohno T, Yamamoto K et al:Induction of macrophage protein-3α gene expression by TNFdependent NF-κB activation. J. Immunol 168:5621-5628, 2002.
 
42) Imaizumi Y, Sugita S, Yamamoto K et al.:Human T cell leukemia virus type-I Tax activates human macrophage inflammatory protein-3a/CCL20 genetranscription via the NF-κB pathway. Int. Immunol. 14:147-155, 2002.
 
43) Fuj iie S, Hieshima K, Izawa D et al.:Proinflammatory cytokines induce liver and activation-regulated chemokine/macrophage inflammatory protein-3a/CCL20 in mucosal epithelial cells through NF-κB[correction of NK-κB]. Int. Immunol. 13:1255-1263, 2001. Erratum in:Int. Immunol. 13:1443, 2001.
 
44) Kwon JH, Keates S, Simeonidis S et al.:ESE-1, an enterocyte-specific Ets transcription factor, regulates MIP-3agene expression in Caco-2 human colonic epithelial cells. J. Biol. Chem. 278:875-884, 2003.
PubMed
45) Hiroyama T, Iwama A, N akamura Y et al.:Fractalkine shares signal sequerlce with TARC:gene structures and expression profiles of two chemokine genes. Genomics 75:3-5, 2001.
 
46) Niu H:The proto-oncogene BCL-6 in normal and malignant B cell development. Hematol Oncol. 20:155-166, 2002.
PubMed
47) Schaffer A, Yu X, He Y et al.:BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13:199-212, 2000.
 
48) Shiraishi K, Fukuda S, Mori T et al.:Identification of fractalkine, a CX3C chemokine, as a direct target of p53. Cancer Res. 60:3722-3726, 2000.
PubMed

神経 : 内分泌・免疫相関

P.543 掲載の参考文献
1) 深田順一:免疫系と内分泌系の相関. 最新内科学大系 12, 間脳・下垂体疾患(井村裕夫・他編). 中山書店, 東京, 1993, p17-24.
 
2) 深田順一:神経・免疫・内分泌相関. 最新内科学体系 2, 科学としての内科学(井村裕夫・他編). 中山書店, 東京, 1997, p253-261.
 
3) Fulkata J, Imura H, Nakao K:Cytokines as mediators in the regulation of the hypothalamic-pituitary-adrenal function. J. Endocrinol. Invest. 17:141-155, 1994.
 
4) 深田順一:生殖生理と免疫-間脳・下垂体-. 図説産婦人科VIEW. メジカルビュー社, 1997, p11-21.
 
5) 森 崇英, 福岡正恒:性腺とサイトカイン. 内分泌・糖尿病科 3:56-62, 1996.
 
6) Hughes TK, Cadet P, Rady PL et al.:Evidence for the production and action of interleukin-10 in pituitary cells. Cell. Mol. Neurobiol. 14:59-69, 1994.
PubMed
7) 深田順一:副腎とサイトカイン-その相互作用のメカニズムについて-. 内分泌・糖尿病科 3:1-8, 1996.
 
8) Hobisch A, Eder IE, Putz T:Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 58:4640-4645, 1998.
PubMed
9) Yang L, Wang L, Lin HK:Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem. Biophys. Res. Commun. 305:462-469, 2003.
 
10) Morale MC, Batticane N, Gallo F, Barden N, Marchetti B:Disruption of hypothalamic-pituitary-adrenocortical system in transgenic mice expressing type II glucocorticoid receptor antisense ribonucleic acid permanently impairs T cell responsiveness during postnatal development. Endocrinology 136:3949-3960, 1995.
PubMed
11) Sternberg EM, Young WS 3d, Bernardini R et al.:A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc. Natl. Acad. Sci. USA 86:4771-4775, 1989.
 
12) Blalock JE:The immune system as a sensory organ. J. Immunol. 132:1067-1070, 1984.
 
13) Kruszewska B, Felten SY, Moynihan JA:Alteration in cytokine and antibody production following chemical sympathectomy in two strains of mice. J. Immmol. 155:4613-4620, 1995.
 
14) 海塚安郎, 堀 哲郎:脳による免疫系の修飾-条件付け-. 神経内分泌免疫学(井村裕夫・他編). 朝倉書店, 東京, 1993, p90-94.
 
15) 深田順一:サイトカインと副腎機能. 内分泌・糖尿病科 1:216-226, 1995.
 
16) Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP:Effects of glucocorticoids and cate-cholamines on human interleukin(IL)-12 and IL-10 production:implications for the effects of stress on immunity. The 10th International Congress of Endocrinology, June 12-15, 1996. San Francisco Abstract＃OR33-6, 1996.
 
17) Karalis K, Sano H, Redwine J et al.:Autocrine or paracrine inflammatory actions of corticotropin-releasing hormonein vivo. Science 254:421-423, 1991.
PubMed
18) Licinio J, Gold PW, Wong M-L:Amolecular mechanism for stress-induced alterations in susceptibility to disease. Larlcet 346:104-106, 1995.
 
19) Dunn AJ:Cytokine activation of the HPA axis. Ann. NY Acad. Sci. 917:608-617, 2000.
PubMed
20) Matsuoka Y, Furuyashiki T, Bito H et al.:Impaired adrenocorticotropic hormone response to bacterial endotoxin in mice deficient in prostaglandin E receptor EPI and EP3 subtypes. PNAS 100:4132-4137, 2003.
 
21) Pauli S, Linthorst AC, Reul JM:Tumour necrosis factor-alpha and interleukin-2 differentially affect hippocampal serotonergic neurotransmission, behavioural activity, body temperature and hypothalamic-pituitary-adrenocortical axis activity in the rat. Eur. J. Neurosci. 10:868-878, 1998.
PubMed
22) Hillhouse EW:Interleukin-2 stimulates the secretion of arginine vasopressin but not corticotropin-releasing hormone from rat hypothalamic cells in vitro. Brain Res. 650:323-325, 1994.
 
23) Weber MM, Michl P, Auernhammer CJ:Interleukin-3 and interleukin-6 stimulate cortisol secretion from adult human adrenocortical cells. Endocrinology 138:2207-2210, 1997.
PubMed
24) Smith EM, Cadet P, Stefano GB:IL-10 as a mediator in the HPA axis and brain. J. Neuroimmunol. 100:140-148, 1999.
 
25) Chesnokova V, Melmed S:Leukemia inhibitory factor mediates the hypothalamic pituitary adrenal axis response to inflarnmation. Endocrinology 141:4032-4040, 2000.
PubMed
26) Isidori AM, Kaltsas GA, Korbonits M et al.:Response of serum macrophage migration inhibitory factor levels to stimulation or suppression of the hypothalamo-pituitary-adrenal axis in normal subjects and patients with Cushing's disease. J. Clin. Endocrinol. Metab. 87:1834-1840, 2002.
PubMed
27) Fingerele-Rowson G, Koch P, Bikoff R et al.:Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo Am. J. Pathol. 162:47, 2003.
PubMed
28) Koebernick H, Grode L, David JR:Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 99:13681-13686, 2002.
 
29) Benigni F, Atsumi T, Calandra T:The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J. Clin. Invest. 106:1291-1300, 2000.
PubMed
30) Horai R, Asano M Sudo K et al.:Production of mice deficient in genes for interleukin (IL)-1 alpha, IL-1 beta, IL-1 alpha/beta, and IL-1 receptor antagorlist shows that IL-1 beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187:1463-1475, 1998.
 
31) Fantuzzi G, Sacco S, Ghezzi P et al:Physiological and cytokine responses in IL-1 beta-deficient mice after zymosan-induced inflammation. Am. J. Physiol 273:R400-R406, 1997.
PubMed
32) Alheim K, Chai Z, Fantuzzi G et al.:Hyperresponsive febrile reactions to interleukin (IL)-1 alpha and IL-1 beta, and altered brain cytokine mRNA and serum cytokine levels, in IL-1 beta-deficient mice. Proc. Natl. Acad. Sci. USA 94:2681-2686, 1997.
 
33) Kozak W, Kluger MJ:IL-6 and IL-1 beta in fever. Studies using cytokine-deficient (knockout) mice. Ann. NY Acad. Sci. 856:33-47, 1998.
PubMed
34) Ebisui O, Fukata J, Murakami N et al.:Effect of IL-1 receptor antagonist and antiserum to TNF-alpha on LPS-induced plasma ACTH and corticosterone rise in rats. Am. J. Physiol. 266:E986-992, 1994.
 
35) Turnbull AV, Prehar S, Kennedy AR et al.:Interleukin-6 is an afferent signal to the hypothalamo-pituitary-adrenal axis during local inflammation in mice. Endocrinology 144:1894-1906, 2003.
 
36) van Enckevort FH, Sweep CG, Span PN et al.:Reduced adrenal response to bacterial lipopolysaccharide in interleukin-6-deficient mice. J. Endocrinol. Invest. 24:786-795, 2001.
PubMed
37) Manfredi B, Sacerdote P, Gaspani L et al.:IL6 knockout mice show modified basal immune functions, but normal immune responses to stress. Brain Behav. Immun. 12:201-211, 1998.
PubMed
38) Venihaki M, Dikkes P, Carrigan A et al.:Corticotropinreleasing hormone regulates IL-6 expression during inflammation. JCI 108:1159, 2001.
PubMed
39) Muglia LJ, Bethin KE, Jacobson L et al.:Pituitaryadrenal axis regulation in CRH-deficient mice. Endocrine Res. 26:1057-1066, 2000.
PubMed
40) Bethin KE, Vogt SK, Mugha LJ:Interleukin-6 is an essential, corticotrophin-releasing hormoneindependent stimulator of the adrenal axis during immune system activation. PNAS 97:9317-9322, 2000.
 
41) Akita S, Malkin J, Melmed S:Disrupted murine leukemia inhibitory factor (LIF) gene attenuates adrenocorticotropic hormone (ACTH) secretion. Endocrinology 137:3140-3143, 1996.
PubMed
42) Cooper MS, Stewart PM:Corticosteroid insufficiency in acutely ill patients. N. Engl. J. Med. 348:727-734, 2003.
PubMed
43) Shimomura I, Funahashi T, Matsuzawa Y:Significance of adipocytokine, fat-derived hormones, in metabolic syndrome Tanpakushitsu Kakusan Koso 47:1896-1903, 2002.
PubMed
44) Baumann H, Morella KK, White DW:The ful1-length leptin receptor has signaling capabilities of interleukin-6-type cytokine receptors. Proc. Natl. Acad. Sci. USA 93:8374-8378, 1996.
 
45) Yokota T, Oritani K, Takahashi I et al.:Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723-1732, 2000.
PubMed
46) Hotamisligil GS, Spiegelman BM:Tumor necrosis factora:Akey component of the obesity-diabetes link. Diabetes 43:127+1278, 1994.
 
47) Uysal KT Wiesbrock SM, Marino MW et al.:Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610, 1997.
PubMed
48) Schreyer SA, Chu SC, LeBoeuf RC:Obesity and diabetes in TNF-areceptor-deficient mice. J. Clin. Invest. 102:402-411, 1998.
 
49) Paquot N, Castillo MJ, Lefebvre PJ et al.:No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor:Fc fusion protein in obese insulin-resistant patients. J. Clin. Endocrinol. Metab. 85:1316, 2000.
PubMed
50) Hill AG, Jacobson L, Gonzalez J et al.:Chronic central nervous system exposure to interleukin-lbeta causes catabolism in the rat. Am. J. Physiol 271:R1142-1148, 1996.
 
51) Meier CA, Bobbioni E, Gabay C et al.:IL-1 receptor antagonist serum levels are increased in human obesity:apossible link to the resistance to leptin? J. Clin. Endocrinol. Metab. 87:1184, 2002.
 
52) Ueland T, Kristo C, Godang K et al:Interleukin-1 receptor antagonist is associated with fat distribution in endogenous Cushing's syndrome:alongitudinal study. J. Clin. Endocrinol. Metab. 88:1492-1496, 2003.
 
53) Luheshi GN, Gardner JD, Rushforth DA et al.:Leptin action on food intake and body temperature are mediated by IL-1. Proc. Natl. Acad. Sci. USA 96:7047-7052, 1999.
PubMed
54) Wallenius V, Wallenius K, Ahren B et al.:Interleukin-6-deficient mice develop mature-onset obesity. Nature Med. 8:75-79, 2002.
PubMed
55) Li G, Klein R, Matheny M et al.:Induction of uncoupling Protein l by central interleukin-6 gene delivery is dependent on sympathetic innervation of brown adipose tissue and underlies one mechanism of body weight reduction in rats. Neuroscience 116:879-889, 2002.
 
56) Lambert PD, Anderson KD, Sleeman MW et al.:Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc. Natl. Acad, Sci. USA 98:4652-4657, 2001.
PubMed
57) Masu Y, Wolf E, Holtmann B et al.:Disruption of the CNTF gene results in motor neuron degeneration. Nature 365:27-32, 1993.
PubMed
58) Straczkowski M, Dzienis-Straczkowska S, Stepien A et al.:Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J. Clin. Endocrinol. Metab. 87:4602, 2002.
PubMed
59) Esposito K, Pontillo A, Guigliano F:Association of low interleukin-10 levels with the metabolic syndrome in obese women. J. Clin. Endocrinol. Metab. 88:1055-1058, 2003.
 
60) Pinderski Oslund LJ. Hedrick CC et al.:Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 19:2847, 1999.
 
61) Mallat Z, Heymes C, Ohan J et al.:Expression of interleukin-10 in advanced human atherosclerotic plaques:relation to inducible nitric oxide synthase expression and cell death. Atheroscler. Thromb. Vasc. Biol. 19:611-616, 1999.
 
62) Alvarez B, Carbo N, Lopez-Soriano J et al.:Effects of interleukin-15 (IL-15) on adipose tissue mass inrodent obesity modeIs:evidence for direct IL-15 action on adipose tissue. Biochem. Biophys. Acta 1570:33-37, 2002.
 
63) Deboer T, Fontana A, Tobler I et al.:Tumor necrosis factor (TNF) ligand and TNF receptor deficiency affects sleep and the sleep EEG. J. Neurophysiol. 88:839-846, 2002.
PubMed
64) Ershler WB, Keller ET:Age-associated increased interleukin-6 gene expression, late-life disease, and frailty. Annu. Rev, Med. 51:245-270, 2000.
PubMed
65) Vgontzas AN, Zoumakis M, Bixler EO et al.:Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels:physiologic and therapeultic irnplications. J. Clin. Endocrinol. Metab. 88:2087-2095, 2003.
PubMed
66) Boyle WJ, Simonet WS, Lacey DL:Osteoclast differentiatiorl and activation. Nature 423:337-342, 2003.
PubMed
67) Kong Y-Y, Yoshida H, Saosi I et al.:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999.
 
68) Collin-Osdoby P, Rothe L, Anderson F et al.:Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 276:20659-20672, 2001.
PubMed
69) Palmqvist P, Persson E, Conaway HH:IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J. Immunol. 169:3353-3362, 2002.
PubMed
70) Jilka RL, Hangoc G Girasole G et al.:Increased osteoclast development after estrogen loss:mediation by interleukin-6. Science 257:88-91, 1992.
PubMed
71) Bellido T, Jilka RL, Boyce BF et al:Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J. Clin. Invest. 95:2886-2895, 1995.
PubMed
72) Dai J, Lin D, Zang J et al:Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. J. Clin. Invest. 106:887-895, 2000.
 
73) Ogata Y, Kukita A, Kukita T et al.:A novel role of IL-15 in the development of osteoclasts:inability to replace its activity with IL-2. J. Immunol. 162:2754-2760, 1999.
PubMed
74) Weitmann MN, Cenci S, Rifas L et al.:Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogerlic cytokines. Blood 96. 1873-1878, 2000.
 
75) Takayanagi H, Kim S, Matsuo K et al:RANKL maintains bone homeostasis through c-Fosdependent induction of IFN-B. Nature 416:744-749, 2002.
 
76) Tak PP, Hart BA, Kraan MC et al.:The effects of interferon beta treatment on arthritis. Rheumatology 38:362-369, 1999.
PubMed
77) Takayanagi H, Ogasawara K, Hida S et al.:Tcellmediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-γ. Nature 416:744-749, 2002.
 
78) Khapli SM, Mangashetti LS, Yogesha SD et al.:IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappaB ligandinduced osteoclast differentiation by diverting the cells to macrophage lineage. J. Immunol. 171:142-151, 2003.
PubMed
79) Moreno JL, Kaczmarek M, Keegan AD et al.:IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism:irreversible inhibition of the differentiation program activated by RANKL. Blood 102:1078-1086, 2003.
PubMed
80) Horwood NJ, Elliott J, Martin TJ et al.:IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J, Immunol. 166:4915-4921, 2001.
 
81) Udagawa N, Horwood NJ, Elliott J:Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J. Exp. Med. 185:1005-1012, 1997.
 
82) Dovio A, Sartori ML, Masera RG et al:Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. J. Endocrinol. 177:109, 2003.
 
83) Takeuchi Y, Watanabe S, Ishii G et al.:Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J. Biol Chem. 277:49011-49018, 2002.
PubMed
84) Arron JR, Choi Y:Bone versus immune system. Nature 408:535-536, 2000.
PubMed
P.553 掲載の参考文献
1) Kalra SP, Dube MG, Pu S et al.:Interacting appetiteregulating pathways in the hypothalamic regulation of body weight. Endocr. Rev. 20:68-100, 1999.
PubMed
2) Kask A, Harro J, von HS et al.:The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci. Biobehav. Rev. 26:259-283, 2002.
 
3) Navellhan P, Hassanl H, Lucas G et al:Redused antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature 409:513-517, 2001.
 
4) Felten DL, Felten SY, CarIson SL et al.:Noradrenergic and peptidergic innervation of lymphoid tissue. J. Immunol. 135:755-765, 1985.
 
5) Kohm AP, Sanders VM:Norepinephrine and beta2-adrenergic receptor stimulation regulate CD4+T and Blymphocyte function in vitro and in vivo. Pharrnacol Rev. 53:487-525, 2001.
 
6) Michel MC, Beck-Sickinger A, Cox H et al.:International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 50:143-150, 1998.
PubMed
7) Lundberg JM:Pharmacology of cotransmission in the autonomic nervous system:Integrative aspects on amines, neuropeptides, adenosinetriphosphate, amino acids and nitric oxide. Pharmacol. Rev. 48:113-178, 1996.
 
8) Irwin M et al:Neuropeptide Y and natural killer cell activity:findings in depression and Alzheimer caregiver stress. FASEB J. 5:3100-3107, 1991.
PubMed
9) Kawamura N, Tamura H, Obana S et al.:Differential effects of neuropeptides on cytokine production by mouse helper T cell subsets. Neuroimmunomodulation 5:9-15, 1998.
PubMed
10) Straub RH, Schaller T, Miller LE et al.:Neuropeptide Y cotransmission with norepinephrine in the sympathetic nerve-macrophage interplay. J. Neurochem. 75:2464-2471, 2000.
PubMed
11) Dunzendorfer S, Meierhofer C, Wiedermann CJ:Signaling in neuropetide-induced migration of human eosinophils. J. Leuk. Biol 64:828-834, 1998.
 
12) Hauser GJ, Myers AK, Dayao EK et al.:Neuropeptide Y infusion improves hemodynamics and survival in rat endotoxicshock. Am. J. Physiol. 265:1416-1423, 1993.
 
13) Dimitrijevic M, Stanoj evic S, Vujic V et al.:Effect of neuropeptide Y on inflammatory paw edema in the rat:involvement of peripheral NPY YI and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26). J. Neuroimmunol 129:35-42, 2002.
 
14) Bedoui S, Kawamura N, Straub RH et al:Relevance of neuropeptide Y for the neuroimmune crosstalk. J. Neuroimmunol. 134:1-11, 2003.
PubMed
15) Brain SD, Williams TJ, Tippins JR et al.:Calcitonin gene-related peptide is a potent vasodilator. Nature 313:54-56, 1985.
PubMed
16) Woolf C, Wiesenfeld-Hallin Z:Substance P and calcitonin gene-related peptide synergistically modulate the gain of the nociceptive flexor withdrawal reflex in the rat. Neurosci. Lett. 66:226-230, 1986.
PubMed
17) Stangl D, Muff R, Schmolch C et al.:Photoaffinity labeling of rat calcitonin gene-related peptide receptors and adenylate cyclase activation:identification of receptor subtypes. Endocrinology 132:744-750, 1993.
PubMed
18) Rosenfeld SG, Jonas V, Rosenfeld MG et al.:Alternative RNA processing calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240-244, 1982.
 
19) Tran Q, Roesser JR:SRp55 is regulater of calcitonin/CGRP alternative RNA spllcing. Biochemistry 42:951-57, 2003.
 
20) HoPPener JW, Steenbergh PH, Zandberg J et al.:The second human calcitonin/CGRP gene is located on chromosome 11. Hum. Genet. 70:259-263, 1985.
PubMed
21) Katafuchi T, Kikumoto K, Hamano K et al.:Calcitonin receptor-stimulating peptide, a new member of the calcitonin gene-related peptide family. J. Biol. Chem. 278:12046-12054, 2003.
PubMed
22) McLatchie LM, Fraser NJ, Main MJ et al.:RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333-339, 1998.
PubMed
23) Miyauchi K, Tadotsu N, Hayashi T et al.:Molecular cloning and characterization of mouse calcitonin gene-related peptide receptor. Neuropeptides 36:22-33, 2002.
PubMed
24) Lazar P, Reddington M, Streit W et al:The action of calcitonin gene-related peptide on astrocyte morphology and cyclic AMP accumulation in astrocyte cultures from neonatal rat brain, Neurosci. Lett. 130:99-102, 1991.
PubMed
25) Evans BN, Rosenblatt MI, Mnayer Lo et al.:CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adreno-medullin receptors. J Biol. Chem. 275:31438-31443, 2000.
 
26) Chauhan M, Thota CS, Kondapaka S et al.:Evidence for the existerlce of a new receptor for CGRP, which is not CRLR. Peptides 24:65-71, 2003.
 
27) Barnes PJ:Neurogenic inflammation and asthma. J. Asthma 29:165-180, 1992.
PubMed
28) Tokoyoda K, Tsujikawa K, Ono Y et al.:Up-regulation of IL-4 production by the activated cAMP/PKA pathway in CD3/CD28-stimulated naive Tcells. (submitted) 2003.
 
29) Hosoi J, Murphy GF, Egan CL et al.:Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature 363:159-163, 1993.
PubMed
30) Carucci JA, Ignatius R, Wei Y et al.:Calcitonin gene-related pepitide decreases expression of HLA-DR and CD86 by human dendritic cells and dampens dendritic cell-driven T cell-proliferative responses via the type I calcitonin gene-related peptide receptor. J. Immunol 164:3494-3499, 2000.
 
31) Liu J, Chen M, Wang X:Calcitonin gene-related peptide inhibits lipopolysaccharide-induced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway. Immunology 101:61-67, 2000.
 
32) Aoki-Nagase T, Nagase T, Oh-Hashi Y et al.:Attenuation of antigen-induced airway hyper-responsiveness in CGRP-deficient mice. Am. J. Physiol. Lung. Cell. Mol. Physiol. 283:963-970, 2002.
 
33) Delgado M, Ganea D:Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro abd in vivo. J. Immunol 167:966-975, 2001.
 
34) Harmar A, Arimura A, Gozes I et al:Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating Polypeptide (PACAP) . Pharmacol Rev. 50:265-270, 1998.
PubMed
35) Busto R, Carrero I, Bodega G et al.:Immunohisto-chemical and immunochemical evidence for expression of human lung PACAP/VIP receptors. Ann. NY Acad. Sci. 921:308-311, 2000.
 
36) Lara-Marquez M, O'Dorisio M, 0'Dorisio T et al.:Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Immunol 166:2522-2530, 2001.
 
37) Delgado M, Munoz-Elias EJ, Martinez C et al.:VIP and PACAP modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines. Ann. NY Acad Sci. 897:401-410, 1999.
PubMed
38) Delgado M, Munoz-Elias EJ, Gomariz RP et al.:Vasoactive intestinal peptide and pituitary adenylate cyclase-activating Polypeptide enhance IL-10 production by murine macrophages:in vitro and in vivo studies. J. Immunol. 162:1707-1716, 1999.
PubMed
39) Martinez C, Delgado M, Pozo D et al.:Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J. Leuk, Biol. 63:591-601, 1998.
 
40) Delgado M, Ganea D:Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit IL-12 transcription by regulating NFκB and Ets activation. J. Biol. Chem. 274:31930-31940, 1999.
 
41) Delgado M, Munoz-Elias EJ, Kan Y et al.:Vasoactive intestinal peptide and pituitary adenylate cyclaseactivating polypeptide inhibit TNFatranscriptional activation by regulating NF-κB and CREB/c-jun. J. Biol. Chem. 273:31427-31436, 1998.
 
42) Delgado M, Sun W, Leceta J et al.:VIP and PACAP dufferentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7. 1 and B7. 2 expression. J. Immunol 163:4213-4223, 1999.
PubMed
43) Delgado M, Leceta J, Gomariz RP et al.:VIP and PACAP stimulate the induction of Th2 responses by upregulating B7. 2 expression. J. Immunol. 163:3629-3635, 1999.
PubMed
44) Voice JK, Dorsam G, Lee H et al.:Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J. 15:2489-2496, 2001.
PubMed
45) Goetzl EJ, Voice JK, Shen S et al.:Enhanced delayedtype hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide. Proc. Natl. Acad. Sci. USA 98:13854-13859, 2001.
PubMed
46) Delgado M, Martinez C, Pozo D et al.:Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclaseactivating polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNFa and IL-6. J Immunol. 162:1200-1205, 1999.
PubMed
47) Delgado M, Abad C, Matinez C et al.:Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7:563-568, 2001.
 
48) Takeba Y, Suzuki N, Kaneko A et al.:Evidence for neural regulation of inflammatory synovial cell functions by secreting calcitonin gene-related peptide and vasoactive intestinal peptide in patients with rheumatoid arthritis. Arthritis Rheum. 42:2418-2429, 1999.
PubMed
49) Regoli D, Boudon A, Fauchere JL:Receptors and antagonist's for substance P and related peptides. Pharmacol. Rev. 46:551-594, 1994.
 
50) Rameshwar P, Gascon P, Ganea D:Stimulation of IL-2 production in murine lymphocytes by substance-P and related tachykinins. J. Immunol. 151:2484-2496, 1993.
PubMed
51) Lambrecht BN, Germonpre PR, Everaert EG et al.:Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur J Immunol. 29:3815-3825, 1999.
PubMed
52) Kincy-Cain T, Bost KL:Substance P-induced IL-12 production by murine macrophages. J. Immunol 158:2334-2339, 1997.
PubMed
53) Van der Velden VH, Wierenga-Wolf AF, Adriaansen-Soeting PW et al.:Expression of aminopeptidase N and dipeptidyl peptidase IV in the healthy and asthmatic bronchus. Clin. Exp. Allergy 28:110-120, 1998.
PubMed
54) Blum AM, Metwali A, Cook G et al:Substance P modulates antigen-induced, IFN-γproduction in murine Schistosomiasis mansoni J. Immunol. 151:225-233, 1993.
 
55) Kaltreider HB, Ichikawa S, Byrd PK et al:Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung Parenchyma. Am. J. Respir. Cell Mol. Biol. 16:133-144, 1997.
 
56) Joos GF, Germonpre PR, PauweIs RA:Role of tachykinins in asthma. Allergy 554:321-337, 2000.
 
57) Lagente V, Advenier C:Tachykinins and airway function. Pulm. Pharmacol. Ther. 11:331-340, 1998.
 
58) Nenan S, Germain N, Lagente V et al.:Irlhibition ofinflammatory cell recruitment by the tachykinin NK3-receptor antagonist, SR 142801, in a murine model of asthma. Eur. J. Pharmacol. 421:201-205, 2001.
 
59) Reubi JC, Horisberger U, Kappeler A et al.:Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs. Blood 92:191-197, 1998.
PubMed
60) Thermos K:Functional mapping of somatostatin receptors in the retina:areview. Vision Res. 43:1805-1815, 2003.
 
61) Kagnoff MF, Eckmann L:Epithelial cells as sensors for microbial infection. J. Clin. Invest. 100:6-10, 1997.
PubMed
62) Jung HC, Eckmann L, Yang SK et al.:A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J. Clin. Invest. 95:55-65, 1995.
PubMed
63) Chowers Y, Cahalon L, Lahav M et al:Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha-and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. J. Immunol 1616165:2955-2961, 2000.
 
64) Yamamoto H, Morise K, Kusugami K et al.:Abnormal neuropeptide concentration in rectal mucosa of patients with inflammatory boweldisease. J. Gastroenterol 31:525-532, 1996.
 
65) Eliakim R, Karmeli F, Okon E et al.:Octreotide effectively decreases mucosal damage in experimental colitis. Gut 34:264-269, 1993.
PubMed
66) Bergeijk JD, Meeteren ME, Tak CJ et al.:Somatostatin does not attenuate intestinal injury in dextran sodium sulphate-induced subacute colitis. Mediators Inflamm. 7:169-173, 1998.
 
67) Teitelbaum DH, Del Valle J, Reyas B et al:Intestinal intraepithelial lymphocytes influence the production of somatostatin. Surgery 120:227-233, 1996.
PubMed
68) Aguila MC, Rodriguez AM, Aguila-Mansilla HN et al.:Somatostatin antisense oligodeoxynucleotide-mediated stimulation of lymphocyte proliferation in culture. Endocrinology 137:1585-1590, 1996.
PubMed
69) Blum AM, Metwali A, Mathew RC et al.:T iymphocytes in murine Schistosomiasis mansoni have somatostatin receptors and respond to somatostatin with decreased IFN-gamma secretion. J. Immunol 149:3621-3626, 1992.
 

生体内での主な役割

P.568 掲載の参考文献
1) Gresser I, Tovey MG, Bandu ME et al.:Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum I. Rapid evolution of encephalomyocarditis virus infection. J. Exp. Med. 144:1305-1315, 1976.
PubMed
2) Gresser I, Tovey MG, Maury C et al.:Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum H. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and infiuenza viruses. J. Exp, Med. 144:1316-1323, 1976.
 
3) Medzhitov R, Preston-Hurlburt P, Janeway CA Jr:A human homologue of the Drosphila Toll protein signaIs activation of adaptive immunity. Nature 388:394-397, 1997.
 
4) Takeda K, Kaisho T, Akira S:Toll-like receptors. Annu. Rev. Immunol. 21:335-376, 2003.
PubMed
5) Vasselon T, Detmer PA:Toll receptors:acentral element in innate immune responses. Infect. Immun. 70:1033-1041, 2002.
 
6) Takeuchi O, Hoshino K, Kawai T et al:Differential roles of TLR2 and TLR4 in recognition of Gram-positive and Gram-negative cell wall components. Immunity 11:443-451, 1999.
PubMed
7) Underhill DM, Ozinsky A, Smith KD et al.:Toll-like receptor 2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc. Natl. Acad. Sci. USA 96:14459-11463, 1999.
PubMed
8) Poltorak A, He X, Smirnova I et al.:Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice:mutation in T1r4 gene. Science 282:2085-2088, 1998.
 
9) Qureshi ST, Lariviere L, Leveque G et al.:Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (T1r4) . J. Exp. Med. 189:615-625, 1999.
 
10) Hayashi F, Smith KD, Ozinsky A et al.:The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099-1103, 2001.
PubMed
11) Hemmi H, Takeuchi O, Kawai T et ai.:A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745, 2000.
 
12) Alexopoulou L, Holt AC, Medzhitov R et al.:Recognition of double stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413:732-738, 2001.
 
13) Kurt-Jones EA, Popova L, Kwinn L et al.:Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol 1:398-401, 2000.
PubMed
14) Bieback K, Lien E, Klagge IM et al.:Hemagglutinin protein of wild-type measles virus activates Toll-like receptor 2 signaling. J. Virol. 76:8729-8736, 2002.
PubMed
15) Compton T, Kurt-Jones EA, Boehme KW et al.:Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J. Virol 77:4588-4596, 2003.
PubMed
16) Hemmi H, Kaisho T, Takeuchi O et al.:Small antiviral compounds activate immune cells via TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3:196-200, 2002.
PubMed
17) Oshimi H, Matsumoto M, Funami K et al.:TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-γ induction. Nat. Immunol. 4:161-167, 2003.
 
18) Yamamoto M, Sato S, Hemmi H et al.:Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301:640-643, 2003. www. sciencexpress. org/
 
19) Inohara N, Nufiez G:NODs:intracellular proteins involved in inflammation and apoptosis. Nat. Rev. Immunol. 3:371-382, 2003.
 
20) Chamaillard M, Hashimoto M, Horie Y et al.:An essential role for NODI in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol 4:702-707, 2003.
 
21) Girardin SE, Boneca IG, Carneiro LAM et al.:Nodl detects a unique muropeptide from Gram-negativebacterial peptidoglycan. Science 300:1584-1587, 2003.
 
22) Inohara N, Ogura Y, Fontalba A et al.:Host recognition of bacterial muramyl dipeptide mediated through NOD2:implications for Crohn's disease. J. Biol Chem. 278:5509-5512, 2003.
PubMed
23) Girardin SE, Boneca IG, Viala J et al:Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278:8869-8872, 2003.
PubMed
24) Ogura Y, Bonen DK, Inohara N et al.:Aframeshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-606, 2001.
 
25) Micell-Richard C, Lesage S, Rybolad M et al:CARD15 mutation in Blau syndrome. Nat. Genet. 29: 19-20, 2001.
 
26) Bouchon A, Dietrich J, Colonna M:Inflammatory responses can be triggered by TREM-1:anovel receptor expressed on neutrophils and monocytes. J. Immunol. 164:4991-4995, 2000.
 
27) Colonna M:TREMs in the immune system and beyond. Nat. Rev. Immunol. 3:445-453, 2003.
PubMed
28) Bouchon A, Facchetti F, Weigand MA et al.:TREM-1 amphfies inflammation and is a crucial mediator of septic shock. Nature 410:1103-1107, 2001.
PubMed
29) Daws MR, SuUam PM, Nieuri EC et al:Pattern recognition by TREM-2 binding of anionic ligands. J. Immunol 171:594-599, 2003.
 
30) Chensue SW:Molecular machinations:chemokine signaIs in host-pathogen interactions. Clin. Microbiol. Rev. 14:821-835, 2001.
PubMed
31) Peters W, Scott HM, Chambers HF et al.:Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 98:7958-7963, 2001.
PubMed
32) Kurihara T, Warr G, Loy J et al:Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med. 186:1757-1762, 1997.
PubMed
33) Lu B, Rutledge BJ, Gu L et al.:Abnormalities in monocyte recruitment and cytokine suppression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med 187:601-608, 1999.
 
34) Rutledge BJ, Rayburn H, Rosenberg R et al.:High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogen. J. Immunol 155:4838-4843, 1995.
PubMed
35) Cook DN, Smithies O, Strieter RM et al.:CD8+Tcells are a biologically relevant source of macrophage inflammatory protein-1 a in vivo J. Immunol 162:5423-5428, 1999.
 
36) Durr M, Peschel A:Chemokines meet defensins:the merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect. Immun. 70:6515-6517, 2002.
PubMed
37) Cooper AM, Magram J, Ferrante J et al.:Interleukin-12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis J. Exp. Med. 186:39-45, 1997.
 
38) Altare F, Durandy A, Lammas D et al:Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280:1432-1435, 1998.
 
39) De Jong, Altare F, Haagen I-A et al.:Severe mycobacterial and Salmonella enteritidis disseminated infections in interleukin-12 receptor-deficient patients. Science 280:1435-1438, 1998.
 
40) Altare F, Lammas D, Revy P et al:Irlherited interleukin-12 deficiency in a chnd with Bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. J. Clin. Invest. 102:2035-2040, 1998.
 
41) Brombacher F, Dorfmuller A, Magram J et al.:IL-12 is dispensable for innate and adaptive immunity against low doses of Listeriamonocytogenes. Int. Immunol. 11:325-332, 1999.
 
42) Cooper AM, Kipnis A, Turner J et al.:Mice lacking bioactive IL-12 can generate protective, antigenspecific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J. Immunol 168:1322-1327, 2002.
 
43) Oppmann B, Lesley R, Blom B et al.:Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities sirnilar as well as distlnct from IL-12. Immunity 13:715-725, 2000.
 
44) Aggarwal S, Ghilagdi N, Xie M-H et al.:Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278:1910-1914, 2003.
 
45) Pflanz S, Timans JC, Cheung J et al.:IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity 16:779-790, 2002.
PubMed
46) Chen Q, Ghilardi N, Wang H et al.:Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 407:916-920, 2000.
PubMed
47) Sugawara I, Yamda H, Kaneko H et al.:Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect. Immun. 67:2585-2589, 1999.
 
48) Seki E, Tsutsui H, Tsuji NM et al.:Critical roles of rnyeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice. J. Immunol. 169:3863-3868, 2002.
PubMed
49) Kinjo Y, Kawakami K, Uezu K et al.:Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis:a cornparative study with IL-12p40. J. Immunol. 169:323-329, 2002.
PubMed
50) Neighbors M, Xu X, Barrat FJ et al.:Acritical role for interleukin 18 in primary and memory effector responses toListeria monocytogenes that expands beyond in effects on interferon γ production. J. Exp. Med. 194:343-354, 2001.
 
51) Cooper AM, Dalton DK, Stewart TA et al.:Disseminated tuberculosis in IFN-γ gene-disruptedmice. J. Exp. Med. 178:2243-2248, 1993.
 
52) Flynn JL, Chan J, Triebold KJ et al.:An essential role for interferon-γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249-2254, 1993.
 
53) Huang S, Hendriks W, Althage A et al.:Immuneresponse in mice that lack the interferon-γ receptor. Science 259:1742-1745, 1993.
 
54) Newport MJ, Huxley CM, Huston S et al.:Amutation in the interferon-γ receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335:1941-1949, 1996.
 
55) Jouanguy E, Altare F, Lamhamedi S et al.:Interferon-γ receptor deficiency in an infant with fatal Bacille Calmette-Guerin infection. N. Engl. J. Med. 335:1956-1962, 1996.
 
56) Dupuis S, Dargemont C, Fieschi C et al.:Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 293:300-303, 2001.
 
57) Wong P, Pamer EG:CD8 T cell responses to infectious pathogens. Annu. Rev. Immunol 21:29-70, 2003.
PubMed
58) Flynn JL, Goldstein MM, Chan J et al.:Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572, 1995.
 
59) Pfeffer K, Matsuyama T, Kundig TM et al.:Mice deficient for the 55kd tumor necrosIs factor receptor are resistant to endotoxin shock, yet succumb to L. monocytogenes infection. Cell 73:457-467, 1993.
 
60) Rothe J, Lesslauer W, Lotscher H et al.:Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to induction by Listeria monocytogenes Nature 364:798-802, 1993.
 
61) Mizuki M, Nakane A, Sekikawa K et al.:Comparison of host resistance to primary and secondary Listeria monocytogenes infections in mice by intranasal and intravenous routes. Infect. Immun. 70:4805-4811, 2002.
PubMed
62) Ehlers S, Holscher C, Scheu S et al:The lymphotoxin B receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. J. Immunol 170:5210-5218, 2003.
 
63) Roach DR, Briscoe H, Saunders B et al:Secreted lymphotoxin-ais essential for the control of an intracellular bacterial infection. J. Exp. Med. 193:239-246, 2001.
 
64) Serbina NV, Salazar-Mather TP, Biron CA et al:TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19:59-70, 2003.
 
65) Sandor M, Weinstock JV, Wynn TA:Granulomas in schistosome and mycobacterial infections:amodel of local immune responses. Trends Immunol. 24:44-52, 2003.
 
66) Roach DR, Bean AGD, Demangel C et al.:TNF regulates chemokine induction essential for cell recruitment, granuloma formation and clearance of mycobacterial infection. J. Immunol. 168:1420-4627, 2002.
 
67) Kopf M, Baumann G, Freer M et al.:Impaired immune and acute-phase responses in interieukin-6-deficient mice, Nature 368:339-342, 1994.
 
68) Yajima T, Nishimura H, Ishimitus R et al.:Memory phenotype CD8+Tcells in IL-15 transgenic mice are involved in early protection against a primary infection with Listeria monocytogenes. Eur. J. Immunol. 31:757-768, 2001.
 
69) Barber EM, Pollard JW:The uterine NK cell population requires IL-15 but these cells are not required for pregnancy nor the resolution of a Listeria monocytogenes infection. J. Immunol 171:37-46, 2003.
 
70) Dai W, K6hler G, Brombacher F:Both innate and acquired immunity to Listeria monocytogenes infection are increased in IL-10-deficient mice. J. Immunol. 150:2259-2267, 1997.
 
71) Deckert M, Soltek S, Geginat G et al:Endogenous interleukin-10 is required for prevention of a hyperinflammatory intracerebral immune response in Listeria monocytogenes meningoencephalitis. Infect. Immun. 69:4561-4571, 2001.
PubMed
72) Sing A, Rost D, Tvardovskaia N et al. Yersinia V-antigen exploits Toll-like receptor 2 and CD14 for interleukin 10-mediated immuno suppression. J. Exp. Med. 196:1017-1024, 2002.
 
73) Nakane A, Okamoto M, Asano M et al.:Endogenous gamma interferon, tumor necrosis factor, and interlekin-6 in Staphylococcus aureus infection in mice. Infect. Immun. 63:1165-1172, 1995.
 
74) Hu D-L, Omoe K, Sasaki S et al.:Vaccination with non-toxic mutant TSST-1 protects Staphtococcu saureus, infection. J. Infect. Dis. 188:743-752, 2003.
 
75) Sasaki S, Nishikawa S, Miura T et al.:Interleukin-4 and interleukin-10 are involved in host resistance to Staphylococcus aureus infection through regulation of gamma interferon. Infect. Immun. 68:2424-2430, 2000.
PubMed
76) Hultgren OH, Svensson L, Tarkowski A:Critical role of signaling through IL-1 receptor for development of arthritis and sepsis during Staphylococcus aureus infection. J. Immunol 168:5207-5212, 2002.
PubMed
77) Hultgren O, Eugster H-P, Sedgwick JD et al.:TNF/lymphotoxin-adouble-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus J. Immunol. 161:5937-5942, 1998.
 
78) Zhau X-Y, Tarkowski A:Impact of interferon-γreceptor deficiency on experimental Staphylococcus aureus septicemia and arthritis. J. Immunol. 155:5736-5742, 1995.
 
79) Wei X-Q, Leung BP, Niedbala W et al.:Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J. Immunol. 163:2821-2828, 1999.
PubMed
80) Hultgren O, Kopf M, Tarkowski A:Outcome of Staphylococcus aureus-triggered sepsis and arthritis in IL-4-deficient mice depends on the genetic background of the host. Eur. J. Immunol. 29:2400-2405, 1999.
PubMed
81) MUIIer U, Steinhoff U, Reis LFL et al.:Functional role of type I and type II interferons in antiviral defense. Science 264:1918-1921, 1994.
 
82) Park C, Li S, Cha E et al.:Immune response in Stat2 knockout mice. Immunity 13:759-804, 2000.
 
83) Dupuis S, Jouanguy E, Al-Hajjar S et al Impaired response to interferon-α/β and lethal viral disease in human STATI deficiency. Nat. Genet. 33:388-391, 2003.
 
84) Guidotti LG, Chisari FV:Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19:1965-1991, 2001.
 
85) Cousens LP, Peterson R, Hsu S et al.:Two roads diverged:interferon-α/β-and interleukin-12-mediated pathways in promoting T cell interferon γ responses during viral infection. J. Exp. Med. 189:1315-1328, 1999.
 
86) Trinchieri G:Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol 3:133-146, 2003.
PubMed
87) Farrar JD, Smith JD, Murphy TL et al.:Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2. Nat. Immunol 1:65-69, 2000.
PubMed
88) Nguyen KB, Watford WT, Salomon R et al.:Critical role for STAT4 activation by type 1 interferons in the interferon-γresponse to viral infection. Science 297:2063-2066, 2002.
 
89) Sheppard P, Kindsvogel W, Xu W et al.:IL-28, IL-29 and their class n cytokine receptors IL-28R. Nat. Immunol. 4:63-68, 2003.
 
90) Kotenko SV, Gallagher G, Daurin W et al.:IFN-λs mediate antiviral protection through a distinct class Hcytokine receptor complex. Nat. Immunol. 4:69-77, 2003.
 
91) Badovunac VP, Hamilton SE, Harty JT:Viral infection results in massive T cell expansion and mortality in vaccinated perform-deficient mice. Immunity 18:463-474, 2003.
 
92) Alcami A:Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol 3:36-50, 2003.
PubMed
93) Seet BT, Johnston JB, Brunetti CR et al.:Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423, 2003.
PubMed
94) Johnston JB, McFadden G:Poxvirus immunornodulatory strategies:current perspectives. Infect. Immun. 77:6093-6100, 2003.
 
P.581 掲載の参考文献
1) Feng Y, Broder CC, Kennedy PE, Berger EA:HIV-1 entry cofactor:functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see comments]. Science 272:872-877, 1996.
 
2) Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA:CC CKR5:a RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958, 1996.
 
3) Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore Jp, Paxton WA:HIV-lentry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 [see comments]. Nature 381:667-673, 1996.
 
4) Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peipe SC, Schall TJ, Littman DR, Landau NR:Identification of a major co-receptor for primary isolates of HIV-1［see comments］. Nature 381:661-666, 1996.
 
5) Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R:The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47:333-348, 1986.
PubMed
6) Ashorn PA, Berger EA, Moss B:Human immunodeficiency virus envelope glycoprotein/CD4-mediated fussion of nonprimate cells with human cells. J. Virol. 64:2149-2156, 1990.
 
7) Cheng-Mayer C, Seto D, Tateno M, Levy JA:Biologic features of HIV-1 that correlate with virulence in the host. Science 240:80-82, 1988.
PubMed
8) Fenyo EM, Morfeldt-Manson L, Chiodi F, Lind B, von Gegerfelt A, Albert J, Olausson E, Asjo B:Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J. Virol. 62:4414-4419, 1988.
PubMed
9) Alkhatib G, Broder CC, Berger EA:Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. J. Virol 70:5487-5494, 1996.
 
10) Harouse JM, Bhat S, Spitalnik SL, LaughUn M, Stefano K, Silberberg DH, Gonzalez-Scarano F:Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science 253:320-323, 1991.
 
11) Callebaut C, Krust B, Jacotot E, Hovanessian AG:T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+cells. Science 262:2045-2050, 1993.
PubMed
12) Walker CM, Moody DJ, Stites DP, Levy JA:CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563-1566, 1986.
PubMed
13) Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P:Identification of RANTES, MIP-1 alpha, and MIP-lbeta as the major HIV-suppressive factors produced by CD8+ T cells[see comments]. Science 270:1811-1815, 1995.
 
14) Miller LH, Mason SJ, Dvorak JA, McGinniss MH, Rothman IK:Erythrocyte receptors for (Plasmodium knolesi) malaria:Duffy blood group determinants. Science 189:561-563, 1975.
PubMed
15) Peiper SC, Wang ZX, Neote K, Martin AW, Showell HJ, Conklyn MJ, Ogborne K, Hadley TJ, Lu ZH, Hesselgesser J et al.:The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuaIs who iack the erythrocyte receptor. J Exp Med 181:1311-1317, 1995.
 
16) Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjo T:Signal sequence trap:acloning strategy for secreted proteins and type I membrane proteins. Science 261:600-603, 1993.
PubMed
17) Nagasawa T, Kikutani H, Kishimoto T:Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc. Natl. Acad. Sci. USA 91:2305-2309, 1994.
PubMed
18) Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis1, Sodroski J, Springer TA:The lymphocyte chemoattractant SDF-l is a Iigand for LESTR/fusin and blocks HIV-lentry. Nature 382:829-833, 1996.
 
19) Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B:The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell line-adapted HIV-1. Nature 382:833-835, 1996.
 
20) Cairns JS, D'Souza MP:Chemokines and HIV-1 second receptors:the therapeutic connection. Nat. Med. 4:563-568, 1998.
PubMed
21) Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW:A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149-1158, 1996.
PubMed
22) Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J:The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148, 1996.
PubMed
23) Bieniasz PD, Fridell RA, Aramori I, Ferguson SS, Caron MG, Cullen BR:HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. Embo. J, 16:2599-2609, 1997.
PubMed
24) Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P:The V3 domain of the HIV-l gp120 envelope glycoprotein is critical for chemokinemediated blockade of infection［see comments］. Nat. Med. 2:1244-1247, 1996.
 
25) Chan DC, Fass D, BergerJM, Kim PS:Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273, 1997.
 
26) Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC:Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430, 1997.
PubMed
27) Doms RW, Peiper SC:Unwelcomed guests with master keys:how HIV uses chemokine receptors for cellular entry. Virology 235:179-190, 1997.
PubMed
28) Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore Jp, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA:A new classification for HIV-1[letter]. Nature 391:240, 1998.
PubMed
29) Levy JA, Mackewicz CE, Barker E:Controlling HIV pathogenesis:the role of the noncytotoxic anti-HIV response of CD8+Tcells. Immnol Today 17:217-224, 1996.
PubMed
30) Zhang L, Yu W, He T, Yu J, Caffrey RE, Dalmasso EA, Fu S, Pham T, Mei J, Ho JJ, Zhang W, Lopez P, Ho DD:Contribution of human alpha-defensin l, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 298:995-1000, 2002.
 
31) Geiben-Lynn R, Kursar M, Brown NV, Addo MM, Shau H, Lieberman J, Luster AD, Walker BD:HIV-1antiviral activity of recornbinant natural killer cell enhancing factors, NKEF-A and NKEF-B, members of the peroxiredoxin family. J. Biol Chem. 278:1569-1574, 2003.
 
32) Geiben-Lynn R, Brown N, Walker BD, Luster AD:Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor. J. Biol Chem. 277:42352-42357, 2002.
 
33) Fauci AS:Host factors and the pathogenesis of HIV-induced disease. Nature 384:529-534, 1996.
PubMed
34) Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR:Homozygous defect in HIV-1coreceptor accounts for resistance of some multiply-exposed individuaIs to HIV-1 infection. Cell 86:367-377, 1996.
 
35) Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M:Resistance to HIV-1 infection in caucasian individuaIs bearing mutant alleles of the CCR-5 chemokine receptor gene［see comments］. Nature 382:722-725, 1996.
 
36) Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW, Carrington M, Winkler C, Huttley GA, Allikmets R, Schriml L, Gerrard B, Malasky M, Ramos MD, Morlot S, Tzetis M, Oddoux C, di Giovine FS, Nasioulas G, Chandler D, Aseev M, Hanson M, Kalaydjieva L, Glavac D, Gasparini P, Dean M et al.:Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am. J. Hum. Genet. 62:1507-1515, 1998.
PubMed
37) Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, OIBrien TR, Jacobson LP, Kasiow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner MW, 01Brien SJ:Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS) , Multicenter Hemophilia Cohort Study (MHCS) , San Francisco City Cohort (SFCC), ALIVE Study. Science 277:959-965, 1997.
 
38) Winkler C, Modi W, Smith MW, NeIson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O'Brien TR, Jacobson LP, DeteIs R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J, O'Brien SJ:Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS) , Multicenter AIDS Cohort Study (MACS) , Multicenter Hemophilia Cohort Study (MHCS) , San Francisco City Cohort (SFCC) [see comments]. Science 279:389-393, 1998.
 
39) Shioda T, Nakayama EE, Tanaka Y, Xin X, Liu H, Kawana-Tachikawa A, Kato A, Sakai Y, Nagai Y, Iwamoto A:Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5. J. ViroL 75:3462-3468, 2001.
 
40) Martin MP, Dean M, Srnith MW, Winkler C, Gerrard B, Michael NL, Lee B, Doms RW, Margolick J, Buchbinder S, Goedert JJ, O'Brien TR, Hilgartner MW, Vlahov D, O'Brien SJ, Carrington M:Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282:1907-1911, 1998.
 
41) Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X, Takamatsu JK, Saito H, Ishikawa Y, Akaza T, JujiT, Takebe Y, Ohishi T, Fukutake K, Maruyama Y, Yashiki S, Sonoda S, Nakamura T, Nagai Y, Iwamoto A, Shioda T:Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl. Acad. Sci. USA 96:4581-4585, 1999.
PubMed
42) Nakayama EE, Hoshino Y, Xin X, Liu H, Goto M, Watanabe N, Taguchi H, Hitani A, Kawana-Tachikawa A, Fukushima M, Yamada K, Sugiura W, Oka SI, Ajisawa A, Sato H, Takebe Y, Nakamura T, Nagai Y, Iwamoto A, Shioda T:Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J. Virol. 74:5452-5459, 2000.
PubMed
43) Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ, O'Brien TR, Vlahov D, Buchbinder S, Giorgi J, Rinaldo C, Donfield S, Willoughby A, σBrien SJ, Smith MW:Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc. Natl. Acad. Sci. USA 97:14467-14472, 2000.
 
44) Foster CB, Lehrnbecher T, SamueIs S, Stein S, Mol F, Metcalf JA, Wyvill K, Steinberg SM, Kovacs J, Blauvelt A, Yarchoan R, Chanock SJ:An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 96:2562-2567, 2000.
 
45) Garred P, Madsen HO, BaIslev U, Hofmann B, Pedersen C, Gerstoft J, Svejgaard A:Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 349:236-240, 1997.
 
46) Pastinen T, Liitsola K, Niini P, Salminen M, Syvanen AC, O'Brien TR, McDermott DH, Ioannidis JP, Carrington M, Murphy PM, Havlir DV, Richman DD:Contribution of the CCR5 and MBL genes to susceptibility to HIV type 1 infection in the Finnish population. AIDS Res. Hum. Retroviruses 14:695-698, 1998.
 
47) Mariani R, Rutter G, Harris ME, Hope TJ, Krausslich HG, Landau NR:Ablock to human immunodeficiency virus type 1 assembly in murine cells. J. Virol. 74:3859-3870, 2000.
 
P.589 掲載の参考文献
1) Baumann H, Gauldie J:Acute phase response. Immunol. Today 15:74-80, 1994.
PubMed
2) Beutler B, MiIsark IW, Cerami A:Passive immunization against cachectin tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871, 1988.
 
3) Hogg N, Berlin C:Structure and function of adhesion receptors in leukocyte trafficking. Immunol. Today 16:327-330, 1995.
PubMed
4) Matsushima K, Oppenheim JJ:Interleukin 8 and MCAF:Novel inflammatory cytokines inducible by IL-1 and TNE Cytokine 1:2-13, 1989.
 
5) 義江 修:ケモカインスーパーファミリーの構造と機 能. ケモカインハンドブック. (義江 修・他監修). 秀潤社, 2000, p10-11.
 
6) Zlotnik A et al.:Chemokines:anew classification system and their role in immunity. Immunity 12:121-127, 2000.
 
7) Mossman TR, Chervinski H, Bond MW et al.:Two types of mouse helper T cells (I) . Definition of acccording to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348-2353, 1986.
 
8) Romagnnani S:Lymphokine production by human T cells in desease states. Ann. Rev. Immunol. 12:227-257, 1994.
 
9) Moreland LW, Baumgartner SW, Shiff MH et al.:Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N. Engl. J. Med. 337:141-147, 1997.
 
10) Keane J, Gershon S, Wise RP et al.:Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345:1098-1104, 2001.
PubMed
11) Gardam MA, Keystone EC, Menzies R et al.:Anti-tumour necrosis factor agents and tuberculosis risk:mechanisms of action and clinical management. Lancet Infect. Dis. 3:148-155, 2003.
PubMed
P.596 掲載の参考文献
1) Zlotnik A, Yoshie O:Chemokines:anew classification system and their role of immunity. Immunity 12:121-7, 2000.
 
2) Melchers F, Rolink AG, Schaniel C:The role of chemokines in regulating cell migration during humoral immune responses. Cell 99:351-354, 1999.
PubMed
3) Campbell JJ, Butcher EC:Chemokines in tissue-specific and microenvironment-specifc lymphocyte homing. Curr. Opin. Immunol. 12:336-341, 2000.
 
4) Chen XS, Sheller JR, Johnson EN et al.:Role of leukotriens revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372:179-182, 1994.
PubMed
5) Hopken UE, Lu B, Gerard NPet al.:The C5a chemoattractant receptor mediates mucosal defense to infection. Nature 383:86-89, 1996.
 
6) Hopken UE, Lu B, Gerard NP et al.:Impaired inflammatory responses in the reverese arthus reaction through genetic deletion of the C5a receptor. J. Exp. Med. 186:749-456, 1997.
 
7) Matsushima K, Morishita K, Yoshimura T et al.:Molecular cloning of a human monocyte-derived neutrophil chemotactic factors (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J. Exp. Med. 167:1883-1893, 1988.
PubMed
8) Matsushima K, Larsen CG, DuBois GC et al.:Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J. Exp. Med. 169:1485-1490, 1989.
PubMed
9) Sekido N, Mukaida N, Harada A et al.:Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 365:654-657, 1993.
PubMed
10) Harada A, Mukaida N, Matsushima K:Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases. Mol. Med. Today 2:482-489, 1996.
PubMed
11) Cacalano C, Lee J, Kikly K et al:Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science 265:682-684, 1994.
 
12) Wada T, Yokoyama H, Furuichi K et al.:Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1) . FASEB J. 10:1418-1425, 1996.
PubMed
13) Imai T, Yoshida T, Baba M et al.:Molecular cloning of anovel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector. J. Biol Chem. 271:21514-21521, 1996.
 
14) Foster R, Mattis EA, Kremmer E et al.:Aputative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87:1037-1047, 1996.
 
15) Nakano H, Mori S, Yonekawa H et al.:A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on mouse chromosome 4. Blood 91:2886-2895, 1998.
 
16) Gunn MD, Kyuwa S, Tam C et al.:Mice lacking expression of secondary lymphoid organ chemokine have defect in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189:451-461, 1999.
PubMed
17) Onai N, Zhang Y, Yoneyama H et al:Impairment of lymphopoiesis and myelopoiesis in mice reconstituted with bone marrow-hematopoietic progenitor cells expressing SDF-1-intrakine. Blood 96:2074-2080, 2000.
PubMed
18) Ueno T, Hara K, Willis MS et al.:Role of CCR71igands in the emigration of newly generated T lymphocytes from the neonatal thymus. Immunity 16:205-218, 2002.
 
19) Kunkel EJ, Campbell JJ, Haraldsen G et al.:Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestine compartment:Epithelial expression of tissue-specific chemokines as an organizing Principle in regional immunity. J. Exp. Med. 192:761-767, 2000.
PubMed
20) Pan J, Kunkel EJ, Gosslar U et al:Anovel chemokine ligand for CCRIO and CCR3 expressed by epithelial cells in mucosal tissues. J. Immunol, 165:2943-2949, 2000.
 
21) Murai M, Yoneyama H, Ezaki T et al.:Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat. Immunol 4:154-160, 2003.
PubMed
22) O'Carra A:Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275-283, 1998.
 
23) Sallusto F, Lanzavecchia A, Mackay CR:Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today 19:568-574, 1998.
 
24) Sallusto F, Mackey CR, Lanzavecchia A:Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277:2005-2007, 1997.
 
25) Imai T, Nagira M, Takagi S et al.:Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int. Immunol. 11:81-88, 1999.
 
26) Kim CH, Rott L, Kunkel EJ et al.:Rules of chemokine receptor association with T cell polarization in vivo. J. Clin. Invest. 108:1331-1339, 2001.
 
27) Schaerli P, Willimann K, Lang AB et al.:CXCchemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 192:1553-1562, 2000.
 
28) Sallusto F, Lenig D, Foster R et al.:Two subsets of memory T lymphocytes with distinct homing potentiaIs and effector functions. Nature 401:708-712, 1999.
 
29) Yoneyama H, Harada A, Imai T et al.:Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice. J. Clin. Invest. 102:1933-1941, 1998.
PubMed
30) Kawasaki S, Takizawa H, Yoneyama H et al.:Intervention of TARC attenuates the development of allergy airway inflammation and hyperresponsiveness in mice. J. Immunol. 166:2055-2062, 2001.
PubMed
31) Tang HL, Cyster JG:Chemokine up-regulation and activated T cell attraction by maturing dendritic cells. Science 284:819-822, 1998.
 
32) Yoneyama H et al.:Pivotal role of dendritic cellderived CXCLIO in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J. Exp. Med. 195:1257-1266, 2002.
PubMed
33) Banchereau J, Steinman RM:Dendritic cells and the control of immunity. Nature 392:245-252, 1998.
PubMed
34) Dieu M-C, Vanbervliet B, Vicari A et al.:Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomical sites. J. Exp. Med. 188:373-386, 1998.
 
35) Yoneyama H, Matsuno K, Zhang Y et al.:Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease. J. Exp. Med. 193:35-49, 2001.
 
36) Ato M, Stager S, Engwerda CR et al.:Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis. Nat. Immunol. 3:1185-1191, 2002.
 
37) Ishikawa S, Sato T, Abe M et al.:Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by CD11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells toward BLC. J. Exp. Med. 193:1393-1402, 2001.
 
P.607 掲載の参考文献
1) 義江 修, 野見山尚之, 宮坂昌之(監修):ケモカインハンドブック. 秀潤社, 2000.
 
2) Lum AF, Green CE, Simon SI et al.:Dynamic regulation of LFA-1 activation and neutrophil arrest on intercellular adhesion molecule 1 (ICAM-1) in shear flow. J. Biol Chem. 277:20660-20670, 2002.
 
3) Ley K:Arrest Chemokines. Microcirculation 10:289-295, 2003.
PubMed
4) Romagnani S:Cytokines and chemoattractants in allergic inflammation. Mol. Immunol. 38:881-885, 2001.
 
5) Honey B, Alenius H, Zlotnik A et al.:CCL27-CCRIO interactions regulate T cell-mediated skin inflammation. Nat. Med. 8:157-165, 2002.
 
6) Cinamon G, Shinder V, Alon R:Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat. Immunol. 2:515-522, 2001.
PubMed
7) Middleton J, Neil S, Rot A et al.:Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91:385-395, 1997.
PubMed
8) Constantin G, Majeed M, Laudanna C et al.:Chemokines trigger immediate beta2 integrin affinity and mobility changes:differential regulation and roles in lymphocyte arrest under flow. Immunity 13:759-769, 2000.
PubMed
9) 宮坂昌之(監修):接着分子ハンドブック. 秀潤社, 2000.
 
10) Sassetti C, Van Zante A, Rosen SD:Identification of endoglycan, a member of the CD34/podocalyxin family of sialomucins. J. Biol Chem. 275:9001-9010, 2000.
PubMed
11) Samulowitz U, Kuhn A, Vestweber D et al.:Distribution Pattern, expression on high endothelial venules, and decoration with the MECA-79 epitope. Am. J. Pathol. 160:1669-1681, 2002.
PubMed
12) Ellies LG, Tsuboi S, Marth JD et al.:Core 2 oligosaccharide biosynthesis distinguishes between selectin ligands essential for leukocyte homing and inflammation. Immunity 9:881-890, 1998.
PubMed
13) Aigner S, Ramos CL, Ley K et al.:CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J. 12:1241-1251, 1998.
 
14) Steegmaier M, Levinovitz A, Vestweber D et al.:The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature 373:615-620, 1995.
 
15) Picker LJ, Warnock RA, Butcher EC et al.:The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. Cell 66:921-933, 1991.
 
16) Yeh JC, Hiraoka N, Fukuda M et al:Novel sulfated lymphocyte homing receptors and their colltrol by a Corel extension beta 1, 3-N-acetylglucosaminyl-transferase. Cell 105:957-969, 2001.
 
17) Ebisuno Y, Tanaka T, Miyasaka M et al.:The B cell chemokine CXC chemokoine ligand 13/B lymphocyte chemoattractant is expressed in the high endothelial venules of lymph node and Peyer’s patches and affect Bcell trafficking across high endothelial venules. J. Immunol 171:1642-1646, 2003.
 
18) Grant AJ, Lalor PF, Adams DH et al.:Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic comp1ications of inflammatory bowel disease. Lancet 359:150-157, 2002.
 
19) Kawashima H, Hirose M, Miyasaka M et al.:Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J. Biol Chem. 275:35448-35456, 2000.
 
20) Vestweber D:Lymphocyte trafficking through blood and lymphatic vesseIs:more than just selectins, chemokines and integrins. Eur. J. Immunol. 33:1365, 2003.
 
P.618 掲載の参考文献
1) 植木重治, 茆原順一:好酸球. アレルギー・免疫 10:950-957 2003.
 
2) Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, WalIs CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ:Effect of an interleukin-5 blocking monoclonal antibody on eosinophiIs, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2144-2148, 2000.
 
3) 宮坂信之:サイトカインとは-サイトカインと病態. Mebio. 11(2):16-17, 1994.
 
4) Vellenga E, Essekink MT, Straatcn J, Stulp BK, DeWoff THM, Brons R Giannotti J, Smiin JW, Halie R:The supportive effects of IL-70n eosinophil progenitors from human bone marrow cells can be blocked by anti-IL-5. J. Immunol. 149:2992-2995, 1992.
 
5) Warringa RA, Schweizer RC, Maikoe T, Kuijper PHM, Bruijnzeal PLB, Koenderman L:Modulation of eosinophil chemotaxis by interleukin-5. Am. J. Respir. Cell. Mol. Biol. 7:631-6361992.
 
6) Mosmann R, Coffman RL:THI and TH2 cells;different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145, 1989.
 
7) Kay AB, Ying S, Varney V, Gaga M, Durham SR, Moqbel R, Wardlaw AJ, Hamid Q:Messenger RNA expression of the cytokine gene cluster interleukin 3 (IL-3) , IL-4, IL-5 and granulocyte/macrophage colony-stimulating factor, in allergic-induced late-phase cutaneous reaction in atopic subjects. J. Exp. Med. 173:775-778, 1991.
 
8) Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB:Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 326:298-304, 1992.
PubMed
9) Del Prete De Carli M, D EIios MM, Maestrelli P, Ricci M, Fabbri L, Romagnani S:Allergen exposure induces the activation of allergen-specific Th2 cells in the air-way mucosa of patient with allergic respiratory disorders. Eur. J. Immunol. 23:1445-1449, 1993.
 
10) 茆原順一, 三戸 聡:好酸球の特性. アレルギー科 9:58-67, 2000.
 
11) Mantovani A:The chemokine system:redundancy for robust outputs. Immunol Today 20:254-257, 1999.
PubMed
12) Stoeckle MY, Barker KA:Two burgeoning families of platelet factor 4-related proteins:mediators of the inflammatory response. New. Biol. 2:313-323, 1990.
PubMed
13) 松島鋼治:ケモカインの多様な機能. (茆原順一編), ケモカインと疾患, 医薬ジャーナル社, 大阪, 2000, p19-22.
 
14) 長澤丘司:ケモカインと造血. (茆原順一編), ケモカインと疾患, 医薬ジャーナル社, 大阪, 2000, p85- 95.
 
15) Cascieri MA, Springer MS:The chemokine/chemokine-receptor family:potential and progress for therapeutic intervention. Curr. Opin. Chem. Biol. 4:420-427, 2000.
PubMed
16) Homey B, Zlotnik A:Chemokines in allergy. Curr. Opin. Immunol 11:626-634, 1999.
PubMed
17) Horuk R, Chitnis CE, Darbonne WC, Colby TJ, Rybicki A, Hadley TJ, Miller LH:A receptor for the malarial Parasite Plasmodium vivax the erythrocyte chemokine receptor. Science 261:1182-1184, 1993.
PubMed
18) Chaudhuri A, Polyakova J, Zbrzezna V, Williams K, Gulati S, Pogo AO:Cloning of glycoprotein D cDNA, which encodes the major subunit of the Duffy blood group system and the receptor for the Plasmodium vivax malaria parasite. Proc. Natl. Acad. Sci. USA 90:10793-10797, 1993.
PubMed
19) Ahuja SK, Murphy PM:Molecular piracy of mammalian interleukin-8 receptor type B by herpesvirus saimiri. J. Biol. Chem. 268:20691-20694, 1993.
PubMed
20) Nagase H, Miyamasu M, Yamaguchi M, Fujisawa T, Ohta K, Yamamoto K, Morita Y, Hirai K:Expression of CXCR4 in eosinophiIs:functional analyses and cytokine-mediated regulation. J. Immunol 164:5935-5943, 2000.
PubMed
21) Gonzalo JA, Lloyd CM, Peled A, Delaney T, Coyle AJ, Gutierrez-Ramos JC:Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 alpha in the inflammatory component of allergic airway disease. J. Immunol. 165:499-508, 2000.
 
22) Metzger WJ, Henricksen RA, Zaleski T, Donnelly A:Evidence for platelet release and thrombin generation in early and late asthmatic response. (abstract) Clin. Res. 31:A164, 1983.
 
23) 安場広高, 木野稔也, 福田康二:気管支喘息発作時の血小板活性化の関与-洗浄血小板ATP放出能および 血漿β-TG, Platelet Factor 4レベル, β-TG/PF4比 についての検討-. アレルギー 37:1152, 1988.
 
24) Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM:Cytokine RANTES released by throm-bin-stimulated platelets is a potent attractant for human eosinophiIs. J. Exp. Med. 176:587-592, 1992.
 
25) Schall TJ, Bacon K, Toy KJ, Goeddel DV:Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347 (6294):669-671, 1990.
 
26) Alam R, Stafford S, Forsythe P, Harrison R, Faubion D, Lett-Brown MA, Grant JA:RANTES is a chemotactic and activating factor for human eosinophiIs. J. Immunol. 150:3442-3448, 1993.
PubMed
27) Baggiolini M, Dahinden CA:CC chemokines in allergic inflammation. Immunol. Today 15:127-133, 1994.
PubMed
28) 茆原順一, 齋藤紀先:好酸球と接着分子. アレルギー 科 9:97-102, 2000.
 
29) Hayashi N, Chihara J, Kobayashi Y, Kakazu T, Kurachi D, Yamamoto T, Nakajima S:Effect of platelet-activating factor and platelet factor 40n eosinophil adhesion. Int. Arch. Allergy Immunol 104 (suppl. 1):57-59, 1994.
 
30) Chihara J, Maruyama I, Yasuba H, Yasukawa A, Yamamoto T, Kurachi D, Mouri T, Seguchi M, Nakajima S:Possible induction of intercellular adhesion molecule-1 (ICAM-1) expression on endothelial cells by platelet-activating factor (PAF) . J. Lipid. Mediat. 5:159-162, 1992.
PubMed
31) Kakazu T, Chihara J, Saito A, Nakajima S:Effect of RANTES on eosinophil adhesion to plates coated with recombinant soluble intercellular adhesion molecule-1 and expression of beta 2-integrin adhesion molecules on eosinophiIs. Int. Arch. Allergy Immunol. 108 (suppl. 1):9-11, 1995.
 
32) Chihara J, Hayashi N, Kakazu T, Yamamoto T, Kurachi D, Nakajima S:RANTES augrnents radical oxygen products from eosinophiIs. Int. Arch. Allergy Immunol 104 (suppl. 1):52-53, 1994.
 
33) Kakazu T, Chihara J, Saito A, Higashimoto 1, Yamamoto T, Kurachi D, Nakajima S:Effect of RANTES on intra-cellular expression of EG2 antigen in eosinophiIs. Int. Arch. Allergy Immunol. 108 (suppl 1):43-44, 1995.
 
34) 茆原順一, 植木重治, 山田佳之:炎症関連因子-好酸球, 接着分子, ケモカインなど. アレルギー科 8:24-31, 1999.
 
35) Teran LM, Noso N, Carroll M, Davies DE, Holgate S, Schroder JM:Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. J. Immunol 157:1806-1812, 1996.
PubMed
36) Ying S, Meng Q, Zeibecoglou K, Robinson DS, Macfar-lane A, Humbert M, Kay AB:Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (lntrinsic) asthmatics. J. Immunol. 163:6321-6329, 1999.
 
37) Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE:Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte hemotactic protein-4 in human airway inflammation with eosinophilia. J. Immunol. 163:1545-1551, 1999.
 
38) Beck LA, Dalke S, Leiferman KM, Bickel CA, Hamilton R, Rosen H, Bochner BS, Schleimer RP:Cutaneous injection of RANTES causes eosinophil recruitment:comparison of nonallergic and allergic human subjects. J. Immunol. 159:2962-2972, 1997.
PubMed
39) Chihara J, Yamada H, Takamura E, Yoshino K, Nakajima S:Possible presence of RANTES in tears of patients with allergic conjunctivitis. Int. Arch. Allergy Immunol. 106:428, 1995.
PubMed
40) Chihara J, Yasuba H, Tsuda A, Urayama O, Saito N, Honda K, Kayaba H, Yamashita T, Kurimoto F, Yamada H:Elevation of the plasma level of RANTES during asthma attacks. J. Allergy Clin. Immunol. 100:S52-55, 1997.
PubMed
41) EIsner J, Petering H, Kimmig D, WelIs TN, Proudfoot AE, Kapp A:The CC chemokine receptor antagonist met-RANTES inhibits eosinophil effector functions. Int. Arch. Allergy Immunol. 118:462-465, 1999.
 
42) Jose PJ, Griffiths-Johnson DA, Collins PD, WaIsh DT, Moqbel R, Totty NF, Truong O, Hsuan JJ, Williams TJ:Eotaxin:apotent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J. Exp. Med. 179:881-887, 1994.
 
43) Daugherty BL, Siciliano SJ, DeMartino JA, Malkowitz L, Sirotina A, Springer MS:Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J. Exp. Med. 183:2349-2354, 1996.
PubMed
44) Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD:Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat. Med, 2:449-456, 1996.
PubMed
45) Burke-Gaffney A, Hellewell PG:Eotaxin stimulates eosinophil adhesion to human lung microvascular endothelial cells. Biochem Biophys. Res. Commun. 227:35-40, 1996.
PubMed
46) EIsner J, Hochstetter R, Kimmig D, Kapp A:Human eotaxin represents a potent activator of the respiratory burst of human eosinophiIs. Eur. J. Immunol. 26:1919-1925, 1996.
 
47) Tenscher K, Metzner B, Hofmann C, Schopf E, Norgauer J:The monocyte chemotactic protein-4 induces oxygen radical production, actin reorganization, and CD11b up-regulation via a pertussis toxin-sensitive G-protein in human eosinophiIs. Biochem. Biophys. Res. Commun. 240:32-35, 1997.
 
48) Honda K, Chihara J:Eosinophil activation by eotaxin-eotaxin primes the production of reactive oxygen species from eosinophiIs. Allergy 54:1262-1269, 1999.
PubMed
49) Sannohe S, Adachi T, Hamada K, Honda K, Yamada Y, Saito N, Cui CH, Kayaba H, Ishikawa K, Chihara J: Upregulated response to chemokines in oxidative metabolism of eosinophil in asthma and allergic rhinitis. Eur. Respir. J. 21:925-931, 2003.
PubMed
50) Saito N, Yamada Y, Sannohe S, Honda K, Adachi T, Kayaba H, Chihara J:Possible involvement of C-C chemokines in functional augmentation of adhesion molecules in asthmatic patients. LUNG 180:251-263, 2002.
PubMed
51) Brown JR, Kleimberg J, Marini M, Sun G, Bellini A, Mattoli S:Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation. Clin. Exp. Immunol 114:137-146, 1998.
PubMed
52) Nakamura H, Weiss ST, Israel E, Luster AD, Drazen JM, Lilly CM:Eotaxin and impaired lung function in asthma. Am. J. Respir. Crit. Care Med. 160:1952-1956, 1999.
PubMed
53) Yamada H, Yamaguchi M, Yamamoto K, Nakajima T, Hirai K, Morita Y, Sano Y, Yamada H:Eotaxin in induced sputum of asthmatics:relationship with eosinophiIs and eosinophil cationic protein in sputum. Allergy 55:392-397, 2000.
PubMed
54) Fukagawa K, Nakajima T, Tsubota K, Shimmura S, Saito H, Hirai K:Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage. J. Allergy Clin. Immunol. 103:1220-1221, 1999.
PubMed
55) Yawalkar N, Uguccioni M, Scharer J, Braunwalder J, Karlen S, Dewald B, Braathen LR, Baggiolini M Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J. Invest. Dermatol. 113:43-48, 1999.
PubMed
56) Hogan SP, Mishra A, Brandt EB, Foster PS, Rothen-berg ME:Acritical role for eotaxin in experimental oral antigen-induced eosinophilic gastrointestinal allergy. Proc. Natl. Acad. Sci. USA 97:6681-6686, 2000.
 
57) Lilly CM, Nakamura H, Kesselman H, Nagler-Anderson C, Asano K, Garcia-Zepeda EA, Rothenberg ME, Drazen JM, Luster AD:Expression of eotaxin by human lung epithelial cells:induction by cytokines and inhibition by glucocorticoids. J. Clin. Invest. 99:1767-1773, 1997.
PubMed
58) Teran LM, Mochizuki M, BarteIs J, Valencia EL, Nakajima T, Hirai K, Schroder JM:Th1-and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts. Am J. Respir. Cell. Mol. Biol. 20:777-786, 1999.
PubMed
59) Stafford S, Li H, Forsythe PA, Ryan M, Bravo R, Alam R:Monocyte chemotactic protein-3 (MCP-3) /fibrob-last-induced cytokine (FIC) in eosinophilic inflammation of the airways and the inhibitory effects of an anti-MCP-3/FIC antibody. J. Immunol. 158:4953-4960, 1997.
 
60) Stellato C, Collins P, Ponath PD, Soler D, Newman W, La Rosa G, Li H, White J, Schwiebert LM, Bickel C, Liu M, Bochner BS, Williams T, Schleimer RP:Production of the novel C-C chemokine MCP-4 by air-way cells and comparison of its biological activity to other C-C chemokines. J. Clin. Invest. 99:926-936, 1997.
 
61) Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA:RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp. Med. 176:1489-1495, 1992.
PubMed
62) Kukita T, Nomiyama H, Ohmoto Y, Kukita A, Shuto T, Hotokebuchi T, Sugioka Y, Miura R, Iijima T:Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow:its role in regulation of hematopoiesis and osteoclast recruitment. Lab. Invest. 76:399-406, 1997.
PubMed
63) Holgate ST, Bodey KS, Janezic A, Frew AJ, Kaplan AP, Teran LM:Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endo-bronchial allergen challenge. Am. J. Respir. Crit. Care Med. 156:1377-1383, 1997.
 
64) Gonzalo JA, Pan Y, Lloyd CM, Jia GQ, Yu G, DussaultB, Powers CA, Proudfoot AE, Coyle AJ, Gearing D, Gutierrez-Ramos JC:Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inflammation. J. Immunol. 163:403-411, 1999.
PubMed
65) Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, Andrew DP, Warnke R, Ruffing N, Kassam N, Wu L, Butcher EC:The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 400 (6746):776-780, 1999.
 
66) Ochi H, Hirani WM, Yuan Q, Friend DS, Austen KF, Boyce JA:Thelper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med. 190:267-280, 1999.
 
67) Oyamada H, Kamada Y, Kuwasaki T, Yamada Y, Kobayashi Y, Cui CH, Honda K, Kayaba H, Saito N, Chihara J:CCR3 mRNA expression in bronchial epithelial cells and various cells in allergic inflammation. Int. Arch. Allergy Immunol. 120 S1:45-47, 1999.
 
68) Cui CH, Adachi T, Oyamada H, Kaymada Y, Kuwasaki T, Yamada Y, Saito N, Kayaba H, Chihara J:The role of mitogen-activated protein kinases in eotaxin-induced cytokine production from bronchial epithelial cells. Am. J. Respir, Cell. Mol. Biol. 27:329-335, 2002.
 
69) Fujisawa T, Kato Y, Atsuta J, Terada A, Iguchi K, Kamiya H, Yamada H, Nakajima T, Miyamasu M, Hirai K:Chemokine production by the BEAS-2B human bronchial epithelial cells:differential regulation of eotaxin, IL-8, and RANTES by TH2-and THl-derived cytokines. J. Allergy Clin. Immunol. 105:126-133, 2000.
 
70) Saunders J, Tarby CM:Opportunities for novel therapeutic agents acting at chemokine receptors. Drug Discov. Today 4:80-92, 1999.
PubMed
71) Gonzalo JA, Lloyd CM, Wen D, Albar Jp, WelIs TN, Proudfoot A, Martinez-AC, Dorf M, Bjerke T, Coyle AJ, Gutierrez-Ramos JC:The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J. Exp. Med. 188:157-167, 1998.
 
72) Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID:Asthma exacerbations and sputum eosionophil counts:arandomised controlled trial Lancet 360:15, 2002.
 
73) Ueki S, Adachi T, Bourdeaux J, Oyamada H, Yamada Y, Hamada K, Kanda A, Kayaba H, Chihara J:Expression of PPAR gamma in eosinophiIs and its functionalrole in survival and chemotaxis. Immunol. Lett. 86:183, 2003.
 
P.631 掲載の参考文献
1) Osawa M, Hanada K, Hamada H et al.:Long-term lymphohematopoietic reconstitution by a single CD34-low/negetive hematopoietic stem cell. Science 273:242-245, 1996.
 
2) Matsuoka S, Ebihara Y, Xu M et al.:CD34 expression on long-term repopulating hematopoietic stem cells changes during developmental stages. Blood 97:419-425, 2001.
PubMed
3) Larochelle AJ, Vormoor H, Hanenberg JCY et al.:Identification of primitive hematopoietic cells capable of repopulating NOD/SCID mice:imp1ications for gene therapy. Nature Med. 2:1329-1337, 1996.
 
4) Ito M, Hiramatsu H, Kobayashi K et al.:NOD/SCID γ, null mouse:an excellent recipient mouse model for engraftment of human cells. Blood 100:3175-3182, 2002.
 
5) Hiramatsu H, Nishikomori R, Heike T et al.:Complete reconstitution of human lymphocytes from cord blood CD34+ cells using NOD/SCID//γc, null mice model. Blood 102:873-880, 2003.
 
6) Kambe N, Hiramatsu H, Nishikomori R, et al:Human mast cell development in NOD/SCID/γc null mice after transplantation of cord blood hematopoietic stem cells. Blood 2004.
 
7) Ogawa M, Porter PN, Nakahata T:Renewal and commitment to differentiation of hemopoietic stem cells (An interpretive review) . Blood 61:823-829, 1983.
PubMed
8) Matsuda T, Nakamura T, Heike T et al.:STAT3 activation is sufficient for maintaining an undifferentiated state of embryonic stem cells. EMBO J. 15:4261-4269, 1999.
PubMed
9) Mitsui K, Tokuzawa Y, Itoh H et al.:The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113:631-642, 2003.
PubMed
10) Xu M, Tsuji K, Mukouyama Y et al.:Stimulation of mouse and human primitive hematopoiesis by murine embryonic aorta-gonad-mesonephros-derived stromal cells. Blood 192:2032-2040, 1998.
 
11) Zhang J, Niu C, Ye L et al.:Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425:836-841, 2003.
PubMed
12) Calvi LM, Adams GB, Weibrecht KW et al.:Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425:841-846, 2003.
PubMed
13) Tajima S, Tsuji K, Ebihara Y et al.:Analysis of IL-6 receptor and gp130 expressions and proliferative capability of human CD34+cells. J. Exp. Med. 184:1357-1364, 1996.
 
14) Sui X, Tsuji K, Tanaka R et al.:gp130 arld c-Kit signallings synergize for vitro expansion of human primitive hemopoietic progenitor cells. Proc. Natl. Acad. Sci. USA 92:2859-2863, 1995.
 
15) Matsunaga T, Kato T, Miyazaki H et al.:Thrombopoietin promotes the survival of murine hematopoietic long-term reconstituting cells:comparison with the effecta of FLT3/FLK-21igand and interleukin 6. Blood 92:452-461, 1998.
 
16) Ebihara Y, Tsuji K, Muraoka K et al.:Synergistic action of Flt 3 and gp130 signalings in human hematopoiesis. Blood 90:4363-4368, 1997.
 
17) Nakahata T:Ex vivo expansion of human hematopoietic stem cells. Int. J. Hematol. 73:6-13, 2001.
PubMed
18) Ueda Y, Tsuji K, Yoshino H et al.:Expansion of human NOD/SCID-repopulating cells by a combination of stem cell factor, Flk2/Flt3 ligand, thrombopoietin and acomplex of interleukin-6 and soluble interleukin-6 receptor. J. Chn. Invest. 105:1013-1021, 2000.
 
19) Nakahata T, Gross AJ, Ogawa M:Astochastic model of self-renewal and commitment to differentiation of the primitive hemopoietic stem cells in culture. J. Cell. Physiol. 113:455-458, 1982.
 
20) Tsuj i K, Nakahata T:Stochastic model for multimopential hemopoietic progenitor differentiation. J. Cell. Physiol. 139:647-653, 1989.
 
21) Ebihara Y, Xu M, Manabe A et al.:Exclusive expression of G-CSF receptor on myeloid progenitors in bone marrow CD34-cells. Br. J. Haematol 109:153-161, 2000.
PubMed
22) Yang FC, Watanabe S, Tsuji K et al.:Human G-CSF stimulates the development of primitive multipotential progenitors of human G-CSF receptor-transgenic mice, but does not affect their commitment ii vitro and in vivo. Blood 92:1632-1640, 1998.
 
23) Yang FC, Tsuji K, Oda A et al.:Different effects of human granulocyte colony-stimulating factor (hG-CSF) and thrombopoietin on megakaryopoiesis and platelet function in hG-CSF receptor-transgenic mice. Blood 94:950-958, 1999.
 
24) Mitsui T, Watanabe S, Hanada S et al.:Impared neutrophil maturation in truncated G-CSF receptor transgenic mice. Blood 101:2990-2995, 2003.
 
25) Nishijima I, Nakahata T, Hirabayashi Y et al.:Ahuman GM-CSF receptor expressed in transgenic mice stimulates proliferation and differentiation of emopoietic progenitors to all lineages in response to human GM-CSF. Mol Biol. Cell. 6:497-508, 1995.
 
26) Nishijima I, Nakahata T, Watanabe S et al.:Hemopoietic and lymphopoietic responses in human GM-CSF receptor transgenic mice injected with human GM-CSF. Blood 90:1031-1038, 1997.
 
27) Pharr PN, Ogawa M et al.:Expression of an activated erythropoietin or a colony-stimulating factor 1 receptor by pluripotent progenitors enhances colony formation but does not induce differentiation. Proc. Natl Acad. Sci. USA 91:7482-7486, 1994.
 
28) Dubart A, Feger F et al.:Murine pluripotent hemopoietic progenitors constitutively expressing a normal erythropoietin receptor proliferate in response to erythropoietin without preferential erythroid cell differentiation. Mol. Cell. Biol. 14:4834-4842, 1994.
 
29) Sui X, Tsuji K, Tajima S, Tanaka R, Muraoka K, Ebihara Y, Ikebuchi K, Yasukawa K, Taga T, Kishimoto T, Nakahata T:Erythropoietin-independent erythrocyte production:signaIs through gP130 and c-Kit dramatically promote erythropoiesis from human CD34+ cells. J. Exp. Med. 183:837-845, 1996.
 
30) Sui X, Tsuji K, Ebihara Y, Tanaka R, Muraoka K, Yoshida M, Yamada K, Yasukawa K, Taga T, Kishimoto T, Nakahata T:Soluble IL6 receptor with IL-6 stimulates megakaryopoiesis from human CD34+ cells through gp130 signaling. Blood 93:2525-2532, 1999.
PubMed
31) Yoshida K, Taga T, Saito M et al.:Targeted disruption of gp130, a common signal transducer for IL-6-family of cytokines, leads to myocardial arld hematological disorders. Proc. Natl. Acad. Sci. USA 93:407-411, 1996.
 

サイトカインの臨床応用

P.639 掲載の参考文献
1) Flamand V, Sornasse T, Thielemans K et al.:Murine dendritic cells puIsed in vitro with tumor antigen induce tumor resistance in vivo Eur. J. Immnol. 24:605-610, 1994.
PubMed
2) Mayordomo JI, Zorita T, Storkus WJ et al.:Bone marrow-derived dendritic cells puIsed with synthetic tumor peptides elicit protective and therapeutic antitumor immnity. Nature Med. 1:1297-1302, 1995.
 
3) Furihata M, Ohtsuki Y, Ido E et al.:HLA-DR antigen-and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma-their distribution in relation to prognosis. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 61:409-414, 1992.
PubMed
4) Zeid NA, Muller HK:S100 positive dendritic cells in human lung tumors associated with cell differentination and enhanced survival. Pathology 25:338-343, 1993.
PubMed
5) Tsujitani S, KakejiY, Watanabe A et al.:Infiltration of dendritic cells in rotation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 66:2012-2016, 1990.
 
6) Takayama T, Satoh M, Tahara T:Intra-tumor injections of dendritic cells combined with local radiotherapy and systemic administration of IL-2 for advanced cancer patients. 4th International Expert Meeting on Clinical Dendritic Cell Immunotherapy, Nertherlands, June 13-16, 2003.
 
7) Kataoka M, Fujiwara T, Tanaka N:Gene therapy for lung cancer. Nippon Geka Gakkai Zasshi 103:244-249, 2002.
PubMed
8) Song W, Kong HL, Carpenter H et al.:Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a rnodel antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 86:1247-1256, 1997.
 
9) Specht JM, Wang G, Do MT:Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1213-1221, 1997.
 
10) Takayama T, Nishioka Y, Lu L, Lotze M, Tahara H, Thomson AW:Retroviral delivery of viral IL-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of Tcell hyporesponsiveness. Transplantation 66:1567-1574, 1998.
PubMed
11) Takayama T, Morelli AE, Robbins PD, Tahara H, Thomson AW:Feasibility of CTLA41g gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro. Gene Ther. 7:1265-1273, 2000.
 
12) Takayama T, Kaneko K, Morelli AE, Li W, Tahara H, Thomson AW:Retroviral delivery of transforming growth factor-betal to myeloid dendritic cells;Inhibition of T-cell priming ability and influence on allograft survival. Transplantation 74:112-119, 2002.
 
13) Tahara H, Zitovogel L, Storks WJ et al.:Effective eradication of established murine tumors with IL-12 gene therapy using a Polycistronic retroviral vector. J. Immunol 154:6466-6474, 1994.
 
14) Brunda MJ, Luistro L, Warrier RR et al.:Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med. 178:1223, 1993.
PubMed
15) Zivogel L, Tahara H, Robbins PD et al.:Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J. Immunol. 155:1393-1403, 1995.
 
16) Tahara H, Zeh HJ, Storks WJ et al.:Fibroblasts genetically engeneered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54:182-189, 1994.
 
17) Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H:Induction of systernic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 59:4035-4041, 1999.
PubMed
P.647 掲載の参考文献
1) O'Dell JR:Anticytokine therapy. A new era in the treatment of rheumatoid arthritis? N. Engl. J. Med. 340:310-312, 1999.
PubMed
2) Brenann FM, Maini RN, Feldmann M:TNFa-a pivotal role in rhematoid arthritis? Br. J. Rheumatol. 31:293-298, 1992.
 
3) 竹内 勤, 天野宏一:新しい治療法の考え方. 生物製剤の現状と展望. 日本内科学会雑誌89:2146-2153, 2000.
 
4) 竹内 勤, 天野 宏一:関節リウマチ-生物製剤. 最新医学別冊8:183-190, 2002.
 
5) Elliott MJ, Maini RN, Feldmann M et al.:Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factora. Arthritis Rheum. 36:1681-1690, 1993.
 
6) Maini RN et al:Infliximab (chimeric anti-tumorncrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate. Lancet 354:1932-1939, 1999.
 
7) Lipsky PE, Desiree MFM, van der Heiji D et al:Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343:1594-1602, 2000.
 
8) Temekonidis TI, Georgiadis AN, Alamanos Y, Bougias DV, Voulgari PV, Drosos AA:Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann. Rheum. Dis. 61:822-825, 2002.
PubMed
9) Baert F, Noman M, Vermeire S et al.:Influence of immunogenecity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348:601-8, 2003.
 
10) Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM:Tuberculosis associated with infliximab, a tumor necrosis factora-neutralizing agent. N. Engl. J. Med. 345:1098-1104, 2001.
 
11) Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD:Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum. 48:2122-2127, 2003.
PubMed
12) Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC:Ant-tumour necrosis factor agents and tuberculosis risk:mechanisms of action and clinical management. Lancet Infect. Dis. 148-155, 2003.
 
13) Kroesen S, Widmer AF, Tyndall A, Hasler P:Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 42:617-621, 2003.
PubMed
14) De Rycke L, Kruithof E, Van Damme N, Hoffman IEA, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F:Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 48:1015-1023, 2003.
 
15) Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN:Demyelination occurring during anti-tumor necrosis factor therapy for inflammatory arthritides. Arthritis Rheum. 44:2862-2869, 2001.
PubMed
16) Brown SL, Greene MH, Gershon SK et al.:Tumor necrosis factor therapy and lymphoma development. Arthritis Rheum. 46:3151-3158, 2002.
PubMed
17) Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT:Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure:results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133-3140, 2003.
PubMed
18) Moreland LW, Baumgartner SW, Schiff MH et al.:Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75V-Fc fusion protein. N. Engl J. Med. 337:141-147, 1997.
 
19) Weinblatt ME, Kremer JM, Bankhurst AD et al.:A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl J. Med. 340:253-259, 1999.
PubMed
20) Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Fink B:A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343:1586-1593, 2000.
 
21) Genovese MC, Bathon JM, Martin WM, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK:Etanercept versus methotrexate in patients with early rheumatoid arthritis:Two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443-1450, 2002.
 
22) Weinblatt ME, Keystone EC, Furst DE et al:Adalimumab, a fully anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 48:35-45, 2003.
 
23) den Broeder A, van de Putte LBA, Rau R, Schattenkirchner M, van Riel PLCM, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, Kempeni J, Kupper H:Asingle dose, placebo controlled study of the fully human anti-tumor necrosis factor-［alpha］antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol. 22:2288-2298, 2002.
 
24) Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs N-M, Hoffman GS:Etanercept combined with conventional treatment in Wegener's granulomatosis:asix-month open-label trial to evaluate safety. Arthritis Rheum. 44:1149-1154, 2001.
 
25) Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, Guillevin L:Efficacy of the anti-TNF-alpha antibody infliximab against refractory systernic vasculitides:an open pilot study on 10 patients. Rheumatology (Oxford) 10:1126-1132, 2002.
PubMed
26) Cavagna L, CaporaU R, Epis O, Bobbio-Pallavicini F, Montecucco C:Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin. Exp. RheumatolRheumatol 19:329-332, 2001.
 
27) Elaine Husni M, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese MC, Weinblatt ME:Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum. 46:1171-1176, 2002.
 
28) Sfikakis PP:Behget's disease:anew target for anti-tumour necrosis factor treatment. Ann. Rheum. Dis. 61 (suppl. 2):ii51-53, 2002.
 
29) Vassallo R, Matteson E, Thomas CF Jr:Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 122:1093-1096, 2002.
PubMed
30) Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D:Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum. 46:2571-2573, 2002.
 
31) Gottenberg J-E, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, Durbach A, Sibilia J, Dougados M, Mariette X:Anti-tumor necrosis factor therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides:A followup report of tolerability and efficacy. Arthritis Rheum. 48:2019-2024, 2003.
PubMed
32) Yee AMF, Pochapin MB:Treatment of comp1icated sarcoidosis with infliximab anti-tumor necrosis factor-therapy. Ann. Intern. Med. 135:27-31, 2001.
 
33) Utz Jp, Limper AH, Kalra S, Specks U, Scott Jp, Vuk-Pavlovic Z, Schroeder DR:Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124:177-185, 2003.
PubMed
34) Abe T Takeuchi T:Rheumatoid arthritis and tumor necrosis factora. Autoimmunity 34:291-303, 2001.
 
35) Arend P:Cytokine imbalance in the pathogenesis of rheumatoid arthritis:The role of interleukin-1 receptor antagonist. Semin. Arthrits Rheum. 30:1-6, 2001.
 
36) Jiang Y, Genant HK, Watt I et al.:Amulticenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43:1001-1009, 2000.
 
37) Cohen S, Hurd E, Cush J et al.:Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1receptor antagonist, in combination with methotrexate. Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46:614-624, 2002.
 
38) Choy EHS, Isenberg DA, Garrood T et al.:Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 46:3143-3150, 2002.
PubMed
39) Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T:A mult-center, randomized, double-blind placebo-controlled triaIs of humanized anti-IL-6 receptor monoclonal antibody (MRA) in rheumatoid arthritis (RA) . Arthritis Rheum. 47:S559, 2002.
 
P.659 掲載の参考文献
1) Tarner IH, Fathman CG:The potential for gene therapy in the treatment of autoimmune disease. Clin. Immunol. 104:204-216, 2002.
PubMed
2) Wolff JA, Malone RW, Williams P et al.:Direct gene transfer into mouse muscle in vivo. Science 247:1465-1468, 1990.
PubMed
3) Wolff JA, Ludtke JJ, Acsadi G et al.:Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. 1:363-369, 1992.
PubMed
4) Niwa H, Yamamura K, Miyazaki J:Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199, 1991.
PubMed
5) Tokui M, Takei I, Tashiro F et al.:Intramuscular injection of expression plasmid DNA is an effective means of long-term systemic delivery of interleukin-5. Biochem. Biophys. Res. Commun. 233:527-531, 1997.
PubMed
6) Vltadello M, Schiaffino MV, Picard A et al.:Gene transfer in regenerating muscle. Hum. Gene. Ther. 5:11-18, 1994.
 
7) WelIs DJ:Improved gene transfer by direct plasmid injection associated with regeneration in mouse skeletal muscle. FEBS Lett. 332:179-182, 1993.
 
8) Aihara H, Miyazaki J:Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16:867-870, 1998.
PubMed
9) Jiang J, Yamato E, Miyazaki J:Sustained expression of fc-fusion cytokine following in vivo electro-poration and mouse strain differences in expression levels. J. Biochem. (Tokyo) 133:423-427, 2003.
 
10) Adachi O, Nakano A, Sato O et al.:Gene transfer of Fc-fusion cytokine by in v'ivo electroporation:application to gene therapy for viral myocarditis. Gene Ther. 9:577-583, 2002.
 
11) Jiang J, Yamato E, Miyazaki J:Intravenous delivery of naked plasmid DNA for in vivo cytokine expression. Biochem. Biophys. Res. Commun. 289:1088-1092, 2001.
PubMed
12) BergeIson JM, Cunningham JA, Droguett G et al.:Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323, 1997.
 
13) Eisenbarth GS:Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 314:1360-1368, 1986.
PubMed
14) Kay TW, Campbell IL, Harrison LC:Characterization of pancreatic T lymphocytes associated with beta cell destruction in the non-obese diabetic (NOD) mouse. J. Autoimmun. 4:263-276, 1991.
PubMed
15) Kay TW, Chaplin HL, Parker JL et al.:CD4+ and CD8+T lymphocytes:clarification of their pathogenic roles in diabetes in the NOD mouse. Res. Immunol 148:320-327, 1997.
PubMed
16) Wong FS, Janeway CA Jr:The role of CD4 vs. CD8 T cells in IDDM. J. Autoimmun. 13:290-295, 1999.
PubMed
17) Pozzilli P, Signore A, Williams AJ et al.:NOD mouse colonies around the world-recent facts and figures. Immunol. Today 14:193-196, 1993.
PubMed
18) Shimada A, Rohane P, Fathman CG et al:Pathogenic and protective roles of CD45RB (low) CD4+cells correlate with cytokine profiles in the spontaneously autoimmune diabetic mouse. Diabetes 45:71-78, 1996.
PubMed
19) Shimada A, Charlton B, Rohane P et al:Immune regulation in type 1 diabetes. J. Autoimmun. 9:263-269, 1996.
PubMed
20) Pennline KJ, Roque-Gaffney E, Monahan M:Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol Immunopathol. 71:169-175, 1994.
PubMed
21) Zheng XX, Steele AW, Hancock WW et al.:A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotessuppressor phenomena in NOD mice. J. Immunol 158:4507-4513, 1997.
PubMed
22) Nitta Y, Tashiro F, Tokui M et al.:Systemic delivery of interleukin 10 by intramusctllar injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice. Hum. Gene. Ther. 9:1701-1707, 1998.
PubMed
23) Kawamoto S, Nitta Y, Tashiro F et al.:Suppression of T(h) 1 cell activation and prevention of autoimmune diabetes in NOD mice by local expression of viral IL-10. Int. Immunol. 13:685-694, 2001.
 
24) Go NF, Castle BE, Barrett R et al.:Interleukin 10, a novel B cell stimulatory factor:unresponsiveness of Xchromosome-linked immunodeficiency B cells. J. Exp. Med. 172:1625-1631, 1990.
 
25) Hsu DH, de Waal Malefyt R, Fiorentino DF et al.:Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 250:830-832, 1990.
PubMed
26) Thompson-Snipes L, Dhar V, Bond MW et al.:Interleukin 10:anovel stimulatory factor for mast cells and their progenitors. J. Exp. Med. 173:507-510, 1991.
 
27) Vieira P, de Waal-Malefyt R, Dang MN et al.:Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones:homology to Epstein-Barr virus open reading frame BCRFI. Proc. Natl. Acad. Sci. USA 88:1172-1176, 1991.
 
28) Piccirillo CA, Chang Y, Prud'homme GJ:TGF-betal somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J. Immunol. 161:3950-3956, 1998.
 
29) Cameron MJ, Arreaza GA, Waldhauser L et al.:Immunotherapy of spontaneous type 1 diabetes in nonobese diabetic mice by systemic interleukin-4 treatment employing adenovirus vector-mediated gene transfer. Gene Ther. 7:1840-1846, 2000.
PubMed
30) Horiki M, Yamato E, Noso S et al.:High-level expressiorl of interleukin-4 following electroporationmediated gene transfer accelerates Type l diabetes in NOD mice. J. Autoimmun. 20:111-117, 2003.
 
31) Feldmann M, Brennan FM, Maini RN:Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14:397-440, 1996.
PubMed
32) Miossec P, van den Berg W:Th1/Th2 cytokine balance in arthritis. Arthritis Rheum. 40:2105-2115, 1997.
PubMed
33) Robbins PD, Evans CH, Chernajovsky Y:Gene therapy for arthritis. Gene Ther. 10:902-911, 2003.
PubMed
34) Miagkov AV, Varley AW, Munford RS et al.:Endogenous regulation of a therapeutic transgene restores homeostasis in arthritic joints. J. Clin. Invest. 109:1223-1229, 2002.
PubMed
35) Lubberts E, Joosten LA, van Den Bersselaar L et al.:Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J. Immunol 163:4546-4556, 1999.
PubMed
36) Lubberts E, Joosten LA, Chabaud M et al.:IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J. Clin. Invest. 105:1697-1710, 2000.
PubMed
37) Kim SH, Evans CH, Kim S et al.:Gene therapy for established murine collagen-induced arthritis by locai and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Res. 2:293-302, 2000.
 
38) Woods JM, Katschke KJ, Volin MV et al.:IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J. Immunol. 166:1214-1222, 2001.
PubMed
39) Song XY, Gu M, Jin WW et al.:Plasmid DNA encoding transforming growth factor-betal suppresses chronic disease in a streptococcal cell wall-induced arthritis model J. Clin. Invest. 101:2615-2621, 1998.
 
40) Chernajovsky Y, Adams G, Triantaphyllopoulos K et al.:Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model. Gene Ther. 4:553-559, 1997.
 
41) Mi Z, Ghivizzani SC, Lechman E et al:Adverse effects of adenovirus-mediated gene transfer of human transforming growth factor beta 1 into rabbit knees. Arthritis Res. 5:R132-139, 2003.
PubMed
42) Tarner IH, Fathman CG:Gene therapy in autoimmune disease. Curr. Opin. Immunol 13:676-682, 2001.
PubMed
43) Morita Y, Yang J, Gupta R et al.:Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J. Clin. Invest. 107:1275-1284, 2001.
PubMed
44) Setoguchi K, Misaki Y, Araki Y et al.:Antigen-specific T cells transduced with IL-10 ameliorate experimentally induced arthritis without impairing the systemic immune response to the antigen. J. Immunol 165:5980-5986, 2000.
 
45) Lechman ER, Jaffurs D, Ghivizzani SC et al.:Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J. Immunol. 163:2202-2208, 1999.
PubMed
46) Whalen JD, Lechman EL, Carlos CA et al.:Adenoviral transfer of the viral IL-10 gene peri-articularly to mouse paws suppresses deveiopment of collagen-induced arthritis in both injected and uninjected paws. J. Immunol 162:3625-3632, 1999.
 
47) Kim SH, Kim S, Evans CH et al.:Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J. Immunol. 166:3499-3505, 2001.
PubMed
48) Whalen JD, Thomson AW, Lu L et al.:Viral IL-10 gene transfer inhibits DTH responses to soluble antigens:evidence for involvement of genetically modified dendritic cells and macrophages. Mol. Ther. 4:543-550, 2001.
PubMed
49) Hagiwara E, Gourley MF, Lee S et al.:Disease severity in patients with systemic lupus erythe-matosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum. 39:379-385, 1996.
 
50) Tokano Y, Morimoto S, Kaneko H et al.:LeveIs of IL-12 in the sera of patients with systemic lupus erythe-matosus (SLE)-relation to Th1-and Th2-derived cytokines. Clin. Exp. Immunol. 116:169-173, 1999.
 
51) al-Janadi M, al-Balla S, al-Dalaan A et al.:Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J. Clin. Immunol. 13:58-67, 1993.
PubMed
52) Jacob CO, van der Meide PH, McDevitt HO:In vivo treatment of (NZB×NZW) FI lupus-like nephritis with monoclonal antibody to gamma interferon. J. Exp. Med. 166:798-803, 1987.
 
53) Ozmen L, Roman D, Fountoulakis M et al:Experimental therapy of systemic lupus erythematosus:the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 25:6-12, 1995.
PubMed
54) Huang FP, Feng GJ, Lindop G et al.:The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL inverted question markMP-lpr inverted question mark1pr mice. J. Exp. Med. 183:1447-1459, 1996.
 
55) Raz E, Dudler J, Lotz M et al:Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 4:286-292, 1995.
PubMed
56) Prud'homme GJ, Piccirillo CA:The inhibitory effects of transforming growth factor-beta-1 (TGF-betal) in autoimmune diseases. J. Autoimmun. 14:23-42, 2000.
 
57) Gutierrez-Ramos JC, Andreu JL, Revilla Y et al:Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recom-binant virus. Nature 346:271-274, 1990.
 
58) Hagiwara E, Okubo T, Aoki I et al.:IL-12-encoding piasmid has a beneficial effect on spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. Cytokine 12:1035-1041, 2000.
 
59) Lawson BR, Prud'homme GJ, Chang Y et al.:Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. J. Clin. Invest. 106:207-215, 2000.
PubMed
60) Prud'homme GJ, Chang Y:Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/lgGl fusion protein. Gene Ther. 6:771-777, 1999.
PubMed
61) Chang Y, Prud'homme GJ:Intramuscular administration of expression plasmids encoding interferon-gamma receptor/lgGI or IL-4/IgG1 chimeric proteins protects from autoimmunity. J. Gene Med. 1:415-423, 1999.
PubMed
62) Vanderlugt CL, Miller SD:Epitope spreading in immune-mediated diseases:impiications for immunotherapy. Nat. Rev. Immunol 2:85-95, 2002.
 
63) OIson JK, Eagar TN, Miller SD:Functional activation of myelin-specific T cells by virus-induced molecular mimicry. J. Immunol. 169:2719-2726, 2002.
 
64) Ando DG, Clayton J, Kono D et al:Encephalitogenic T cells in the B10. PL model of experimental allergic encephalomyelitis (EAE) are of the Th-11ymphokinesubtype. Cell. Immunol. 124:132-143, 1989.
 
65) Youssef S, Stuve O, Patarroyo JC et al.:The HMGCoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84, 2002.
PubMed
66) Brok HP, Bauer J, Jonker M et al.:Non-human primate modeIs of multiple sclerosis. Immunol. Rev. 183:173-185, 2001.
 
67) Leonard Jp, Waldburger KE, Goldman SJ:Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181:381-386, 1995.
PubMed
68) Falcone M, Rajan AJ, Bloom BR et al.:A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J. Immunol. 160:4822-4830, 1998.
PubMed
69) Rott O, Fleischer B, Cash E:Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 24:1434-1440, 1994.
PubMed
70) Samoilova EB, Horton JL, Chen Y:Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient rnice:roles of interleukin-10 in disease progression and recovery. Cell. Immunol. 188:118-124, 1998.
PubMed
71) Chen Y, Kuchroo VK, Inobe J et al:Regulatory T cell clones induced by oral tolerance:suppression of autoimmune encephalomyelitis. Science 265:1237-1240, 1994.
PubMed
72) Calabresi PA, Fields NS, Maloni HW et al.:Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology 51:289-292, 1998.
PubMed
73) Wiendl H, Hohlfeld R:Therapeutic approaches in multiple sclerosis:lessons from failed and interrupted treatment triaIs. Bio Drugs 16:183-200, 2002.
 
74) Martino G, Furlan R, Comi G et al.:The ependymal route to the CNS:an emerging gene-therapy approach for MS. Trends Immunol. 22:483-490, 2001.
 
75) Croxford JL, Feldmann M, Chernajovsky Y et al.:Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10:acomparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J. Immunol. 166:4124-4130, 2001.
PubMed
76) Croxford JL, Triantaphyllopoulos K, Podhajcer OL et al.:Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol 160:5181-5187, 1998.
PubMed
77) Cua DJ, Hutchins B, LaFace DM et al.:Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J. Immunol. 166:602-608, 2001.
PubMed
78) Martino G, Poliani PL, Furlan R et al.:Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system:anovel gene therapy approach. J. Neuroimmunol. 107:184-190, 2000.
 
79) Furlan R, Poliani PL, Galbiati F et al.:Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. Hum. Gene Ther. 9:2605-2617, 1998.
PubMed
80) Furlan R, Poliani PL, Marconi PC et al.:Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther. 8:13-19, 2001.
 
81) Poliani PL, Brok H, Furlan R et al:Delivery to the central nervous system of a non replicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyeutis. Hum. Gene Ther. 12:905-920, 2001.
 
82) Butter C, Baker D, 0, Neill JK et al.:Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice. J. Neurol. Sci. 104:9-12, 1991.
 
83) Saunders NR, Habgood MD, Dziegielewska KM:Barrier mechanisms in the brain, 1. Adult brain. Clin. Exp. Pharmacol. Physiol 26:11-19, 1999.
PubMed
84) Lowenstein PR:Immunology of viral-vector-mediated gene transfer into the brain:an evolutionary and developmental perspective. Trends Immunol. 23:23-30, 2002.
 
85) Thomas CE, Schiedner G, Kochanek S et al.:Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animaIs injected intracranially with first-generation, but not with high-capacity, adenovirus vectors:toward realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. USA 97:7482-7487, 2000.
 
86) Kay MA, Glorioso JC, Naldini L:Viral vectors for gene therapy:the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7:33-40, 2001.
PubMed
87) Goudy K, Song S, Wasserfall C et al.:Adenoassociated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc. Natl Acad. Sci. USA 98:13913-13918, 2001.
PubMed
88) Ko KS, Lee M, Koh JJ et al.:Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice. Mol. Ther. 4:313-316, 2001.
PubMed
89) Moritani M, Yoshimoto K, Ii S et al.:Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes. J. Clin. Invest. 98:1851-1859, 1996.
PubMed
90) Pauza ME, Neal H, Hagenbaugh A et al.:T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes. Diabetes 48:1948-1953, 1999.
PubMed
91) Koh JJ, Ko KS, Lee M et al:Degradable polymeric carrier for the delivery of IL-10 plasmid DNA to prevent autoimmune insulitis of NOD mice. GeneTher. 7:2099-2104, 2000.
PubMed
92) Cottard V, Mulleman D, Bouille P et al.:Adenoassociated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Ther. 7:1930-1939, 2000.
PubMed
93) Tarner IH, Nakajima A, Seroogy CM et al.:Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4. Clin. Immunol 105:304-314, 2002.
PubMed
94) Bessis N, Honiger J, Damotte D et al.:Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-40r IL-13 ameliorates murine collageninduced arthritis (CIA) . Clin. Exp. Immunol. 117:376-382, 1999.
 
95) Kim KN, Watanabe S, Ma Y et al.:Viral IL10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirusmediated gene transfer. J. Immunol. 164:1576-1581, 2000.
PubMed
96) Woods JM, Amin MA, Katschke KJ Jr et al.:Interleukin-13 gene therapy reduces inflalnmation, vascularization, and bony destruction in rat adjuvantinduced arthritis. Hum. Gene Ther. 13:381-393, 2002.
PubMed
97) Nakajima A, Seroogy CM, Sandora MR et al.:Antigenspecific T cell-mediated gene therapy in collageninduced arthritis. J. Clin. Invest. 107:1293-1301, 2001.
PubMed
98) W山enborg DO, Fordham SA, Cowden WB et al.:Cytokines and murine autoimmune encephalomyelitis:inhibition or enhancement of disease with antibodies to select cytokines, or by delivery of exogenous cytokines using a recombinant vaccinia virus system. Scand. J. Immunol. 41:31-41, 1995.
 
99) Piccirillo CA, Prudlhomme GJ:Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors. Hum. Gene Ther. 10:1915-1922, 1999.
 
100) Lobell A, Weissert R, Eltayeb S et al.:Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis. J. Immunol. 163:4754-4762, 1999.
PubMed
101) Garren H, Ruiz PJ, Watkins TA et al.:Combination ofgene delivery and DNA vaccination to protect from and reverse Thl autoimmune disease via deviation to the Th2 pathway. Immunity 15:15-22, 2001.
 
102) Broberg E, Setala N, Roytta M et al:Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis. Gene Ther. 8:769-777, 2001.
PubMed
103) Shaw MK, Lorens JB, Dhawan A et al.:Local delivery of interleukin 4 by retrovirus-transduced T lympho-CyteS ameliorateS experimental autoimmune encephalomyelitis. J. Exp. Med. 185:1711-1714, 1997.
 
104) Dal Canto RA, Costa G, Shaw MD et al.:Local delivery of cytokines by retrovirally transduced antigen-specific TCR+hybridoma cells in experimental autoimmune encephalomyelitis. Eur. Cytokine Netw. 9:83-91, 1998.
PubMed
105) Mathisen PM, Yu M, Johnson JM et al.:Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J. Exp. Med. 186:159-164, 1997.
PubMed
106) Furlan R, Brambilla E, Ruffini F et al, :Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J. Immunol. 167:1821-1829, 2001.
PubMed
107) Dal Canto RA, Shaw MK, Nolan GP et al.:Local delivery of TNF by retrovirus-transduced T lymphocytes exacerbates experimental autoimmune encephalomyelitis. Clin. Immunol 90:10-14, 1999.
PubMed
108) Chen LZ, Hochwald GM, Huang C et al.:Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-betal. Proc. Natl. Acad. Sci. USA 95:12516-12521, 1998.
 
109) Flugel A, Matsumuro K, Neumann H et al.:Antiinflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis:inhibition of monocyte transendothelial migration. Eur. J. Immunol 31:11-22, 2001.
PubMed
110) Baker D, Hankey DJ:Gene therapy in autoimmune, demyelinating disease of the central nervous system. Gene Ther. 10:844-853, 2003.
PubMed
P.672 掲載の参考文献
1) Juang T, Shauer U, Heusset C et al:Detection of intracellular cytokines by flow cytometry. J. Immunol Methods 159:197-205, 1993.
 
2) Mosmann TR, Bond MW, Coffman RI et al.:Tcells and mast cell lines respond to B cell stimulatory factor-1. Proc. Natl. Acad. Sci. USA 83:5654-5658, 1986.
 
3) Hannum CH, Wilcox J, Ared WP et al.:Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343:341-346, 1990.
 
4) Thavasu PW, Longhurst S, Joel SP et al.:Measuring cytokine levels in blood. Importance of anticoagulants, processing, storing. J. Immunol. Methods 153:115-124, 1992.
 
5) Shapiro, L, Clark BD, Orencloe, SF et al.:Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J. Infect. Dis. 167:1344-1350, 1993.
 
6) Ko Y, Mukaida N, Ishiyama S et al.:Elevated interleukin-8levels in the urine of patients with urinary tract infections. Infect. Immun. 61:1307-1314, 1993.
 
7) Calandra T, Baumgartner JD, Grau GF et al.:Prognostic values of tumor necrosis factor/cachectin, IL-1, interferon-a, and inteferon-γ in the serum of patients with septic shock. J. Infect. Dis. 161:982-987, 1990.
 
8) Gogos C, Drosou E, Bassatis HP et al.:Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis:amarker for prognosis and future therapeutic options. J. Infect. Dis. 181:176-180, 2000.
 
9) Eastgate JA, Symons JA, Wood NC et al.:Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 1:706-709, 1998.
 
10) Corrigan, CJ, Haczku A, Gemou E et al.:CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy. Am. Rev. Respir. Dis. 147:540-547, 1993.
 
11) Marcon L, Rubin LA Kurman CC et al.:Elevated serum levels of soluble Tac peptide in adult T-cell leukamia:Correlation with clinical status during chemotherapy. Ann. Int. Med. 109:274-279, 1998.
 
12) 瀬戸山陽子, 今井浄子, 石川隆之・他:非ポジキン悪性リンパ腫における血清可溶型IL-2レセプターa鎖 値測定の有用性. 臨床病理 42:834-842, 1994.
 
13) Holler E, Kolb HJ, Moller A et al.:Increased serum levels of tumor necrosis factor a precede major comp1ication of bone marrow transplantatin. Blood 75:1011-1016, 1990.
 
14) Symington FW, Pepe MS, Chen AB et al.:Serum tumor nocrosis factor alpha associated with acute graft-versus-host disease in human. Transplantation 50:518-520, 1990.
 
15) Ohozato H, Yoshizaki, K, Nishimoto N et al.:IL-6 as a new indicator for the inflammatory status:detection of serum levles of IL-6 and C-reactive protein follwing surgical oPeration. Surgery 3:201-209, 1992.
 

書評

最近チェックした商品履歴

Loading...